Document_and_Entity_Informatio
Document and Entity Information (USD $) | 12 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | |
Document and Entity Information [Abstract] | ' | ' |
Document period end date | ' | 31-Dec-13 |
Amendment flag | ' | 'false |
Entity registrant name | ' | 'FRESENIUS MEDICAL CARE AG & Co. KGaA |
Entity current reporting status | ' | 'Yes |
Entity voluntary filers | ' | 'Yes |
Entity central index key | ' | '0001333141 |
Document type | ' | '20-F |
Current fiscal year end date | ' | '--12-31 |
Entity filer category | ' | 'Large Accelerated Filer |
Entity well known seasoned issuer | ' | 'Yes |
Entity common stock shares outstanding | ' | 300,164,922 |
Entity public float | ' | $14,275,786,095 |
Document Fiscal Year Focus | ' | '2013 |
Document Fiscal Period Focus | 'FY | ' |
Consolidated_Statements_of_Inc
Consolidated Statements of Income (USD $) | 12 Months Ended | ||
In Thousands, except Per Share data, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Net revenue: | ' | ' | ' |
Dialysis Care Revenue | $11,414,734 | $10,772,124 | $9,507,173 |
Less: Patient service bad debt provision | 284,648 | 280,365 | 224,545 |
Net Dialysis Care | 11,130,086 | 10,491,759 | 9,282,628 |
Dialysis Products Revenue | 3,479,641 | 3,308,523 | 3,287,887 |
Net revenue | 14,609,727 | 13,800,282 | 12,570,515 |
Costs of revenue: | ' | ' | ' |
Dialysis Care Cost of Revenue | 8,266,635 | 7,649,514 | 6,861,197 |
Dialysis Products Cost of Revenue | 1,604,695 | 1,549,515 | 1,557,277 |
Cost of revenues | 9,871,330 | 9,199,029 | 8,418,474 |
Gross profit | 4,738,397 | 4,601,253 | 4,152,041 |
Operating expenses: | ' | ' | ' |
Selling, general and administrative | 2,391,927 | 2,224,715 | 2,001,825 |
Gain on sale of dialysis clinics | -9,426 | -36,224 | -4,551 |
Research and development | 125,805 | 111,631 | 110,834 |
Income from at equity method investees | 26,105 | 17,442 | 30,959 |
Other operating expenses | 0 | -100,000 | ' |
Operating income | 2,256,196 | 2,218,573 | 2,074,892 |
Other (income) expense: | ' | ' | ' |
Interest income | -38,942 | -44,474 | -59,825 |
Interest expense | 447,503 | 470,534 | 356,358 |
Investment gain | 0 | 139,600 | ' |
Income before income taxes | 1,847,635 | 1,932,113 | 1,778,359 |
Income tax expense | 592,012 | 605,136 | 601,097 |
Net Income | 1,255,623 | 1,326,977 | 1,177,262 |
Less: Net income attributable to noncontrolling interests | 145,733 | 140,168 | 106,108 |
Net Income attributable to the Company | $1,109,890 | $1,186,809 | $1,071,154 |
Basic income per Ordinary share | $3.65 | $3.89 | $3.54 |
Fully diluted income per Ordinary share | $3.65 | $3.87 | $3.51 |
Consolidated_Statements_of_Com
Consolidated Statements of Comprehensive Income (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Consolidated Statements of Comprehensive Income | ' | ' | ' |
Net Income | $1,255,623 | $1,326,977 | $1,177,262 |
Other Comprehensive Income Derivatives Qualifying As Hedges Before Tax Portion Attributable To Parent | 22,532 | 24,019 | -102,446 |
Actuarial gains (losses) on defined benefit pension plans | 64,989 | -103,178 | -81,906 |
(Loss) gain related to foreign currency translation | -114,439 | 63,803 | -181,234 |
Income tax (expense) benefit related to components of other comprehensive income | -33,600 | 8,831 | 72,617 |
Other comprehensive income (loss), net of tax | -60,518 | -6,525 | -292,969 |
Total comprehensive income | 1,195,105 | 1,320,452 | 884,293 |
Comprehensive income attributable to noncontrolling interests | -143,689 | -139,989 | -104,861 |
Comprehensive income attributable to the Company | $1,051,416 | $1,180,463 | $779,432 |
Consolidated_Balance_Sheets
Consolidated Balance Sheets (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Current assets: | ' | ' |
Cash and cash equivalents | $682,777 | $688,040 |
Trade accounts receivable less allowance for doubtful accounts of $328,893 in 2012 and $299,751 in 2011 | 3,037,274 | 3,019,424 |
Accounts receivable from related parties | 153,118 | 137,809 |
Inventories | 1,097,104 | 1,036,809 |
Prepaid expenses and other current assets | 1,037,391 | 977,537 |
Deferred tax asset, current | 279,052 | 267,837 |
Total current assets | 6,286,716 | 6,127,456 |
Property, plant and equipment, net | 3,091,954 | 2,940,603 |
Intangible assets | 757,876 | 710,116 |
Goodwill | 11,658,187 | 11,421,889 |
Deferred tax asset, non-current | 104,167 | 89,152 |
Equity Method Investments | 664,446 | 637,373 |
Other assets | 556,560 | 399,409 |
Total assets | 23,119,906 | 22,325,998 |
Current liabilities: | ' | ' |
Accounts payable | 542,597 | 622,294 |
Accounts payable to related parties | 123,929 | 123,350 |
Accrued expenses and other current liabilities | 2,012,533 | 1,787,471 |
Short-term borrowings and other financial liabilities | 96,648 | 117,850 |
Short-term borrowings from related parties | 62,342 | 3,973 |
Current portion of long-term debt and capital lease obligations | 511,370 | 334,747 |
Income tax payable, current | 170,360 | 150,003 |
Deferred tax liability, current | 34,194 | 30,303 |
Total current liabilities | 3,553,973 | 3,169,991 |
Long-term debt and capital lease obligations less current maturities | 7,746,920 | 7,785,740 |
Other liabilities | 329,561 | 260,257 |
Pension liabilities | 435,858 | 457,673 |
Income tax payable, non-current | 176,933 | 201,642 |
Deferred tax liability, non-current | 743,390 | 664,001 |
Total liabilities | 12,986,635 | 12,595,478 |
Noncontrolling interests subject to put provisions | 648,251 | 523,260 |
Company shareholders' equity: | ' | ' |
Preferred stock, no par value, 1.00 Euro nominal value, 7,066,522 shares authorized, 3,973,333 issued and outstanding | 0 | 4,462 |
Common stock, no par value, 1.00 Euro nominal value, 385,396,450 shares authorized, 302,739,758 issued and outstanding | 382,411 | 374,915 |
Additional paid-in capital | 3,530,337 | 3,491,581 |
Retained earnings | 6,377,417 | 5,563,661 |
Accumulated other comprehensive (loss) | -550,587 | -492,113 |
Total Company shareholders' equity | 9,234,564 | 8,942,506 |
Noncontrolling interests not subject to put provisions | 250,456 | 264,754 |
Total equity | 9,485,020 | 9,207,260 |
Total liabilities and equity | 23,119,906 | 22,325,998 |
Treasury stock, at cost | -505,014 | ' |
Long term debt from related parties | ' | $56,174 |
Consolidated_Balance_Sheets_Pa
Consolidated Balance Sheets (Parentheticals) (USD $) | Dec. 31, 2013 |
In Thousands, except Share data, unless otherwise specified | |
Consolidated Balance Sheets | ' |
Trade accounts receivable allowance for doubtful accounts | $413,165 |
Common stock authorized | 392,462,972 |
Common stock issued | 308,995,730 |
Common stock outstanding | 301,446,779 |
Consolidated_Statements_of_Cas
Consolidated Statements of Cash Flows (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Operating Activities: | ' | ' | ' |
Net Income | $1,255,623 | $1,326,977 | $1,177,262 |
Adjustments to reconcile net income to net cash provided by operating activities: | ' | ' | ' |
Depreciation and amortization | 648,225 | 602,896 | 557,283 |
Investment in equity method investees, net | 2,335 | 22,512 | -30,959 |
Change in deferred taxes, net | 15,913 | 75,170 | 159,181 |
(Gain) loss on sale of investments | -9,426 | -36,224 | -7,679 |
(Gain) loss on sale of fixed assets | -23,558 | 6,700 | -1,306 |
Investment gain | 0 | 139,600 | ' |
Stock Option Compensation Expense | 13,593 | 26,476 | 29,071 |
Cash outflow from hedging | -4,073 | -13,947 | -58,113 |
Changes in assets and liabilities, net of amounts from businesses acquired: | ' | ' | ' |
Trade accounts receivable, net | -41,280 | -43,344 | -252,794 |
Inventories, net | -54,918 | -48,279 | -151,890 |
Prepaid expenses, other current and non-current assets | 67,875 | 88,413 | -130,858 |
Accounts receivable, related parties | -10,968 | -25,859 | -11,669 |
Accounts payable, related parties | -3,743 | 10,064 | -4,495 |
Accounts payable, accrued expenses and other current and non-current liabilities | 215,264 | 225,586 | 132,406 |
Income tax payable | -36,057 | -38,478 | 41,042 |
Net cash provided by (used in) operating activities | 2,034,805 | 2,039,063 | 1,446,482 |
Investing Activities: | ' | ' | ' |
Purchases of property, plant and equipment | -747,938 | -675,310 | -597,855 |
Proceeds from sale of property, plant and equipment | 19,847 | 9,667 | 27,325 |
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets | -495,725 | -1,878,908 | -1,785,329 |
Proceeds from divestitures | 18,276 | 263,306 | 9,990 |
Net cash (used in) provided by investing activities | -1,205,540 | -2,281,245 | -2,345,869 |
Effect of exchange rate changes on cash and cash equivalents | -26,488 | 4,590 | 40,650 |
Cash and Cash Equivalents: | ' | ' | ' |
Net (decrease) in cash and cash equivalents | -5,263 | 230,748 | -65,578 |
Cash and cash equivalents at beginning of period | 688,040 | 457,292 | 522,870 |
Cash and cash equivalents at end of period | 682,777 | 688,040 | 457,292 |
Financing Activities: | ' | ' | ' |
Proceeds from short-term borrowings and other financial liabilities | 381,603 | 174,391 | 189,987 |
Repayments of short-term borrowings and other financial liabilities | -397,682 | -163,059 | -248,821 |
Proceeds from short-term borrowings from related parties | 18,593 | 39,829 | 146,872 |
Repayments of short-term borrowings from related parties | -18,228 | -64,112 | -127,015 |
Proceeds from long-term debt and capital lease obligations (net of debt issuance costs of $178,593 in 2012 and $127,854 in 2011) | 441,278 | 4,750,730 | 2,706,105 |
Repayments of long-term debt and capital lease obligations | -617,499 | -3,589,013 | -957,235 |
Redemption of Trust Preferred Securities | ' | 0 | 653,760 |
Increase (decrease) of accounts receivable securitization program | 189,250 | -372,500 | 24,500 |
Proceeds from exercise of stock options | 111,300 | 121,126 | 94,893 |
Proceeds from conversion of preference shares into ordinary shares | 34,784 | ' | ' |
Purchase of treasury stock | -505,014 | ' | ' |
Payment of dividends [N] | -296,134 | -271,733 | -280,649 |
Distributions to Noncontrolling interests | -216,758 | -195,023 | -129,542 |
Contributions from noncontrolling interests | 66,467 | 37,704 | 27,824 |
Net cash (used in) provided by financing activities | ($808,040) | $468,340 | $793,159 |
Consolidated_Statements_of_Sha
Consolidated Statements of Shareholders' Equity (USD $) | Total | Preferred Stock, No par value [Member] | Common Stock, No par value [Member] | Additional paid in capital [Member] | Retained earnings [Member] | Accumulated other comprehensive income (loss) [Member] | Total FMC-AG and Co. KGaA [Member] | Noncontrolling interests not subject to put provisions [Member] | Treasury Stock |
In Thousands, except Share data, unless otherwise specified | |||||||||
Shareholders equity at Dec. 31, 2010 | $7,523,911 | $4,440 | $369,002 | $3,339,781 | $3,858,080 | ($194,045) | $7,377,258 | $146,653 | ' |
Shares issued at Dec. 31, 2010 | ' | 3,957,168 | 298,279,001 | ' | ' | ' | ' | ' | ' |
Proceeds from exercise of options and related tax effects | 88,546 | 12 | 2,647 | 85,887 | ' | ' | 88,546 | ' | ' |
Shares from exercise of options and related tax effects | ' | 8,523 | 1,885,921 | ' | ' | ' | ' | ' | ' |
Compensation expense related to stock options | 29,071 | ' | ' | 29,071 | ' | ' | 29,071 | ' | ' |
Dividends paid | -280,649 | ' | ' | ' | -280,649 | ' | -280,649 | ' | ' |
Purchase (sale) of noncontrolling interests | 3,789 | ' | ' | -5,873 | ' | ' | -5,873 | 9,662 | ' |
Cash contributions from noncontrolling interests | -59,066 | ' | ' | ' | ' | ' | ' | -59,066 | ' |
Changes in fair value of noncontrolling interests | -86,233 | ' | ' | -86,233 | ' | ' | -86,233 | ' | ' |
Comprehensive income (loss) | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net Income | 1,134,405 | ' | ' | ' | 1,071,154 | ' | 1,071,154 | 63,251 | ' |
Other comprehensive income (loss) - net | -292,757 | ' | ' | ' | ' | -291,722 | -291,722 | -1,035 | ' |
Total comprehensive income | 841,648 | ' | ' | ' | ' | ' | 779,432 | 62,216 | ' |
Shareholders equity at Dec. 31, 2011 | 8,061,017 | 4,452 | 371,649 | 3,362,633 | 4,648,585 | -485,767 | 7,901,552 | 159,465 | ' |
Shares issued at Dec. 31, 2011 | ' | 3,965,691 | 300,164,922 | ' | ' | ' | ' | ' | ' |
Proceeds from exercise of options and related tax effects | 113,786 | 10 | 3,266 | 110,510 | ' | ' | 113,786 | ' | ' |
Shares from exercise of options and related tax effects | ' | 7,642,000 | 2,574,836,000 | ' | ' | ' | ' | ' | ' |
Compensation expense related to stock options | 26,476 | ' | ' | 26,476 | ' | ' | 26,476 | ' | ' |
Dividends paid | -271,733 | ' | ' | ' | -271,733 | ' | -271,733 | ' | ' |
Purchase (sale) of noncontrolling interests | 59,787 | ' | ' | -26,918 | ' | ' | -26,918 | 86,705 | ' |
Cash contributions from noncontrolling interests | -26,428 | ' | ' | ' | ' | ' | ' | -26,428 | ' |
Changes in fair value of noncontrolling interests | 18,880 | ' | ' | 18,880 | ' | ' | 18,880 | ' | ' |
Comprehensive income (loss) | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net Income | 1,232,259 | ' | ' | ' | 1,186,809 | ' | 1,186,809 | 45,450 | ' |
Other comprehensive income (loss) - net | -6,784 | ' | ' | ' | ' | -6,346 | -6,346 | -438 | ' |
Total comprehensive income | 1,225,475 | ' | ' | ' | ' | ' | 1,180,463 | 45,012 | ' |
Shareholders equity at Dec. 31, 2012 | 9,207,260 | 4,462 | 374,915 | 3,491,581 | 5,563,661 | -492,113 | 8,942,506 | 264,754 | ' |
Shares issued at Dec. 31, 2012 | ' | 3,973,333 | 302,739,758 | ' | ' | ' | ' | ' | ' |
Proceeds from exercise of options and related tax effects | 105,554 | 3 | 3,031 | 102,520 | ' | ' | 105,554 | ' | ' |
Shares from exercise of options and related tax effects | ' | 2,200 | 2,280,439 | ' | ' | ' | ' | ' | ' |
Compensation expense related to stock options | 13,593 | ' | ' | 13,593 | ' | ' | 13,593 | ' | ' |
Dividends paid | -296,134 | ' | ' | ' | -296,134 | ' | -296,134 | ' | ' |
Purchase (sale) of noncontrolling interests | -15,173 | ' | ' | -3,566 | ' | ' | -3,566 | -11,607 | ' |
Cash contributions from noncontrolling interests | -32,275 | ' | ' | ' | ' | ' | ' | -32,275 | ' |
Changes in fair value of noncontrolling interests | -108,575 | ' | ' | -108,575 | ' | ' | -108,575 | ' | ' |
Comprehensive income (loss) | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net Income | 1,142,467 | ' | ' | ' | 1,109,890 | ' | 1,109,890 | 32,577 | ' |
Other comprehensive income (loss) - net | -61,467 | ' | ' | ' | ' | -58,474 | -58,474 | -2,993 | ' |
Total comprehensive income | 1,081,000 | ' | ' | ' | ' | ' | 1,051,416 | 29,584 | ' |
Proceeds from conversion of preference shares into ordinary shares | 34,784 | -4,465 | 4,465 | 34,784 | ' | ' | 34,784 | ' | ' |
Proceeds From Repurchase Of Equity | -505,014 | ' | ' | ' | ' | ' | -505,014 | ' | -505,014 |
Shares converted from preference shares | ' | -3,975,533 | 3,975,533 | ' | ' | ' | ' | ' | ' |
Shares from purchase of treasury stock | -7,548,951 | ' | ' | ' | ' | ' | ' | ' | ' |
Shareholders equity at Dec. 31, 2013 | $9,485,020 | $0 | $382,411 | $3,530,337 | $6,377,417 | ($550,587) | $9,234,564 | $250,456 | ($505,014) |
Shares issued at Dec. 31, 2013 | ' | 0 | 308,995,730 | ' | ' | ' | ' | ' | -7,548,951 |
The_Company_and_Basis_of_Prese
The Company and Basis of Presentation | 12 Months Ended | |||||
Dec. 31, 2013 | ||||||
Notes to Consolidated Financial Statements [Abstract] | ' | |||||
The Company and Basis of Presentation | ' | |||||
1. The Company and Basis of Presentation | ||||||
The Company | ||||||
Fresenius Medical Care AG & Co. KGaA (“FMC-AG & Co. KGaA” or the “Company”), a German partnership limited by shares (Kommanditgesellschaft auf Aktien), is the world's largest kidney dialysis company, operating in both the field of dialysis care and the field of dialysis products for the treatment of end-stage renal disease (“ESRD”). The Company's dialysis care business, in addition to providing dialysis treatments, includes pharmacy services and vascular access surgery services (together, the “Expanded Services”). The Company's dialysis products business includes manufacturing and distributing products for the treatment of ESRD. The Company's dialysis business is vertically integrated, providing dialysis treatment at dialysis clinics it owns or operates and supplying these clinics with a broad range of products. In addition, the Company sells dialysis products to other dialysis service providers. In the United States (“U.S.”) the Company also provides laboratory testing services, and inpatient dialysis services as well as other services under contract to hospitals. | ||||||
In these Notes, “FMC-AG & Co. KGaA,” or the “Company,” “we,” “us” or “our” refers to the Company or the Company and its subsidiaries on a consolidated basis, as the context requires. The term “North America Segment” refers to the North America operating segment. The term “International Segment” refers to the combined Europe, Middle East, Africa and Latin America (“EMEALA”) operating segment and the Asia-Pacific operating segment. For further discussion of our operating segments, see Note 24 “Segment and Corporate Information”. | ||||||
Basis of Presentation | ||||||
The accompanying consolidated financial statements have been prepared in accordance with the United States' generally accepted accounting principles (“U.S. GAAP”). | ||||||
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Such financial statements reflect all adjustments that, in the opinion of management, are necessary for a fair presentation of the results of the periods presented. All such adjustments are of a normal recurring nature. | ||||||
Certain items in the prior years' comparative consolidated financial statements have been reclassified to conform to the current year's presentation. Pension liabilities in the amount of $34,312 for the year ended December 31, 2012 have been reclassified from “Other liabilities” to “Pension liabilities” within the Consolidated Balance Sheet to appropriately depict the Company's pension plans outside of Germany and the US (see Note 12). Deferred tax assets in the amount of $39,776 and $44,601 for the current and non-current portions of deferred taxes have also been reclassified from “Deferred taxes (current)” and “Deferred taxes (non-current)” to “Prepaids and other current assets” and “Other assets and notes receivable”, respectively, for the year ended December 31, 2012 to conform to the current year's presentation for the deferred tax effects on intercompany sales and purchases of assets (see Note 18). | ||||||
Summary of Significant Accounting Policies | ||||||
a) Principles of Consolidation | ||||||
The consolidated financial statements include the earnings of all companies in which the Company has legal or effective control. This includes variable interest entities (“VIEs”) for which the Company is deemed the primary beneficiary. In accordance with current accounting principles, the Company also consolidates certain clinics that it manages and financially controls. Noncontrolling interests represent the proportionate equity interests in the Company's consolidated entities that are not wholly owned by the Company. Noncontrolling interests of acquired entities are valued at fair value. The equity method of accounting is used for investments in associated companies over which the Company has significant exercisable influence, even when the Company holds 50% or less of the common stock of the entity. All significant intercompany transactions and balances have been eliminated. | ||||||
The Company has entered into various arrangements with certain dialysis clinics and a dialysis product distributor to provide management services, financing and product supply. The dialysis clinics and the dialysis product distributor have either negative equity or are unable to provide their own funding for their operations. Therefore, the Company has agreed to fund their operations through loans. The compensation for the funding can carry interest, exclusive product supply agreements, or entitle the Company to a pro rata share of profits, if any. The Company has a right of first refusal in the event the owners sell the business or assets. These clinics and the dialysis product distributor are VIEs in which the Company has been determined to be the primary beneficiary and which therefore have been fully consolidated. All VIEs generated approximately $203,333, $205,858 and $195,296 in revenue in 2013, 2012, and 2011, respectively. The Company provided funding to VIEs through loans and accounts receivable of $150,300 and $146,500 in 2013 and 2012, respectively. The table below shows the carrying amounts of the assets and liabilities of VIEs at December 31, 2013 and 2012: | ||||||
2013 | 2012 | |||||
Trade accounts receivable, net | $ | 102,549 | $ | 99,061 | ||
Other current assets | 59,695 | 57,741 | ||||
Property, plant and equipment, intangible assets & other non-current assets | 26,274 | 26,823 | ||||
Goodwill | 32,759 | 31,678 | ||||
Accounts payable, accrued expenses and other liabilities | 133,977 | 122,891 | ||||
Non-current loans from related parties | 12,998 | 12,998 | ||||
Equity | 74,302 | 79,414 | ||||
b) Cash and Cash Equivalents | ||||||
Cash and cash equivalents comprise cash funds and all short-term, liquid investments with original maturities of up to three months. | ||||||
Inventories | ||||||
Inventories are stated at the lower of cost (determined by using the average or first-in, first-out method) or market value (see Note 4). Costs included in inventories are based on invoiced costs and/or production costs or the marked to market valuation, as applicable. Included in production costs are material, direct labor and production overhead, including depreciation charges. | ||||||
Property, Plant and Equipment | ||||||
Property, plant, and equipment are stated at cost less accumulated depreciation (see Note 6). Significant improvements are capitalized; repairs and maintenance costs that do not extend the useful lives of the assets are charged to expense as incurred. Property and equipment under capital leases are stated at the present value of future minimum lease payments at the inception of the lease, less accumulated depreciation. Depreciation on property, plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets ranging from 3 to 40 years for buildings and improvements with a weighted average life of 13 years and 3 to 15 years for machinery and equipment with a weighted average life of 10 years. Equipment held under capital leases and leasehold improvements are amortized using the straight-line method over the shorter of the lease term or the estimated useful life of the asset. Internal use platform software that is integral to the computer equipment it supports is included in property, plant and equipment. The Company capitalizes interest on borrowed funds during construction periods. Interest capitalized during 2013, 2012, and 2011 was $7,358, $3,952 and $3,784, respectively. | ||||||
Intangible Assets and Goodwill | ||||||
Intangible assets such as non-compete agreements, technology, distribution rights, patents, licenses to treat, licenses to manufacture, distribute and sell pharmaceutical drugs, exclusive contracts and exclusive licenses, trade names, management contracts, application software, acute care agreements, customer relationships, lease agreements, and licenses acquired in a business combination are recognized and reported apart from goodwill (see Note 7). | ||||||
Goodwill and identifiable intangibles with indefinite useful lives are not amortized but tested for impairment annually or when an event becomes known that could trigger an impairment. The Company identified trade names and certain qualified management contracts as intangible assets with indefinite useful lives because, based on an analysis of all of the relevant factors, there is no foreseeable limit to the period over which those assets are expected to generate net cash inflows for the Company. Intangible assets with finite useful lives are amortized over their respective useful lives to their residual values. The Company amortizes non-compete agreements over their useful life which on average is 8 years. Technology is amortized over its useful life of 16 years. Licenses to manufacture, distribute and sell pharmaceutical drugs, exclusive contracts and exclusive licenses are amortized over their useful life which on average is 9 years. Customer relationships are amortized over their useful life of 15 years. All other intangible assets are amortized over their weighted average useful lives of 7 years. The weighted average useful life of all amortizable intangible assets is 9 years. Intangible assets with finite useful lives are evaluated for impairment when events have occurred that may give rise to an impairment. | ||||||
To perform the annual impairment test of goodwill, the Company identified its reporting units and determined their carrying value by assigning the assets and liabilities, including the existing goodwill and intangible assets, to those reporting units. One reporting unit was identified in the North America Segment. The EMEALA operating segment is divided into two reporting units (Europe and Latin America), while only one reporting unit exists in the operating segment Asia-Pacific. For the purpose of goodwill impairment testing, all corporate assets are allocated to the reporting units. | ||||||
In a first step, the Company compares the fair value of a reporting unit to its carrying amount. Fair value is determined using estimated future cash flows for the unit discounted by an after-tax weighted average cost of capital (“WACC”) specific to that reporting unit. Estimating the future cash flows involves significant assumptions, especially regarding future reimbursement rates and sales prices, number of treatments, sales volumes and costs. In determining discounted cash flows, the Company utilizes for every reporting unit, its three-year budget, projections for years 4 to 10 and a representative growth rate for all remaining years. Projections for up to ten years are possible due to the stability of the Company's business which, results from the non-discretionary nature of the healthcare services we provide, the need for products utilized to provide such services and the availability of government reimbursement for a substantial portion of our services. The reporting units' respective expected growth rates for the period beyond ten years are: North America Segment 1%, Europe 0%, Latin America 4%, and Asia-Pacific 4%. The discount factor is determined by the WACC of the respective reporting unit. The Company's WACC consisted of a basic rate of 6.17% for 2013. The basic rate is then adjusted by a country-specific risk rate and, if appropriate, by a factor to reflect higher risks associated with the cash flows from recent material acquisitions, until they are appropriately integrated, within each reporting unit. In 2013, WACCs for the reporting units ranged from 6.12% to 13.83%. | ||||||
In the case that the fair value of the reporting unit is less than its carrying value, a second step would be performed which compares the implied fair value of the reporting unit's goodwill to the carrying value of its goodwill. If the fair value of the goodwill is less than the carrying value, the difference is recorded as an impairment. | ||||||
To evaluate the recoverability of intangible assets with indefinite useful lives, the Company compares the fair values of intangible assets with their carrying values. An intangible asset's fair value is determined using a discounted cash flow approach or other methods, if appropriate. | ||||||
Derivative Financial Instruments | ||||||
Derivative financial instruments, which primarily include foreign currency forward contracts and interest rate swaps, are recognized as assets or liabilities at fair value in the balance sheet (see Note 21). Changes in the fair value of derivative financial instruments classified as fair value hedges and in the corresponding underlying assets and liabilities are recognized periodically in earnings, while the effective portion of changes in fair value of derivative financial instruments classified as cash flow hedges is recognized in accumulated other comprehensive income (loss) (“AOCI”) in shareholders' equity. The ineffective portion is recognized in current net earnings. The change in fair value of derivatives that do not qualify for hedge accounting are recorded in the income statement and usually offset the changes in value recorded in the income statement for the underlying asset or liability. | ||||||
Foreign Currency Translation | ||||||
For purposes of these consolidated financial statements, the U.S. dollar is the reporting currency. Substantially all assets and liabilities of the parent company and all non-U.S. subsidiaries are translated at year-end exchange rates, while revenues and expenses are translated at average exchange rates. Adjustments for foreign currency translation fluctuations are excluded from net earnings and are reported in AOCI. In addition, the translation adjustments of certain intercompany borrowings, which are of a long-term nature, are reported in AOCI. | ||||||
Revenue Recognition and Allowance for Doubtful Accounts | ||||||
Revenue Recognition | ||||||
Dialysis care revenues are recognized on the date the patient receives treatment and includes amounts related to certain services, products and supplies utilized in providing such treatment. The patient is obligated to pay for dialysis care services at amounts estimated to be receivable based upon the Company's standard rates or at rates determined under reimbursement arrangements. In the U.S., these arrangements are generally with third party payors, like Medicare, Medicaid or commercial insurers. Outside the U.S., the reimbursement is usually made through national or local government programs with reimbursement rates established by statute or regulation. | ||||||
Dialysis product revenues are recognized upon transfer of title to the customer, either at the time of shipment, upon receipt or upon any other terms that clearly define passage of title. Product revenues are normally based upon pre-determined rates that are established by contractual arrangement. | ||||||
For both dialysis care revenues and dialysis product revenues, patients, third party payors and customers are billed at our standard rates net of contractual allowances, discounts or rebates to reflect the estimated amounts to be receivable from these payors. | ||||||
As of January 1, 2012, the Company adopted ASU 2011-07, Health Care Entities-Presentation and Disclosure of Patient Service Revenue, Provision for Bad Debts, and the Allowance for Doubtful Accounts and as a result, for services performed for patients where the collection of the billed amount or a portion of the billed amount cannot be determined at the time services are performed, the difference between the receivable recorded and the amount estimated to be collectible must be recorded as a provision and the expense is presented as a reduction of dialysis care revenue. The provision includes such items as amounts due from patients without adequate insurance coverage and patient co-payment and deductible amounts due from patients with health care coverage. The Company bases the provision mainly on past collection history and reports it as “Patient service bad debt provision” on the Consolidated Statements of Income. | ||||||
A minor portion of International Segment product revenues is generated from arrangements which give the customer, typically a healthcare provider, the right to use dialysis machines. In the same contract the customer agrees to purchase the related treatment disposables at a price marked up from the standard price list. If the right to use the machine is conveyed through an operating lease, FMC-AG & Co. KGaA does not recognize revenue upon delivery of the dialysis machine but recognizes revenue on the sale of disposables. If the lease of the machines is a sales type lease, ownership of the dialysis machine is transferred to the user upon installation of the dialysis machine at the customer site. In this type of contract, revenue is recognized in accordance with the accounting principles for sales type leases. | ||||||
Any tax assessed by a governmental authority that is incurred as a result of a revenue transaction (e.g. sales tax) is excluded from revenues and the related revenue is reported on a net basis. | ||||||
Allowance for doubtful accounts | ||||||
In the North America Segment for receivables generated from dialysis care services, the accounting for the allowance for doubtful accounts is based on an analysis of collection experience and recognizing the differences between payors. The Company also performs an aging of accounts receivable which enables the review of each customer and their payment pattern. From time to time, accounts receivable are reviewed for changes from the historic collection experience to ensure the appropriateness of the allowances. | ||||||
The allowance for doubtful accounts in the International Segment and the North America Segment dialysis products business is an estimate comprised of customer specific evaluations regarding their payment history, current financial stability, and applicable country specific risks for receivables that are overdue more than one year. The changes in the allowance for these receivables are recorded in Selling, general and administrative as an expense. | ||||||
When all efforts to collect a receivable, including the use of outside sources where required and allowed, have been exhausted, and after appropriate management review, a receivable deemed to be uncollectible is considered a bad debt and written off. | ||||||
Research and Development expenses | ||||||
Research and development expenses are expensed as incurred. | ||||||
Income Taxes | ||||||
Current taxes are calculated based on the profit (loss) of the fiscal year and in accordance with local tax rules of the respective tax jurisdictions. Expected and executed additional tax payments and tax refunds for prior years are also taken into account. Benefits from income tax positions have been recognized only when it was more likely than not that the Company would be entitled to the economic benefits of the tax positions. The more-likely-than-not threshold has been determined based on the technical merits that the position will be sustained upon examination. If a tax position meets the more-likely-than-not recognition threshold, management estimates the largest amount of tax benefit that is more than fifty percent likely to be realized upon settlement with a taxing authority, which becomes the amount of benefit recognized. If a tax position is not considered more likely than not to be sustained based solely on its technical merits, no benefits are recognized. | ||||||
The Company recognizes deferred tax assets and liabilities for future consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, tax credits and tax loss carryforwards which are more likely than not to be utilized. Deferred tax assets and liabilities are measured using the respective countries enacted tax rates to be applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. In addition, the recognition of deferred tax assets considers the budget planning of the Company and implemented tax strategies. A valuation allowance is recorded to reduce the carrying amount of the deferred tax assets unless it is more likely than not that such assets will be realized (see Note 18). | ||||||
It is the Company's policy that assets on uncertain tax positions are recognized to the extent it is more likely than not the tax will be recovered. It is also the Company's policy to recognize interest and penalties related to its tax positions as income tax expense. | ||||||
Impairment | ||||||
The Company reviews the carrying value of its long-lived assets or asset groups with definite useful lives to be held and used for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. Recoverability of these assets is measured by a comparison of the carrying value of an asset to the future net cash flows directly associated with the asset. If assets are considered to be impaired, the impairment recognized is the amount by which the carrying value exceeds the fair value of the asset. The Company uses a discounted cash flow approach or other methods, if appropriate, to assess fair value. | ||||||
Long-lived assets to be disposed of by sale are reported at the lower of carrying value or fair value less cost to sell and depreciation is ceased. Long-lived assets to be disposed of other than by sale are considered to be held and used until disposal. | ||||||
For the Company's policy related to goodwill impairment, see 1e) above. | ||||||
Debt Issuance Costs | ||||||
Certain costs related to the issuance of debt are amortized over the term of the related obligation (see Note 11). | ||||||
Self-Insurance Programs | ||||||
Under the insurance programs for professional, product and general liability, auto liability and worker's compensation claims, the Company's largest subsidiary is partially self-insured for professional liability claims. For all other coverage, the Company assumes responsibility for incurred claims up to predetermined amounts above which third party insurance applies. Reported liabilities for the year represent estimated future payments of the anticipated expense for claims incurred (both reported and incurred but not reported) based on historical experience and existing claim activity. This experience includes both the rate of claims incidence (number) and claim severity (cost) and is combined with individual claim expectations to estimate the reported amounts. | ||||||
Concentration of Risk | ||||||
The Company is engaged in the manufacture and sale of products for all forms of kidney dialysis, principally to healthcare providers throughout the world, and in providing kidney dialysis treatment, clinical laboratory testing, and other medical ancillary services. The Company performs ongoing evaluations of its customers' financial condition and, generally, requires no collateral. | ||||||
Approximately 32%, 32% and 30% of the Company's worldwide revenues were earned and subject to regulations under Medicare and Medicaid, governmental healthcare programs administered by the United States government in 2013, 2012, and 2011, respectively. | ||||||
No single debtor other than U.S. Medicaid and Medicare accounted for more than 5% of total trade accounts receivable in any of these years. Trade accounts receivable in the International Segment are for a large part due from government or government-sponsored organizations that are established in the various countries within which we operate. Amounts pending approval from third party payors represent less than 3% at December 31, 2013. | ||||||
See Note 4 for discussion of suppliers with long-term purchase commitments. | ||||||
Legal Contingencies | ||||||
From time to time, during the ordinary course of the Company's operations, the Company is party to litigation and arbitration and is subject to investigations relating to various aspects of its business (see Note 20). The Company regularly analyzes current information about such claims for probable losses and provides accruals for such matters, including the estimated legal expenses and consulting services in connection with these matters, as appropriate. The Company utilizes its internal legal department as well as external resources for these assessments. In making the decision regarding the need for loss accrual, the Company considers the degree of probability of an unfavorable outcome and its ability to make a reasonable estimate of the amount of loss. | ||||||
The filing of a suit or formal assertion of a claim or assessment, or the disclosure of any such suit or assertion, does not necessarily indicate that accrual of a loss is appropriate. | ||||||
Earnings per Share | ||||||
Basic earnings per share is calculated by dividing net income attributable to shareholders by the weighted average number of shares outstanding during the year. Prior to the conversion of preference shares to ordinary shares during the second quarter of 2013, basic earnings per share was computed according to the two-class method by dividing net income attributable to shareholders, less preference amounts, by the weighted number of ordinary and preference shares outstanding during the year. Diluted earnings per share include the effect of all potentially dilutive instruments on ordinary shares and previously outstanding preference shares that would have been outstanding during the years presented had the dilutive instruments been issued. | ||||||
Equity-settled awards granted under the Company's stock incentive plans (see Note 17), are potentially dilutive equity instruments. | ||||||
Treasury Stock | ||||||
The Company may, from time to time, acquire its own shares (“Treasury Stock”) as approved by its shareholders. The acquisition, sale or retirement of its Treasury Stock is recorded separately in equity. For the calculation of basic earnings per share, treasury stock is not considered outstanding and is therefore deducted from the number of shares outstanding with the value of such Treasury Stock shown as a reduction of the Company's equity. | ||||||
Employee Benefit Plans | ||||||
For the Company's funded benefit plans, the defined benefit obligation is offset against the fair value of plan assets (funded status). A pension liability is recognized in the Consolidated Balance Sheets if the defined benefit obligation exceeds the fair value of plan assets. A pension asset is recognized (and reported under other assets in the balance sheet) if the fair value of plan assets exceeds the defined benefit obligation and if the Company has a right of reimbursement against the fund or a right to reduce future payments to the fund. Changes in the funded status of a plan resulting from actuarial gains or losses and prior service costs or credits that are not recognized as components of the net periodic benefit cost are recognized through accumulated other comprehensive income, net of tax, in the year in which they occur. Actuarial gains or losses and prior service costs are subsequently recognized as components of net periodic benefit cost when realized. The Company uses December 31 as the measurement date when measuring the funded status of all plans. | ||||||
Recent Pronouncements | ||||||
Recently Implemented Accounting Pronouncements | ||||||
On January 31, 2013, FASB issued Accounting Standards Update 2013-01 (“ASU 2013-01”) an update to Balance Sheet (Topic 210), Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities (“Topic 210”). The main purpose of ASU 2013-01 is to clarify the scope of balance sheet offsetting under Topic 210 to include derivatives, repurchase agreements and reverse repurchase agreements, and securities borrowing and securities lending transactions that are offset or subject to master netting agreements. The disclosures required under Topic 210 would apply to these transactions and other types of financial assets or liabilities will no longer be subject to Topic 210. The update is effective for fiscal years and interim periods within those years beginning on or after January 1, 2013. The Company does not utilize balance sheet offsetting for its derivative transactions. See Note 21 of the Notes to the Consolidated Financial Statements, “Financial Instruments,” included in this report for more information. | ||||||
Recent Accounting Pronouncements Not Yet Adopted | ||||||
On February 28, 2013 FASB issued Accounting Standards Update 2013-04 (“ASU 2013-04”) Liabilities (Topic 405), Obligations Resulting from Joint and Several Liability Arrangements for which the Total Amount of the Obligations is Fixed at the Reporting Date.” ASU 2013-04's objective is to provide guidance and clarification on the recognition, measurement and disclosure of obligations resulting from joint and several liability arrangements such as debt arrangements, other contractual obligations and settled litigation and judicial rulings. The update is effective for fiscal years and interim periods within those years beginning on or after December 15, 2013. The Company will adopt ASU 2013-04 as of January 1, 2014. The Company has determined that the impact will be the inclusion of a disclosure within the Notes to the Consolidated Financial Statements. | ||||||
On March 4, 2013 FASB issued Accounting Standards Update 2013-05 (“ASU 2013-05”) Foreign Currency Matters (Topic 830), Parent's Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity. The purpose of ASU 2013-05 is to provide clarification and further refinement regarding the treatment of the release of a cumulative translation adjustment into net income. This occurs in instances where the parent sells either a part or all of its investment in a foreign entity, as well as when a company ceases to hold a controlling interest in a subsidiary or group of assets that is a nonprofit activity or business within a foreign entity. The update is effective for fiscal years and interim periods within those years beginning on or after December 15, 2013. The Company will adopt ASU 2013-05 as of January 1, 2014. ASU 2013-05 will not have a material impact on the Company and its consolidated financial statements. | ||||||
On July 17, 2013, FASB issued Accounting Standards Update 2013-10 (“ASU 2013-10”) Derivatives and Hedging (Topic 815), Inclusion of the Fed Funds Effective Swap Rate (or Overnight Index Swap Rate) as a Benchmark Interest Rate for Hedge Accounting Purposes. The purpose of 2013-10 is to provide the inclusion of the Fed Funds Effective Swap Rate as a U.S. benchmark interest rate for hedge accounting purposes. This rate will now be available to use along with U.S. government interest rates and the London Interbank Offered Rate. This update is effective prospectively for new or designated hedging relationships entered into on or after July 17, 2013. Currently, we do not intend to utilize the newly available Fed Funds Effective Swap Rate for our hedge accounting. | ||||||
On July 18, 2013, FASB issued Accounting Standards Update 2013-11 (“ASU 2013-11”) Income Taxes (Topic 740) Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. The purpose of ASU 2013-11 is to align the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss or a tax credit carryforward exists. In most cases, the unrecognized tax benefit should be presented as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss or a tax credit carryforward. The update is effective for fiscal years and interim periods within those years beginning on or after December 15, 2013. The Company will adopt ASU 2013-11 as of January 1, 2014. ASU 2013-11 will not have a material impact on the Company and its consolidated financial statements. |
Acquisition_of_Liberty_Dialysi
Acquisition of Liberty Dialysis Holdings | 12 Months Ended | |||
Dec. 31, 2013 | ||||
Notes to Consolidated Financial Statements [Abstract] | ' | |||
Acquisition of Liberty Dialysis Holdings | ' | |||
2. Acquisition of Liberty Dialysis Holdings | ||||
On February 28, 2012, the Company acquired 100% of the equity of Liberty Dialysis Holdings, Inc. (“LD Holdings”), the owner of Liberty Dialysis and owner of a 51% stake in Renal Advantage Partners, LLC (the “Liberty Acquisition”). The Company accounted for this transaction as a business combination and finalized the acquisition accounting on February 28, 2013. | ||||
Total consideration for the Liberty Acquisition was $2,181,358, consisting of $1,696,659 cash, net of cash acquired and $484,699 non-cash consideration. Accounting standards for business combinations require previously held equity interests to be fair valued at the time of acquisition with the difference to book value to be recognized as a gain or loss in income. Prior to the Liberty Acquisition, the Company had a 49% equity investment in Renal Advantage Partners, LLC, the fair value of which, $ 201,915, was included as part of the non-cash consideration. The fair value was determined based on the discounted cash flow method, utilizing a discount rate of approximately 13%. In addition to the Company's investment, it also had a loan receivable from Renal Advantage Partners, LLC of $279,793, at a fair value of $ 282,784, which was retired as part of the transaction. | ||||
The following table summarizes the final fair values of assets acquired and liabilities assumed at the date of the acquisition. Any adjustments to acquisition accounting from December 31, 2012 until finalization on February 28, 2013, net of related income tax effects, were recorded with a corresponding adjustment to goodwill: | ||||
Assets held for sale | $ | 164,068 | ||
Trade accounts receivable | 149,219 | |||
Other current assets | 17,458 | |||
Deferred tax assets | 14,932 | |||
Property, plant and equipment | 168,335 | |||
Intangible assets and other assets | 84,556 | |||
Goodwill | 2,003,465 | |||
Accounts payable, accrued expenses and other current liabilities | -105,403 | |||
Income tax payable and deferred taxes | -33,597 | |||
Short-term borrowings, other financial liabilities, long-term debt and capital lease obligations | -72,101 | |||
Other liabilities | -39,923 | |||
Noncontrolling interests (subject and not subject to put provisions) | -169,651 | |||
Total acquisition cost | $ | 2,181,358 | ||
Less non-cash contributions at fair value | ||||
Investment at acquisition date | -201,915 | |||
Long-term Notes Receivable | -282,784 | |||
Total non-cash items | -484,699 | |||
Net Cash paid | $ | 1,696,659 | ||
The amortizable intangible assets acquired in this acquisition have weighted average useful lives of 6-8 years. | ||||
Goodwill, in the amount of $2,003,465 was acquired as part of the Liberty Acquisition and was allocated to the North America Segment. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Goodwill arises principally due to the fair value placed on an estimated stream of future cash flows versus building a similar franchise. Of the goodwill recognized in this acquisition, approximately $436,000 is deductible for tax purposes and is being amortized over a 15 year period which began on the date of the acquisition. | ||||
The noncontrolling interests acquired as part of the acquisition are stated at fair value based upon contractual multiples typically utilized by the Company for such arrangements as well as the Company's overall experience. | ||||
The fair valuation of the Company's investment at the time of the Liberty Acquisition resulted in a non-taxable gain of $139,600. The retirement of the loan receivable resulted in a benefit of $8,501. | ||||
Divestitures | ||||
In connection with the Federal Trade Commission's consent order relating to regulatory clearance of the Liberty Acquisition under the Hart-Scott-Rodino Antitrust Improvements Act, the Company agreed to divest a total of 62 renal dialysis centers. During 2012, 61 clinics were sold, 24 of which were FMC-AG & Co. KGaA legacy clinics which generated a gain of $33,455. During 2013, the remaining clinic required to be sold was sold for a gain of $7,705. The 38 clinics acquired and subsequently sold were categorized as Assets held for sale in the table above at the time of the Liberty Acquisition. | ||||
Acquisition_of_Liberty_Dialysi1
Acquisition of Liberty Dialysis Holdings- Pro Forma | 12 Months Ended |
Dec. 31, 2013 | |
Notes to Consolidated Financial Statements [Abstract] | ' |
Acquisition of Liberty Dialysis Holding | ' |
Pro Forma Financial Information | |
The following financial information, on a pro forma basis, reflects the consolidated results of operations as if the Liberty Acquisition and the divestitures described above had been consummated on January 1, 2011. The pro forma information includes adjustments primarily for elimination of the investment gain and the gain from the retirement of debt. The pro-forma financial information is not necessarily indicative of the results of operations as it would have been had the transactions been consummated on January 1, 2011. |
Acquisitions_And_Investments
Acquisitions And Investments | 12 Months Ended | ||||||
Dec. 31, 2013 | |||||||
Notes to Consolidated Financial Statements [Abstract] | ' | ||||||
Acquisitions and Investments | ' | ||||||
For the years ended December 31, | |||||||
2012 | 2011 | ||||||
Pro forma net revenue | $ | 13,900,540 | $ | 13,215,111 | |||
Pro forma net income attributable to shareholders of FMC - AG & Co. KGaA | 1,054,872 | 1,077,218 | |||||
Pro forma income per ordinary share | |||||||
Basic | $ | 3.46 | $ | 3.56 | |||
Fully diluted | $ | 3.44 | $ | 3.53 |
Related_Party_Transactions
Related Party Transactions | 12 Months Ended |
Dec. 31, 2012 | |
Notes to Consolidated Financial Statements [Abstract] | ' |
Related Party Transactions | ' |
3. Related Party Transactions | |
The Company's parent, Fresenius SE & Co. KGaA (“Fresenius SE”), a German partnership limited by shares owns 100% of the share capital of Fresenius Medical Care Management AG, the Company's general partner (“General Partner”). Fresenius SE is also the Company's largest shareholder and owned approximately 31.3% of the Company's shares at December 31, 2013, excluding the shares purchased through the Company's share buyback program as they are not considered to be outstanding shares (see Note 14). The Company has entered into certain arrangements for the purchase and sale of products and services with Fresenius SE or its subsidiaries and with certain of the Company's joint ventures as described in items a), b) and d) below. The Company's terms related to the receivables or payables for these products and services are generally consistent with the normal terms of the Company's business. Financing arrangements as described in item c) below normally have agreed upon terms which are determined at the time such financing transactions occur and usually reflect market rates at the time of the transaction. Our related party transactions are settled through Fresenius SE's cash management system where appropriate. | |
a) Service and Lease Agreements | |
The Company is party to service agreements with Fresenius SE and certain of its affiliates (collectively the “Fresenius SE Companies”) to receive services, including, but not limited to: administrative services, management information services, employee benefit administration, insurance, information technology services, tax services and treasury management services. In 2013, the Company entered into a new five year information technology services agreement, expiring in 2018, which has an automatic continuation for an additional 5 year period with short-term continuations thereafter unless either party terminates the agreement at the end of the then-current term. The Company has complied with all corporate governance procedures for this agreement. During 2013, 2012 and 2011, amounts charged by Fresenius SE Companies to the Company under the terms of these agreements were $103,577, $80,778 and $75,969, respectively. The Company also provides certain services to the Fresenius SE Companies, including research and development, central purchasing and warehousing. The Company charged $7,550, $5,810, $6,555 for services rendered to the Fresenius SE Companies during 2013, 2012 and 2011, respectively. | |
Under real estate operating lease agreements entered into with the Fresenius SE Companies, which are leases for the corporate headquarters in Bad Homburg, Germany and production sites in Schweinfurt and St. Wendel, Germany, the Company paid the Fresenius SE Companies $26,976, $25,179 and $25,833 during 2013, 2012 and 2011, respectively. The majority of the leases expire in 2016 and contain renewal options. | |
The Company's Articles of Association provide that the General Partner shall be reimbursed for any and all expenses in connection with management of the Company's business, including remuneration of the members of the General Partner's supervisory board and the members of the General Partner's management board (“Management Board”). The aggregate amount reimbursed to the General Partner was $16,327, $18,995 and $13,511, respectively, for its management services during 2013, 2012 and 2011 and included $159, $94 and $84, respectively, as compensation for its exposure to risk as general partner. The Company's Articles of Association set the annual compensation for assuming unlimited liability at 4% of the amount of the General Partner's share capital (€3,000). | |
b) Products | |
During 2013, 2012 and 2011 the Company sold products to the Fresenius SE Companies for $30,062, $22,098 and $20,220 respectively. During the same periods, the Company made purchases from the Fresenius SE Companies in the amount of $34,201, $46,072 and $52,587 respectively. | |
In addition to the purchases noted above, Fresenius Medical Care Holdings, Inc. (“FMCH”) currently purchases heparin supplied by Fresenius Kabi USA, Inc. (“Kabi USA”), through an independent group purchasing organization (“GPO”). Kabi USA is wholly-owned by Fresenius Kabi AG, a wholly-owned subsidiary of Fresenius SE. The Company has no direct supply agreement with Kabi USA and does not submit purchase orders directly to Kabi USA. During 2013, 2012 and 2011, FMCH acquired approximately $17,700, $14,136 and $24,106, respectively, of heparin from Kabi USA through the GPO contract, which was negotiated by the GPO at arm's length on behalf of all members of the GPO. | |
c) Financing Provided by and to Fresenius SE and the General Partner | |
The Company receives short-term financing from and provides short-term financing to Fresenius SE. In addition, the Company utilizes Fresenius SE's cash management system for the settlement of certain intercompany receivables and payables with its subsidiaries and other related parties. As of December 31, 2013 and December 31, 2012, the Company had accounts receivables from Fresenius SE in the amount of $112,568 and $120,071, respectively. As of December 31, 2013 and December 31, 2012, the Company had accounts payables to Fresenius SE in the amount of $102,731 and $82,029, respectively. The interest rate for these cash management arrangements are set on a daily basis and are based on the then-prevailing overnight reference rate for the respective currencies. | |
At December 31, 2013, the Company provided a loan to Fresenius SE of €4,400 ($6,068 at December 31, 2013) at an interest rate of 1.563%. This loan was repaid on January 3, 2014. | |
On August 19, 2009, the Company borrowed €1,500 ($2,069 at December 31, 2013) from the General Partner at 1.335%. The loan repayment has been extended periodically and is currently due August 20, 2014 with an interest rate of 1.796%. On November 28, 2013, the Company borrowed an additional €1,500 ($2,069 at December 31, 2013) from the General Partner at 1.875%. This loan is due on November 28, 2014. | |
At December 31, 2013, the Company borrowed CNY 352,372 ($58,204 at December 31, 2013) from a subsidiary of Fresenius SE at an interest rate of 6.1% and a maturity date of May 23, 2014. | |
For further information about short-term borrowings from and short-term financing provided to related parties at December 31, 2013, see Note 10. | |
d) Other | |
The Company performs clinical studies for certain of its joint ventures for which services the Company received $2,106, $7,432 and $9,355 in 2013, 2012, and 2011 respectively. In addition, the Company also performs marketing and distribution services for a joint venture for which services the Company received $19,541, $19,170 and $4,018 for 2013, 2012 and 2011, respectively. | |
At December 31, 2013 and 2012, a subsidiary of Fresenius SE held Senior Notes issued by the Company in the amount of €11,800 and €12,800 ($16,273 and $16,888), respectively. The respective Senior Notes have a coupon rate of 5.25% interest and were issued in 2011 and 2012. See Note 11 “Long-term Debt and Capital Lease Obligations and Long-term Debt from Related Parties-Senior Notes”. The Company paid interest related to these holdings in the amount of €678, €790, and €620 ($900, $1,015, and $863) during 2013, 2012 and 2011, respectively. | |
The Chairman of the Company's Supervisory Board is also the Chairman of the Supervisory Board of Fresenius SE and of the general partner of Fresenius SE. He is also a member of the Supervisory Board of the Company's General Partner. | |
The Vice Chairman of the Company's Supervisory Board is a member of the Supervisory Board of the general partner of Fresenius SE and Vice Chairman of the Supervisory Board of the Company's General Partner. He is also Chairman of the Advisory Board of a charitable foundation that is the sole shareholder of the general partner of Fresenius SE. He is also a partner in a law firm which provided services to the Company and certain of its subsidiaries. The Company incurred expenses in the amount of $1,268, $ 1,519, and $2,120 for these services during 2013, 2012, and 2011, respectively. Five of the six members of the Company's Supervisory Board, including the Chairman and Vice Chairman, are also members of the Supervisory Board of the Company's General Partner. | |
The Chairman of the Supervisory Board of the Company's general partner is also the Chairman of the Management Board of the general partner of Fresenius SE, and the Chairman and Chief Executive Officer of the Management Board of the Company's general partner is a member of the Management Board of the general partner of Fresenius SE. |
Inventories
Inventories | 12 Months Ended | ||||||
Dec. 31, 2013 | |||||||
Notes to Consolidated Financial Statements [Abstract] | ' | ||||||
Inventories | ' | ||||||
4. Inventories | |||||||
At December 31, 2013 and December 31, 2012, inventories consisted of the following: | |||||||
2013 | 2012 | ||||||
Finished goods | $ | 640,355 | $ | 627,338 | |||
Health care supplies | 195,519 | 154,840 | |||||
Raw materials and purchased components | 185,146 | 171,373 | |||||
Work in process | 76,084 | 83,258 | |||||
Inventories | $ | 1,097,104 | $ | 1,036,809 | |||
Under the terms of certain unconditional purchase agreements, the Company is obligated to purchase approximately $612,925 of materials, of which $337,027 is committed at December 31, 2013 for 2014. The terms of these agreements run 1 to 7 years. | |||||||
Healthcare supplies inventories at December 31, 2013 and 2012 included $33,294 and $29,704, respectively, of Erythropoietin ("EPO"). On January 1, 2012, the Company entered into a three-year sourcing and supply agreement with its EPO supplier. |
Prepaid_Expenses_and_Other_Cur
Prepaid Expenses and Other Current Assets | 12 Months Ended | ||||||
Dec. 31, 2013 | |||||||
Notes to Consolidated Financial Statements [Abstract] | ' | ||||||
Other Current Assets Disclosure [Text Block] | ' | ||||||
5. Prepaid Expenses and Other Current Assets | |||||||
At December 31, 2013 and 2012, prepaid expenses and other current assets consisted of the following: | |||||||
2013 | 2012 | ||||||
Taxes Refundable | $ | 133,673 | $ | 149,536 | |||
Cost Report Receivable from Medicare and Medicaid | 130,236 | 86,566 | |||||
Receivables for supplier rebates | 105,994 | 61,248 | |||||
Other deferred charges | 62,555 | 53,517 | |||||
Prepaid rent | 49,409 | 44,894 | |||||
Leases receivable | 48,538 | 46,198 | |||||
Prepaid insurance | 41,039 | 24,935 | |||||
Payments on account | 33,934 | 35,660 | |||||
Amounts due from managed locations | 22,676 | 17,298 | |||||
Receivable for sale of investment to third party | 21,846 | 16,527 | |||||
Deposit / Guarantee / Security | 19,212 | 20,903 | |||||
Derivatives | 16,664 | 31,235 | |||||
Other | 351,615 | 389,020 | |||||
Total prepaid expenses and other current assets | $ | 1,037,391 | $ | 977,537 | |||
The other item in the table above includes interest receivables, notes receivables and loans to customers |
Property_Plant_And_Equipment
Property, Plant And Equipment | 12 Months Ended | ||||||
Dec. 31, 2013 | |||||||
Notes to Consolidated Financial Statements [Abstract] | ' | ||||||
Property, Plant and Equipment | ' | ||||||
2013 | 2012 | ||||||
Land | $ | 46,689 | $ | 54,775 | |||
Buildings and improvements | 2,432,824 | 2,257,002 | |||||
Machinery and equipment | 3,808,356 | 3,470,972 | |||||
Machinery, equipment and rental equipment under capitalized leases | 43,239 | 36,316 | |||||
Construction in progress | 267,653 | 256,401 | |||||
6,598,761 | 6,075,466 | ||||||
Accumulated depreciation | -3,506,807 | -3,134,863 | |||||
Property, plant and equipment, net | $ | 3,091,954 | $ | 2,940,603 | |||
Depreciation expense for property, plant and equipment amounted to $555,125, $515,455 and $479,438 for the years ended December 31, 2013, 2012, and 2011, respectively. | |||||||
Included in machinery and equipment at December 31, 2013 and 2012 were $597,024 and $532,088, respectively, of peritoneal dialysis cycler machines which the Company leases to customers with end-stage renal disease on a month-to-month basis and hemodialysis machines which the Company leases to physicians under operating leases. | |||||||
Accumulated depreciation related to machinery, equipment and rental equipment under capital leases was $21,201 and $19,027 at December 31, 2013 and 2012, respectively. |
Intangible_Assets_and_Goodwill
Intangible Assets and Goodwill | 12 Months Ended | |||||||||||||||
Dec. 31, 2013 | ||||||||||||||||
Notes to Consolidated Financial Statements [Abstract] | ' | |||||||||||||||
Intangible Assets and Goodwill | ' | |||||||||||||||
7. Intangible Assets and Goodwill | ||||||||||||||||
At December 31, 2013 and 2012, the carrying value and accumulated amortization of intangible assets other than goodwill consisted of the following: | ||||||||||||||||
2013 | 2012 | |||||||||||||||
Gross | Gross | |||||||||||||||
Carrying | Accumulated | Carrying | Accumulated | |||||||||||||
Amount | Amortization | Amount | Amortization | |||||||||||||
Amortizable Intangible Assets | ||||||||||||||||
Non-compete agreements | $ | 325,335 | $ | -240,412 | $ | 317,080 | $ | -213,639 | ||||||||
Technology | 106,510 | -44,584 | 107,696 | -40,849 | ||||||||||||
Licenses and distribution agreements | 223,701 | -112,697 | 225,393 | -98,757 | ||||||||||||
Customer Relationships | 98,000 | -650 | - | - | ||||||||||||
Self-developed software | 105,087 | -46,097 | 72,328 | -32,496 | ||||||||||||
Other | 350,475 | -264,031 | 343,867 | -246,239 | ||||||||||||
Construction in progress | 39,570 | - | 57,677 | - | ||||||||||||
$ | 1,248,678 | $ | -708,471 | $ | 1,124,041 | $ | -631,980 | |||||||||
At December 31, 2013 and 2012 the carrying value of non-amortizable intangible assets other than goodwill consisted of the following: | ||||||||||||||||
2013 | 2012 | |||||||||||||||
Carrying | Carrying | |||||||||||||||
Amount | Amount | |||||||||||||||
Non-amortizable Intangible Assets | ||||||||||||||||
Tradename | $ | 210,630 | $ | 209,712 | ||||||||||||
Management contracts | 7,039 | 8,343 | ||||||||||||||
$ | 217,669 | $ | 218,055 | |||||||||||||
Total Intangible Assets | $ | 757,876 | $ | 710,116 | ||||||||||||
The amortization on intangible assets amounted to $93,100, $87,441 and $77,845 for the years ended December 31, 2013, 2012, and 2011, respectively. The table shows the estimated amortization expense of these assets for the following five years. | ||||||||||||||||
Estimated Amortization Expense | ||||||||||||||||
2014 | $ | 79,830 | ||||||||||||||
2015 | $ | 76,717 | ||||||||||||||
2016 | $ | 74,303 | ||||||||||||||
2017 | $ | 70,362 | ||||||||||||||
2018 | $ | 67,793 | ||||||||||||||
Goodwill | ||||||||||||||||
In 2013 and 2012, goodwill related to general manufacturing operations was reclassified from the North America and International Segments to Corporate (see Note 24). For the purpose of goodwill impairment testing, all corporate assets are allocated to the reporting units (see Note 1 e). | ||||||||||||||||
Changes in the carrying amount of goodwill are mainly a result of acquisitions and the impact of foreign currency translations. During 2013 and 2012, the Company's acquisitions consisted primarily of the acquisition of clinics in the normal course of operations, the expansion of the laboratory business in 2013 and in 2012, the Liberty Acquisition. The changes to goodwill in 2013 and 2012 are as follows: | ||||||||||||||||
North | Segment | |||||||||||||||
America | International | Total | Corporate | Total | ||||||||||||
Balance as of December 31, 2011 | $ | 7,314,622 | $ | 1,464,089 | $ | 8,778,711 | $ | 407,939 | $ | 9,186,650 | ||||||
Goodwill acquired, net of divestitures | 2,172,181 | 21,106 | 2,193,287 | - | 2,193,287 | |||||||||||
Reclassifications | - | -5,188 | -5,188 | 5,188 | - | |||||||||||
Foreign Currency Translation Adjustment | 210 | 41,352 | 41,562 | 390 | 41,952 | |||||||||||
Balance as of December 31, 2012 | $ | 9,487,013 | $ | 1,521,359 | $ | 11,008,372 | $ | 413,517 | $ | 11,421,889 | ||||||
Goodwill acquired, net of divestitures | 158,582 | 99,634 | 258,216 | - | 258,216 | |||||||||||
Reclassifications | - | -3,807 | -3,807 | 4,226 | 419 | |||||||||||
Foreign Currency Translation Adjustment | 52 | -23,029 | -22,977 | 640 | -22,337 | |||||||||||
Balance as of December 31, 2013 | $ | 9,645,647 | $ | 1,594,157 | $ | 11,239,804 | $ | 418,383 | $ | 11,658,187 |
Other_Assets_and_Notes_Receiva
Other Assets and Notes Receivable (Disclosure) | 12 Months Ended |
Dec. 31, 2013 | |
Notes to Consolidated Financial Statements [Abstract] | ' |
Other Assets Disclosure [Text Block] | ' |
8. Other Assets and Notes Receivables | |
On August 12, 2013, FMCH made an investment-type transaction by providing a credit facility to a middle-market dialysis provider in the amount of up to $200,000 to fund general corporate purposes. The transaction is in the form of subordinated notes with a maturity date of July 4, 2020 (unless prepaid) and a payment-in-kind (“PIK”) feature that will allow interest payments in the form of cash (at 10.75%) or PIK (at 11.75%). The PIK feature, if used, allows for the addition of the accrued interest to the then outstanding principal. The collateral for this loan is 100% of the equity interest in this middle-market dialysis provider. The availability period for drawdowns on this loan is 18 months ending on February 12, 2015 and amounts drawn, whether repaid or prepaid, cannot be re-borrowed. The Company assesses the recoverability of this investment based on quarterly financial statements and other information obtained, used for an assessment of profitability and business plan objectives, as well as by analyzing general economic and market conditions in which the provider operates. At December 31, 2013, $170,000 had been drawn ($165,542, net of commitment and closing fees) with $3,097 of interest income accrued. Interest is payable on a semi-annual basis for the length of the loan. The first interest payment was due and received on October 31, 2013. |
Accrued_Expenses_and_Other_Cur
Accrued Expenses and Other Current Liabilties | 12 Months Ended | |||||
Dec. 31, 2013 | ||||||
Notes to Consolidated Financial Statements [Abstract] | ' | |||||
Accrued Expenses and Other Current Liabilties | ' | |||||
9. Accrued Expenses and Other Current Liabilities | ||||||
At December 31, 2013 and 2012, accrued expenses and other current liabilities consisted of the following: | ||||||
2013 | 2012 | |||||
Accrued salaries, wages and incentive plan compensations | $ | 542,230 | $ | 481,920 | ||
Unapplied cash and receivable credits | 302,337 | 198,834 | ||||
Accrued insurance | 201,346 | 187,254 | ||||
Accrued interest | 122,166 | 111,532 | ||||
Special charge for legal matters | 115,000 | 115,000 | ||||
Accrued operating expenses | 102,914 | 91,529 | ||||
Withholding tax and VAT | 93,407 | 96,157 | ||||
Derivative financial instruments | 25,701 | 26,578 | ||||
Other | 507,432 | 478,667 | ||||
Total accrued expenses and other current liabilities | $ | 2,012,533 | $ | 1,787,471 | ||
In 2001, the Company recorded a $258,159 special charge to address legal matters relating to transactions pursuant to the Agreement and Plan of Reorganization dated at February 4, 1996 by and between W.R. Grace & Co. and Fresenius SE (the “Merger”), estimated liabilities and legal expenses arising in connection with the W.R. Grace & Co. Chapter 11 proceedings (the “Grace Chapter 11 Proceedings”) and the cost of resolving pending litigation and other disputes with certain commercial insurers. During the second quarter of 2003, the court supervising the Grace Chapter 11 Proceedings approved a definitive settlement agreement entered into among the Company, the committees representing the asbestos creditors and W.R. Grace & Co. Under the settlement agreement, the Company had agreed to pay $115,000, without interest, upon plan confirmation. On February 3, 2014, the plan was confirmed and became effective. The Company paid the $115,000 at that time. All other matters included in the special charge have now been resolved (see Note 20). | ||||||
Included in the other item in the table above are accruals for legal and compliance costs, physician compensation, commissions, short-term portion of pension liabilities, bonuses and rebates, accrued rents, and pending payments for purchase considerations for certain acquisitions. |
ShortTerm_Borrowings_and_Other
Short-Term Borrowings and Other Financial Liabilities, and Short-Term Borrowings from Related Parties | 12 Months Ended |
Dec. 31, 2013 | |
Notes to Consolidated Financial Statements [Abstract] | ' |
Short-Term Borrowings and Other Financial Liabilities, and Short-Term Borrowings from Related Parties | ' |
Short-term Borrowings under lines of credit | |
Short-term borrowings of $96,648 and $117,850 at December 31, 2013 and 2012, respectively, represented amounts borrowed by the Company's subsidiaries under lines of credit with commercial banks. The average interest rates on these borrowings at December 31, 2013 and 2012 were 4.00% and 4.93%, respectively. | |
Excluding amounts available under the 2012 Credit Agreement (see Note 11 below), at December 31, 2013 and 2012, the Company had $232,943 and $261,825 available under other commercial bank agreements. In some instances, lines of credit are secured by assets of the Company's subsidiary that is party to the agreement or may require the Company's guarantee. In certain circumstances, the subsidiary may be required to meet certain covenants. | |
Short-term Borrowings from related parties | |
From time to time during each of the years presented, the Company received advances under the existing loan agreements with Fresenius SE for those years. During the year ended December 31, 2013, the Company received advances ranging from €3,200 to €99,946 with interest rates ranging from 1.363% to 1.541%. During the year ended December 31, 2012, the Company received advances ranging from €8,300 to €196,400 with interest rates ranging from 1.365% to 1.838%. For further information on short-term borrowings from related party outstanding at December 31, 2013 and 2012, see Note 3 c. Annual interest expense on these borrowings during the years presented was $547, $1,458 and $2,362 for the years 2013, 2012 and 2011, respectively. |
Longterm_Debt_and_Capital_Leas
Long-term Debt and Capital Lease Obligations | 12 Months Ended | |||||||||||||||||||
Dec. 31, 2013 | ||||||||||||||||||||
Notes to Consolidated Financial Statements [Abstract] | ' | |||||||||||||||||||
Long-term Debt and Capital Lease Obligations | ' | |||||||||||||||||||
11. Long-term Debt and Capital Lease Obligations and Long-term Debt from Related Parties | ||||||||||||||||||||
As of December 31, 2013 and December 31, 2012, long-term debt and capital lease obligations and long-term debt from related parties consisted of the following: | ||||||||||||||||||||
31-Dec-13 | 31-Dec-12 | |||||||||||||||||||
2012 Credit Agreement | $ | 2,707,145 | $ | 2,659,340 | ||||||||||||||||
Senior Notes | 4,824,753 | 4,743,442 | ||||||||||||||||||
Euro Notes | 46,545 | 51,951 | ||||||||||||||||||
European Investment Bank Agreements | 193,074 | 324,334 | ||||||||||||||||||
Accounts receivable facility | 351,250 | 162,000 | ||||||||||||||||||
Capital lease obligations | 24,264 | 15,618 | ||||||||||||||||||
Other | 111,259 | 163,802 | ||||||||||||||||||
Long-term debt and capital lease obligations | 8,258,290 | 8,120,487 | ||||||||||||||||||
Less current maturities | -511,370 | -334,747 | ||||||||||||||||||
Long-term debt and capital lease obligations, less current portion | 7,746,920 | 7,785,740 | ||||||||||||||||||
Long-term debt from related parties | - | 56,174 | ||||||||||||||||||
Long-term debt and capital lease obligations and long-term debt from related parties | $ | 7,746,920 | $ | 7,841,914 | ||||||||||||||||
The Company's long-term debt, all of which ranks equally in rights of payment, consists mainly of borrowings related to its 2012 Credit Agreement, its Senior Notes, its Euro Notes, borrowings under its European Investment Bank Agreements, borrowings under its accounts receivable facility (“A/R Facility”) and certain other borrowings as follows: | ||||||||||||||||||||
2012 Credit Agreement | ||||||||||||||||||||
The Company entered into a $3,850,000 syndicated credit facility (the “2012 Credit Agreement”) with a large group of banks and institutional investors (collectively, the “Lenders”) on October 30, 2012 which replaced a prior credit agreement. The credit facility consists of: | ||||||||||||||||||||
a 5-year revolving credit facility of approximately $1,250,000 comprising a $400,000 multicurrency revolving facility, a $200,000 revolving facility and a €500,000 revolving facility which will be due and payable on October 30, 2017. | ||||||||||||||||||||
a 5-year term loan facility of originally $2,600,000, also scheduled to mature on October 30, 2017, requiring 17 quarterly payments of $50,000 each, which began in the third quarter of 2013 that permanently reduce the term loan facility. The remaining balance is due on October 30, 2017. | ||||||||||||||||||||
Interest on the credit facilities is, at the Company's option, at a rate equal to either (i) LIBOR or EURIBOR (as applicable) plus an applicable margin or (ii) the Base Rate as defined in the 2012 Credit Agreement plus an applicable margin. At December 31, 2013, the dollar-denominated tranches outstanding under the 2012 Credit Agreement had a weighted average interest rate of 2.00%. The euro-denominated tranche had an interest rate of 1.95%. | ||||||||||||||||||||
The applicable margin is variable and depends on the Company's Consolidated Leverage Ratio which is a ratio of its Consolidated Funded Debt less cash and cash equivalents held by the Consolidated Group to Consolidated EBITDA (as these terms are defined in the 2012 Credit Agreement). | ||||||||||||||||||||
In addition to scheduled principal payments, indebtedness outstanding under the 2012 Credit Agreement will be reduced by portions of the net cash proceeds received from certain sales of assets and the issuance of certain additional debt. | ||||||||||||||||||||
Obligations under the 2012 Credit Agreement are secured by pledges of capital stock of certain material subsidiaries in favor of the Lenders. | ||||||||||||||||||||
The 2012 Credit Agreement contains affirmative and negative covenants with respect to the Company and its subsidiaries and other payment restrictions. Certain of the covenants limit indebtedness of the Company and investments by the Company, and require the Company to maintain certain financial ratios defined in the agreement. Additionally, the 2012 Credit Agreement provides for a limitation on dividends and other restricted payments which is €330,000 ($455,103 based upon the December 31, 2013 spot rate) for dividends to be paid in 2014, and increases in subsequent years. In default, the outstanding balance under the 2012 Credit Agreement becomes immediately due and payable at the option of the Lenders. The Company was in compliance with all covenants at December 31, 2013. | ||||||||||||||||||||
The following table shows the available and outstanding amounts under the 2012 Credit Agreement at December 31, 2013 and 2012: | ||||||||||||||||||||
Maximum Amount Available December 31, 2013 | Balance Outstanding December 31, 2013 | |||||||||||||||||||
Revolving Credit USD | $ | 600,000 | $ | 600,000 | $ | 138,190 | $ | 138,190 | ||||||||||||
Revolving Credit EUR | € | 500,000 | $ | 689,550 | € | 50,000 | $ | 68,955 | ||||||||||||
Term Loan A | $ | 2,500,000 | $ | 2,500,000 | $ | 2,500,000 | $ | 2,500,000 | ||||||||||||
$ | 3,789,550 | $ | 2,707,145 | |||||||||||||||||
Maximum Amount Available December 31, 2012 | Balance Outstanding December 31, 2012 | |||||||||||||||||||
Revolving Credit USD | $ | 600,000 | $ | 600,000 | $ | 59,340 | $ | 59,340 | ||||||||||||
Revolving Credit EUR | € | 500,000 | $ | 659,700 | € | - | $ | - | ||||||||||||
Term Loan A | $ | 2,600,000 | $ | 2,600,000 | $ | 2,600,000 | $ | 2,600,000 | ||||||||||||
$ | 3,859,700 | $ | 2,659,340 | |||||||||||||||||
In addition, at December 31, 2013 and December 31, 2012, the Company had letters of credit outstanding in the amount of $9,444 and $77,188, respectively, under the revolving credit facility, which are not included above as part of the balance outstanding at those dates but which reduce available borrowings under the respective revolving credit facility. | ||||||||||||||||||||
Senior Notes | ||||||||||||||||||||
At December 31, 2013, the Company's Senior Notes consisted of the following: | ||||||||||||||||||||
Issuer/Transaction | Face Amount | Maturity | Coupon | Book value | ||||||||||||||||
FMC Finance VI S.A. 2010 | € | 250,000 | 15-Jul-16 | 5.50% | $ | 342,944 | ||||||||||||||
FMC Finance VIII S.A. 2011(1) | € | 100,000 | 15-Oct-16 | 3.73% | $ | 137,910 | ||||||||||||||
FMC US Finance, Inc. 2007 | $ | 500,000 | 15-Jul-17 | 6.88% | $ | 496,894 | ||||||||||||||
FMC Finance VIII S.A. 2011 | € | 400,000 | 15-Sep-18 | 6.50% | $ | 546,531 | ||||||||||||||
FMC US Finance II, Inc. 2011 | $ | 400,000 | 15-Sep-18 | 6.50% | $ | 396,297 | ||||||||||||||
FMC US Finance II, Inc. 2012 | $ | 800,000 | 31-Jul-19 | 5.63% | $ | 800,000 | ||||||||||||||
FMC Finance VIII S.A. 2012 | € | 250,000 | 31-Jul-19 | 5.25% | $ | 344,775 | ||||||||||||||
FMC US Finance, Inc. 2011 | $ | 650,000 | 15-Feb-21 | 5.75% | $ | 645,672 | ||||||||||||||
FMC Finance VII S.A. 2011 | € | 300,000 | 15-Feb-21 | 5.25% | $ | 413,730 | ||||||||||||||
FMC US Finance II, Inc. 2012 | $ | 700,000 | 31-Jan-22 | 5.88% | $ | 700,000 | ||||||||||||||
$ | 4,824,753 | |||||||||||||||||||
(1) This note carries a variable interest rate which was 3.73% at December 31, 2013. | ||||||||||||||||||||
In January 2012, $800,000 and $700,000 of dollar-denominated senior notes and €250,000 ($344,775 at December 31, 2013) of euro-denominated notes were issued at par. Both the $800,000 Senior Notes and the €250,000 euro-denominated Senior Notes are due July 31, 2019 while the $700,000 Senior Notes are due January 31, 2022. The proceeds were used for acquisitions and for general corporate purposes. | ||||||||||||||||||||
In October 2011, €100,000 ($137,910 at December 31, 2013) of floating rate senior notes were issued at par. These floating rate senior notes are due October 15, 2016. Proceeds were used for acquisitions, to refinance indebtedness and for general corporate purposes. | ||||||||||||||||||||
In September 2011, $400,000 of dollar-denominated senior notes and €400,000 ($546,531, net of discount, at December 31, 2013) of euro-denominated senior notes were issued at an issue price of 98.623%. Both the dollar- and euro-denominated senior notes have a coupon of 6.50% and a yield to maturity of 6.75% and mature on September 15, 2018. Proceeds were used for acquisitions, to refinance indebtedness and for general corporate purposes. | ||||||||||||||||||||
In February 2011, $650,000 of dollar-denominated senior notes and €300,000 ($413,730 at December 31, 2013) of euro-denominated senior notes were issued with coupons of 5.75% and 5.25%, respectively, at an issue price of 99.060% and par, respectively. The dollar-denominated senior notes had a yield to maturity of 5.875%. Both the dollar- and euro-denominated senior notes mature on February 15, 2021. Proceeds were used to repay indebtedness for acquisitions and for general corporate purposes. | ||||||||||||||||||||
In January 2010, €250,000 ($342,944, net of discount, at December 31, 2013) of senior notes were issued with a coupon of 5.50% at an issue price of 98.6636%. These senior notes had a yield to maturity of 5.75% and are due July 15, 2016. Proceeds were used to repay short-term indebtedness and for general corporate purposes. | ||||||||||||||||||||
In June 2007, FMC Finance III S.A. (“FMC Finance III”) issued $500,000 6 7/8% Senior Notes due 2017 (the “6 7/8% Senior Notes”). The 6 7/8% Notes were issued with a coupon of 6 7/8% at a discount, resulting in an effective interest rate of 7 1/8%. In June 2011, Fresenius Medical Care US Finance, Inc. acquired substantially all of the assets of FMC Finance III and assumed all obligations of FMC Finance III under the 6 7/8% Notes and the related indenture. The guarantees of the Company and its subsidiaries, FMCH and Fresenius Medical Care Deutschland GmbH (“D-GmbH”), (together, the “Guarantor Subsidiaries”) for the 6 7/8% Senior Notes have not been amended and remain in full force and effect. | ||||||||||||||||||||
All Senior Notes are unsecured and guaranteed on a senior basis jointly and severally by the Company and the Guarantor Subsidiaries. The issuers may redeem the Senior Notes (except for the Floating Rate Senior Notes) at any time at 100% of principal plus accrued interest and a premium calculated pursuant to the terms of the indenture. The holders have the right to request that the issuers repurchase the Senior Notes at 101% of principal plus accrued interest upon the occurrence of a change of control of the Company followed by a decline in the ratings of the respective Senior Notes. | ||||||||||||||||||||
The Company has agreed to a number of covenants to provide protection to the holders which, under certain circumstances, limit the ability of the Company and its subsidiaries to, among other things, incur debt, incur liens, engage in sale-leaseback transactions and merge or consolidate with other companies or sell assets. At December 31, 2013, the Company was in compliance with all of its covenants under the Senior Notes. | ||||||||||||||||||||
Euro Notes | ||||||||||||||||||||
In April 2009, the Company issued euro-denominated notes (“Euro Notes”) totaling €200,000, which are senior, unsecured and guaranteed by FMCH and D-GmbH, which originally consisted of 4 tranches having terms of 3.5 and 5.5 years with floating and fixed interest rate tranches. At December 31, 2013, only 2 tranches remain outstanding, which are due on April 27, 2014 and October 27, 2014. At December 31, 2013, the Company was in compliance with all of its covenants under the Euro Notes. At December 31, 2013, the Euro Notes had an outstanding balance of €33,750 ($46,545). | ||||||||||||||||||||
European Investment Bank Agreements | ||||||||||||||||||||
The Company entered into various credit agreements with the European Investment Bank (“EIB”) in 2005, 2006 and 2009. The EIB is a not-for-profit long-term lending institution of the European Union and lends funds at favourable rates for the purpose of capital investment and R&D projects, normally for up to half of the funds required for such projects. | ||||||||||||||||||||
Borrowings under the four EIB credit facilities available at December 31, 2013 and 2012 are shown below: | ||||||||||||||||||||
Balance outstanding | ||||||||||||||||||||
December 31, | ||||||||||||||||||||
Maturity | 2013 | 2012 | ||||||||||||||||||
Revolving Credit | 2013 | $ | - | $ | 90,812 | |||||||||||||||
Loan 2005 | 2013 | - | 48,806 | |||||||||||||||||
Loan 2006 | 2014 | 124,119 | 118,746 | |||||||||||||||||
Loan 2009 | 2014 | 68,955 | 65,970 | |||||||||||||||||
$ | 193,074 | $ | 324,334 | |||||||||||||||||
While the EIB agreements were granted in euro, advances under the Revolving Credit, Loan 2005 and Loan 2006 could be denominated in certain foreign currencies, including U.S. dollars. As a result, the borrowings under the Revolving Credit and Loan 2005 were drawn down in U.S. dollars, while the borrowings under Loan 2006 and Loan 2009 were drawn down in euro. | ||||||||||||||||||||
In 2013, both the Revolving Credit and Loan 2005 matured and have been repaid. The balances of the remaining two loans outstanding on December 31, 2013 had been classified as Current portion of Long-term debt and capital lease obligations and were repaid on their maturity on February 3, 2014 for the Loan 2006 and February 17, 2014 for the Loan 2009. | ||||||||||||||||||||
Loans 2006 and 2009 had variable interest rates that changed quarterly. The borrowings under these loan agreements had interest rates of 0.201% and 2.426% at December 31, 2013. At December 31, 2012, the dollar borrowings had an interest rate of 0.438% and the euro borrowings had interest rates of 0.171% and 2.40%, respectively. | ||||||||||||||||||||
Borrowings under the 2006 agreement were secured by bank guarantees while the 2009 agreement was guaranteed by FMCH and D-GmbH. EIB agreements had customary covenants. At December 31, 2013, the Company was in compliance with the respective covenants. | ||||||||||||||||||||
Accounts Receivable Facility | ||||||||||||||||||||
The Company refinanced the A/R Facility on January 17, 2013 for a term expiring on January 15, 2016 with the available borrowings at $800,000. At December 31, 2013 there were outstanding borrowings under the A/R Facility of $351,250. The Company also had letters of credit outstanding under the A/R Facility in the amount of $65,622 at December 31, 2013. These letters of credit were not included above as part of the balance outstanding at December 31, 2013; however, they reduced available borrowings under the A/R Facility. | ||||||||||||||||||||
Under the A/R Facility, certain receivables are sold to NMC Funding Corporation (“NMC Funding”), a wholly-owned subsidiary. NMC Funding then assigns percentage ownership interests in the accounts receivable to certain bank investors. Under the terms of the A/R Facility, NMC Funding retains the right, at any time, to recall all the then outstanding transferred interests in the accounts receivable. Consequently, the receivables remain on the Company's Consolidated Balance Sheet and the proceeds from the transfer of percentage ownership interests are recorded as long-term debt. | ||||||||||||||||||||
NMC Funding pays interest to the bank investors calculated based on the commercial paper rates for the particular tranches selected. The average interest rate during 2013 was 1.044%. Refinancing fees, which include legal costs and bank fees, are amortized over the term of the facility. | ||||||||||||||||||||
Other | ||||||||||||||||||||
At December 31, 2013 and 2012, in conjunction with certain acquisitions and investments, the Company had pending payments of purchase considerations totaling approximately $94,084 and $142,229, respectively, of which $60,036 and $75,266, respectively, were classified as the current portion of long-term debt. | ||||||||||||||||||||
Annual Payments | ||||||||||||||||||||
Aggregate annual payments applicable to the 2012 Credit Agreement, Senior Notes, Euro Notes, EIB agreements, capital leases, the A/R Facility and other borrowings for the five years subsequent to December 31, 2013 and thereafter are: | ||||||||||||||||||||
2014 | $ | 511,370 | ||||||||||||||||||
2015 | 233,589 | |||||||||||||||||||
2016 | 1,038,599 | |||||||||||||||||||
2017 | 2,613,096 | |||||||||||||||||||
2018 | 953,423 | |||||||||||||||||||
Thereafter | 2,926,290 | |||||||||||||||||||
$ | 8,276,367 | |||||||||||||||||||
Employee_Benefit_Plans
Employee Benefit Plans | 12 Months Ended | ||||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||||
Notes to Consolidated Financial Statements [Abstract] | ' | ||||||||||||||||||
Employee Benefit Plans | ' | ||||||||||||||||||
12. Employee Benefit Plans | |||||||||||||||||||
General | |||||||||||||||||||
FMC-AG & Co. KGaA recognizes pension costs and related pension liabilities for current and future benefits to qualified current and former employees of the Company. The Company's pension plans are structured in accordance with the differing legal, economic and fiscal circumstances in each country. The Company currently has two types of plans, defined benefit and defined contribution plans. In general, plan benefits in defined benefit plans are based on all or a portion of the employees' years of services and final salary. Plan benefits in defined contribution plans are determined by the amount of contribution by the employee and the employer, both of which may be limited by legislation, and the returns earned on the investment of those contributions. | |||||||||||||||||||
Upon retirement under defined benefit plans, the Company is required to pay defined benefits to former employees when the defined benefits become due. Defined benefit plans may be funded or unfunded. The Company has two major defined benefit plans, one funded plan in the U.S. and an unfunded plan in Germany. | |||||||||||||||||||
Actuarial assumptions generally determine benefit obligations under defined benefit plans. The actuarial calculations require the use of estimates. The main factors used in the actuarial calculations affecting the level of the benefit obligations are: assumptions on life expectancy, the discount rate and future salary and benefit levels. Under the Company's funded plans, assets are set aside to meet future payment obligations. An estimated return on the plan assets is recognized as income in the respective period. Actuarial gains and losses are generated when there are variations in the actuarial assumptions and by differences between the actual and the estimated projected benefits obligations and the return on plan assets for that year. The Company's pension liability is impacted by these actuarial gains or losses. | |||||||||||||||||||
Under defined contribution plans, the Company pays defined contributions to an independent third party as directed by the employee during the employee's service life, which satisfies all obligations of the Company to the employee. The employee retains all rights to the contributions made by the employee and to the vested portion of the Company paid contributions upon leaving the Company. The Company has a defined contribution plan in the U.S. | |||||||||||||||||||
Defined Benefit Pension Plans | |||||||||||||||||||
During the first quarter of 2002 FMCH, the Company's U.S. subsidiary, curtailed its defined benefit and supplemental executive retirement plans. Under the curtailment amendment for substantially all employees eligible to participate in the plan, benefits have been frozen as of the curtailment date and no additional defined benefits for future services will be earned. The Company has retained all employee benefit obligations as of the curtailment date. Each year FMCH contributes at least the minimum amount required by the Employee Retirement Income Security Act of 1974, as amended. In 2013, FMCH's minimum funding requirement was $6,100. In addition to the compulsory contributions, the Company voluntarily provided $5,239 to the defined benefit plan. Expected funding for 2014 is $42,585. | |||||||||||||||||||
The benefit obligation for all defined benefit plans at December 31, 2013, was $660,860 (2012: $655,447) which consists of the gross benefit obligation of $378,170 (2012: $423,509) for the U.S. plan, which is funded by plan assets, and the benefit obligation of $282,690 (2012: $231,938) for the German unfunded plan. | |||||||||||||||||||
The following table shows the changes in benefit obligations, the changes in plan assets, the funded status of the pension plans and the net pension liability. Benefits paid as shown in the changes in benefit obligations represent payments made from both the funded and unfunded plans while the benefits paid as shown in the changes in plan assets include only benefit payments from the Company's funded benefit plan. | |||||||||||||||||||
2013 | 2012 | ||||||||||||||||||
Change in benefit obligation: | |||||||||||||||||||
Benefit obligation at beginning of year | $ | 655,447 | $ | 512,745 | |||||||||||||||
Foreign currency translation | 11,998 | 4,955 | |||||||||||||||||
Other Adjustments | 2,203 | - | |||||||||||||||||
Service cost | 15,900 | 10,704 | |||||||||||||||||
Interest cost | 26,859 | 26,194 | |||||||||||||||||
Transfer of plan participants | -32 | -68 | |||||||||||||||||
Actuarial (gain) loss | -34,698 | 122,800 | |||||||||||||||||
Benefits paid | -16,817 | -21,883 | |||||||||||||||||
Benefit obligation at end of year | $ | 660,860 | $ | 655,447 | |||||||||||||||
Change in plan assets: | |||||||||||||||||||
Fair value of plan assets at beginning of year | $ | 228,393 | $ | 218,990 | |||||||||||||||
Actual return on plan assets | 23,058 | 18,356 | |||||||||||||||||
Employer contributions | 11,339 | 10,804 | |||||||||||||||||
Benefits paid | -14,295 | -19,757 | |||||||||||||||||
Fair value of plan assets at end of year | $ | 248,495 | $ | 228,393 | |||||||||||||||
Funded status at end of year | $ | 412,365 | $ | 427,054 | |||||||||||||||
Benefit plans offered by other subsidiaries | $ | 29,321 | $ | 35,798 | |||||||||||||||
Net Pension Liability | $ | 441,686 | $ | 462,852 | |||||||||||||||
The Company had a pension liability of $412,365 and $427,054 at December 31, 2013 and 2012, respectively. The pension liability consists of a current portion of $4,221 (2012: $3,693) which is recognized as a current liability in the line item “Accrued expenses and other current liabilities” in the balance sheet. The non-current portion of $408,144 (2012: $423,361) is recorded as non-current pension liability in the balance sheet. Approximately 80% of the beneficiaries are located in the U.S. with the majority of the remaining 20% located in Germany. | |||||||||||||||||||
The accumulated benefit obligation for all defined benefit pension plans was $614,576 and $616,572 at December 31, 2013 and 2012, respectively. The accumulated benefit obligation for all defined benefit pension plans with an obligation in excess of plan assets was $614,576 and $616,572 at December 31, 2013 and 2012, respectively; the related plan assets had a fair value of $248,495 and $228,393 at December 31, 2013 and 2012, respectively. | |||||||||||||||||||
Benefit plans offered by other subsidiaries outside of the U.S. and Germany contain separate benefit obligations. The total net pension liability for these other plans was $29,321 and $35,798 at December 31, 2013 and 2012 respectively and consists of a pension asset of $77 (2012: $74) recognized as “Other non-current assets and notes receivables” and a current pension liability of $1,684 (2012: $1,560), which is recognized as a current liability in the line item “Accrued expenses and other current liabilities”. The non-current pension liability of $27,714 (2012: $34,312) for these plans is recorded as “non-current pension liability” in the balance sheet. | |||||||||||||||||||
At December 31, 2013 the weighted average duration of the defined benefit obligation was 18 years (2012: 18 years). | |||||||||||||||||||
The table below reflects pre-tax effects of actuarial losses (gains) in other comprehensive income (“OCI”) relating to pension liabilities. At December 31, 2013, there are no cumulative effects of prior service costs included in other comprehensive income. | |||||||||||||||||||
Actuarial (gains) losses | |||||||||||||||||||
Actuarial (gains) losses recognized in OCI at December 31, 2010 | $ | 102,872 | |||||||||||||||||
Actuarial (gain) loss for the year | 91,693 | ||||||||||||||||||
Amortization of unrealized losses | -8,737 | ||||||||||||||||||
Foreign currency translation | -1,050 | ||||||||||||||||||
Actuarial (gains) losses recognized in OCI at December 31, 2011 | $ | 184,778 | |||||||||||||||||
Actuarial (gain) loss for the year | $ | 119,685 | |||||||||||||||||
Amortization of unrealized losses | -18,334 | ||||||||||||||||||
Foreign currency translation | 1,827 | ||||||||||||||||||
Actuarial (gains) losses recognized in OCI at December 31, 2012 | $ | 287,956 | |||||||||||||||||
Actuarial (gain) loss for the year | $ | -44,118 | |||||||||||||||||
Other Adjustments | 563 | ||||||||||||||||||
Amortization of unrealized losses | -25,418 | ||||||||||||||||||
Foreign currency translation | 3,984 | ||||||||||||||||||
Actuarial (gains) losses recognized in OCI at December 31, 2013 | $ | 222,967 | |||||||||||||||||
The actuarial loss expected to be amortized from other comprehensive income into net periodic pension cost over the next year is $16,541. | |||||||||||||||||||
The discount rates for all plans are based upon yields of portfolios of equity and highly rated debt instruments with maturities that mirror the plan's benefit obligation. The Company's discount rates at December 31, 2012 and at December 31, 2013 are the weighted average of these plans based upon their benefit obligations. The following weighted-average assumptions were utilized in determining benefit obligations at December 31: | |||||||||||||||||||
in % | 2013 | 2012 | |||||||||||||||||
Discount rate | 4.55 | 4.14 | |||||||||||||||||
Rate of compensation increase | 3.29 | 3.32 | |||||||||||||||||
Sensitivity analysis | |||||||||||||||||||
Increases and decreases in principal actuarial assumptions by 0,5 percentage points would affect the pension liability at December 31, 2013 as follows: | |||||||||||||||||||
0.5% increase | 0.5% decrease | ||||||||||||||||||
Discount rate | $ | -54,247 | $ | 62,866 | |||||||||||||||
Rate of compensation increase | 7,230 | -7,159 | |||||||||||||||||
Rate of pensions increase | 18,573 | -16,893 | |||||||||||||||||
The sensitivity analysis was calculated based on the average duration of the pension obligations determined at December 31, 2013. The calculations were performed isolated for each significant actuarial parameter, in order to show the effect on the fair value of the pension liability separately. | |||||||||||||||||||
The sensitivity analysis for compensation increases and for pension increases excludes the U.S. pension plan because it is frozen and therefore is not affected by changes from these two actuarial assumptions. | |||||||||||||||||||
The defined benefit pension plans' net periodic benefit costs are comprised of the following components for each of the years ended December 31: | |||||||||||||||||||
2013 | 2012 | 2011 | |||||||||||||||||
Components of net periodic benefit cost: | |||||||||||||||||||
Service cost | $ | 15,900 | $ | 10,704 | $ | 10,625 | |||||||||||||
Interest cost | 26,859 | 26,194 | 24,822 | ||||||||||||||||
Expected return on plan assets | -13,638 | -15,241 | -17,750 | ||||||||||||||||
Amortization of unrealized losses | 25,418 | 18,334 | 8,737 | ||||||||||||||||
Net periodic benefit costs | $ | 54,539 | $ | 39,991 | $ | 26,434 | |||||||||||||
Net periodic benefit cost is allocated as personnel expense within costs of revenues, selling, general and administrative expense or research and development expense. This is depending upon the area in which the beneficiary is employed. | |||||||||||||||||||
The following weighted-average assumptions were used in determining net periodic benefit cost for the year ended December 31: | |||||||||||||||||||
in % | 2013 | 2012 | 2011 | ||||||||||||||||
Discount rate | 4.14 | 5.1 | 5.7 | ||||||||||||||||
Expected return of plan assets | 6 | 7 | 7.5 | ||||||||||||||||
Rate of compensation increase | 3.32 | 3.69 | 4 | ||||||||||||||||
Expected benefit payments for the next five years and in the aggregate for the five years thereafter are as follows: | |||||||||||||||||||
2014 | $ | 17,824 | |||||||||||||||||
2015 | 19,294 | ||||||||||||||||||
2016 | 21,041 | ||||||||||||||||||
2017 | 22,963 | ||||||||||||||||||
2018 | 24,542 | ||||||||||||||||||
2019 - 2023 | 156,106 | ||||||||||||||||||
Plan Assets | |||||||||||||||||||
The following table presents the fair values of the Company´s pension plan assets at December 31, 2013 and 2012. | |||||||||||||||||||
Fair Value Measurements at December 31, 2013 | Fair Value Measurements at December 31, 2012 | ||||||||||||||||||
Quoted Prices in Active Markets for Identical Assets | Significant Observable Inputs | Quoted Prices in Active Markets for Identical Assets | Significant Observable Inputs | ||||||||||||||||
Asset Category | Total | (Level 1) | (Level 2) | Total | (Level 1) | (Level 2) | |||||||||||||
Equity Investments | |||||||||||||||||||
Index Funds(1) | $ | 62,003 | $ | 205 | $ | 61,798 | $ | 58,511 | $ | - | $ | 58,511 | |||||||
Fixed Income Investments | |||||||||||||||||||
Government Securities(2) | 4,913 | 3,735 | 1,178 | 9,859 | 8,504 | 1,355 | |||||||||||||
Corporate Bonds(3) | 155,389 | - | 155,389 | 152,332 | - | 152,332 | |||||||||||||
Other Bonds(4) | 1,437 | - | 1,437 | 457 | - | 457 | |||||||||||||
U.S. Treasury Money Market Funds(5) | 19,150 | 19,150 | - | 2,975 | 2,975 | - | |||||||||||||
Other types of investments | |||||||||||||||||||
Cash, Money Market and Mutual Funds(6) | 5,603 | 5,603 | - | 4,259 | 4,259 | - | |||||||||||||
Total | $ | 248,495 | $ | 28,693 | $ | 219,802 | $ | 228,393 | $ | 15,738 | $ | 212,655 | |||||||
(1) This category comprises low-cost equity index funds not actively managed that track the S&P 500, S&P 400, Russell 2000, MSCI Emerging Markets Index and the Morgan Stanley International EAFE Index | |||||||||||||||||||
(2) This Category comprises fixed income investments by the U.S. government and government sponsored entities | |||||||||||||||||||
(3) This Category primarily represents investment grade bonds of U.S. issuers from diverse industries | |||||||||||||||||||
(4) This Category comprises private placement bonds as well as collateralized mortgage obligations | |||||||||||||||||||
(5) This Category represents funds that invest in treasury obligations directly or in treasury backed obligations | |||||||||||||||||||
(6) This Category represents cash, money market funds as well as mutual funds comprised of high grade corporate bonds | |||||||||||||||||||
The methods and inputs used to measure the fair value of plan assets are as follows: | |||||||||||||||||||
Common stocks are valued at their market prices at the balance sheet date. | |||||||||||||||||||
Index funds are valued based on market quotes. | |||||||||||||||||||
Government bonds are valued based on both market prices and market quotes. | |||||||||||||||||||
Corporate bonds and other bonds are valued based on market quotes at the balance sheet date. | |||||||||||||||||||
Cash is stated at nominal value which equals the fair value. | |||||||||||||||||||
U.S. Treasury money market funds as well as other money market and mutual funds are valued at their market price. | |||||||||||||||||||
Plan Investment Policy and Strategy | |||||||||||||||||||
For the U.S. funded plan, the Company periodically reviews the assumption for long-term expected return on pension plan assets. As part of the assumptions review, a range of reasonable expected investment returns for the pension plan as a whole was determined based on an analysis of expected future returns for each asset class weighted by the allocation of the assets. The range of returns developed relies both on forecasts, which include the actuarial firm's expected long-term rates of return for each significant asset class or economic indicator, and on broad-market historical benchmarks for expected return, correlation, and volatility for each asset class. As a result, the Company's expected rate of return on pension plan assets was 6.00% for 2013. | |||||||||||||||||||
The Company´s overall investment strategy is to achieve a mix of approximately 96% of investments for long-term growth and 4% for near-term benefit payments with a wide diversification of asset types, fund strategies and fund managers. | |||||||||||||||||||
The investment policy, utilizing a revised target investment allocation of 30% equity and 70% long-term U.S. bonds, considers that there will be a time horizon for invested funds of more than 5 years. The total portfolio will be measured against a policy index that reflects the asset class benchmarks and the target asset allocation. The Plan policy does not allow investments in securities of the Company or other related party securities. The performance benchmarks for the separate asset classes include: S&P 500 Index, S&P 400 Index, Russell 2000 Growth Index, MSCI EAFE Index, MSCI Emerging Markets Index, Barclays Capital Long Term Government Index and Barclays Capital US Strips 20+ Year Index. | |||||||||||||||||||
Defined Contribution Plans | |||||||||||||||||||
Most FMCH employees are eligible to join a 401(k) savings plan. Employees can deposit up to 75% of their pay up to a maximum of $17.5 if under 50 years old ($23 if 50 or over) under this savings plan. The Company will match 50% of the employee deposit up to a maximum Company contribution of 3% of the employee's pay. The Company's total expense under this defined contribution plan for the years ended December 31, 2013, 2012, and 2011, was $38,999, $38,582 and $33,741, respectively. |
Noncontrolling_Interests_Subje
Noncontrolling Interests Subject to Put Provisions | 12 Months Ended | |||||||||
Dec. 31, 2013 | ||||||||||
Notes to Consolidated Financial Statements [Abstract] | ' | |||||||||
Noncontrolling Interests Subject to Put Provisions | ' | |||||||||
13. Noncontrolling Interests Subject to Put Provisions | ||||||||||
The Company has potential obligations to purchase the noncontrolling interests held by third parties in certain of its consolidated subsidiaries. These obligations are in the form of put provisions and are exercisable at the third-party owners' discretion within specified periods as outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase all or part of third-party owners' noncontrolling interests at the appraised fair value at the time of exercise. The methodology the Company uses to estimate the fair values of the noncontrolling interest subject to put provisions assumes the greater of net book value or a multiple of earnings, based on historical earnings, development stage of the underlying business and other factors. The estimated fair values of the noncontrolling interests subject to these put provisions can also fluctuate and the implicit multiple of earnings at which these noncontrolling interest obligations may ultimately be settled could vary significantly from our current estimates depending upon market conditions. | ||||||||||
At December 31, 2013 and December 31, 2012 the Company's potential obligations under these put options were $648,251 and $523,260, respectively, of which, at December 31, 2013, put options with an aggregate purchase obligation of $275,468 were exercisable. In the last three fiscal years ending December 31, 2013, three such put provisions have been exercised for a total consideration of $7,105. | ||||||||||
The following is a roll forward of noncontrolling interests subject to put provisions for the years ended December 31, 2013, 2012 and 2011: | ||||||||||
2013 | 2012 | 2011 | ||||||||
Beginning balance at January 1, | $ | 523,260 | $ | 410,491 | $ | 279,709 | ||||
Contributions to noncontrolling interests | -122,179 | -114,536 | -43,104 | |||||||
Purchase/ sale of noncontrolling interests | 6,723 | 134,643 | 37,786 | |||||||
Contributions from noncontrolling interests | 17,767 | 16,565 | 7,222 | |||||||
Changes in fair value of noncontrolling interests | 108,575 | -18,880 | 86,233 | |||||||
Net income | 113,156 | 94,718 | 42,857 | |||||||
Other comprehensive income (loss) | 949 | 259 | -212 | |||||||
Ending balance at December 31, | $ | 648,251 | $ | 523,260 | $ | 410,491 | ||||
2013 | 2012 | 2011 | ||||||||
Beginning balance at January 1, | $ | 523,260 | $ | 410,491 | $ | 279,709 | ||||
Contributions to noncontrolling interests | -122,179 | -114,536 | -43,104 | |||||||
Purchase/ sale of noncontrolling interests | 6,723 | 134,643 | 37,786 | |||||||
Contributions from noncontrolling interests | 17,767 | 16,565 | 7,222 | |||||||
Changes in fair value of noncontrolling interests | 108,575 | -18,880 | 86,233 | |||||||
Net income | 113,156 | 94,718 | 42,857 | |||||||
Other comprehensive income (loss) | 949 | 259 | -212 | |||||||
Ending balance at December 31, | $ | 648,251 | $ | 523,260 | $ | 410,491 |
Shareholders_Equity
Shareholders' Equity | 12 Months Ended | ||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||
Notes to Consolidated Financial Statements [Abstract] | ' | ||||||||||||||||
Shareholders' Equity | ' | ||||||||||||||||
14. Shareholders' Equity | |||||||||||||||||
Capital Stock | |||||||||||||||||
The General Partner has no equity interest in the Company and, therefore, does not participate in either the assets or the profits and losses of the Company. However, the General Partner is compensated for all outlays in connection with conducting the Company's business, including the remuneration of members of the management board and the supervisory board (see Note 3). | |||||||||||||||||
The general meeting of a partnership limited by shares may approve Authorized Capital (genehmigtes Kapital). The resolution creating Authorized Capital requires the affirmative vote of a majority of three quarters of the capital represented at the vote and may authorize the management board to issue shares up to a stated amount for a period of up to five years. The nominal value of any proposed increase of the Authorized Capital may not exceed half of the issued capital stock at the time of the authorization. | |||||||||||||||||
In addition, the general meeting of a partnership limited by shares may create Conditional Capital (bedingtes Kapital) for the purpose of issuing (i) shares to holders of convertible bonds or other securities which grant a right to shares, (ii) shares as the consideration in a merger with another company, or (iii) shares offered to management or employees. In each case, the authorizing resolution requires the affirmative vote of a majority of three quarters of the capital represented at the vote. The nominal value for any proposed increase of the Conditional Capital may not exceed half or, in the case of Conditional Capital created for the purpose of issuing shares to management and employees, 10% of the Company's issued capital at the time of the resolution. | |||||||||||||||||
All resolutions increasing the capital of a partnership limited by shares also require the consent of the General Partner for their effectiveness. | |||||||||||||||||
During the Annual General Meeting (“AGM”) and the Preference Shareholder Meeting held on May 16, 2013, resolutions were passed on the conversion of the Company's preference shares to ordinary shares. The preference share conversion was effected on June 28, 2013 with 3,975,533 preference shares in the amount of €3,976 ($4,465) converted on a 1:1 basis to ordinary shares. In addition, 32,006 options associated with the preference shares were converted into options associated with ordinary shares. At the time of preference share conversion, there were no dividend arrearages. | |||||||||||||||||
On July 5, 2013, the Company received a €27,000 ($34,784) premium from the largest former preference shareholder, a European financial institution, for the conversion of their preference shares to ordinary shares. This amount was recorded as an increase in equity. | |||||||||||||||||
Authorized Capital | |||||||||||||||||
By resolution of the AGM on May 11, 2010, the General Partner was authorized, with the approval of the supervisory board, to increase, on one or more occasions, the Company's share capital until May 10, 2015 up to a total of €35,000 through issue of new bearer ordinary shares for cash contributions, “Authorized Capital 2010/I”. Additionally, the newly issued shares may be taken up by financial institutions nominated by the General Partner with the obligation to offer them to the shareholders of the Company (indirect pre-emption rights). The General Partner is entitled, subject to the approval of the supervisory board, to exclude the pre-emption rights of the shareholders. However, such an exclusion of pre-emption rights will be permissible for fractional amounts. No Authorized Capital 2010/I has been issued at December 31, 2013. | |||||||||||||||||
In addition, by resolution of the AGM of shareholders on May 11, 2010, the General Partner was authorized, with the approval of the supervisory board, to increase, on one or more occasions, the share capital of the Company until May 10, 2015 up to a total of €25,000 through the issue of new bearer ordinary shares for cash contributions or contributions in kind, “Authorized Capital 2010/II”. The General Partner is entitled, subject to the approval of the supervisory board, to exclude the pre-emption rights of the shareholders. However, such exclusion of pre-emption rights will be permissible only if (i) in case of a capital increase against cash contributions, the nominal value of the issued shares does not exceed 10% of the nominal share value of the Company's share capital and the issue price for the new shares is at the time of the determination by the General Partner not significantly lower than the stock price in Germany of the existing listed shares of the same class and with the same rights or, (ii) in case of a capital increase against contributions in kind, the purpose of such increase is to acquire an enterprise, parts of an enterprise or an interest in an enterprise. No Authorized Capital 2010/II has been issued at December 31, 2013. | |||||||||||||||||
Authorized Capital 2010/I and Authorized Capital 2010/II became effective upon registration with the commercial register of the local court in Hof an der Saale on May 25, 2010. | |||||||||||||||||
Conditional Capital | |||||||||||||||||
By resolution of the Company's AGM on May 12, 2011, the Company's share capital was conditionally increased with regards to the 2011 Stock Option Plan (“2011 SOP”) by up to €12,000 subject to the issue of up to twelve million non-par value bearer ordinary shares with a nominal value of €1.00 each. For further information, see Note 17. | |||||||||||||||||
By resolution of the Company's AGM on May 9, 2006, as amended by the AGM on May 15, 2007, resolving a three-for-one share split, the Company's share capital was conditionally increased by up to €15,000 corresponding to 15 million ordinary shares with no par value and a nominal value of €1.00. This Conditional Capital increase can only be effected by the exercise of stock options under the Company's Stock Option Plan 2006 with each stock option awarded exercisable for one ordinary share (see Note 17). The Company has the right to deliver ordinary shares that it owns or purchases in the market in place of increasing capital by issuing new shares. | |||||||||||||||||
Through the Company's other employee participation programs, the Company has issued convertible bonds and stock option/subscription rights (Bezugsrechte) to employees and the members of the Management Board of the General Partner and employees and members of management of affiliated companies that entitle these persons to receive shares. At December 31, 2013, 10,790,755 convertible bonds or options remained outstanding with a remaining average term of 4.83 years under these programs. For the year ending December 31, 2013, 2,282,639 options had been exercised under these employee participation plans (see Note 17). | |||||||||||||||||
As the result of the Company's three-for-one stock split for both then-outstanding preference and ordinary shares, which was approved by the shareholders at the AGM on May 15, 2007, on June 15, 2007 the Company's Conditional Capital was increased by $6,557 (€4,454). Conditional Capital available for all programs at December 31, 2013 is $32,364 (€23,467) which includes $16,549 (€12,000) for the 2011 SOP, $10,425 (€7,559) for the 2006 Plan and $5,390 (€3,908) for the 2001 Plan (see Note 17). | |||||||||||||||||
Treasury Stock | |||||||||||||||||
By resolution of the Company's AGM on May 12, 2011, the Company was authorized to conduct a share buy-back program to repurchase ordinary shares. On April 4, 2013, the Company issued an ad hoc announcement of a share buy-back program in the aggregate value of up to €385,000 (approximately $500,000). The buy-back started on May 20, 2013 and was completed on August 14, 2013 after 7,548,951 shares had been repurchased in the amount of €384,966 ($505,014). These shares are restricted treasury stock which means there are no associated dividends or voting rights. These treasury shares will be used solely to either reduce the registered share capital of the Company by cancellation of the acquired shares, or to fulfill employee participation programs of the Company. | |||||||||||||||||
The following tabular disclosure provides the monthly detail of shares repurchased during the buy-back program, which ended on August 14, 2013: | |||||||||||||||||
Period | Average price paid per share | Total number of shares purchased as part of publicly announced plans or programs | Total Value of Shares Repurchased | ||||||||||||||
in € | in $(1) | in €(3) | in $(2), (3) | ||||||||||||||
in thousands | |||||||||||||||||
May-13 | 52.96 | 68.48 | 1,078,255 | 57,107 | 73,842 | ||||||||||||
Jun-13 | 53.05 | 69.95 | 2,502,552 | 132,769 | 175,047 | ||||||||||||
Jul-13 | 49.42 | 64.63 | 2,972,770 | 146,916 | 192,124 | ||||||||||||
Aug-13 | 48.4 | 64.3 | 995,374 | 48,174 | 64,001 | ||||||||||||
Total | 51 | 66.9 | 7,548,951 | 384,966 | 505,014 | ||||||||||||
(1) The dollar value is calculated using the daily exchange rate for the share repurchases made during the month. | |||||||||||||||||
(2) The value of the shares repurchased in Dollar is calculated using the total value of the shares purchased in Euro converted using the daily exchange rate for the transactions. | |||||||||||||||||
(3) This amount is inclusive of fees (net of taxes) paid in the amount of approximately $106 (€81) for services rendered. | |||||||||||||||||
Dividends | |||||||||||||||||
Under German law, the amount of dividends available for distribution to shareholders is based upon the unconsolidated retained earnings of Fresenius Medical Care AG & Co. KGaA as reported in its balance sheet determined in accordance with the German Commercial Code (Handelsgesetzbuch). In addition, the payment of dividends by FMC-AG & Co. KGaA is subject to limitations under the 2012 Credit Agreement (see Note 11). | |||||||||||||||||
Cash dividends of $296,134 for 2012 in the amount of €0.77 per then-outstanding preference share and €0.75 per ordinary share were paid on May 17, 2013. | |||||||||||||||||
Cash dividends of $271,733 for 2011 in the amount of €0.71 per preference share and €0.69 per ordinary share were paid on May 11, 2012. | |||||||||||||||||
Cash dividends of $280,649 for 2010 in the amount of €0.67 per preference share and €0.65 per ordinary share were paid on May 13, 2011. |
Sources_Of_Revenue
Sources Of Revenue | 12 Months Ended | ||||||
Dec. 31, 2013 | |||||||
Notes to Consolidated Financial Statements [Abstract] | ' | ||||||
Sources of Revenue | ' | ||||||
15. Sources of Revenue | |||||||
Below is a table showing the sources of our U.S. patient service revenue (net of contractual allowance and discounts but before patient service bad debt provision), included in the Company's dialysis care revenue, for the years ended December 31, 2013 and 2012. Outside of the U.S., the Company does not recognize patient service revenue at the time the services are rendered without assessing the patient's ability to pay. Accordingly, the additional disclosure requirements introduced with ASU 2011-07 only apply to the U.S. patient service revenue. | |||||||
2013 | 2012 | ||||||
Medicare ESRD program | $ | 4,411,285 | $ | 4,029,773 | |||
Private/alternative payors | 3,841,473 | 3,605,081 | |||||
Medicaid and other government sources | 392,908 | 474,520 | |||||
Hospitals | 411,340 | 400,791 | |||||
Total patient service revenue | $ | 9,057,006 | $ | 8,510,165 |
Earnings_Per_Share
Earnings Per Share | 12 Months Ended | |||||||||||||||||
Dec. 31, 2013 | ||||||||||||||||||
Notes to Consolidated Financial Statements [Abstract] | ' | |||||||||||||||||
Earnings Per Share | ' | |||||||||||||||||
16. Earnings Per Share | ||||||||||||||||||
The following table contains reconciliations of the numerators and denominators of the basic and diluted earnings per ordinary share computations for 2013, 2012 and 2011: | ||||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||||
Numerators: | ||||||||||||||||||
Net income attributable to shareholders of FMC-AG & Co. KGaA | $ | 1,109,890 | $ | 1,186,809 | $ | 1,071,154 | ||||||||||||
less: | ||||||||||||||||||
Dividend preference on Preference shares(a) | - | 102 | 110 | |||||||||||||||
Income available to all classes of shares | $ | 1,109,890 | $ | 1,186,707 | $ | 1,071,044 | ||||||||||||
Denominators: | ||||||||||||||||||
Weighted average number of: | ||||||||||||||||||
Ordinary shares outstanding | 301,877,303 | 301,139,652 | 299,012,744 | |||||||||||||||
Preference shares outstanding | 1,937,819 | 3,969,307 | 3,961,617 | |||||||||||||||
Total weighted average shares outstanding | 303,815,122 | 305,108,959 | 302,974,361 | |||||||||||||||
Potentially dilutive Ordinary shares | 673,089 | 1,761,064 | 1,795,743 | |||||||||||||||
Potentially dilutive Preference shares(a) | - | 16,851 | 20,184 | |||||||||||||||
Total weighted average Ordinary shares outstanding assuming dilution | 302,550,392 | 302,900,716 | 300,808,487 | |||||||||||||||
Total weighted average Preference shares outstanding assuming dilution | 1,937,819 | 3,986,158 | 3,981,801 | |||||||||||||||
Basic earnings per share | $ | 3.65 | $ | 3.89 | $ | 3.54 | ||||||||||||
Fully diluted earnings per share | $ | 3.65 | $ | 3.87 | $ | 3.51 | ||||||||||||
(a) As of the preference share conversion on June 28th, 2013, the Company no longer has two classes of shares. |
Stock_Options
Stock Options | 12 Months Ended | |||||||||||
Dec. 31, 2013 | ||||||||||||
Notes to Consolidated Financial Statements [Abstract] | ' | |||||||||||
Stock Options | ' | |||||||||||
17. Stock Options | ||||||||||||
In connection with its equity-settled stock option programs, the Company incurred compensation expense of $13,593, $26,476 and $29,071 for the years ending December 31, 2013, 2012, and 2011, respectively. There were no capitalized compensation costs in any of the three years presented. The Company also recorded a related deferred income tax of $3,828, $6,854 and $8,195 for the years ending December 31, 2013, 2012, and 2011, respectively. | ||||||||||||
Stock Options and other Share-Based Plans | ||||||||||||
At December 31, 2013, the Company has various stock-based compensation plans as follows: | ||||||||||||
Fresenius Medical Care AG & Co. KGaA Long Term Incentive Program 2011 | ||||||||||||
On May 12, 2011, the Fresenius Medical Care AG & Co. KGaA Stock Option Plan 2011 (“2011 SOP”) was established by resolution of the Company's AGM. The 2011 SOP, together with the Phantom Stock Plan 2011, which was established by resolution of the General Partner's Management and Supervisory Boards, forms the Company's Long Term Incentive Program 2011 (“2011 Incentive Program”). Under the 2011 Incentive Program, participants may be granted awards, which will consist of a combination of stock options and phantom stock. Awards under the 2011 Incentive Program will be granted over a five year period and can be granted on the last Monday in July and/or the first Monday in December each year. Prior to the respective grants, participants will be able to choose how much of the granted value is granted in the form of stock options and phantom stock in a predefined range of 75:25 to 50:50, stock options vs. phantom stock. The number of phantom shares that plan participants may choose to receive instead of stock options within the aforementioned predefined range is determined on the basis of a fair value assessment pursuant to a binomial model. With respect to grants made in July, this fair value assessment will be conducted on the day following the Company's AGM and with respect to the grants made in December, on the first Monday in October. Awards under the 2011 Incentive Program are subject to a four-year vesting period. Vesting of the awards granted is subject to achievement of performance targets. The 2011 Incentive Program was established with a conditional capital increase up to €12,000 subject to the issue of up to twelve million non-par value bearer ordinary shares with a nominal value of €1.00, each of which can be exercised to obtain one ordinary share. | ||||||||||||
The Management Board, members of the management boards of the Company's affiliated companies and the managerial staff members of the Company and of certain affiliated companies are entitled to participate in the 2011 Incentive Program. With respect to participants who are members of the Management Board, the General Partner's Supervisory Board has sole authority to grant awards and exercise other decision making powers under the 2011 Incentive Program (including decisions regarding certain adjustments and forfeitures). The General Partner has such authority with respect to all other participants in the 2011 Incentive Program. | ||||||||||||
The exercise price of stock options granted under the 2011 Incentive Program shall be the average stock exchange price on the Frankfurt Stock Exchange of the Company's shares during the 30 calendar days immediately prior to each grant date. Stock options granted under the 2011 Incentive Program have an eight-year term and can be exercised only after a four-year vesting period. Stock options granted under the 2011 Incentive Program to U.S. participants are non-qualified stock options under the United States Internal Revenue Code of 1986, as amended. Options under the 2011 Incentive Program are not transferable by a participant or a participant's heirs, and may not be pledged, assigned, or disposed of otherwise. | ||||||||||||
Phantom stock awards under the 2011 Incentive Program entitle the holders to receive payment in Euro from the Company upon exercise of the phantom stock. The payment per phantom share in lieu of the issuance of such stock shall be based upon the share price on the Frankfurt Stock Exchange of one of the Company's shares on the exercise date. Phantom stock awards have a five-year term and can be exercised only after a four-year vesting period, beginning with the grant date, however a shorter period may apply for certain exceptions. For participants who are U.S. tax payers, the phantom stock is deemed to be exercised in any event in the month of March following the end of the vesting period. | ||||||||||||
During 2013, under the 2011 Incentive Program, the Company awarded 2,141,076 stock options, including 328,680 stock options granted to the Management Board, at an average exercise price of $68.61 (€49.75), an average fair value of $11.88 each and a total fair value of $25,431 which will be amortized over the four-year vesting period. The Company also awarded 186,392 shares of phantom stock, including 25,006 shares of phantom stock granted to members of the Management Board at a measurement date average fair value of $66.50 (€48.22) each and a total fair value of $12,395, which will be revalued if the fair value changes, and amortized over the four-year vesting period. | ||||||||||||
During 2012, the Company awarded 2,166,035 stock options under the 2011 Incentive Program, including 310,005 stock options granted to the Management Board at an average exercise price of $75.41 (€57.15), an average fair value of $15.48 each and a total fair value of $33,538, which will be amortized over the four-year vesting period. The Company awarded 178,729 phantom shares, including 23,407 phantom shares granted to the Management Board at a measurement date average fair value of $64.58 (€48.95) each and a total fair value of $11,543 which will be revalued if the fair value changes, and amortized over the four year vesting period. | ||||||||||||
Incentive plan | ||||||||||||
In 2013, the Management Board was eligible for performance–related compensation that depended upon achievement of targets. The targets are measured by reference to operating income margin, net income growth and free cash flow (net cash provided by operating activities after capital expenditures before acquisitions and investments) in percentage of revenue, and are derived from the comparison of targeted and actually achieved current year figures. Targets are divided into Group level targets and those to be achieved in individual regions and areas of responsibility. | ||||||||||||
Performance-related bonuses for fiscal year 2013 will consist proportionately of a cash component and a share-based component which will be paid in cash. Upon meeting the annual targets, the cash component will be paid after the end of 2013. The share-based component is subject to a three- or four-year vesting period, although a shorter period may apply in special cases. The amount of cash for the payment relating to the share-based component shall be based on the closing share price of Fresenius Medical Care AG & Co. KGaA ordinary shares upon exercise. The amount of the achievable bonus for each of the members of the Management Board is capped. | ||||||||||||
Share-based compensation incurred under this plan for years 2013, 2012 and 2011 was $1,110, $2,751 and $2,306, respectively. | ||||||||||||
Fresenius Medical Care AG & Co. KGaA Stock Option Plan 2006 | ||||||||||||
The Fresenius Medical Care AG & Co. KGaA Stock Option Plan 2006 (“Amended 2006 Plan”) was established with a conditional capital increase up to €12,800, subject to the issue of up to five million non-par value bearer ordinary shares with a nominal value of €1.00, each of which can be exercised to obtain one ordinary share. In connection with the share split affected in 2007, the principal amount was adjusted to the same proportion as the share capital out of the capital increase up to €15,000 by the issue of up to 15 million new non-par value bearer ordinary shares. After December 2010, no further grants were issued under the Amended 2006 Plan. Options granted under this plan are exercisable through December 2017. | ||||||||||||
Options granted under the Amended 2006 Plan to US participants are non-qualified stock options under the United States Internal Revenue Code of 1986, as amended. Options under the Amended 2006 Plan are not transferable by a participant or a participant's heirs, and may not be pledged, assigned, or otherwise disposed of. | ||||||||||||
Fresenius Medical Care 2001 International Stock Option Plan | ||||||||||||
Under the Fresenius Medical Care 2001 International Stock Incentive Plan (the “2001 Plan”), options in the form of convertible bonds with a principal of up to €10,240 were issued to the Management Board and other employees of the Company representing grants for up to 4 million non-voting preference shares. The convertible bonds originally had a par value of €2.56 and bear interest at a rate of 5.5%. In connection with the share split affected in 2007, the principal amount was adjusted in the same proportion as the share capital out of the capital increase and the par value of the convertible bonds was adjusted to €0.85 without affecting the interest rate. | ||||||||||||
Based on the resolution of the Annual General Meeting and the separate Meeting of the Preference Shareholders on May 16, 2013 regarding the conversion of all preference shares into ordinary shares, the 2001 Plan was amended accordingly. The partial amount of the capital increase which was formerly referred to as the issuance of bearer preference shares will now be referred exclusively to the issuance of bearer ordinary shares. | ||||||||||||
Effective May 2006, no further grants can be issued under the 2001 Plan and no options were granted under this plan after 2005. The outstanding options will expire before 2016. | ||||||||||||
Additional stock option plans information | ||||||||||||
At December 31, 2013, the Management Board held 1,993,305 stock options and employees of the Company held 8,797,450 stock options under the various stock-based compensation plans of the Company. No stock options for preference shares were outstanding, due to the preference share conversion during the second quarter of 2013. | ||||||||||||
At December 31, 2013, the Management Board held 77,886 phantom shares and employees of the Company held 474,901 phantom shares under the 2011 Incentive Plan. | ||||||||||||
The table below provides reconciliations for stock options outstanding at December 31, 2013, as compared to December 31, 2012. | ||||||||||||
Weighted | Weighted | |||||||||||
average | average | |||||||||||
Options | exercise | exercise | ||||||||||
(in thousands) | price | price | ||||||||||
Stock options for ordinary shares | € | $ | ||||||||||
Balance at December 31, 2012 | 11,147 | 42.66 | 58.83 | |||||||||
Granted | 2,141 | 49.75 | 68.61 | |||||||||
Exercised | 2,280 | 33.76 | 46.56 | |||||||||
Converted from preference shares | 32 | 18.86 | 26.01 | |||||||||
Forfeited | 249 | 44.75 | 61.71 | |||||||||
Balance at December 31, 2013 | 10,791 | 45.83 | 63.2 | |||||||||
Stock options for preference shares | ||||||||||||
Balance at December 31, 2012 | 38 | 19.26 | 26.56 | |||||||||
Exercised | 2 | 18.35 | 25.31 | |||||||||
Forfeited | 4 | 23.56 | 32.49 | |||||||||
Converted into ordinary shares | 32 | 18.86 | 26.01 | |||||||||
Balance at December 31, 2013 | 0 | 0 | 0 | |||||||||
The following table provides a summary of fully vested options outstanding and exercisable at December 31, 2013: | ||||||||||||
Fully Vested Outstanding and Exercisable Options | ||||||||||||
Weighted | ||||||||||||
average | Weighted | Weighted | ||||||||||
Number | remaining | average | average | Aggregate | Aggregate | |||||||
of | contractual | exercise | exercise | intrinsic | intrinsic | |||||||
Options | life in years | price | price | value | value | |||||||
(in thousands) | € | US$ | € | US$ | ||||||||
Options for ordinary shares | 4,711 | 2.51 | 36.41 | 50.21 | 72,198 | 99,568 | ||||||
At December 31, 2013, there was $48,355 of total unrecognized compensation costs related to non-vested options granted under all plans. These costs are expected to be recognized over a weighted-average period of 2.00 years. | ||||||||||||
During the years ended December 31, 2013, 2012, and 2011, the Company received cash of $102,418, $100,118 and $81,883, respectively, from the exercise of stock options (see Note 14). The intrinsic value of convertible bonds and stock options exercised for the twelve-month periods ending December 31, 2013, 2012, and 2011 was $52,203, $83,690 and $50,687, respectively. The Company recorded a related tax benefit of $8,882, $21,008 and $13,010 for the years ending December 31, 2013, 2012, and 2011, respectively. | ||||||||||||
In connection with cash-settled share based payment transactions under the 2011 Incentive Program the Company recognized expense of $3,559, $5,144 and $1,859 for the years ending December 31, 2013, 2012 and 2011, respectively. | ||||||||||||
Fair Value Information | ||||||||||||
The Company used a binomial option-pricing model in determining the fair value of the awards under the 2011 SOP and the Amended 2006 Plan. Option valuation models require the input of subjective assumptions including expected stock price volatility. The Company's assumptions are based upon its past experiences, market trends and the experiences of other entities of the same size and in similar industries. Expected volatility is based on historical volatility of the Company's shares. To incorporate the effects of expected early exercise in the model, an early exercise of vested options was assumed as soon as the share price exceeds 155% of the exercise price. The Company's stock options have characteristics that vary significantly from traded options and changes in subjective assumptions can materially affect the fair value of the option. The assumptions used to determine the fair value of the 2013 and 2012 grants are as follows: | ||||||||||||
2013 | 2012 | |||||||||||
Expected dividend yield | 2.02% | 1.61% | ||||||||||
Risk-free interest rate | 1.33% | 1.09% | ||||||||||
Expected volatility | 22.44% | 22.20% | ||||||||||
Expected life of options | 8 years | 8 years | ||||||||||
Weighted average exercise price (in €) | 49.75 | 57.15 | ||||||||||
Weighted average exercise price (in US-$) | 68.61 | 75.41 |
Income_Taxes
Income Taxes | 12 Months Ended | |||||||||
Dec. 31, 2013 | ||||||||||
Notes to Consolidated Financial Statements [Abstract] | ' | |||||||||
Income Taxes | ' | |||||||||
18. Income Taxes | ||||||||||
Income before income taxes is attributable to the following geographic locations: | ||||||||||
2013 | 2012 | 2011 | ||||||||
Germany | $ | 234,336 | $ | 263,651 | $ | 344,267 | ||||
United States | 1,254,690 | 1,356,094 | 1,122,800 | |||||||
Other | 358,609 | 312,368 | 311,292 | |||||||
$ | 1,847,635 | $ | 1,932,113 | $ | 1,778,359 | |||||
Income tax expense (benefit) for the years ended December 31, 2013, 2012, and 2011, consisted of the following: | ||||||||||
2013 | 2012 | 2011 | ||||||||
Current: | ||||||||||
Germany | $ | 81,117 | $ | 52,862 | $ | 67,484 | ||||
United States | 387,017 | 342,250 | 278,634 | |||||||
Other | 116,186 | 139,136 | 106,087 | |||||||
584,320 | 534,248 | 452,205 | ||||||||
Deferred: | ||||||||||
Germany | -33,106 | 10,478 | 14,565 | |||||||
United States | 47,298 | 98,200 | 139,282 | |||||||
Other | -6,500 | -37,790 | -4,955 | |||||||
7,692 | 70,888 | 148,892 | ||||||||
$ | 592,012 | $ | 605,136 | $ | 601,097 | |||||
In 2013, 2012 and 2011, the Company was subject to German federal corporation income tax at a base rate of 15% plus a solidarity surcharge of 5.5% on federal corporation taxes payable and a trade tax rate of 13.34%, 12.88% and 12.64% for the fiscal years ended December 31, 2013, 2012 and 2011, respectively. | ||||||||||
A reconciliation between the expected and actual income tax expense is shown below. The expected corporate income tax expense is computed by applying the German corporation tax rate (including the solidarity surcharge) and the trade tax rate on income before income taxes. The combined tax rates were 29.16%, 28.71% and 28.46% for the fiscal years ended December 31, 2013, 2012, and 2011, respectively. | ||||||||||
2013 | 2012 | 2011 | ||||||||
Expected corporate income tax expense | $ | 538,770 | $ | 554,613 | $ | 506,121 | ||||
Tax free income | -64,141 | -90,943 | -38,926 | |||||||
Income from at equity investments | -4,869 | -2,133 | -6,883 | |||||||
Tax rate differentials | 132,977 | 137,527 | 140,079 | |||||||
Non-deductible expenses | 20,564 | 19,961 | 4,536 | |||||||
Taxes for prior years | -6,389 | 22,420 | 144 | |||||||
Change in valuation allowance | 3,154 | -19,680 | 5,544 | |||||||
Noncontrolling partnership interests | -55,023 | -49,081 | -31,300 | |||||||
Other | 26,969 | 32,452 | 21,782 | |||||||
Actual income tax expense | $ | 592,012 | $ | 605,136 | $ | 601,097 | ||||
Effective tax rate | 32.00% | 31.30% | 33.80% | |||||||
The tax effects of the temporary differences that give rise to deferred tax assets and liabilities at December 31, 2013 and 2012, are presented below: | ||||||||||
2013 | 2012 | |||||||||
Deferred tax assets: | ||||||||||
Accounts receivable | $ | 8,789 | $ | 5,847 | ||||||
Inventory | 9,731 | 9,434 | ||||||||
Property, plant and equipment, intangible and other non-current assets | 20,093 | 28,470 | ||||||||
Accrued expenses and other liabilities | 305,664 | 318,827 | ||||||||
Pensions | 97,958 | 123,363 | ||||||||
Net operating loss carryforwards, tax credit carryforwards and interest carryforwards | 141,727 | 107,595 | ||||||||
Derivatives | 2,169 | 4,856 | ||||||||
Stock-based compensation | 22,710 | 24,758 | ||||||||
Other | 13,632 | 13,136 | ||||||||
Total deferred tax assets | $ | 622,473 | $ | 636,286 | ||||||
Less: valuation allowance | -48,563 | -44,191 | ||||||||
Net deferred tax assets | $ | 573,910 | $ | 592,095 | ||||||
Deferred tax liabilities: | ||||||||||
Accounts receivable | $ | 43,031 | $ | 17,036 | ||||||
Inventory | 12,264 | 11,847 | ||||||||
Property, plant and equipment, intangible and other non-current assets | 776,254 | 748,271 | ||||||||
Accrued expenses and other liabilities | 17,197 | 21,651 | ||||||||
Derivatives | 2,274 | 2,202 | ||||||||
Other | 117,255 | 128,403 | ||||||||
Total deferred tax liabilities | 968,275 | 929,410 | ||||||||
Net deferred tax assets (liabilities) | $ | -394,365 | $ | -337,315 | ||||||
The valuation allowance increased by $4,372 in 2013 and decreased by $36,227 in 2012. | ||||||||||
The expiration of net operating losses is as follows: | ||||||||||
2014 | $ | 38,550 | ||||||||
2015 | 38,134 | |||||||||
2016 | 54,139 | |||||||||
2017 | 55,956 | |||||||||
2018 | 50,907 | |||||||||
2019 | 39,707 | |||||||||
2020 | 33,619 | |||||||||
2021 | 34,042 | |||||||||
2022 | 34,046 | |||||||||
2023 and thereafter | 34,676 | |||||||||
Without expiration date | 92,906 | |||||||||
Total | $ | 506,682 | ||||||||
In assessing the realizability of deferred taxes, management considers whether it is more-likely-than-not that some portion or all of a deferred tax asset will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities and projected future taxable income in making this assessment. Based upon the level of historical taxable income and projections for future taxable income over the periods in which the deferred tax assets are deductible, management believes it is more-likely-than-not the Company will realize the benefits of these deductible differences, net of the existing valuation allowances at December 31, 2013. | ||||||||||
The Company provides for income taxes and foreign withholding taxes on the cumulative earnings of foreign subsidiaries that will not be reinvested. At December 31, 2013, the Company provided for $8,396 of deferred tax liabilities associated with earnings that are likely to be distributed in 2014 and the following years. Provision has not been made for additional taxes on $6,269,794 undistributed earnings of foreign subsidiaries as these earnings are considered indefinitely reinvested. The earnings could become subject to additional tax if remitted or deemed remitted as dividends; however calculation of such additional tax is not practicable. These taxes would predominantly comprise foreign withholding tax on dividends of foreign subsidiaries, and German income tax of approximately 1.4% on all dividends and capital gains. | ||||||||||
FMC-AG & Co. KGaA companies are subject to tax audits in Germany and the U.S. on a regular basis and on-going tax audits in other jurisdictions. | ||||||||||
In Germany, the tax years 2002 through 2009 are currently under audit by the tax authorities. The Company recognized and recorded the current proposed adjustments of this audit period in the financial statements. All proposed adjustments are deemed immaterial. Fiscal years 2010 until 2013 are open to audit. | ||||||||||
In the U.S., the tax years 2009 and 2010 are currently under audit by the tax authorities. Fiscal years 2011 until 2013 are open to audit. FMCH is also subject to audit in various state jurisdictions. A number of these audits are in progress and various years are open to audit in various state jurisdictions. All expected results for both federal and state income tax audits have been recognized in the financial statements. | ||||||||||
The Company filed claims for refunds contesting the Internal Revenue Service's (“IRS”) disallowance of FMCH's deductions for civil settlement payments taken by FMCH in prior year tax returns. As a result of a settlement agreement with the IRS, the Company received a partial refund in September 2008 of $37,000, inclusive of interest and preserved its right to pursue claims in the United States Courts for refunds of all other disallowed deductions, which totaled approximately $126,000. On December 22, 2008, the Company filed a complaint for complete refund in the United States District Court for the District of Massachusetts, styled as Fresenius Medical Care Holdings, Inc. v. United States. On August 15, 2012, a jury entered a verdict for FMCH granting additional deductions of $95,000. On May 31, 2013, the District Court entered final judgment for FMCH in the amount of $50,400. On September 18, 2013, the IRS appealed the District Court's ruling to the United States Court of Appeals for the First Circuit (Boston). | ||||||||||
Subsidiaries of FMC-AG & Co. KGaA in a number of countries outside of Germany and the U.S. are also subject to tax audits. The Company estimates that the effects of such tax audits are not material to these consolidated financial statements. | ||||||||||
The following table shows the reconciliation of the beginning and ending amounts of unrecognized tax benefits: | ||||||||||
Unrecognized tax benefits (net of interest) | 2013 | 2012 | 2011 | |||||||
Balance at January 1, | $ | 225,198 | $ | 223,829 | $ | 405,900 | ||||
Increases in unrecognized tax benefits prior periods | 25,260 | 13,232 | 24,046 | |||||||
Decreases in unrecognized tax benefits prior periods | -11,445 | -5,913 | -24,897 | |||||||
Increases in unrecognized tax benefits current period | 10,062 | 17,903 | 16,157 | |||||||
Changes related to settlements with tax authorities | -52,325 | -14,763 | -208,484 | |||||||
Reductions as a result of a lapse of the statute of limitations | - | - | -3,100 | |||||||
Foreign currency translation | 3,174 | -9,090 | 14,207 | |||||||
Balance at December 31, | $ | 199,924 | $ | 225,198 | $ | 223,829 | ||||
Included in the balance at December 31, 2013 were $203,497 of unrecognized tax benefits which would affect the effective tax rate if recognized. The Company is currently not in a position to forecast the timing and magnitude of changes in other unrecognized tax benefits. | ||||||||||
During the years ended December 31, 2013, 2012 and 2011 the Company recognized $2,155, $11,071 and $20,494 in interest and penalties, respectively. At December 31, 2013 and December 31, 2012 the Company had a total accrual of tax related interest and penalties of $17,580 and $33,749, |
Operating_Leases
Operating Leases | 12 Months Ended | ||
Dec. 31, 2013 | |||
Notes to Consolidated Financial Statements [Abstract] | ' | ||
Operating Leases | ' | ||
19. Operating Leases | |||
The Company leases buildings and machinery and equipment under various lease agreements expiring on dates through 2039. Rental expense recorded for operating leases for the years ended December 31, 2013, 2012 and 2011 was $670,963, $617,195 and $601,070, respectively. For information regarding intercompany operating leases, see Note 3 a). | |||
Future minimum rental payments under noncancelable operating leases for the five years succeeding December 31, 2013 and thereafter are: | |||
2014 | $ | 609,521 | |
2015 | 524,898 | ||
2016 | 456,143 | ||
2017 | 354,705 | ||
2018 | 277,940 | ||
Thereafter | 1,002,340 | ||
3,225,547 |
Commitments_and_Contingencies
Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2013 | |
Notes to Consolidated Financial Statements [Abstract] | ' |
Commitments and Contingencies | ' |
20. Commitments and Contingencies | |
Legal and Regulatory Matters | |
The Company is routinely involved in numerous claims, lawsuits, regulatory and tax audits, investigations and other legal matters arising, for the most part, in the ordinary course of its business of providing healthcare services and products. Legal matters that the Company currently deems to be material are described below. For the matters described below in which the Company believes a loss is both reasonably possible and estimable, an estimate of the loss or range of loss exposure is provided. For the other matters described below, the Company believes that the loss probability is remote and/or the loss or range of possible losses cannot be reasonably estimated at this time. The outcome of litigation and other legal matters is always difficult to predict accurately and outcomes that are not consistent with the Company's view of the merits can occur. The Company believes that it has valid defenses to the legal matters pending against it and is defending itself vigorously. Nevertheless, it is possible that the resolution of one or more of the legal matters currently pending or threatened could have a material adverse effect on its business, results of operations and financial condition. | |
Commercial Litigation | |
The Company was originally formed as a result of a series of transactions it completed pursuant to the Agreement and Plan of Reorganization dated as of February 4, 1996, by and between W.R. Grace & Co. and Fresenius SE (the "Merger"). At the time of the Merger, a W.R. Grace & Co. subsidiary known as W.R. Grace & Co.-Conn. had significant liabilities arising out of product-liability related litigation (including asbestos-related actions), pre-Merger tax claims and other claims unrelated to National Medical Care, Inc. (“NMC”), which was W.R. Grace & Co.'s dialysis business prior to the Merger. In connection with the Merger, W.R. Grace & Co.-Conn. agreed to indemnify the Company, FMCH, and NMC against all liabilities of W.R. Grace & Co., whether relating to events occurring before or after the Merger, other than liabilities arising from or relating to NMC's operations. W.R. Grace & Co. and certain of its subsidiaries filed for reorganization under Chapter 11 of the U.S. Bankruptcy Code (the “Grace Chapter 11 Proceedings”) on April 2, 2001. | |
Prior to and after the commencement of the Grace Chapter 11 Proceedings, class action complaints were filed against W.R. Grace & Co. and FMCH by plaintiffs claiming to be creditors of W.R. Grace & Co.-Conn., and by the asbestos creditors' committees on behalf of the W.R. Grace & Co. bankruptcy estate in the Grace Chapter 11 Proceedings, alleging, among other things that the Merger was a fraudulent conveyance, violated the uniform fraudulent transfer act and constituted a conspiracy. All such cases have been dismissed as part of the Grace Chapter 11 Proceedings. | |
In 2003, the Company reached agreement with the asbestos creditors' committees on behalf of the W.R. Grace & Co. bankruptcy estate and W.R. Grace & Co. in the matters pending in the Grace Chapter 11 Proceedings for the settlement of all fraudulent conveyance and tax claims against it and other claims related to the Company that arise out of the bankruptcy of W.R. Grace & Co. The District Court approved the terms of the settlement agreement as amended (the “Settlement Agreement”), in 2003, and included the terms of the Settlement Agreement within the First Amended Plan of reorganization (“the Grace Bankruptcy Plan”) that was ultimately approved and confirmed by the District Court. On February 3, 2014, the Court of Appeals dismissed the last of the appeals of the District Court order confirming the plan of reorganization, and the Grace Bankruptcy Plan went effective on that date. Pursuant to the terms of the Settlement Agreement and the Grace Bankruptcy Plan, all actions asserting fraudulent conveyance and other claims raised on behalf of asbestos claimants were dismissed with prejudice and the Company received protection against existing and potential future W.R. Grace & Co. related claims, including fraudulent conveyance and asbestos claims by operation of injunctions and releases and the Company also received indemnification against income tax claims related to the non-NMC members of the W.R. Grace & Co. consolidated tax group. Also, pursuant to the Settlement Agreement on February 3, 2014, the Company paid a total of $115,000, which had previously been accrued and is included on the Company's Consolidated Balance Sheets, to the asbestos personal injury and property damage trusts created under the Grace Bankruptcy Plan. No admission of liability was made. | |
On April 4, 2003, FMCH filed a suit in the U. S. District Court for the Northern District of California, styled Fresenius USA, Inc., et al., v. Baxter International Inc., et al., Case No. C 03-1431, seeking a declaratory judgment that FMCH does not infringe patents held by Baxter International Inc. and its subsidiaries and affiliates (“Baxter”), that the patents are invalid, and that Baxter is without right or authority to threaten or maintain suit against FMCH for alleged infringement of Baxter's patents. In general, the asserted patents concern the use of touch screen interfaces for hemodialysis machines. Baxter filed counterclaims against FMCH seeking more than $140,000 in monetary damages and injunctive relief, and alleging that FMCH willfully infringed on Baxter's patents. On July 17, 2006, the court entered judgment on a jury verdict in favor of FMCH finding all asserted claims of Baxter patents invalid as obvious and/or anticipated in light of prior art. | |
On February 13, 2007, the court granted Baxter's motion to set aside the jury's verdict in favor of FMCH and reinstated the patents and entered judgment of infringement. Following a trial on damages, the court entered judgment on November 6, 2007 in favor of Baxter on a jury award of $14,300. On April 4, 2008, the court denied Baxter's motion for a new trial, established a royalty payable to Baxter of 10% of the sales price for continuing sales of FMCH's 2008K hemodialysis machines and 7% of the sales price of related disposables, parts and service beginning November 7, 2007, and enjoined sales of the touchscreen-equipped 2008K machine effective January 1, 2009. The Company appealed the court's rulings to the United States Court of Appeals for the Federal Circuit (“Federal Circuit”). On September 10, 2009, the Federal Circuit reversed the district court's decision and determined that the asserted claims in two of the three patents at issue are invalid. As to the third patent, the Federal Circuit affirmed the district court's decision; however, the Court also vacated the injunction and award of damages. These issues were remanded to the District Court for reconsideration in light of the invalidity ruling on most of the claims. Upon remand, the district court reduced the post-verdict damages award to $10,000. Separately, the U.S. Patent and Trademark Office (“USPTO”) and the Board of Patent Appeals and Interferences ruled that the remaining Baxter patent is invalid. On May 17, 2012 the Federal Circuit affirmed the USPTO's ruling and invalidated the final remaining Baxter patent. Baxter appealed to the Federal Circuit claiming that approximately $20,000 of damages awarded to it by the District Court before the Federal Circuit affirmed the USPTO ruling constituted a final judgment that may be collected. On July 2, 2013, the Federal Circuit denied Baxter's appeal and ordered the District Court to dismiss the case. The court-approved escrow account has been terminated and the escrow funds have been returned to FMCH. | |
On August 27, 2012, Baxter filed suit in the U.S. District Court for the Northern District of Illinois, styled Baxter International Inc., et al., v. Fresenius Medical Care Holdings, Inc., Case No. 12-cv-06890, alleging that the Company's LibertyTM cycler infringes certain U.S. patents that were issued to Baxter between October 2010 and June 2012. The Company believes it has valid defenses to these claims, and will defend this litigation vigorously. | |
On April 5, 2013, the U.S. Judicial Panel on Multidistrict Litigation ordered that the numerous lawsuits filed and anticipated to be filed in various federal courts alleging wrongful death and personal injury claims against FMCH and certain of its affiliates relating to FMCH's acid concentrate products NaturaLyte® and Granuflo® be transferred and consolidated for pretrial management purposes into a consolidated multidistrict litigation in the United States District Court for the District of Massachusetts, styled In Re: Fresenius Granuflo/Naturalyte Dialysate Products Liability Litigation, Case No. 2013-md-02428. The Massachusetts state courts subsequently established a similar consolidated litigation for such cases filed in Massachusetts county courts, styled In Re: Consolidated Fresenius Cases, Case No. MICV 2013-03400-O (Massachusetts Superior Court, Middlesex County). These lawsuits allege generally that inadequate labeling and warnings for these products caused harm to patients. In addition, similar cases have been filed in several state courts that may or may not eventually be formally consolidated with the federal multidistrict litigation. FMCH believes that these lawsuits are without merit, and will defend them vigorously. | |
Other Litigation and Potential Exposures | |
On February 15, 2011, a qui tam relator's complaint under the False Claims Act against FMCH was unsealed by order of the United States District Court for the District of Massachusetts and served by the relator. The United States has not intervened in the case United States ex rel. Chris Drennen v. Fresenius Medical Care Holdings, Inc., 2009 Civ. 10179 (D. Mass.). The relator's complaint, which was first filed under seal in February 2009, alleges that the Company seeks and receives reimbursement from government payors for serum ferritin and hepatitis B laboratory tests that are medically unnecessary or not properly ordered by a physician. On March 6, 2011, the United States Attorney for the District of Massachusetts issued a subpoena seeking the production of documents related to the same laboratory tests that are the subject of the relator's complaint. FMCH has cooperated fully in responding to the subpoena, and will vigorously contest the relator's complaint. | |
Subpoenas, or search warrants have been issued by federal and state law enforcement authorities under the supervision of the United States Attorneys for the Districts of Connecticut, Southern Florida, Southern New York, Eastern Virginia and Rhode Island to American Access Care LLC (AAC), which the Company acquired in October 2011, and to the Company's Fresenius Vascular Access subsidiary which now operates former AAC centers as well as its own original facilities. Subpoenas have also been issued to certain of the Company's outpatient hemodialysis facilities for records relating to vascular access treatment and monitoring. The Company is cooperating fully in these investigations. Communications with certain of the investigating United States Attorney Offices indicate that the inquiry encompasses invoicing and coding for procedures commonly performed in vascular access centers and the documentary support for the medical necessity of such procedures. The AAC acquisition agreement contains customary indemnification obligations with respect to breaches of representations, warranties or covenants and certain other specified matters. As of October 18, 2013, a group of the prior owners of AAC exercised their right pursuant to the terms of the acquisition agreement to assume responsibility for responding to certain of the subpoenas. Pursuant to the AAC acquisition agreement the prior owners are obligated to indemnify the Company for certain liabilities that might arise from those subpoenas. | |
The Company has received communications alleging certain conduct in certain countries outside the U.S. and Germany that may violate the U.S. Foreign Corrupt Practices Act (“FCPA”) or other anti-bribery laws. The Audit and Corporate Governance Committee of the Company's Supervisory Board is conducting an internal review with the assistance of independent counsel retained for such purpose. The Company voluntarily advised the U.S. Securities and Exchange Commission ( “SEC”) and the U.S. Department of Justice (“DOJ”) that allegations have been made and of the Company's internal review. The Company's review and dialogue with the SEC and DOJ are ongoing. | |
The review has identified conduct that raises concerns under the FCPA or other anti-bribery laws that may result in monetary penalties or other sanctions. In addition, the Company's ability to conduct business in certain jurisdictions could be negatively impacted. Given the current status of the internal review, the Company cannot reasonably estimate the possible loss or range of possible loss that may result from the identified matters or from the final outcome of the continuing internal review. Accordingly, no provision with respect to these matters has been made in the accompanying consolidated financial statements. | |
The Company's independent counsel, in conjunction with the Company's Compliance Department, have reviewed the Company's anti-corruption compliance program, including internal controls related to compliance with international anti-bribery laws, and appropriate enhancements are being implemented. The Company is fully committed to FCPA compliance. | |
In December 2012 and January 2013, FMCH received subpoenas from the United States Attorneys for the District of Massachusetts and the Western District of Louisiana requesting production of a broad range of documents. Communications with the investigating United States Attorney Offices indicate that the inquiry relates to products manufactured by FMCH, which encompasses the Granuflo® and Naturalyte® acid concentrate products that are also the subject of personal injury litigation described above, as well as electron-beam sterilization of dialyzers, the Liberty peritoneal dialysis cycler, and 2008 series hemodialysis machines as related to the use of Granuflo® and Naturalyte®. FMCH is cooperating fully in the government's investigation. | |
The Company filed claims for refunds contesting the Internal Revenue Service's (“IRS”) disallowance of FMCH's deductions for civil settlement payments taken by FMCH in prior year tax returns. As a result of a settlement agreement with the IRS, the Company received a partial refund in September 2008 of $37,000, inclusive of interest and preserved its right to pursue claims in the United States Courts for refunds of all other disallowed deductions, which totaled approximately $126,000. On December 22, 2008, the Company filed a complaint for complete refund in the United States District Court for the District of Massachusetts, styled as Fresenius Medical Care Holdings, Inc. v. United States. On August 15, 2012, a jury entered a verdict for FMCH granting additional deductions of $95,000. On May 31, 2013, the District Court entered final judgment for FMCH in the amount of $50,400. On September 18, 2013, the IRS appealed the District Court's ruling to the United States Court of Appeals for the First Circuit (Boston). | |
From time to time, the Company is a party to or may be threatened with other litigation or arbitration, claims or assessments arising in the ordinary course of its business. Management regularly analyzes current information including, as applicable, the Company's defenses and insurance coverage and, as necessary, provides accruals for probable liabilities for the eventual disposition of these matters. | |
The Company, like other healthcare providers, conducts its operations under intense government regulation and scrutiny. It must comply with regulations which relate to or govern the safety and efficacy of medical products and supplies, the marketing and distribution of such products, the operation of manufacturing facilities, laboratories and dialysis clinics, and environmental and occupational health and safety. With respect to its development, manufacture, marketing and distribution of medical products, if such compliance is not maintained, the Company could be subject to significant adverse regulatory actions by the FDA and comparable regulatory authorities outside the U.S. These regulatory actions could include warning letters or other enforcement notices from the FDA, and/or comparable foreign regulatory authority which may require the Company to expend significant time and resources in order to implement appropriate corrective actions. If the Company does not address matters raised in warning letters or other enforcement notices to the satisfaction of the FDA and/or comparable regulatory authorities outside the U.S., these regulatory authorities could take additional actions, including product recalls injunctions against the distribution of products or operation of manufacturing plants, civil penalties, seizures of the Company's products and/or criminal prosecution. The Company must also comply with the laws of the United States, including the federal Anti-Kickback Statute, the federal False Claims Act, the federal Stark Law and the federal Foreign Corrupt Practices Act as well as other federal and state fraud and abuse laws. Applicable laws or regulations may be amended, or enforcement agencies or courts may make interpretations that differ from the Company's interpretations or the manner in which it conducts its business. Enforcement has become a high priority for the federal government and some states. In addition, the provisions of the False Claims Act authorizing payment of a portion of any recovery to the party bringing the suit encourage private plaintiffs to commence “qui tam” or “whistle blower” actions. In May 2009, the scope of the False Claims Act was expanded and additional protections for whistle blowers and procedural provisions to aid whistle blowers' ability to proceed in a False Claims Act case were added. By virtue of this regulatory environment, the Company's business activities and practices are subject to extensive review by regulatory authorities and private parties, and continuing audits, subpoenas, other inquiries, claims and litigation relating to the Company's compliance with applicable laws and regulations. The Company may not always be aware that an inquiry or action has begun, particularly in the case of “whistle blower” actions, which are initially filed under court seal. | |
The Company operates many facilities throughout the United States and other parts of the world. In such a decentralized system, it is often difficult to maintain the desired level of oversight and control over the thousands of individuals employed by many affiliated companies. The Company relies upon its management structure, regulatory and legal resources, and the effective operation of its compliance program to direct, manage and monitor the activities of these employees. On occasion, the Company may identify instances where employees or other agents deliberately, recklessly or inadvertently contravene the Company's policies or violate applicable law. The actions of such persons may subject the Company and its subsidiaries to liability under the Anti-Kickback Statute, the Stark Law, the False Claims Act and the Foreign Corrupt Practices Act, among other laws and comparable laws of other countries. | |
Physicians, hospitals and other participants in the healthcare industry are also subject to a large number of lawsuits alleging professional negligence, malpractice, product liability, worker's compensation or related claims, many of which involve large claims and significant defense costs. The Company has been and is currently subject to these suits due to the nature of its business and expects that those types of lawsuits may continue. Although the Company maintains insurance at a level which it believes to be prudent, it cannot assure that the coverage limits will be adequate or that insurance will cover all asserted claims. A successful claim against the Company or any of its subsidiaries in excess of insurance coverage could have a material adverse effect upon it and the results of its operations. Any claims, regardless of their merit or eventual outcome, could have a material adverse effect on the Company's reputation and business. | |
The Company has also had claims asserted against it and has had lawsuits filed against it relating to alleged patent infringements or businesses that it has acquired or divested. These claims and suits relate both to operation of the businesses and to the acquisition and divestiture transactions. The Company has, when appropriate, asserted its own claims, and claims for indemnification. A successful claim against the Company or any of its subsidiaries could have a material adverse effect upon its business, financial condition, and the results of its operations. Any claims, regardless of their merit or eventual outcome, could have a material adverse effect on the Company's reputation and business. | |
Financial_Instruments
Financial Instruments | 12 Months Ended | ||||||||||||||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||||||||||||||
Notes to Consolidated Financial Statements [Abstract] | ' | ||||||||||||||||||||||||||||
Financial Instruments | ' | ||||||||||||||||||||||||||||
21. Financial Instruments | |||||||||||||||||||||||||||||
Non-derivative Financial Instruments | |||||||||||||||||||||||||||||
The following table presents the carrying amounts and fair values of the Company's non-derivative financial instruments at December 31, 2013, and December 31, 2012. | |||||||||||||||||||||||||||||
2013 | 2012 | ||||||||||||||||||||||||||||
Fair Value | Carrying | Fair | Carrying | Fair | |||||||||||||||||||||||||
Hierarchy | Amount | Value | Amount | Value | |||||||||||||||||||||||||
Assets | |||||||||||||||||||||||||||||
Cash and cash equivalents | 1 | $ | 682,777 | $ | 682,777 | $ | 688,040 | $ | 688,040 | ||||||||||||||||||||
Accounts Receivable(1) | 2 | 3,190,392 | 3,190,392 | 3,157,233 | 3,157,233 | ||||||||||||||||||||||||
Long-term Notes Receivable | 3 | 165,807 | 175,768 | - | - | ||||||||||||||||||||||||
Liabilities | |||||||||||||||||||||||||||||
Accounts payable(1) | 2 | $ | 666,526 | $ | 666,526 | $ | 745,644 | $ | 745,644 | ||||||||||||||||||||
Short-term borrowings(1) | 2 | 158,990 | 158,990 | 121,823 | 121,823 | ||||||||||||||||||||||||
Long term debt, excluding 2012 Credit Agreement, Euro Notes and Senior Notes | 2 | 679,847 | 679,847 | 721,928 | 721,928 | ||||||||||||||||||||||||
2012 Credit Agreement | 2 | 2,707,145 | 2,710,270 | 2,659,340 | 2,652,840 | ||||||||||||||||||||||||
Senior Notes | 2 | 4,824,753 | 5,348,679 | 4,743,442 | 5,296,325 | ||||||||||||||||||||||||
Euro Notes | 2 | 46,545 | 47,423 | 51,951 | 54,574 | ||||||||||||||||||||||||
Noncontrolling interests subject to put provisions | 3 | 648,251 | 648,251 | 523,260 | 523,260 | ||||||||||||||||||||||||
(1) Also includes amounts from related parties. | |||||||||||||||||||||||||||||
The carrying amounts in the table are included in the consolidated balance sheet under the indicated captions or in the case of long-term debt, in the captions shown in Note 11. | |||||||||||||||||||||||||||||
The significant methods and assumptions used in estimating the fair values of non-derivative financial instruments are as follows: | |||||||||||||||||||||||||||||
Cash and cash equivalents are stated at nominal value which equals the fair value. | |||||||||||||||||||||||||||||
Short-term financial instruments such as accounts receivable, accounts payable and short-term borrowings are valued at their carrying amounts, which are reasonable estimates of the fair value due to the relatively short period to maturity of these instruments. | |||||||||||||||||||||||||||||
The valuation of long-term notes receivable was determined using significant unobservable inputs. They were valued using a constructed index based upon similar instruments with comparable credit ratings, terms, tenor, interest rates and that are within the Company's industry. The Company tracked the prices of the constructed index from the note issuance date to the reporting date to determine fair value. See Note 8 for further information on the long-term notes receivable. | |||||||||||||||||||||||||||||
The fair values of major long-term financial liabilities are calculated on the basis of market information. Instruments for which market quotes are available are measured using these quotes. The fair values of the other long-term financial liabilities are calculated at the present value of the respective future cash flows. To determine these present values, the prevailing interest rates and credit spreads for the Company as of the balance sheet date are used. | |||||||||||||||||||||||||||||
The valuation of noncontrolling interests subject to put provisions is determined using significant unobservable inputs. See Note 13 for a discussion of the Company's methodology for estimating the fair value of these noncontrolling interests subject to put obligations. | |||||||||||||||||||||||||||||
Currently, there is no indication that a decrease in the value of the Company's financing receivables is probable. Therefore, the allowances on credit losses of financing receivables are immaterial. | |||||||||||||||||||||||||||||
Derivative Financial Instruments | |||||||||||||||||||||||||||||
The Company is exposed to market risk from changes in foreign exchange rates and interest rates. In order to manage the risk of currency exchange rate and interest rate fluctuations, the Company enters into various hedging transactions by means of derivative instruments with highly rated financial institutions as authorized by the Company's General Partner. On a quarterly basis, the Company performs an assessment of its counterparty credit risk. The Company currently considers this risk to be low. The Company's policy, which has been consistently followed, is that financial derivatives be used only for the purpose of hedging foreign currency and interest rate exposure. | |||||||||||||||||||||||||||||
In certain instances, the Company enters into derivative contracts that do not qualify for hedge accounting but are utilized for economic purposes (“economic hedges”). The Company does not use financial instruments for trading purposes. | |||||||||||||||||||||||||||||
The Company established guidelines for risk assessment procedures and controls for the use of financial instruments. They include a clear segregation of duties with regard to execution on one side and administration, accounting and controlling on the other. | |||||||||||||||||||||||||||||
To reduce the credit risk arising from derivatives the Company concluded Master Netting Agreements with banks. Through such agreements, positive and negative fair values of the derivative contracts could be offset against one another if a partner becomes insolvent. This offsetting is valid for transactions where the aggregate amount of obligations owed to and receivable from are not equal. If insolvency occurs, the party which owes the larger amount is obliged to pay the other party the difference between the amounts owed in the form of one net payment. | |||||||||||||||||||||||||||||
The Company elects not to offset the fair values of derivative financial instruments subject to master netting agreements in the Consolidated Balance Sheets. | |||||||||||||||||||||||||||||
At December 31, 2013 and December 31, 2012, the Company had $18,334 and $32,044 of derivative financial assets subject to netting arrangements and $16,371 and $19,193 of derivative financial liabilities subject to netting arrangements. Offsetting these derivative financial instruments would have resulted in net assets of $12,169 and $20,773 as well as net liabilities of $10,207 and $7,922 at December 31, 2013 and December 31, 2012, respectively. | |||||||||||||||||||||||||||||
Foreign Exchange Risk Management | |||||||||||||||||||||||||||||
The Company conducts business on a global basis in various currencies, though a majority of its operations are in Germany and the United States. For financial reporting purposes, the Company has chosen the U.S. dollar as its reporting currency. Therefore, changes in the rate of exchange between the U.S. dollar and the local currencies in which the financial statements of the Company's international operations are maintained affect its results of operations and financial position as reported in its consolidated financial statements. | |||||||||||||||||||||||||||||
The Company's exposure to market risk for changes in foreign exchange rates relates to transactions such as sales and purchases. The Company has significant amounts of sales of products invoiced in euro from its European manufacturing facilities to its other international operations and, to a lesser extent, sales of products invoiced in other non-functional currencies. This exposes the subsidiaries to fluctuations in the rate of exchange between the euro and the currency in which their local operations are conducted. For the purpose of hedging existing and foreseeable foreign exchange transaction exposures the Company enters into foreign exchange forward contracts and, on a small scale, foreign exchange options. At December 31, 2013 the Company had no foreign exchange options. | |||||||||||||||||||||||||||||
Changes in the fair value of the effective portion of foreign exchange forward contracts designated and qualifying as cash flow hedges of forecasted product purchases and sales are reported in AOCI. Additionally, in connection with intercompany loans in foreign currency, the Company uses foreign exchange swaps thus assuring that no foreign exchange risks arise from those loans, which, if they qualify for cash flow hedge accounting, are also reported in AOCI. These amounts recorded in AOCI are subsequently reclassified into earnings as a component of cost of revenues for those contracts that hedge product purchases or as an adjustment of interest income/expense for those contracts that hedge loans, in the same period in which the hedged transaction affects earnings. The notional amounts of foreign exchange contracts in place that are designated and qualify as cash flow hedges totaled $238,983 and $611,488 at December 31, 2013 and December 31, 2012, respectively. | |||||||||||||||||||||||||||||
The Company also enters into derivative contracts for forecasted product purchases and sales and for intercompany loans in foreign currency that do not qualify for hedge accounting but are utilized for economic hedges as defined above. In these cases, the change in value of the economic hedge is recorded in the income statement and usually offsets the change in value recorded in the income statement for the underlying asset or liability. The notional amounts of economic hedges that do not qualify for hedge accounting totaled $1,512,559 and $1,574,667 at December 31, 2013 and December 31, 2012, respectively. | |||||||||||||||||||||||||||||
Interest Rate Risk Management | |||||||||||||||||||||||||||||
The Company enters into derivatives, particularly interest rate swaps and to a certain extent, interest rate options, to protect against the risk of rising interest rates. These interest rate derivatives are designated as cash flow hedges and have been entered into in order to effectively convert payments based on variable interest rates into payments at a fixed interest rate. The euro-denominated interest rate swaps expire in 2016 and have an interest rate of 1.73%. Interest payable and receivable under the swap agreements is accrued and recorded as an adjustment to interest expense. | |||||||||||||||||||||||||||||
At December 31, 2013 and December 31, 2012, the notional amount of the euro-denominated interest rate swaps in place was €100,000 and €100,000 ($137,910 and $131,940 at December 31, 2013 and December 31, 2012, respectively). | |||||||||||||||||||||||||||||
Derivative Financial Instruments Valuation | |||||||||||||||||||||||||||||
The following table shows the carrying amounts of the Company's derivatives at December 31, 2013 and December 31, 2012. | |||||||||||||||||||||||||||||
2013 | 2012 | ||||||||||||||||||||||||||||
Assets(2) | Liabilities(2) | Assets(2) | Liabilities(2) | ||||||||||||||||||||||||||
Derivatives in cash flow hedging relationships(1) | |||||||||||||||||||||||||||||
Current | |||||||||||||||||||||||||||||
Foreign exchange contracts | 4,985 | -2,719 | 7,839 | -7,510 | |||||||||||||||||||||||||
Non-current | |||||||||||||||||||||||||||||
Foreign exchange contracts | 759 | -374 | 942 | -187 | |||||||||||||||||||||||||
Interest rate contracts | - | -4,392 | - | -6,221 | |||||||||||||||||||||||||
Total | $ | 5,744 | $ | -7,485 | $ | 8,781 | $ | -13,918 | |||||||||||||||||||||
Derivatives not designated as hedging instruments(1) | |||||||||||||||||||||||||||||
Current | |||||||||||||||||||||||||||||
Foreign exchange contracts | 11,679 | -22,982 | 23,396 | -19,068 | |||||||||||||||||||||||||
Non-current | |||||||||||||||||||||||||||||
Foreign exchange contracts | 1,060 | -820 | 132 | -292 | |||||||||||||||||||||||||
Total | $ | 12,739 | $ | -23,802 | $ | 23,528 | $ | -19,360 | |||||||||||||||||||||
(1) At December 31, 2013 and December 31, 2012, the valuation of the Company's derivatives was determined using Significant Other Observable Inputs (Level 2) in accordance with the fair value hierarchy levels established in U.S. GAAP. | |||||||||||||||||||||||||||||
(2) Derivative instruments are marked to market each reporting period resulting in carrying amounts being equal to fair values at the reporting date. | |||||||||||||||||||||||||||||
The carrying amounts for the current portion of derivatives indicated as assets in the table above are included in Prepaid expenses and other current assets in the Consolidated Balance Sheets while the current portion of those indicated as liabilities are included in Accrued expenses and other current liabilities. The non-current portions indicated as assets or liabilities are included in the Consolidated Balance Sheets in Other assets or Other liabilities, respectively. | |||||||||||||||||||||||||||||
The significant methods and assumptions used in estimating the fair values of derivative financial instruments are as follows: | |||||||||||||||||||||||||||||
The fair value of interest rate swaps is calculated by discounting the future cash flows on the basis of the market interest rates applicable for the remaining term of the contract as of the balance sheet date. To determine the fair value of foreign exchange forward contracts, the contracted forward rate is compared to the current forward rate for the remaining term of the contract as of the balance sheet date. The result is then discounted on the basis of the market interest rates prevailing at the balance sheet date for the applicable currency. | |||||||||||||||||||||||||||||
The Company includes its own credit risk for financial instruments deemed liabilities and counterparty-credit risks for financial instruments deemed assets when measuring the fair value of derivative financial instruments. | |||||||||||||||||||||||||||||
The Effect of Derivatives on the Consolidated Financial Statements | |||||||||||||||||||||||||||||
Amount of Gain or (Loss) Recognized in AOCI on Derivatives | Location of (Gain) or Loss Reclassified from AOCI in Income | Amount of (Gain) or Loss Reclassified from AOCI in Income | |||||||||||||||||||||||||||
Derivatives in Cash Flow Hedging Relationships | |||||||||||||||||||||||||||||
(Effective Portion) for the year ended December 31, | (Effective Portion) for the year ended December 31, | ||||||||||||||||||||||||||||
2013 | 2012 | (Effective Portion) | 2013 | 2012 | |||||||||||||||||||||||||
Interest rate contracts | $ | -6,601 | $ | -16,762 | Interest income/expense | $ | 28,111 | $ | 23,779 | ||||||||||||||||||||
Foreign exchange contracts | 3,684 | 21,834 | Costs of Revenue | -3,251 | -5,414 | ||||||||||||||||||||||||
Foreign exchange contracts | Interest income/expense | 589 | 582 | ||||||||||||||||||||||||||
$ | -2,917 | $ | 5,072 | $ | 25,449 | $ | 18,947 | ||||||||||||||||||||||
Derivatives not Designated as Hedging Instruments | Amount of (Gain) or Loss Recognized in Income on Derivatives for the year ended December 31, | ||||||||||||||||||||||||||||
Location of (Gain) or Loss Recognized in Income on Derivatives | |||||||||||||||||||||||||||||
2013 | 2012 | ||||||||||||||||||||||||||||
Foreign exchange contracts | Selling, general and administrative expense | ||||||||||||||||||||||||||||
$ | -15,190 | $ | -8,804 | ||||||||||||||||||||||||||
Foreign exchange contracts | Interest income/expense | 7,161 | 8,033 | ||||||||||||||||||||||||||
$ | -8,029 | $ | -771 | ||||||||||||||||||||||||||
For foreign exchange derivatives, the Company expects to recognize $2,351 of losses deferred in AOCI at December 31, 2013, in earnings during the next twelve months. | |||||||||||||||||||||||||||||
The Company expects to incur additional interest expense of $22,927 over the next twelve months which is currently deferred in AOCI. This amount reflects the projected amortization of the settlement amount of the terminated swaps and the current fair value of the additional interest payments resulting from the remaining interest rate swap maturing in 2016 at December 31, 2013. | |||||||||||||||||||||||||||||
At December 31, 2013, the Company had foreign exchange derivatives with maturities of up to 23 months and interest rate swaps with maturities of up to 34 months. |
Other_Comprehensive_Income_Los
Other Comprehensive Income (Loss) | 12 Months Ended | |||||||||||||||||||
Dec. 31, 2013 | ||||||||||||||||||||
Notes to Consolidated Financial Statements [Abstract] | ' | |||||||||||||||||||
Other Comprehensive Income (Loss) | ' | |||||||||||||||||||
22. Other Comprehensive Income (Loss) | ||||||||||||||||||||
The changes in the components of other comprehensive income (loss) for the years ended December 31, 2013, 2012, and 2011 are as follows: | ||||||||||||||||||||
Pretax | Tax effect | Net, before non-controlling interests | Non-controlling interests | Other comprehensive income (loss), net of tax | ||||||||||||||||
Year ended December 31, 2011 | ||||||||||||||||||||
Other comprehensive income (loss) relating to cash flow hedges: | ||||||||||||||||||||
Changes in fair value of cash flow hedges during the period | $ | -104,130 | $ | 41,825 | $ | -62,305 | $ | - | $ | -62,305 | ||||||||||
Reclassification adjustments | 1,684 | -796 | 888 | - | 888 | |||||||||||||||
Total other comprehensive income (loss) relating to cash flow hedges | -102,446 | 41,029 | -61,417 | - | -61,417 | |||||||||||||||
Foreign-currency translation adjustment | -179,987 | - | -179,987 | -1,247 | -181,234 | |||||||||||||||
Defined benefit pension plans: | ||||||||||||||||||||
Actuarial (loss) gain on defined benefit pension plans | -90,643 | 34,930 | -55,713 | - | -55,713 | |||||||||||||||
Reclassification adjustments | 8,737 | -3,342 | 5,395 | - | 5,395 | |||||||||||||||
Total other comprehensive income (loss) relating to defined benefit pension plans | -81,906 | 31,588 | -50,318 | - | -50,318 | |||||||||||||||
Other comprehensive income (loss) | $ | -364,339 | $ | 72,617 | $ | -291,722 | $ | -1,247 | $ | -292,969 | ||||||||||
Year ended December 31, 2012 | ||||||||||||||||||||
Other comprehensive income (loss) relating to cash flow hedges: | ||||||||||||||||||||
Changes in fair value of cash flow hedges during the period | $ | 5,072 | $ | -21,171 | $ | -16,099 | $ | - | $ | -16,099 | ||||||||||
Reclassification adjustments | 18,947 | -4,968 | 13,979 | - | 13,979 | |||||||||||||||
Total other comprehensive income (loss) relating to cash flow hedges | 24,019 | -26,139 | -2,120 | - | -2,120 | |||||||||||||||
Foreign-currency translation adjustment | 63,982 | - | 63,982 | -179 | 63,803 | |||||||||||||||
Defined benefit pension plans: | ||||||||||||||||||||
Actuarial (loss) gain on defined benefit pension plans | -121,512 | 42,159 | -79,353 | - | -79,353 | |||||||||||||||
Reclassification adjustments | 18,334 | -7,189 | 11,145 | - | 11,145 | |||||||||||||||
Total other comprehensive income (loss) relating to defined benefit pension plans | -103,178 | 34,970 | -68,208 | - | -68,208 | |||||||||||||||
Other comprehensive income (loss) | $ | -15,177 | $ | 8,831 | $ | -6,346 | $ | -179 | $ | -6,525 | ||||||||||
Year ended December 31, 2013 | ||||||||||||||||||||
Other comprehensive income (loss) relating to cash flow hedges: | ||||||||||||||||||||
Changes in fair value of cash flow hedges during the period | $ | -2,917 | $ | 1,346 | $ | -1,571 | $ | - | $ | -1,571 | ||||||||||
Reclassification adjustments | 25,449 | -7,393 | 18,056 | - | 18,056 | |||||||||||||||
Total other comprehensive income (loss) relating to cash flow hedges | 22,532 | -6,047 | 16,485 | - | 16,485 | |||||||||||||||
Foreign-currency translation adjustment | -112,395 | - | -112,395 | -2,044 | -114,439 | |||||||||||||||
Defined benefit pension plans: | ||||||||||||||||||||
Actuarial (loss) gain on defined benefit pension plans | 39,571 | -17,828 | 21,743 | - | 21,743 | |||||||||||||||
Reclassification adjustments | 25,418 | -9,725 | 15,693 | - | 15,693 | |||||||||||||||
Total other comprehensive income (loss) relating to defined benefit pension plans | 64,989 | -27,553 | 37,436 | - | 37,436 | |||||||||||||||
Other comprehensive income (loss) | $ | -24,874 | $ | -33,600 | $ | -58,474 | $ | -2,044 | $ | -60,518 | ||||||||||
Changes in AOCI by component for the years ended December 31, 2013, 2012, and 2011 are as follows: | ||||||||||||||||||||
Gain (Loss) related to cash flow hedges | Actuarial gain (loss) on defined benefit pension plans | Gain (Loss) related to foreign-currency translation | Total, before non-controlling interests | Non-controlling interests | Total | |||||||||||||||
Balance at December 31, 2010 | $ | -74,804 | $ | -60,897 | $ | -58,344 | $ | -194,045 | $ | 4,295 | $ | -189,750 | ||||||||
Other comprehensive income before reclassifications | -62,305 | -55,713 | -179,987 | -298,005 | -1,247 | -299,252 | ||||||||||||||
Amounts reclassified from AOCI | 888 | 5,395 | - | 6,283 | - | 6,283 | ||||||||||||||
Net current-period other comprehensive income | -61,417 | -50,318 | -179,987 | -291,722 | -1,247 | -292,969 | ||||||||||||||
Balance at December 31, 2011 | $ | -136,221 | $ | -111,215 | $ | -238,331 | $ | -485,767 | $ | 3,048 | $ | -482,719 | ||||||||
Other comprehensive income before reclassifications | -16,099 | -79,353 | 63,982 | -31,470 | -179 | -31,649 | ||||||||||||||
Amounts reclassified from AOCI | 13,979 | 11,145 | - | 25,124 | - | 25,124 | ||||||||||||||
Net current-period other comprehensive income | -2,120 | -68,208 | 63,982 | -6,346 | -179 | -6,525 | ||||||||||||||
Balance at December 31, 2012 | $ | -138,341 | $ | -179,423 | $ | -174,349 | $ | -492,113 | $ | 2,869 | $ | -489,244 | ||||||||
Other comprehensive income before reclassifications | -1,571 | 21,743 | -112,395 | -92,223 | -2,044 | -94,267 | ||||||||||||||
Amounts reclassified from AOCI | 18,056 | 15,693 | - | 33,749 | - | 33,749 | ||||||||||||||
Net current-period other comprehensive income | 16,485 | 37,436 | -112,395 | -58,474 | -2,044 | -60,518 | ||||||||||||||
Balance at December 31, 2013 | $ | -121,856 | $ | -141,987 | $ | -286,744 | $ | -550,587 | $ | 825 | $ | -549,762 | ||||||||
Reclassifications out of AOCI for the years ended December 31, 2013, 2012, and 2011 are as follows: | ||||||||||||||||||||
Details about AOCI Components | Amount of (Gain) Loss reclassified from AOCI in Income | Location of (Gain) Loss reclassified from AOCI in Income | ||||||||||||||||||
For the years ended December 31, | ||||||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||||||
(Gain) Loss related to cash flow hedges | ||||||||||||||||||||
Interest rate contracts | $ | 28,111 | $ | 23,779 | $ | 5,946 | Interest income/expense | |||||||||||||
foreign exchange contracts | -3,251 | -5,414 | -4,262 | Costs of Revenue | ||||||||||||||||
foreign exchange contracts | 589 | 582 | - | Interest income/expense | ||||||||||||||||
25,449 | 18,947 | 1,684 | Total before tax | |||||||||||||||||
-7,393 | -4,968 | -796 | Tax expense or benefit | |||||||||||||||||
$ | 18,056 | $ | 13,979 | $ | 888 | Net of tax | ||||||||||||||
Actuarial (Gain) Loss on defined benefit pension plans | ||||||||||||||||||||
Actuarial (gains) losses | $ | 25,418 | $ | 18,334 | $ | 8,737 | -1 | |||||||||||||
25,418 | 18,334 | 8,737 | Total before tax | |||||||||||||||||
-9,725 | -7,189 | -3,342 | Tax expense or benefit | |||||||||||||||||
$ | 15,693 | $ | 11,145 | $ | 5,395 | Net of tax | ||||||||||||||
Total reclassifications for the period | $ | 33,749 | $ | 25,124 | $ | 6,283 | Net of tax | |||||||||||||
(1) Included in the computation of net periodic pension cost (see Note 12 for additional details). |
Business_Segment_Information
Business Segment Information | 12 Months Ended | ||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||
Notes to Consolidated Financial Statements [Abstract] | ' | ||||||||||||||||
Business Segment Information | ' | ||||||||||||||||
24. Segment and Corporate Information | |||||||||||||||||
The Company has identified three operating segments, North America Segment, EMEALA, and Asia-Pacific, which were determined based upon how the Company manages its businesses. All segments are primarily engaged in providing dialysis care services and the distribution of products and equipment for the treatment of ESRD. The Company has aggregated the EMEALA and Asia-Pacific operating segments as the “International Segment”. The segments are aggregated due to their similar economic characteristics. These characteristics include same services provided and same products sold, the same type of patient population, similar methods of distribution of products and services and similar economic environments. The General Partner's management board member responsible for the profitability and cash flow of each segment's various businesses supervises the management of each operating segment. The accounting policies of the segments are the same as those the Company applies in preparing the consolidated financial statements under U.S. GAAP. | |||||||||||||||||
Management evaluates each segment using a measure that reflects all of the segment's controllable revenues and expenses. With respect to the performance of business operations, management believes that the most appropriate measure in this regard is operating income which measures the Company's source of earnings. The Company does not include the effects of certain transactions, such as the investment gain resulting from the 2012 Liberty Acquisition nor income taxes as it believes these items to be outside the segments' control. Financing is a corporate function, which the Company's segments do not control. Therefore, the Company does not include interest expense relating to financing as a segment measurement. Similarly, the Company does not allocate certain costs which relate primarily to certain headquarters overhead charges, including accounting and finance, global research and development, etc. (“Corporate”), because the Company believes that these costs are also not within the control of the individual segments. Production of products, production asset management, quality management and procurement are centrally managed at Corporate by Global Manufacturing Operations. These Corporate activities do not fulfill the definition of a segment. Products are transferred to the segments at cost; therefore no internal profit is generated. The associated internal revenues for the product transfers and their elimination are recorded as Corporate activities. Capital expenditures for production are based on the expected demand of the segments and consolidated profitability considerations. In addition, certain revenues, investments and intangible assets, as well as any related expenses, are not allocated to a segment but are accounted for as Corporate. | |||||||||||||||||
Information pertaining to the Company's segment and Corporate activities for the twelve-month periods ended December 31, 2013, 2012 and 2011 is set forth below. | |||||||||||||||||
North America Segment | International Segment | Segment Total | Corporate | Total | |||||||||||||
2013 | |||||||||||||||||
Net revenue external customers | $ | 9,606,111 | $ | 4,970,319 | $ | 14,576,430 | $ | 33,297 | $ | 14,609,727 | |||||||
Inter - segment revenue | 7,045 | - | 7,045 | -7,045 | - | ||||||||||||
Revenue | 9,613,156 | 4,970,319 | 14,583,475 | 26,252 | 14,609,727 | ||||||||||||
Depreciation and amortization | -330,371 | -185,570 | -515,941 | -132,284 | -648,225 | ||||||||||||
Operating Income | 1,623,984 | 858,308 | 2,482,292 | -226,096 | 2,256,196 | ||||||||||||
Income (loss) from equity method investees | 19,297 | 1,672 | 20,969 | 5,136 | 26,105 | ||||||||||||
Segment assets | 14,698,039 | 6,177,482 | 20,875,521 | 2,244,385 | 23,119,906 | ||||||||||||
thereof investments in equity method investees | 268,370 | 396,524 | 664,894 | -448 | 664,446 | ||||||||||||
Capital expenditures, acquisitions and investments (1) | 789,340 | 286,420 | 1,075,760 | 167,903 | 1,243,663 | ||||||||||||
2012 | |||||||||||||||||
Net revenue external customers | $ | 9,031,108 | $ | 4,740,132 | $ | 13,771,240 | $ | 29,042 | $ | 13,800,282 | |||||||
Inter - segment revenue | 10,072 | - | 10,072 | -10,072 | - | ||||||||||||
Revenue | 9,041,180 | 4,740,132 | 13,781,312 | 18,970 | 13,800,282 | ||||||||||||
Depreciation and amortization | -310,216 | -175,504 | -485,720 | -117,176 | -602,896 | ||||||||||||
Operating Income | 1,615,348 | 809,269 | 2,424,617 | -206,044 | 2,218,573 | ||||||||||||
Income (loss) from equity method investees | 23,408 | 919 | 24,327 | -6,885 | 17,442 | ||||||||||||
Segment assets | 14,170,453 | 5,892,477 | 20,062,930 | 2,263,068 | 22,325,998 | ||||||||||||
thereof investments in equity method investees | 266,521 | 378,626 | 645,147 | -7,774 | 637,373 | ||||||||||||
Capital expenditures, acquisitions and investments (2) | 2,147,522 | 230,888 | 2,378,410 | 175,808 | 2,554,218 | ||||||||||||
2011 | |||||||||||||||||
Net revenue external customers | $ | 7,925,472 | $ | 4,627,950 | $ | 12,553,422 | $ | 17,093 | $ | 12,570,515 | |||||||
Inter - segment revenue | 9,196 | - | 9,196 | -9,196 | - | ||||||||||||
Revenue | 7,934,668 | 4,627,950 | 12,562,618 | 7,897 | 12,570,515 | ||||||||||||
Depreciation and amortization | -269,055 | -173,600 | -442,655 | -114,628 | -557,283 | ||||||||||||
Operating Income | 1,435,450 | 807,437 | 2,242,887 | -167,995 | 2,074,892 | ||||||||||||
Income (loss) from equity method investees | 32,387 | 69 | 32,456 | -1,497 | 30,959 | ||||||||||||
Segment assets | 11,761,777 | 5,589,421 | 17,351,198 | 2,181,652 | 19,532,850 | ||||||||||||
thereof investments in equity method investees | 322,990 | 370,447 | 693,437 | -1,412 | 692,025 | ||||||||||||
Capital expenditures, acquisitions and investments (3) | 1,055,183 | 1,161,825 | 2,217,008 | 166,176 | 2,383,184 | ||||||||||||
(1) North America and International acquisitions exclude $48,231 and $18,686, respectively, of non-cash acquisitions and investments for 2013. | |||||||||||||||||
(2) North America and International acquisitions exclude $484,699 and $6,624, respectively, of non-cash acquisitions and investments for 2012. | |||||||||||||||||
(3) North America and International acquisitions exclude $6,000 and $225,034, respectively, of non-cash acquisitions and investments for 2011. | |||||||||||||||||
For the geographic presentation, revenues are attributed to specific countries based on the end user's location for products and the country in which the service is provided. Information with respect to the Company's geographic operations is set forth in the table below: | |||||||||||||||||
Germany | North America | Rest of the World | Total | ||||||||||||||
2013 | |||||||||||||||||
Net revenue | $ | 437,459 | $ | 9,606,111 | $ | 4,566,157 | $ | 14,609,727 | |||||||||
Long-lived assets | 609,040 | 12,891,384 | 3,226,779 | 16,727,203 | |||||||||||||
2012 | |||||||||||||||||
Net revenue | $ | 409,195 | $ | 9,031,108 | $ | 4,359,979 | $ | 13,800,282 | |||||||||
Long-lived assets | 493,782 | 12,428,762 | 3,185,773 | 16,108,317 | |||||||||||||
2011 | |||||||||||||||||
Net revenue | $ | 422,476 | $ | 7,925,472 | $ | 4,222,567 | $ | 12,570,515 | |||||||||
Long-lived assets | 420,573 | 10,326,615 | 3,040,872 | 13,788,060 |
Supplementary_Cash_Flow_Inform
Supplementary Cash Flow Information | 12 Months Ended | |||||||||
Dec. 31, 2013 | ||||||||||
Notes to Consolidated Financial Statements [Abstract] | ' | |||||||||
Cash Flow Supplemental Disclosures [Text Block] | ' | |||||||||
23. Supplementary Cash Flow Information | ||||||||||
The following additional information is provided with respect to the consolidated statements of cash flows: | ||||||||||
2013 | 2012 | 2011 | ||||||||
Supplementary cash flow information: | ||||||||||
Cash paid for interest | $ | 374,648 | $ | 349,415 | $ | 259,835 | ||||
Cash paid for income taxes(1) | $ | 542,625 | $ | 552,711 | $ | 455,805 | ||||
Cash inflow for income taxes from stock option exercises | $ | 8,882 | $ | 21,008 | $ | 13,010 | ||||
Supplemental disclosures of cash flow information: | ||||||||||
Details for acquisitions: | ||||||||||
Assets acquired | $ | -417,669 | $ | -2,519,189 | $ | -1,684,630 | ||||
Liabilities assumed | 31,335 | 241,342 | 215,253 | |||||||
Noncontrolling interest subject to put provisions | 15,460 | 123,210 | 26,684 | |||||||
Noncontrolling interest | 9,104 | 104,947 | 20,983 | |||||||
Obligations assumed in connection with acquisition | 66,917 | 6,624 | 20,016 | |||||||
Cash paid | -294,853 | -2,043,066 | -1,401,694 | |||||||
Less cash acquired | 6,858 | 173,278 | 47,461 | |||||||
Net cash paid for acquisitions | -287,995 | -1,869,788 | -1,354,233 | |||||||
Cash paid for investments | -195,921 | -387 | -419,040 | |||||||
Cash paid for intangible assets | -11,809 | -8,733 | -12,056 | |||||||
Total cash paid for acquisitions and investments, net of cash acquired, and purchases of intangible assets | $ | -495,725 | $ | -1,878,908 | $ | -1,785,329 | ||||
(1) Net of tax refund. |
Supplemental_Condensed_Combini
Supplemental Condensed Combining Information | 12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2010 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes to Consolidated Financial Statements [Abstract] | ' | ' | ' | ' | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Supplemental Condensed Combining Information | ' | ' | ' | ' | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
25. Supplemental Condensed Combining Information | For the year ended December 31, 2012 | For the year ended December 31, 2011 | For the year ended December 31, 2011 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FMC Finance III, a former wholly-owned subsidiary of the Company, issued 6⅞% Senior Notes due 2017 in July 2007. On June 20, 2011, Fresenius Medical Care US Finance, Inc. (“US Finance”) acquired substantially all of the assets of FMC Finance III and assumed its obligations, including the 6⅞% Senior Notes and the related indenture. The 6⅞% Senior Notes are fully and unconditionally guaranteed, jointly and severally on a senior basis, by the Company and by the Guarantor Subsidiaries. The 6⅞% Senior Notes and related guarantees were issued in an exchange offer registered under the Securities Act of 1933. The financial statements in this report present the financial condition of the Company, on a consolidated basis at December 31, 2013 and December 31, 2012 and its results of operations and cash flows for the periods ended December 31, 2013, 2012 and 2011. The following combining financial information for the Company is at December 31, 2013 and December 31, 2012 and for the periods ended December 31, 2013, 2012 and 2011, | Issuer | Guarantors | Issuer | Guarantors | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | Issuer | Guarantors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
For the year ended December 31, 2013 | FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuer | Guarantors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | Net revenue | $ | - | $ | - | $ | 1,884,622 | $ | - | $ | 14,806,815 | $ | -2,891,155 | $ | 13,800,282 | Net Income | $ | 3,334 | $ | 1,071,154 | $ | 14,915 | $ | 600,613 | $ | 999,109 | $ | -1,511,863 | $ | 1,177,262 | Net revenue | $ | - | $ | - | $ | 1,931,016 | $ | - | $ | 13,498,566 | $ | -2,859,067 | $ | 12,570,515 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cost of revenue | - | - | 1,197,337 | - | 10,876,513 | -2,874,821 | 9,199,029 | Gain (loss) related to cash flow hedges | - | -124,662 | -269 | 49,857 | -27,372 | - | -102,446 | Cost of revenue | - | - | 1,210,733 | - | 10,020,572 | -2,812,831 | 8,418,474 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net revenue | $ | - | $ | - | $ | 2,084,014 | $ | - | $ | 15,825,782 | $ | -3,300,069 | $ | 14,609,727 | Gross profit | - | - | 687,285 | - | 3,930,302 | -16,334 | 4,601,253 | Actuarial gain (loss) on defined benefit pension plans | - | -174 | -6,457 | -74,921 | -354 | - | -81,906 | Gross profit | - | - | 720,283 | - | 3,477,994 | -46,236 | 4,152,041 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cost of revenue | - | - | 1,356,114 | - | 11,789,397 | -3,274,181 | 9,871,330 | Operating expenses (income): | Gain (loss) related to foreign currency translation | - | -9,754 | -7,047 | - | -165,371 | 938 | -181,234 | Operating expenses (income): | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gross profit | - | - | 727,900 | - | 4,036,385 | -25,888 | 4,738,397 | Selling, general and administrative (1) | - | 59,222 | 203,284 | -51,963 | 2,030,970 | 29,536 | 2,271,049 | Income tax (expense) benefit related to components of other comprehensive income | - | 36,864 | 1,966 | 9,964 | 23,823 | - | 72,617 | Selling, general and administrative (1) | 1 | 158,222 | 208,022 | 67,587 | 1,611,194 | -78,711 | 1,966,315 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Operating expenses (income): | Research and development | - | - | 69,025 | - | 42,442 | 164 | 111,631 | Other comprehensive income (loss), net of tax | - | -97,726 | -11,807 | -15,100 | -169,274 | 938 | -292,969 | Research and development | - | - | 68,876 | - | 41,958 | - | 110,834 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Selling, general and administrative(1) | - | 184,054 | 284,589 | -128,356 | 2,150,296 | -134,187 | 2,356,396 | Operating (loss) income | - | -59,222 | 414,976 | 51,963 | 1,856,890 | -46,034 | 2,218,573 | Total comprehensive income | $ | 3,334 | $ | 973,428 | $ | 3,108 | $ | 585,513 | $ | 829,835 | $ | -1,510,925 | $ | 884,293 | Operating (loss) income | -1 | -158,222 | 443,385 | -67,587 | 1,824,842 | 32,475 | 2,074,892 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Research and development | - | - | 72,638 | - | 53,336 | -169 | 125,805 | Other (income) expense: | Comprehensive income attributable to noncontrolling interests | - | - | - | - | - | 104,861 | 104,861 | Other (income) expense: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Operating (loss) income | - | -184,054 | 370,673 | 128,356 | 1,832,753 | 108,468 | 2,256,196 | Investment gain | - | - | - | - | -139,600 | - | -139,600 | Comprehensive income attributable to shareholders of FMC-AG & Co. KGaA | $ | 3,334 | $ | 973,428 | $ | 3,108 | $ | 585,513 | $ | 829,835 | $ | -1,615,786 | $ | 779,432 | Interest, net | -5,351 | 90,148 | 6,867 | 82,205 | 140,567 | -17,903 | 296,533 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other (income) expense: | Interest, net | -6,839 | 216,914 | 2,682 | 156,794 | 71,797 | -15,288 | 426,060 | Other, net | - | -1,379,577 | 297,281 | -691,312 | - | 1,773,608 | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest, net | -6,871 | 210,759 | 5,922 | 176,643 | 22,108 | - | 408,561 | Other, net | - | -1,531,505 | 261,505 | -921,180 | - | 2,191,180 | - | For the year ended December 31, 2011 | Income (loss) before income taxes | 5,350 | 1,131,207 | 139,237 | 541,520 | 1,684,275 | -1,723,230 | 1,778,359 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other, net | - | -1,545,184 | 259,165 | -824,853 | - | 2,110,872 | - | Income (loss) before income taxes | 6,839 | 1,255,369 | 150,789 | 816,349 | 1,924,693 | -2,221,926 | 1,932,113 | Issuer | Guarantors | Income tax expense (benefit) | 2,016 | 60,053 | 124,322 | -59,093 | 685,166 | -211,367 | 601,097 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income (loss) before income taxes | 6,871 | 1,150,371 | 105,586 | 776,566 | 1,810,645 | -2,002,404 | 1,847,635 | Income tax expense (benefit) | 2,482 | 68,560 | 119,255 | -41,356 | 698,353 | -242,158 | 605,136 | FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | Net Income (loss) | 3,334 | 1,071,154 | 14,915 | 600,613 | 999,109 | -1,511,863 | 1,177,262 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income tax expense (benefit) | 2,494 | 40,481 | 108,837 | -19,049 | 652,672 | -193,423 | 592,012 | Net Income (loss) | 4,357 | 1,186,809 | 31,534 | 857,705 | 1,226,340 | -1,979,768 | 1,326,977 | Net Income attributable to noncontrolling interests | - | - | - | - | - | 106,108 | 106,108 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net Income (loss) | 4,377 | 1,109,890 | -3,251 | 795,615 | 1,157,973 | -1,808,981 | 1,255,623 | Net Income attributable to noncontrolling interests | - | - | - | - | 140,168 | - | 140,168 | Operating Activities: | Net income (loss) attributable to shareholders of FMC-AG & Co. KGaA | $ | 3,334 | $ | 1,071,154 | $ | 14,915 | $ | 600,613 | $ | 999,109 | $ | -1,617,971 | $ | 1,071,154 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net Income attributable to noncontrolling interests | - | - | - | - | 145,733 | - | 145,733 | Net income (loss) attributable to shareholders of FMC-AG & Co. KGaA | $ | 4,357 | $ | 1,186,809 | $ | 31,534 | $ | 857,705 | $ | 1,086,172 | $ | -1,979,768 | $ | 1,186,809 | Net income (loss) | $ | 3,334 | $ | 1,071,154 | $ | 14,915 | $ | 600,613 | $ | 999,109 | $ | -1,511,863 | $ | 1,177,262 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net income (loss) attributable to shareholders of FMC-AG & Co. KGaA | $ | 4,377 | $ | 1,109,890 | $ | -3,251 | $ | 795,615 | $ | 1,012,240 | $ | -1,808,981 | $ | 1,109,890 | Adjustments to reconcile net income to net cash provided by (used in) operating activities: | (1) Selling, general and administrative is presented net of gain on sale of dialysis clinics and net of income from equity method investees. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(1) Selling, general and administrative is presented net of gain on sale of dialysis clinics, net of income from equity method investees and net of other operating expenses. | Equity affiliate income | - | -872,048 | - | -691,312 | - | 1,563,360 | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(1) Selling, general and administrative is presented net of gain on sale of dialysis clinics and net of income from equity method investees. | For the year ended December 31, 2012 | Depreciation and amortization | - | 858 | 49,207 | 5,768 | 514,843 | -13,393 | 557,283 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
For the year ended December 31, 2013 | Issuer | Guarantors | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | Change in deferred taxes, net | - | 12,593 | 2,724 | - | 150,598 | -6,734 | 159,181 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuer | Guarantors | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | (Gain) loss on sale of fixed assets and investments | - | -10 | -184 | - | -8,791 | - | -8,985 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | (Gain) loss on investments | - | 31,502 | 186 | - | - | -31,688 | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net Income | $ | 4,357 | $ | 1,186,809 | $ | 31,534 | $ | 857,705 | $ | 1,226,340 | $ | -1,979,768 | $ | 1,326,977 | (Write Up) write-off loans from related parties | - | 44,807 | - | - | - | -44,807 | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net Income | $ | 4,377 | $ | 1,109,890 | $ | -3,251 | $ | 795,615 | $ | 1,157,973 | $ | -1,808,981 | $ | 1,255,623 | Gain (loss) related to cash flow hedges | - | -4,465 | -9 | 11,725 | 16,768 | - | 24,019 | Compensation expense related to stock options | - | 29,071 | - | - | - | - | 29,071 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain (loss) related to cash flow hedges | - | 21,020 | - | - | 1,512 | - | 22,532 | Actuarial gain (loss) on defined benefit pension plans | - | -2,091 | -46,830 | -49,796 | -4,461 | - | -103,178 | Cash outflow from hedging | - | - | - | - | -58,113 | - | -58,113 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Actuarial gain (loss) on defined benefit pension plans | - | -971 | -15,150 | 83,597 | -2,487 | - | 64,989 | Gain (loss) related to foreign currency translation | - | -84,026 | 18,540 | - | 132,627 | -3,338 | 63,803 | Investments in equity method investees, net | - | - | - | - | -30,959 | - | -30,959 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain (loss) related to foreign currency translation | - | -158,328 | 32,934 | - | -12,896 | 23,851 | -114,439 | Income tax (expense) benefit related to components of other comprehensive income | - | 3,615 | 13,447 | 15,019 | -23,250 | - | 8,831 | Changes in assets and liabilities, net of amounts from businesses acquired: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income tax (expense) benefit related to components of other comprehensive income | - | -6,317 | -4,418 | 32,979 | -55,844 | - | -33,600 | Other comprehensive income (loss), net of tax | - | -86,967 | -14,852 | -23,052 | 121,684 | -3,338 | -6,525 | Trade accounts receivable, net | - | - | -13,401 | - | -239,393 | - | -252,794 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other comprehensive income (loss), net of tax | - | -144,596 | 13,366 | 116,576 | -69,715 | 23,851 | -60,518 | Total comprehensive income | $ | 4,357 | $ | 1,099,842 | $ | 16,682 | $ | 834,653 | $ | 1,348,024 | $ | -1,983,106 | $ | 1,320,452 | Inventories | - | - | -47,022 | - | -135,071 | 30,203 | -151,890 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total comprehensive income | $ | 4,377 | $ | 965,294 | $ | 10,115 | $ | 912,191 | $ | 1,088,258 | $ | -1,785,130 | $ | 1,195,105 | Comprehensive income attributable to noncontrolling interests | - | - | - | - | - | 139,989 | 139,989 | Prepaid expenses and other current and non-current assets | - | -133,691 | -3,048 | 86,497 | -80,570 | -46 | -130,858 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Comprehensive income attributable to noncontrolling interests | - | - | - | - | - | 143,689 | 143,689 | Comprehensive income attributable to shareholders of FMC-AG & Co. KGaA | $ | 4,357 | $ | 1,099,842 | $ | 16,682 | $ | 834,653 | $ | 1,348,024 | $ | -2,123,095 | $ | 1,180,463 | Accounts receivable from / payable to related parties | -12,372 | -1,183,881 | -51,617 | 54,300 | 1,239,464 | -62,058 | -16,164 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Comprehensive income attributable to shareholders of FMC-AG & Co. KGaA | $ | 4,377 | $ | 965,294 | $ | 10,115 | $ | 912,191 | $ | 1,088,258 | $ | -1,928,819 | $ | 1,051,416 | Accounts payable, accrued expenses and other current and non-current liabilities | 13,775 | -40,619 | 28,385 | 79 | 131,427 | -641 | 132,406 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
At December 31, 2012 | Income tax payable | 2,016 | 80,461 | - | -59,093 | -509 | 18,167 | 41,042 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
At December 31, 2013 | Issuer | Guarantors | Net cash provided by (used in) operating activities | 6,753 | -959,803 | -19,855 | -3,148 | 2,482,035 | -59,500 | 1,446,482 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuer | Guarantors | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | Current assets: | Investing Activities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Current assets: | Cash and cash equivalents | $ | 1 | $ | 78 | $ | 501 | $ | - | $ | 686,457 | $ | 1,003 | $ | 688,040 | Purchases of property, plant and equipment | - | -221 | -54,545 | - | -569,645 | 26,556 | -597,855 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash and cash equivalents | $ | 0 | $ | 13 | $ | 4,490 | $ | - | $ | 672,206 | $ | 6,068 | $ | 682,777 | Trade accounts receivable, less allowance for doubtful accounts | - | - | 170,627 | - | 2,848,797 | - | 3,019,424 | Proceeds from sale of property, plant and equipment | - | - | 775 | - | 26,550 | - | 27,325 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trade accounts receivable, less allowance for doubtful accounts | - | - | 152,480 | - | 2,882,736 | 2,058 | 3,037,274 | Accounts receivable from related parties | 1,269,471 | 2,257,445 | 1,449,317 | 3,562,953 | 4,398,630 | -12,800,007 | 137,809 | Disbursement of loans to related parties | - | 1,571,874 | 200 | -1,118,399 | - | -453,675 | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounts receivable from related parties | 1,269,092 | 960,137 | 815,748 | 1,643,394 | 4,073,975 | -8,609,228 | 153,118 | Inventories | - | - | 271,039 | - | 885,613 | -119,843 | 1,036,809 | Acquisitions and investments, net of cash acquired, and purchases of intangible assets | - | -148,331 | -4,554 | - | -2,529,849 | 897,405 | -1,785,329 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories | - | - | 287,625 | - | 946,790 | -137,311 | 1,097,104 | Prepaid expenses and other current assets | - | 72,022 | 27,693 | 167 | 837,152 | 40,503 | 977,537 | Proceeds from divestitures | - | - | 418 | - | 9,990 | -418 | 9,990 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Prepaid expenses and other current assets | - | 71,939 | 41,240 | 167 | 879,085 | 44,960 | 1,037,391 | Deferred taxes | - | - | - | - | 311,280 | -43,443 | 267,837 | Net cash provided by (used in) investing activities | - | 1,423,322 | -57,706 | -1,118,399 | -3,062,954 | 469,868 | -2,345,869 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deferred taxes | - | - | - | - | 322,337 | -43,285 | 279,052 | Total current assets | 1,269,472 | 2,329,545 | 1,919,177 | 3,563,120 | 9,967,929 | -12,921,787 | 6,127,456 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total current assets | 1,269,092 | 1,032,089 | 1,301,583 | 1,643,561 | 9,777,129 | -8,736,738 | 6,286,716 | Financing Activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property, plant and equipment, net | - | 611 | 206,873 | - | 2,856,000 | -122,881 | 2,940,603 | Short-term borrowings, net | - | 26,284 | 77,481 | -298 | -142,444 | - | -38,977 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property, plant and equipment, net | - | 734 | 238,469 | - | 2,980,268 | -127,517 | 3,091,954 | Intangible assets | - | 584 | 67,874 | - | 641,714 | -56 | 710,116 | Long-term debt and capital lease obligations, net | -64,252 | -221,594 | - | 433,455 | 1,147,586 | 453,675 | 1,748,870 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Intangible assets | - | 501 | 73,166 | - | 684,290 | -81 | 757,876 | Goodwill | - | - | 54,848 | - | 11,367,041 | - | 11,421,889 | Redemption of trust preferred securities | - | - | - | - | -653,760 | - | -653,760 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill | - | - | 62,829 | - | 11,595,358 | - | 11,658,187 | Deferred taxes | - | 51,111 | 10,123 | - | 131,452 | -103,534 | 89,152 | Increase (decrease) of accounts receivable securitization program | - | - | - | - | 24,500 | - | 24,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deferred taxes | - | 80,931 | 14,209 | - | 118,306 | -109,279 | 104,167 | Other assets (1) | - | 12,675,998 | 650,255 | 11,766,104 | -4,751,531 | -19,304,044 | 1,036,782 | Proceeds from exercise of stock options | - | 81,883 | - | - | 13,010 | - | 94,893 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other assets (1) | - | 13,955,933 | 47,661 | 12,583,246 | 5,234,132 | -30,599,966 | 1,221,006 | Total assets | $ | 1,269,472 | $ | 15,057,849 | $ | 2,909,150 | $ | 15,329,224 | $ | 20,212,605 | $ | -32,452,302 | $ | 22,325,998 | Dividends paid | - | -280,649 | - | - | 22 | -22 | -280,649 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total assets | $ | 1,269,092 | $ | 15,070,188 | $ | 1,737,917 | $ | 14,226,807 | $ | 30,389,483 | $ | -39,573,581 | $ | 23,119,906 | Capital increase (decrease) | 57,500 | - | - | 688,390 | 151,097 | -896,987 | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Current liabilities: | Distributions to noncontrolling interest | - | - | - | - | -129,542 | - | -129,542 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Current liabilities: | Accounts payable | $ | - | $ | 1,935 | $ | 41,114 | $ | - | $ | 579,245 | $ | - | $ | 622,294 | Contributions from noncontrolling interest | - | - | - | - | 27,824 | - | 27,824 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounts payable | $ | - | $ | 2,193 | $ | 28,689 | $ | - | $ | 511,715 | $ | - | $ | 542,597 | Accounts payable to related parties | - | 2,234,205 | 491,525 | 1,598,852 | 8,663,240 | -12,864,472 | 123,350 | Net cash provided by (used in) financing activities | -6,752 | -394,076 | 77,481 | 1,121,547 | 438,293 | -443,334 | 793,159 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounts payable to related parties | - | 1,896,712 | 522,719 | 1,600,480 | 4,931,344 | -8,827,326 | 123,929 | Accrued expenses and other current liabilities | 29,771 | 27,530 | 102,728 | 3,157 | 1,611,997 | 12,288 | 1,787,471 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued expenses and other current liabilities | 29,770 | 45,897 | 129,727 | 9,403 | 1,786,709 | 11,027 | 2,012,533 | Short-term borrowings and other financial liabilities | - | 38 | - | - | 117,812 | - | 117,850 | Effect of exchange rate changes on cash and cash equivalents | - | -216,618 | -1 | - | 257,247 | 22 | 40,650 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term borrowings and other financial liabilities | - | 60 | - | - | 96,588 | - | 96,648 | Short-term borrowings from related parties | - | - | - | - | 3,973 | - | 3,973 | Cash and Cash Equivalents: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term borrowings from related parties | - | - | - | - | 62,342 | - | 62,342 | Current portion of long-term debt and capital lease obligations | - | 207,160 | - | 100,000 | 27,587 | - | 334,747 | Net increase (decrease) in cash and cash equivalents | 1 | -147,175 | -81 | - | 114,621 | -32,944 | -65,578 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Current portion of long-term debt and capital lease obligations | - | 271,090 | - | 200,000 | 40,280 | - | 511,370 | Cash and cash equivalents at beginning of period | - | 147,177 | 225 | - | 342,524 | 32,944 | 522,870 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income tax payable | - | 130,636 | - | - | 19,367 | - | 150,003 | Cash and cash equivalents at end of period | $ | 1 | $ | 2 | $ | 144 | $ | - | $ | 457,145 | $ | - | $ | 457,292 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income tax payable | - | 114,197 | - | - | 56,163 | - | 170,360 | Deferred taxes | - | 1,622 | 8,126 | - | 61,774 | -41,219 | 30,303 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deferred taxes | - | 2,331 | 9,002 | - | 64,539 | -41,678 | 34,194 | Total current liabilities | 29,771 | 2,603,126 | 643,493 | 1,702,009 | 11,084,995 | -12,893,403 | 3,169,991 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total current liabilities | 29,770 | 2,332,480 | 690,137 | 1,809,883 | 7,549,680 | -8,857,977 | 3,553,973 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long term debt and capital lease obligations, less current portion | 1,172,397 | 285,049 | - | 2,559,340 | 7,020,190 | -3,251,236 | 7,785,740 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long term debt and capital lease obligations, less current portion | 1,167,466 | 96,699 | - | 2,438,189 | 7,478,944 | -3,434,378 | 7,746,920 | Long term debt from related parties | - | 3,212,455 | 657,284 | 2,019,925 | 64,530 | -5,898,020 | 56,174 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long term debt from related parties | - | 3,359,606 | - | 2,092,818 | 6,940 | -5,459,364 | - | Other liabilities | - | 6,696 | 12,679 | 110,637 | 96,322 | 33,923 | 260,257 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other liabilities | - | 5,616 | 6,028 | - | 298,313 | 19,604 | 329,561 | Pension liabilities | - | 7,753 | 202,219 | - | 247,701 | - | 457,673 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pension liabilities | - | 10,377 | 254,233 | - | 171,248 | - | 435,858 | Income tax payable | 2,113 | 264 | - | - | 52,684 | 146,581 | 201,642 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income tax payable | 2,287 | 30,846 | - | - | 20,262 | 123,538 | 176,933 | Deferred taxes | - | - | - | - | 685,158 | -21,157 | 664,001 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deferred taxes | - | - | - | - | 768,156 | -24,766 | 743,390 | Total liabilities | 1,204,281 | 6,115,343 | 1,515,675 | 6,391,911 | 19,251,580 | -21,883,312 | 12,595,478 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total liabilities | 1,199,523 | 5,835,624 | 950,398 | 6,340,890 | 16,293,543 | -17,633,343 | 12,986,635 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Noncontrolling interests subject to put provisions | - | - | - | - | 523,260 | - | 523,260 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Noncontrolling interests subject to put provisions | - | - | 0 | - | 648,251 | - | 648,251 | Total FMC-AG & Co. KGaA shareholders' equity | 65,191 | 8,942,506 | 1,393,475 | 8,937,313 | 173,011 | -10,568,990 | 8,942,506 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total FMC-AG & Co. KGaA shareholders' equity | 69,569 | 9,234,564 | 787,519 | 7,885,917 | 13,197,233 | -21,940,238 | 9,234,564 | Noncontrolling interests not subject to put provisions | - | - | - | - | 264,754 | - | 264,754 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Noncontrolling interests not subject to put provisions | - | - | - | - | 250,456 | - | 250,456 | Total equity | 65,191 | 8,942,506 | 1,393,475 | 8,937,313 | 437,765 | -10,568,990 | 9,207,260 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total equity | 69,569 | 9,234,564 | 787,519 | 7,885,917 | 13,447,689 | -21,940,238 | 9,485,020 | Total liabilities and equity | $ | 1,269,472 | $ | 15,057,849 | $ | 2,909,150 | $ | 15,329,224 | $ | 20,212,605 | $ | -32,452,302 | $ | 22,325,998 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total liabilities and equity | $ | 1,269,092 | $ | 15,070,188 | $ | 1,737,917 | $ | 14,226,807 | $ | 30,389,483 | $ | -39,573,581 | $ | 23,119,906 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(1) Other assets are presented net of investment in equity method investees. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(1) Other assets are presented net of investment in equity method investees. | For the year ended December 31, 2012 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
For the year ended December 31, 2013 | Issuer | Guarantors | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuer | Guarantors | FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Operating Activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Operating Activities: | Net income (loss) | $ | 4,357 | $ | 1,186,809 | $ | 31,534 | $ | 857,705 | $ | 1,226,340 | $ | -1,979,768 | $ | 1,326,977 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net income (loss) | $ | 4,377 | $ | 1,109,890 | $ | -3,251 | $ | 795,615 | $ | 1,157,973 | $ | -1,808,981 | $ | 1,255,623 | Adjustments to reconcile net income to net cash provided by (used in) operating activities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adjustments to reconcile net income to net cash provided by (used in) operating activities: | Equity affiliate income | - | -1,002,965 | - | -921,180 | - | 1,924,145 | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity affiliate income | - | -924,138 | - | -824,853 | - | 1,748,991 | - | Depreciation and amortization | - | 519 | 47,832 | - | 583,375 | -28,830 | 602,896 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Depreciation and amortization | - | 689 | 52,029 | - | 629,071 | -33,564 | 648,225 | Change in deferred taxes, net | - | 1,994 | 4,113 | - | 71,744 | -2,681 | 75,170 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Change in deferred taxes, net | - | -34,548 | 3,149 | - | 46,888 | 424 | 15,913 | (Gain) loss on sale of fixed assets and investments | - | -40 | -163 | - | -29,321 | - | -29,524 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Gain) loss on sale of fixed assets and investments | - | -43 | 437 | - | -33,378 | - | -32,984 | (Gain) loss on investments | - | 1,247 | - | - | - | -1,247 | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Gain) loss on investments | - | - | -61 | - | - | 61 | - | (Write Up) write-off loans from related parties | - | 7,527 | - | - | - | -7,527 | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Write Up) write-off loans from related parties | - | 91,593 | - | - | - | -91,593 | - | Investment (gain) | - | - | - | - | -139,600 | - | -139,600 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Compensation expense related to stock options | - | 13,593 | - | - | - | - | 13,593 | Compensation expense related to stock options | - | 26,476 | - | - | - | - | 26,476 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash inflow (outflow) from hedging | - | -4,073 | - | - | - | - | -4,073 | Cash inflow (outflow) from hedging | - | 1,322 | - | - | -15,269 | - | -13,947 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investments in equity method investees, net | - | 22,945 | - | - | -20,610 | - | 2,335 | Investments in equity method investees, net | - | 36,453 | - | - | -13,941 | - | 22,512 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Changes in assets and liabilities, net of amounts from businesses acquired: | Changes in assets and liabilities, net of amounts from businesses acquired: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trade accounts receivable, net | - | - | 14,851 | - | -54,149 | -1,982 | -41,280 | Trade accounts receivable, net | - | - | -23,848 | - | -19,496 | - | -43,344 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories | - | - | -4,162 | - | -70,848 | 20,092 | -54,918 | Inventories | - | - | -40,910 | - | -11,532 | 4,163 | -48,279 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Prepaid expenses and other current and non-current assets | - | 46,352 | -11,519 | -123,972 | 151,907 | 5,107 | 67,875 | Prepaid expenses and other current and non-current assets | - | 148,172 | -13,633 | -38,496 | 11,299 | -18,929 | 88,413 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounts receivable from / payable to related parties | -8 | -334,000 | 644,752 | 128,185 | -559,991 | 106,351 | -14,711 | Accounts receivable from / payable to related parties | -3,724 | 1,653,955 | -49,477 | 117,090 | -1,788,646 | 55,007 | -15,795 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounts payable, accrued expenses and other current and non-current liabilities | - | 11,469 | 21,203 | 6,246 | 181,426 | -5,080 | 215,264 | Accounts payable, accrued expenses and other current and non-current liabilities | - | -1,884 | 33,157 | 1,024 | 193,756 | -467 | 225,586 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income tax payable | 174 | 7,917 | - | -19,049 | -23,818 | -1,281 | -36,057 | Income tax payable | 97 | -137 | - | -41,356 | 24,316 | -21,398 | -38,478 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net cash provided by (used in) operating activities | 4,543 | 7,646 | 717,428 | -37,828 | 1,404,471 | -61,455 | 2,034,805 | Net cash provided by (used in) operating activities | 730 | 2,059,448 | -11,395 | -25,213 | 93,025 | -77,532 | 2,039,063 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investing Activities: | Investing Activities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Purchases of property, plant and equipment | - | -320 | -76,096 | - | -712,213 | 40,691 | -747,938 | Purchases of property, plant and equipment | - | -485 | -78,272 | - | -638,394 | 41,841 | -675,310 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from sale of property, plant and equipment | - | 48 | 583 | - | 19,216 | - | 19,847 | Proceeds from sale of property, plant and equipment | - | 40 | 407 | - | 9,220 | - | 9,667 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disbursement of loans to related parties | - | 911,133 | - | 141,347 | - | -1,052,480 | - | Disbursement of loans to related parties | - | -1,551,372 | - | 289,879 | - | 1,261,493 | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acquisitions and investments, net of cash acquired, and purchases of intangible assets | - | -103,308 | -24,503 | -1,000 | -492,683 | 125,769 | -495,725 | Acquisitions and investments, net of cash acquired, and purchases of intangible assets | - | -1,618,662 | -2,021 | - | -1,876,310 | 1,618,085 | -1,878,908 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from divestitures | - | - | - | - | 18,276 | - | 18,276 | Proceeds from divestitures | - | 44 | - | - | 263,306 | -44 | 263,306 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net cash provided by (used in) investing activities | - | 807,553 | -100,016 | 140,347 | -1,167,404 | -886,020 | -1,205,540 | Net cash provided by (used in) investing activities | - | -3,170,435 | -79,886 | 289,879 | -2,242,178 | 2,921,375 | -2,281,245 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financing Activities: | Financing Activities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term borrowings, net | - | 20 | -613,593 | - | 597,859 | - | -15,714 | Short-term borrowings, net | - | -24,338 | 91,628 | - | -80,241 | - | -12,951 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term debt and capital lease obligations, net | -4,544 | -140,374 | - | 1,629,443 | -2,713,226 | 1,052,480 | -176,221 | Long-term debt and capital lease obligations, net | -730 | 1,308,572 | - | -264,666 | 1,380,034 | -1,261,493 | 1,161,717 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Increase (decrease) of accounts receivable securitization program | - | - | - | - | 189,250 | - | 189,250 | Increase (decrease) of accounts receivable securitization program | - | - | - | - | -372,500 | - | -372,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from exercise of stock options | - | 102,419 | - | - | 8,881 | - | 111,300 | Proceeds from exercise of stock options | - | 100,178 | - | - | 20,948 | - | 121,126 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from conversion of preference shares into ordinary shares | - | 34,784 | - | - | - | - | 34,784 | Dividends paid | - | -271,733 | - | - | -241 | 241 | -271,733 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Purchase of treasury stock | - | -505,014 | - | - | - | - | -505,014 | Capital increase (decrease) | - | - | - | - | 1,581,588 | -1,581,588 | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dividends paid | - | -296,134 | - | - | -2,884 | 2,884 | -296,134 | Distributions to noncontrolling interest | - | - | - | - | -195,023 | - | -195,023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Capital increase (decrease) | - | - | - | -1,731,962 | 1,834,786 | -102,824 | - | Contributions from noncontrolling interest | - | - | - | - | 37,704 | - | 37,704 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Distributions to noncontrolling interest | - | - | - | - | -216,758 | - | -216,758 | Net cash provided by (used in) financing activities | -730 | 1,112,679 | 91,628 | -264,666 | 2,372,269 | -2,842,840 | 468,340 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contributions from noncontrolling interest | - | - | - | - | 66,467 | - | 66,467 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net cash provided by (used in) financing activities | -4,544 | -804,299 | -613,593 | -102,519 | -235,625 | 952,540 | -808,040 | Effect of exchange rate changes on cash and cash equivalents | - | -1,616 | 10 | - | 6,196 | - | 4,590 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash and Cash Equivalents: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Effect of exchange rate changes on cash and cash equivalents | - | -10,965 | 170 | - | -15,693 | - | -26,488 | Net increase (decrease) in cash and cash equivalents | - | 76 | 357 | - | 229,312 | 1,003 | 230,748 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash and Cash Equivalents: | Cash and cash equivalents at beginning of period | 1 | 2 | 144 | - | 457,145 | - | 457,292 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net increase (decrease) in cash and cash equivalents | -1 | -65 | 3,989 | - | -14,251 | 5,065 | -5,263 | Cash and cash equivalents at end of period | $ | 1 | $ | 78 | $ | 501 | $ | - | $ | 686,457 | $ | 1,003 | $ | 688,040 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash and cash equivalents at beginning of period | 1 | 78 | 501 | - | 686,457 | 1,003 | 688,040 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash and cash equivalents at end of period | $ | 0 | $ | 13 | $ | 4,490 | $ | - | $ | 672,206 | $ | 6,068 | $ | 682,777 |
Development_of_Allowance_for_D
Development of Allowance for Doubtful Accounts (text) | 12 Months Ended | ||||||||
Dec. 31, 2013 | |||||||||
Notes to Consolidated Financial Statements [Abstract] | ' | ||||||||
Development of Allowance for Doubtful Accounts Disclosure [Text Block] | ' | ||||||||
FRESENIUS MEDICAL CARE AG & Co. KGaA | |||||||||
Schedule II – Valuation and Qualifying Accounts | |||||||||
(in thousands, except share data) | |||||||||
Development of allowance for doubtful accounts | |||||||||
2013 | 2012 | 2011 | |||||||
Allowance for doubtful accounts as of January 1 | $ | 328,893 | $ | 299,751 | $ | 277,139 | |||
Change in valuation allowances as recorded in the consolidated statements of income | 336,090 | 303,508 | 241,598 | ||||||
Write-offs and recoveries of amounts previously written-off | -249,783 | -273,643 | -214,612 | ||||||
Foreign currency translation | -2,035 | -723 | -4,374 | ||||||
Allowance for doubtful accounts as of December 31 | $ | 413,165 | $ | 328,893 | $ | 299,751 |
The_Company_and_Basis_of_Prese1
The Company and Basis of Presentation (Policies) | 12 Months Ended | |||||
Dec. 31, 2013 | ||||||
Significant Accounting Policies [Abstract] | ' | |||||
Principles of Consolidation | ' | |||||
2013 | 2012 | |||||
Trade accounts receivable, net | $ | 102,549 | $ | 99,061 | ||
Other current assets | 59,695 | 57,741 | ||||
Property, plant and equipment, intangible assets & other non-current assets | 26,274 | 26,823 | ||||
Goodwill | 32,759 | 31,678 | ||||
Accounts payable, accrued expenses and other liabilities | 133,977 | 122,891 | ||||
Non-current loans from related parties | 12,998 | 12,998 | ||||
Equity | 74,302 | 79,414 | ||||
Cash and Cash Equivalents | ' | |||||
b) Cash and Cash Equivalents | ||||||
Cash and cash equivalents comprise cash funds and all short-term, liquid investments with original maturities of up to three months. | ||||||
Inventories | ' | |||||
Inventories | ||||||
Inventories are stated at the lower of cost (determined by using the average or first-in, first-out method) or market value (see Note 4). Costs included in inventories are based on invoiced costs and/or production costs or the marked to market valuation, as applicable. Included in production costs are material, direct labor and production overhead, including depreciation charges. | ||||||
Property, Plant and Equipment | ' | |||||
Property, Plant and Equipment | ||||||
Property, plant, and equipment are stated at cost less accumulated depreciation (see Note 6). Significant improvements are capitalized; repairs and maintenance costs that do not extend the useful lives of the assets are charged to expense as incurred. Property and equipment under capital leases are stated at the present value of future minimum lease payments at the inception of the lease, less accumulated depreciation. Depreciation on property, plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets ranging from 3 to 40 years for buildings and improvements with a weighted average life of 13 years and 3 to 15 years for machinery and equipment with a weighted average life of 10 years. Equipment held under capital leases and leasehold improvements are amortized using the straight-line method over the shorter of the lease term or the estimated useful life of the asset. Internal use platform software that is integral to the computer equipment it supports is included in property, plant and equipment. The Company capitalizes interest on borrowed funds during construction periods. Interest capitalized during 2013, 2012, and 2011 was $7,358, $3,952 and $3,784, respectively. | ||||||
Intangible Assets and Goodwill | ' | |||||
Intangible Assets and Goodwill | ||||||
Intangible assets such as non-compete agreements, technology, distribution rights, patents, licenses to treat, licenses to manufacture, distribute and sell pharmaceutical drugs, exclusive contracts and exclusive licenses, trade names, management contracts, application software, acute care agreements, customer relationships, lease agreements, and licenses acquired in a business combination are recognized and reported apart from goodwill (see Note 7). | ||||||
Goodwill and identifiable intangibles with indefinite useful lives are not amortized but tested for impairment annually or when an event becomes known that could trigger an impairment. The Company identified trade names and certain qualified management contracts as intangible assets with indefinite useful lives because, based on an analysis of all of the relevant factors, there is no foreseeable limit to the period over which those assets are expected to generate net cash inflows for the Company. Intangible assets with finite useful lives are amortized over their respective useful lives to their residual values. The Company amortizes non-compete agreements over their useful life which on average is 8 years. Technology is amortized over its useful life of 16 years. Licenses to manufacture, distribute and sell pharmaceutical drugs, exclusive contracts and exclusive licenses are amortized over their useful life which on average is 9 years. Customer relationships are amortized over their useful life of 15 years. All other intangible assets are amortized over their weighted average useful lives of 7 years. The weighted average useful life of all amortizable intangible assets is 9 years. Intangible assets with finite useful lives are evaluated for impairment when events have occurred that may give rise to an impairment. | ||||||
To perform the annual impairment test of goodwill, the Company identified its reporting units and determined their carrying value by assigning the assets and liabilities, including the existing goodwill and intangible assets, to those reporting units. One reporting unit was identified in the North America Segment. The EMEALA operating segment is divided into two reporting units (Europe and Latin America), while only one reporting unit exists in the operating segment Asia-Pacific. For the purpose of goodwill impairment testing, all corporate assets are allocated to the reporting units. | ||||||
In a first step, the Company compares the fair value of a reporting unit to its carrying amount. Fair value is determined using estimated future cash flows for the unit discounted by an after-tax weighted average cost of capital (“WACC”) specific to that reporting unit. Estimating the future cash flows involves significant assumptions, especially regarding future reimbursement rates and sales prices, number of treatments, sales volumes and costs. In determining discounted cash flows, the Company utilizes for every reporting unit, its three-year budget, projections for years 4 to 10 and a representative growth rate for all remaining years. Projections for up to ten years are possible due to the stability of the Company's business which, results from the non-discretionary nature of the healthcare services we provide, the need for products utilized to provide such services and the availability of government reimbursement for a substantial portion of our services. The reporting units' respective expected growth rates for the period beyond ten years are: North America Segment 1%, Europe 0%, Latin America 4%, and Asia-Pacific 4%. The discount factor is determined by the WACC of the respective reporting unit. The Company's WACC consisted of a basic rate of 6.17% for 2013. The basic rate is then adjusted by a country-specific risk rate and, if appropriate, by a factor to reflect higher risks associated with the cash flows from recent material acquisitions, until they are appropriately integrated, within each reporting unit. In 2013, WACCs for the reporting units ranged from 6.12% to 13.83%. | ||||||
In the case that the fair value of the reporting unit is less than its carrying value, a second step would be performed which compares the implied fair value of the reporting unit's goodwill to the carrying value of its goodwill. If the fair value of the goodwill is less than the carrying value, the difference is recorded as an impairment. | ||||||
To evaluate the recoverability of intangible assets with indefinite useful lives, the Company compares the fair values of intangible assets with their carrying values. An intangible asset's fair value is determined using a discounted cash flow approach or other methods, if appropriate. | ||||||
Derivative Financial Instruments | ' | |||||
Derivative Financial Instruments | ||||||
Derivative financial instruments, which primarily include foreign currency forward contracts and interest rate swaps, are recognized as assets or liabilities at fair value in the balance sheet (see Note 21). Changes in the fair value of derivative financial instruments classified as fair value hedges and in the corresponding underlying assets and liabilities are recognized periodically in earnings, while the effective portion of changes in fair value of derivative financial instruments classified as cash flow hedges is recognized in accumulated other comprehensive income (loss) (“AOCI”) in shareholders' equity. The ineffective portion is recognized in current net earnings. The change in fair value of derivatives that do not qualify for hedge accounting are recorded in the income statement and usually offset the changes in value recorded in the income statement for the underlying asset or liability. | ||||||
Foreign Currency Translation | ' | |||||
Foreign Currency Translation | ||||||
For purposes of these consolidated financial statements, the U.S. dollar is the reporting currency. Substantially all assets and liabilities of the parent company and all non-U.S. subsidiaries are translated at year-end exchange rates, while revenues and expenses are translated at average exchange rates. Adjustments for foreign currency translation fluctuations are excluded from net earnings and are reported in AOCI. In addition, the translation adjustments of certain intercompany borrowings, which are of a long-term nature, are reported in AOCI. | ||||||
Revenue Recognition Policy | ' | |||||
Revenue Recognition and Allowance for Doubtful Accounts | ||||||
Revenue Recognition | ||||||
Dialysis care revenues are recognized on the date the patient receives treatment and includes amounts related to certain services, products and supplies utilized in providing such treatment. The patient is obligated to pay for dialysis care services at amounts estimated to be receivable based upon the Company's standard rates or at rates determined under reimbursement arrangements. In the U.S., these arrangements are generally with third party payors, like Medicare, Medicaid or commercial insurers. Outside the U.S., the reimbursement is usually made through national or local government programs with reimbursement rates established by statute or regulation. | ||||||
Dialysis product revenues are recognized upon transfer of title to the customer, either at the time of shipment, upon receipt or upon any other terms that clearly define passage of title. Product revenues are normally based upon pre-determined rates that are established by contractual arrangement. | ||||||
For both dialysis care revenues and dialysis product revenues, patients, third party payors and customers are billed at our standard rates net of contractual allowances, discounts or rebates to reflect the estimated amounts to be receivable from these payors. | ||||||
As of January 1, 2012, the Company adopted ASU 2011-07, Health Care Entities-Presentation and Disclosure of Patient Service Revenue, Provision for Bad Debts, and the Allowance for Doubtful Accounts and as a result, for services performed for patients where the collection of the billed amount or a portion of the billed amount cannot be determined at the time services are performed, the difference between the receivable recorded and the amount estimated to be collectible must be recorded as a provision and the expense is presented as a reduction of dialysis care revenue. The provision includes such items as amounts due from patients without adequate insurance coverage and patient co-payment and deductible amounts due from patients with health care coverage. The Company bases the provision mainly on past collection history and reports it as “Patient service bad debt provision” on the Consolidated Statements of Income. | ||||||
A minor portion of International Segment product revenues is generated from arrangements which give the customer, typically a healthcare provider, the right to use dialysis machines. In the same contract the customer agrees to purchase the related treatment disposables at a price marked up from the standard price list. If the right to use the machine is conveyed through an operating lease, FMC-AG & Co. KGaA does not recognize revenue upon delivery of the dialysis machine but recognizes revenue on the sale of disposables. If the lease of the machines is a sales type lease, ownership of the dialysis machine is transferred to the user upon installation of the dialysis machine at the customer site. In this type of contract, revenue is recognized in accordance with the accounting principles for sales type leases. | ||||||
Any tax assessed by a governmental authority that is incurred as a result of a revenue transaction (e.g. sales tax) is excluded from revenues and the related revenue is reported on a net basis. | ||||||
Allowance for doubtful accounts | ||||||
In the North America Segment for receivables generated from dialysis care services, the accounting for the allowance for doubtful accounts is based on an analysis of collection experience and recognizing the differences between payors. The Company also performs an aging of accounts receivable which enables the review of each customer and their payment pattern. From time to time, accounts receivable are reviewed for changes from the historic collection experience to ensure the appropriateness of the allowances. | ||||||
The allowance for doubtful accounts in the International Segment and the North America Segment dialysis products business is an estimate comprised of customer specific evaluations regarding their payment history, current financial stability, and applicable country specific risks for receivables that are overdue more than one year. The changes in the allowance for these receivables are recorded in Selling, general and administrative as an expense. | ||||||
When all efforts to collect a receivable, including the use of outside sources where required and allowed, have been exhausted, and after appropriate management review, a receivable deemed to be uncollectible is considered a bad debt and written off. | ||||||
Research and Development expenses | ' | |||||
Research and Development expenses | ||||||
Research and development expenses are expensed as incurred. | ||||||
Income Taxes | ' | |||||
Income Taxes | ||||||
Current taxes are calculated based on the profit (loss) of the fiscal year and in accordance with local tax rules of the respective tax jurisdictions. Expected and executed additional tax payments and tax refunds for prior years are also taken into account. Benefits from income tax positions have been recognized only when it was more likely than not that the Company would be entitled to the economic benefits of the tax positions. The more-likely-than-not threshold has been determined based on the technical merits that the position will be sustained upon examination. If a tax position meets the more-likely-than-not recognition threshold, management estimates the largest amount of tax benefit that is more than fifty percent likely to be realized upon settlement with a taxing authority, which becomes the amount of benefit recognized. If a tax position is not considered more likely than not to be sustained based solely on its technical merits, no benefits are recognized. | ||||||
The Company recognizes deferred tax assets and liabilities for future consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, tax credits and tax loss carryforwards which are more likely than not to be utilized. Deferred tax assets and liabilities are measured using the respective countries enacted tax rates to be applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. In addition, the recognition of deferred tax assets considers the budget planning of the Company and implemented tax strategies. A valuation allowance is recorded to reduce the carrying amount of the deferred tax assets unless it is more likely than not that such assets will be realized (see Note 18). | ||||||
It is the Company's policy that assets on uncertain tax positions are recognized to the extent it is more likely than not the tax will be recovered. It is also the Company's policy to recognize interest and penalties related to its tax positions as income tax expense. | ||||||
Impairment | ' | |||||
Impairment | ||||||
The Company reviews the carrying value of its long-lived assets or asset groups with definite useful lives to be held and used for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. Recoverability of these assets is measured by a comparison of the carrying value of an asset to the future net cash flows directly associated with the asset. If assets are considered to be impaired, the impairment recognized is the amount by which the carrying value exceeds the fair value of the asset. The Company uses a discounted cash flow approach or other methods, if appropriate, to assess fair value. | ||||||
Long-lived assets to be disposed of by sale are reported at the lower of carrying value or fair value less cost to sell and depreciation is ceased. Long-lived assets to be disposed of other than by sale are considered to be held and used until disposal. | ||||||
For the Company's policy related to goodwill impairment, see 1e) above. | ||||||
Legal Contingencies | ' | |||||
Legal Contingencies | ||||||
From time to time, during the ordinary course of the Company's operations, the Company is party to litigation and arbitration and is subject to investigations relating to various aspects of its business (see Note 20). The Company regularly analyzes current information about such claims for probable losses and provides accruals for such matters, including the estimated legal expenses and consulting services in connection with these matters, as appropriate. The Company utilizes its internal legal department as well as external resources for these assessments. In making the decision regarding the need for loss accrual, the Company considers the degree of probability of an unfavorable outcome and its ability to make a reasonable estimate of the amount of loss. | ||||||
The filing of a suit or formal assertion of a claim or assessment, or the disclosure of any such suit or assertion, does not necessarily indicate that accrual of a loss is appropriate. | ||||||
Earnings per Ordinary share and Preference share | ' | |||||
Earnings per Share | ||||||
Basic earnings per share is calculated by dividing net income attributable to shareholders by the weighted average number of shares outstanding during the year. Prior to the conversion of preference shares to ordinary shares during the second quarter of 2013, basic earnings per share was computed according to the two-class method by dividing net income attributable to shareholders, less preference amounts, by the weighted number of ordinary and preference shares outstanding during the year. Diluted earnings per share include the effect of all potentially dilutive instruments on ordinary shares and previously outstanding preference shares that would have been outstanding during the years presented had the dilutive instruments been issued. | ||||||
Equity-settled awards granted under the Company's stock incentive plans (see Note 17), are potentially dilutive equity instruments. | ||||||
Employee Benefit Plans | ' | |||||
Employee Benefit Plans | ||||||
For the Company's funded benefit plans, the defined benefit obligation is offset against the fair value of plan assets (funded status). A pension liability is recognized in the Consolidated Balance Sheets if the defined benefit obligation exceeds the fair value of plan assets. A pension asset is recognized (and reported under other assets in the balance sheet) if the fair value of plan assets exceeds the defined benefit obligation and if the Company has a right of reimbursement against the fund or a right to reduce future payments to the fund. Changes in the funded status of a plan resulting from actuarial gains or losses and prior service costs or credits that are not recognized as components of the net periodic benefit cost are recognized through accumulated other comprehensive income, net of tax, in the year in which they occur. Actuarial gains or losses and prior service costs are subsequently recognized as components of net periodic benefit cost when realized. The Company uses December 31 as the measurement date when measuring the funded status of all plans. | ||||||
Treasury Stock Policy Text | ' | |||||
Treasury Stock | ||||||
The Company may, from time to time, acquire its own shares (“Treasury Stock”) as approved by its shareholders. The acquisition, sale or retirement of its Treasury Stock is recorded separately in equity. For the calculation of basic earnings per share, treasury stock is not considered outstanding and is therefore deducted from the number of shares outstanding with the value of such Treasury Stock shown as a reduction of the Company's equity. | ||||||
Recovered_Sheet1
The Company and Basis Of Presentation (Tables) | 12 Months Ended | |||||
Dec. 31, 2013 | ||||||
Company Basis of Presentation Healthcare Reform and Significant Accounting Policies (Tables) [Abstract] | ' | |||||
Schedule Of Variable Interest Entities Text Block | ' | |||||
2013 | 2012 | |||||
Trade accounts receivable, net | $ | 102,549 | $ | 99,061 | ||
Other current assets | 59,695 | 57,741 | ||||
Property, plant and equipment, intangible assets & other non-current assets | 26,274 | 26,823 | ||||
Goodwill | 32,759 | 31,678 | ||||
Accounts payable, accrued expenses and other liabilities | 133,977 | 122,891 | ||||
Non-current loans from related parties | 12,998 | 12,998 | ||||
Equity | 74,302 | 79,414 |
Acquisition_of_Liberty_Dialysi2
Acquisition of Liberty Dialysis Holdings (Tables) | 12 Months Ended | ||||||
Dec. 31, 2013 | |||||||
Business Acquisition Date of Acquisition | ' | ||||||
Acquisition | ' | ||||||
Assets held for sale | $ | 164,068 | |||||
Trade accounts receivable | 149,219 | ||||||
Other current assets | 17,458 | ||||||
Deferred tax assets | 14,932 | ||||||
Property, plant and equipment | 168,335 | ||||||
Intangible assets and other assets | 84,556 | ||||||
Goodwill | 2,003,465 | ||||||
Accounts payable, accrued expenses and other current liabilities | -105,403 | ||||||
Income tax payable and deferred taxes | -33,597 | ||||||
Short-term borrowings, other financial liabilities, long-term debt and capital lease obligations | -72,101 | ||||||
Other liabilities | -39,923 | ||||||
Noncontrolling interests (subject and not subject to put provisions) | -169,651 | ||||||
Total acquisition cost | $ | 2,181,358 | |||||
Less non-cash contributions at fair value | |||||||
Investment at acquisition date | -201,915 | ||||||
Long-term Notes Receivable | -282,784 | ||||||
Total non-cash items | -484,699 | ||||||
Net Cash paid | $ | 1,696,659 | |||||
For the years ended December 31, | |||||||
2012 | 2011 | ||||||
Pro forma net revenue | $ | 13,900,540 | $ | 13,215,111 | |||
Pro forma net income attributable to shareholders of FMC - AG & Co. KGaA | 1,054,872 | 1,077,218 | |||||
Pro forma income per ordinary share | |||||||
Basic | $ | 3.46 | $ | 3.56 | |||
Fully diluted | $ | 3.44 | $ | 3.53 |
Inventories_Tables
Inventories (Tables) | 12 Months Ended | ||||||
Dec. 31, 2013 | |||||||
Inventories (Tables) [Abstract] | ' | ||||||
Inventory Disclosure Tables [Text Block] | ' | ||||||
2013 | 2012 | ||||||
Finished goods | $ | 640,355 | $ | 627,338 | |||
Health care supplies | 195,519 | 154,840 | |||||
Raw materials and purchased components | 185,146 | 171,373 | |||||
Work in process | 76,084 | 83,258 | |||||
Inventories | $ | 1,097,104 | $ | 1,036,809 |
Prepaid_Expenses_and_Other_Cur1
Prepaid Expenses and Other Current Assets (Tables) | 12 Months Ended | ||||||
Dec. 31, 2013 | |||||||
Prepaid Expenses And Other Current Assets (Tables ) [Abstract] | ' | ||||||
Schedule of Other Assets [Table Text Block] | ' | ||||||
2013 | 2012 | ||||||
Taxes Refundable | $ | 133,673 | $ | 149,536 | |||
Cost Report Receivable from Medicare and Medicaid | 130,236 | 86,566 | |||||
Receivables for supplier rebates | 105,994 | 61,248 | |||||
Other deferred charges | 62,555 | 53,517 | |||||
Prepaid rent | 49,409 | 44,894 | |||||
Leases receivable | 48,538 | 46,198 | |||||
Prepaid insurance | 41,039 | 24,935 | |||||
Payments on account | 33,934 | 35,660 | |||||
Amounts due from managed locations | 22,676 | 17,298 | |||||
Receivable for sale of investment to third party | 21,846 | 16,527 | |||||
Deposit / Guarantee / Security | 19,212 | 20,903 | |||||
Derivatives | 16,664 | 31,235 | |||||
Other | 351,615 | 389,020 | |||||
Total prepaid expenses and other current assets | $ | 1,037,391 | $ | 977,537 |
Property_Plant_and_Equipment_T
Property, Plant and Equipment (Tables) | 12 Months Ended | ||||||
Dec. 31, 2013 | |||||||
Property Plant And Equipment (Tables) [Abstract] | ' | ||||||
Schedule of property plant and equipment | ' | ||||||
2013 | 2012 | ||||||
Land | $ | 46,689 | $ | 54,775 | |||
Buildings and improvements | 2,432,824 | 2,257,002 | |||||
Machinery and equipment | 3,808,356 | 3,470,972 | |||||
Machinery, equipment and rental equipment under capitalized leases | 43,239 | 36,316 | |||||
Construction in progress | 267,653 | 256,401 | |||||
6,598,761 | 6,075,466 | ||||||
Accumulated depreciation | -3,506,807 | -3,134,863 | |||||
Property, plant and equipment, net | $ | 3,091,954 | $ | 2,940,603 |
Intangible_Assets_and_Goodwill1
Intangible Assets and Goodwill (Tables) | 12 Months Ended | |||||||||||||||
Dec. 31, 2013 | ||||||||||||||||
Intangible Assets And Goodwill (Tables) [Abstract] | ' | |||||||||||||||
Schedule Of Finite Lived Intangible Assets Table Text Block | ' | |||||||||||||||
2013 | 2012 | |||||||||||||||
Gross | Gross | |||||||||||||||
Carrying | Accumulated | Carrying | Accumulated | |||||||||||||
Amount | Amortization | Amount | Amortization | |||||||||||||
Amortizable Intangible Assets | ||||||||||||||||
Non-compete agreements | $ | 325,335 | $ | -240,412 | $ | 317,080 | $ | -213,639 | ||||||||
Technology | 106,510 | -44,584 | 107,696 | -40,849 | ||||||||||||
Licenses and distribution agreements | 223,701 | -112,697 | 225,393 | -98,757 | ||||||||||||
Customer Relationships | 98,000 | -650 | - | - | ||||||||||||
Self-developed software | 105,087 | -46,097 | 72,328 | -32,496 | ||||||||||||
Other | 350,475 | -264,031 | 343,867 | -246,239 | ||||||||||||
Construction in progress | 39,570 | - | 57,677 | - | ||||||||||||
$ | 1,248,678 | $ | -708,471 | $ | 1,124,041 | $ | -631,980 | |||||||||
Estimated Amortization Expense | ||||||||||||||||
2014 | $ | 79,830 | ||||||||||||||
2015 | $ | 76,717 | ||||||||||||||
2016 | $ | 74,303 | ||||||||||||||
2017 | $ | 70,362 | ||||||||||||||
2018 | $ | 67,793 | ||||||||||||||
Schedule Of Indefinite Lived Intangible Assets Table Text Block | ' | |||||||||||||||
2013 | 2012 | |||||||||||||||
Carrying | Carrying | |||||||||||||||
Amount | Amount | |||||||||||||||
Non-amortizable Intangible Assets | ||||||||||||||||
Tradename | $ | 210,630 | $ | 209,712 | ||||||||||||
Management contracts | 7,039 | 8,343 | ||||||||||||||
$ | 217,669 | $ | 218,055 | |||||||||||||
Total Intangible Assets | $ | 757,876 | $ | 710,116 | ||||||||||||
Schedule Of Goodwill Text Block | ' | |||||||||||||||
North | Segment | |||||||||||||||
America | International | Total | Corporate | Total | ||||||||||||
Balance as of December 31, 2011 | $ | 7,314,622 | $ | 1,464,089 | $ | 8,778,711 | $ | 407,939 | $ | 9,186,650 | ||||||
Goodwill acquired, net of divestitures | 2,172,181 | 21,106 | 2,193,287 | - | 2,193,287 | |||||||||||
Reclassifications | - | -5,188 | -5,188 | 5,188 | - | |||||||||||
Foreign Currency Translation Adjustment | 210 | 41,352 | 41,562 | 390 | 41,952 | |||||||||||
Balance as of December 31, 2012 | $ | 9,487,013 | $ | 1,521,359 | $ | 11,008,372 | $ | 413,517 | $ | 11,421,889 | ||||||
Goodwill acquired, net of divestitures | 158,582 | 99,634 | 258,216 | - | 258,216 | |||||||||||
Reclassifications | - | -3,807 | -3,807 | 4,226 | 419 | |||||||||||
Foreign Currency Translation Adjustment | 52 | -23,029 | -22,977 | 640 | -22,337 | |||||||||||
Balance as of December 31, 2013 | $ | 9,645,647 | $ | 1,594,157 | $ | 11,239,804 | $ | 418,383 | $ | 11,658,187 |
Longterm_Debt_and_Capital_Leas1
Long-term Debt and Capital Lease Obligations (Tables) | 12 Months Ended | |||||||||||||||||||
Dec. 31, 2013 | ||||||||||||||||||||
Long Term Debt and Capital Lease Obligations (Tables) [Abstract] | ' | |||||||||||||||||||
Schedule of long-term debt | ' | |||||||||||||||||||
31-Dec-13 | 31-Dec-12 | |||||||||||||||||||
2012 Credit Agreement | $ | 2,707,145 | $ | 2,659,340 | ||||||||||||||||
Senior Notes | 4,824,753 | 4,743,442 | ||||||||||||||||||
Euro Notes | 46,545 | 51,951 | ||||||||||||||||||
European Investment Bank Agreements | 193,074 | 324,334 | ||||||||||||||||||
Accounts receivable facility | 351,250 | 162,000 | ||||||||||||||||||
Capital lease obligations | 24,264 | 15,618 | ||||||||||||||||||
Other | 111,259 | 163,802 | ||||||||||||||||||
Long-term debt and capital lease obligations | 8,258,290 | 8,120,487 | ||||||||||||||||||
Less current maturities | -511,370 | -334,747 | ||||||||||||||||||
Long-term debt and capital lease obligations, less current portion | 7,746,920 | 7,785,740 | ||||||||||||||||||
Long-term debt from related parties | - | 56,174 | ||||||||||||||||||
Long-term debt and capital lease obligations and long-term debt from related parties | $ | 7,746,920 | $ | 7,841,914 | ||||||||||||||||
2006 Senior Credit Agreement Table | ' | |||||||||||||||||||
Maximum Amount Available December 31, 2013 | Balance Outstanding December 31, 2013 | |||||||||||||||||||
Revolving Credit USD | $ | 600,000 | $ | 600,000 | $ | 138,190 | $ | 138,190 | ||||||||||||
Revolving Credit EUR | € | 500,000 | $ | 689,550 | € | 50,000 | $ | 68,955 | ||||||||||||
Term Loan A | $ | 2,500,000 | $ | 2,500,000 | $ | 2,500,000 | $ | 2,500,000 | ||||||||||||
$ | 3,789,550 | $ | 2,707,145 | |||||||||||||||||
Maximum Amount Available December 31, 2012 | Balance Outstanding December 31, 2012 | |||||||||||||||||||
Revolving Credit USD | $ | 600,000 | $ | 600,000 | $ | 59,340 | $ | 59,340 | ||||||||||||
Revolving Credit EUR | € | 500,000 | $ | 659,700 | € | - | $ | - | ||||||||||||
Term Loan A | $ | 2,600,000 | $ | 2,600,000 | $ | 2,600,000 | $ | 2,600,000 | ||||||||||||
$ | 3,859,700 | $ | 2,659,340 | |||||||||||||||||
Schedule of senior notes | ' | |||||||||||||||||||
Issuer/Transaction | Face Amount | Maturity | Coupon | Book value | ||||||||||||||||
FMC Finance VI S.A. 2010 | € | 250,000 | 15-Jul-16 | 5.50% | $ | 342,944 | ||||||||||||||
FMC Finance VIII S.A. 2011(1) | € | 100,000 | 15-Oct-16 | 3.73% | $ | 137,910 | ||||||||||||||
FMC US Finance, Inc. 2007 | $ | 500,000 | 15-Jul-17 | 6.88% | $ | 496,894 | ||||||||||||||
FMC Finance VIII S.A. 2011 | € | 400,000 | 15-Sep-18 | 6.50% | $ | 546,531 | ||||||||||||||
FMC US Finance II, Inc. 2011 | $ | 400,000 | 15-Sep-18 | 6.50% | $ | 396,297 | ||||||||||||||
FMC US Finance II, Inc. 2012 | $ | 800,000 | 31-Jul-19 | 5.63% | $ | 800,000 | ||||||||||||||
FMC Finance VIII S.A. 2012 | € | 250,000 | 31-Jul-19 | 5.25% | $ | 344,775 | ||||||||||||||
FMC US Finance, Inc. 2011 | $ | 650,000 | 15-Feb-21 | 5.75% | $ | 645,672 | ||||||||||||||
FMC Finance VII S.A. 2011 | € | 300,000 | 15-Feb-21 | 5.25% | $ | 413,730 | ||||||||||||||
FMC US Finance II, Inc. 2012 | $ | 700,000 | 31-Jan-22 | 5.88% | $ | 700,000 | ||||||||||||||
$ | 4,824,753 | |||||||||||||||||||
(1) This note carries a variable interest rate which was 3.73% at December 31, 2013. | ||||||||||||||||||||
Schedule of European Investment Bank Arrangement | ' | |||||||||||||||||||
Balance outstanding | ||||||||||||||||||||
December 31, | ||||||||||||||||||||
Maturity | 2013 | 2012 | ||||||||||||||||||
Revolving Credit | 2013 | $ | - | $ | 90,812 | |||||||||||||||
Loan 2005 | 2013 | - | 48,806 | |||||||||||||||||
Loan 2006 | 2014 | 124,119 | 118,746 | |||||||||||||||||
Loan 2009 | 2014 | 68,955 | 65,970 | |||||||||||||||||
$ | 193,074 | $ | 324,334 | |||||||||||||||||
Long-term debt by maturity | ' | |||||||||||||||||||
2014 | $ | 511,370 | ||||||||||||||||||
2015 | 233,589 | |||||||||||||||||||
2016 | 1,038,599 | |||||||||||||||||||
2017 | 2,613,096 | |||||||||||||||||||
2018 | 953,423 | |||||||||||||||||||
Thereafter | 2,926,290 | |||||||||||||||||||
$ | 8,276,367 | |||||||||||||||||||
Noncontrolling_Interests_Subje1
Noncontrolling Interests Subject To Put Provisions (Tables) | 12 Months Ended | |||||||||
Dec. 31, 2013 | ||||||||||
Noncontrolling Interests Subject To Put Provisions (Tables) [Abstract] | ' | |||||||||
Noncontrolling Interests Subject to Put Provisions | ' | |||||||||
13. Noncontrolling Interests Subject to Put Provisions | ||||||||||
The Company has potential obligations to purchase the noncontrolling interests held by third parties in certain of its consolidated subsidiaries. These obligations are in the form of put provisions and are exercisable at the third-party owners' discretion within specified periods as outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase all or part of third-party owners' noncontrolling interests at the appraised fair value at the time of exercise. The methodology the Company uses to estimate the fair values of the noncontrolling interest subject to put provisions assumes the greater of net book value or a multiple of earnings, based on historical earnings, development stage of the underlying business and other factors. The estimated fair values of the noncontrolling interests subject to these put provisions can also fluctuate and the implicit multiple of earnings at which these noncontrolling interest obligations may ultimately be settled could vary significantly from our current estimates depending upon market conditions. | ||||||||||
At December 31, 2013 and December 31, 2012 the Company's potential obligations under these put options were $648,251 and $523,260, respectively, of which, at December 31, 2013, put options with an aggregate purchase obligation of $275,468 were exercisable. In the last three fiscal years ending December 31, 2013, three such put provisions have been exercised for a total consideration of $7,105. | ||||||||||
The following is a roll forward of noncontrolling interests subject to put provisions for the years ended December 31, 2013, 2012 and 2011: | ||||||||||
2013 | 2012 | 2011 | ||||||||
Beginning balance at January 1, | $ | 523,260 | $ | 410,491 | $ | 279,709 | ||||
Contributions to noncontrolling interests | -122,179 | -114,536 | -43,104 | |||||||
Purchase/ sale of noncontrolling interests | 6,723 | 134,643 | 37,786 | |||||||
Contributions from noncontrolling interests | 17,767 | 16,565 | 7,222 | |||||||
Changes in fair value of noncontrolling interests | 108,575 | -18,880 | 86,233 | |||||||
Net income | 113,156 | 94,718 | 42,857 | |||||||
Other comprehensive income (loss) | 949 | 259 | -212 | |||||||
Ending balance at December 31, | $ | 648,251 | $ | 523,260 | $ | 410,491 | ||||
2013 | 2012 | 2011 | ||||||||
Beginning balance at January 1, | $ | 523,260 | $ | 410,491 | $ | 279,709 | ||||
Contributions to noncontrolling interests | -122,179 | -114,536 | -43,104 | |||||||
Purchase/ sale of noncontrolling interests | 6,723 | 134,643 | 37,786 | |||||||
Contributions from noncontrolling interests | 17,767 | 16,565 | 7,222 | |||||||
Changes in fair value of noncontrolling interests | 108,575 | -18,880 | 86,233 | |||||||
Net income | 113,156 | 94,718 | 42,857 | |||||||
Other comprehensive income (loss) | 949 | 259 | -212 | |||||||
Ending balance at December 31, | $ | 648,251 | $ | 523,260 | $ | 410,491 |
Shareholders_Equity_Table
Shareholders' Equity (Table) | 12 Months Ended | ||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||
Shareholders Equity Table [Abstract] | ' | ||||||||||||||||
Share Buyback [Table] | ' | ||||||||||||||||
Period | Average price paid per share | Total number of shares purchased as part of publicly announced plans or programs | Total Value of Shares Repurchased | ||||||||||||||
in € | in $(1) | in €(3) | in $(2), (3) | ||||||||||||||
in thousands | |||||||||||||||||
May-13 | 52.96 | 68.48 | 1,078,255 | 57,107 | 73,842 | ||||||||||||
Jun-13 | 53.05 | 69.95 | 2,502,552 | 132,769 | 175,047 | ||||||||||||
Jul-13 | 49.42 | 64.63 | 2,972,770 | 146,916 | 192,124 | ||||||||||||
Aug-13 | 48.4 | 64.3 | 995,374 | 48,174 | 64,001 | ||||||||||||
Total | 51 | 66.9 | 7,548,951 | 384,966 | 505,014 | ||||||||||||
(1) The dollar value is calculated using the daily exchange rate for the share repurchases made during the month. | |||||||||||||||||
(2) The value of the shares repurchased in Dollar is calculated using the total value of the shares purchased in Euro converted using the daily exchange rate for the transactions. | |||||||||||||||||
(3) This amount is inclusive of fees (net of taxes) paid in the amount of approximately $106 (€81) for services rendered. |
Sources_Of_Revenue_Tables
Sources Of Revenue (Tables) | 12 Months Ended | ||||||
Dec. 31, 2013 | |||||||
Patient Service Revenues by Payor | ' | ||||||
Patient Service Revenue | ' | ||||||
2013 | 2012 | ||||||
Medicare ESRD program | $ | 4,411,285 | $ | 4,029,773 | |||
Private/alternative payors | 3,841,473 | 3,605,081 | |||||
Medicaid and other government sources | 392,908 | 474,520 | |||||
Hospitals | 411,340 | 400,791 | |||||
Total patient service revenue | $ | 9,057,006 | $ | 8,510,165 |
Stock_Options_Tables
Stock Options (Tables) | 12 Months Ended | |||||||||||
Dec. 31, 2013 | ||||||||||||
Stock Options (Tables) [Abstract] | ' | |||||||||||
Schedule of share-based compensation arrangements by share-based payment award | ' | |||||||||||
Weighted | Weighted | |||||||||||
average | average | |||||||||||
Options | exercise | exercise | ||||||||||
(in thousands) | price | price | ||||||||||
Stock options for ordinary shares | € | $ | ||||||||||
Balance at December 31, 2012 | 11,147 | 42.66 | 58.83 | |||||||||
Granted | 2,141 | 49.75 | 68.61 | |||||||||
Exercised | 2,280 | 33.76 | 46.56 | |||||||||
Converted from preference shares | 32 | 18.86 | 26.01 | |||||||||
Forfeited | 249 | 44.75 | 61.71 | |||||||||
Balance at December 31, 2013 | 10,791 | 45.83 | 63.2 | |||||||||
Stock options for preference shares | ||||||||||||
Balance at December 31, 2012 | 38 | 19.26 | 26.56 | |||||||||
Exercised | 2 | 18.35 | 25.31 | |||||||||
Forfeited | 4 | 23.56 | 32.49 | |||||||||
Converted into ordinary shares | 32 | 18.86 | 26.01 | |||||||||
Balance at December 31, 2013 | 0 | 0 | 0 | |||||||||
Schedule of fully vested options outstanding and exerciseable | ' | |||||||||||
Fully Vested Outstanding and Exercisable Options | ||||||||||||
Weighted | ||||||||||||
average | Weighted | Weighted | ||||||||||
Number | remaining | average | average | Aggregate | Aggregate | |||||||
of | contractual | exercise | exercise | intrinsic | intrinsic | |||||||
Options | life in years | price | price | value | value | |||||||
(in thousands) | € | US$ | € | US$ | ||||||||
Options for ordinary shares | 4,711 | 2.51 | 36.41 | 50.21 | 72,198 | 99,568 | ||||||
Schedule of stock options fair value assumptions | ' | |||||||||||
2013 | 2012 | |||||||||||
Expected dividend yield | 2.02% | 1.61% | ||||||||||
Risk-free interest rate | 1.33% | 1.09% | ||||||||||
Expected volatility | 22.44% | 22.20% | ||||||||||
Expected life of options | 8 years | 8 years | ||||||||||
Weighted average exercise price (in €) | 49.75 | 57.15 | ||||||||||
Weighted average exercise price (in US-$) | 68.61 | 75.41 |
Income_Taxes_Tables
Income Taxes (Tables) | 12 Months Ended | |||||||||
Dec. 31, 2013 | ||||||||||
Income Taxes (Tables) [Abstract] | ' | |||||||||
Schedule of income before income taxes by jurisdiction | ' | |||||||||
2013 | 2012 | 2011 | ||||||||
Current: | ||||||||||
Germany | $ | 81,117 | $ | 52,862 | $ | 67,484 | ||||
United States | 387,017 | 342,250 | 278,634 | |||||||
Other | 116,186 | 139,136 | 106,087 | |||||||
584,320 | 534,248 | 452,205 | ||||||||
Deferred: | ||||||||||
Germany | -33,106 | 10,478 | 14,565 | |||||||
United States | 47,298 | 98,200 | 139,282 | |||||||
Other | -6,500 | -37,790 | -4,955 | |||||||
7,692 | 70,888 | 148,892 | ||||||||
$ | 592,012 | $ | 605,136 | $ | 601,097 | |||||
Schedule of income tax expense reconciliation | ' | |||||||||
2013 | 2012 | 2011 | ||||||||
Expected corporate income tax expense | $ | 538,770 | $ | 554,613 | $ | 506,121 | ||||
Tax free income | -64,141 | -90,943 | -38,926 | |||||||
Income from at equity investments | -4,869 | -2,133 | -6,883 | |||||||
Tax rate differentials | 132,977 | 137,527 | 140,079 | |||||||
Non-deductible expenses | 20,564 | 19,961 | 4,536 | |||||||
Taxes for prior years | -6,389 | 22,420 | 144 | |||||||
Change in valuation allowance | 3,154 | -19,680 | 5,544 | |||||||
Noncontrolling partnership interests | -55,023 | -49,081 | -31,300 | |||||||
Other | 26,969 | 32,452 | 21,782 | |||||||
Actual income tax expense | $ | 592,012 | $ | 605,136 | $ | 601,097 | ||||
Effective tax rate | 32.00% | 31.30% | 33.80% | |||||||
Schedule of components of deferred tax assets | ' | |||||||||
2013 | 2012 | |||||||||
Deferred tax assets: | ||||||||||
Accounts receivable | $ | 8,789 | $ | 5,847 | ||||||
Inventory | 9,731 | 9,434 | ||||||||
Property, plant and equipment, intangible and other non-current assets | 20,093 | 28,470 | ||||||||
Accrued expenses and other liabilities | 305,664 | 318,827 | ||||||||
Pensions | 97,958 | 123,363 | ||||||||
Net operating loss carryforwards, tax credit carryforwards and interest carryforwards | 141,727 | 107,595 | ||||||||
Derivatives | 2,169 | 4,856 | ||||||||
Stock-based compensation | 22,710 | 24,758 | ||||||||
Other | 13,632 | 13,136 | ||||||||
Total deferred tax assets | $ | 622,473 | $ | 636,286 | ||||||
Less: valuation allowance | -48,563 | -44,191 | ||||||||
Net deferred tax assets | $ | 573,910 | $ | 592,095 | ||||||
Deferred tax liabilities: | ||||||||||
Accounts receivable | $ | 43,031 | $ | 17,036 | ||||||
Inventory | 12,264 | 11,847 | ||||||||
Property, plant and equipment, intangible and other non-current assets | 776,254 | 748,271 | ||||||||
Accrued expenses and other liabilities | 17,197 | 21,651 | ||||||||
Derivatives | 2,274 | 2,202 | ||||||||
Other | 117,255 | 128,403 | ||||||||
Total deferred tax liabilities | 968,275 | 929,410 | ||||||||
Net deferred tax assets (liabilities) | $ | -394,365 | $ | -337,315 | ||||||
Summary of operating loss carryforwards | ' | |||||||||
2014 | $ | 38,550 | ||||||||
2015 | 38,134 | |||||||||
2016 | 54,139 | |||||||||
2017 | 55,956 | |||||||||
2018 | 50,907 | |||||||||
2019 | 39,707 | |||||||||
2020 | 33,619 | |||||||||
2021 | 34,042 | |||||||||
2022 | 34,046 | |||||||||
2023 and thereafter | 34,676 | |||||||||
Without expiration date | 92,906 | |||||||||
Total | $ | 506,682 | ||||||||
Summary of income tax contingencies | ' | |||||||||
Unrecognized tax benefits (net of interest) | 2013 | 2012 | 2011 | |||||||
Balance at January 1, | $ | 225,198 | $ | 223,829 | $ | 405,900 | ||||
Increases in unrecognized tax benefits prior periods | 25,260 | 13,232 | 24,046 | |||||||
Decreases in unrecognized tax benefits prior periods | -11,445 | -5,913 | -24,897 | |||||||
Increases in unrecognized tax benefits current period | 10,062 | 17,903 | 16,157 | |||||||
Changes related to settlements with tax authorities | -52,325 | -14,763 | -208,484 | |||||||
Reductions as a result of a lapse of the statute of limitations | - | - | -3,100 | |||||||
Foreign currency translation | 3,174 | -9,090 | 14,207 | |||||||
Balance at December 31, | $ | 199,924 | $ | 225,198 | $ | 223,829 |
Operating_Leases_Tables
Operating Leases (Tables) | 12 Months Ended | ||
Dec. 31, 2013 | |||
Operating Leases (Tables) [Abstract] | ' | ||
Schedule of the future minimum lease payments due | ' | ||
2014 | $ | 609,521 | |
2015 | 524,898 | ||
2016 | 456,143 | ||
2017 | 354,705 | ||
2018 | 277,940 | ||
Thereafter | 1,002,340 | ||
3,225,547 |
Financial_Instrument_Tables
Financial Instrument (Tables) | 12 Months Ended | ||||||||||||||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||||||||||||||
Financial Instruments (Tables) [Abstract] | ' | ||||||||||||||||||||||||||||
Non-Derivative Financial Instruments | ' | ||||||||||||||||||||||||||||
2013 | 2012 | ||||||||||||||||||||||||||||
Fair Value | Carrying | Fair | Carrying | Fair | |||||||||||||||||||||||||
Hierarchy | Amount | Value | Amount | Value | |||||||||||||||||||||||||
Assets | |||||||||||||||||||||||||||||
Cash and cash equivalents | 1 | $ | 682,777 | $ | 682,777 | $ | 688,040 | $ | 688,040 | ||||||||||||||||||||
Accounts Receivable(1) | 2 | 3,190,392 | 3,190,392 | 3,157,233 | 3,157,233 | ||||||||||||||||||||||||
Long-term Notes Receivable | 3 | 165,807 | 175,768 | - | - | ||||||||||||||||||||||||
Liabilities | |||||||||||||||||||||||||||||
Accounts payable(1) | 2 | $ | 666,526 | $ | 666,526 | $ | 745,644 | $ | 745,644 | ||||||||||||||||||||
Short-term borrowings(1) | 2 | 158,990 | 158,990 | 121,823 | 121,823 | ||||||||||||||||||||||||
Long term debt, excluding 2012 Credit Agreement, Euro Notes and Senior Notes | 2 | 679,847 | 679,847 | 721,928 | 721,928 | ||||||||||||||||||||||||
2012 Credit Agreement | 2 | 2,707,145 | 2,710,270 | 2,659,340 | 2,652,840 | ||||||||||||||||||||||||
Senior Notes | 2 | 4,824,753 | 5,348,679 | 4,743,442 | 5,296,325 | ||||||||||||||||||||||||
Euro Notes | 2 | 46,545 | 47,423 | 51,951 | 54,574 | ||||||||||||||||||||||||
Noncontrolling interests subject to put provisions | 3 | 648,251 | 648,251 | 523,260 | 523,260 | ||||||||||||||||||||||||
(1) Also includes amounts from related parties. | |||||||||||||||||||||||||||||
Derivative Financial Instruments Valuation | ' | ||||||||||||||||||||||||||||
2013 | 2012 | ||||||||||||||||||||||||||||
Assets(2) | Liabilities(2) | Assets(2) | Liabilities(2) | ||||||||||||||||||||||||||
Derivatives in cash flow hedging relationships(1) | |||||||||||||||||||||||||||||
Current | |||||||||||||||||||||||||||||
Foreign exchange contracts | 4,985 | -2,719 | 7,839 | -7,510 | |||||||||||||||||||||||||
Non-current | |||||||||||||||||||||||||||||
Foreign exchange contracts | 759 | -374 | 942 | -187 | |||||||||||||||||||||||||
Interest rate contracts | - | -4,392 | - | -6,221 | |||||||||||||||||||||||||
Total | $ | 5,744 | $ | -7,485 | $ | 8,781 | $ | -13,918 | |||||||||||||||||||||
Derivatives not designated as hedging instruments(1) | |||||||||||||||||||||||||||||
Current | |||||||||||||||||||||||||||||
Foreign exchange contracts | 11,679 | -22,982 | 23,396 | -19,068 | |||||||||||||||||||||||||
Non-current | |||||||||||||||||||||||||||||
Foreign exchange contracts | 1,060 | -820 | 132 | -292 | |||||||||||||||||||||||||
Total | $ | 12,739 | $ | -23,802 | $ | 23,528 | $ | -19,360 | |||||||||||||||||||||
(1) At December 31, 2013 and December 31, 2012, the valuation of the Company's derivatives was determined using Significant Other Observable Inputs (Level 2) in accordance with the fair value hierarchy levels established in U.S. GAAP. | |||||||||||||||||||||||||||||
(2) Derivative instruments are marked to market each reporting period resulting in carrying amounts being equal to fair values at the reporting date. | |||||||||||||||||||||||||||||
Effect of Derivatives on the Consolidated Financial Statements | ' | ||||||||||||||||||||||||||||
The Effect of Derivatives on the Consolidated Financial Statements | |||||||||||||||||||||||||||||
Amount of Gain or (Loss) Recognized in AOCI on Derivatives | Location of (Gain) or Loss Reclassified from AOCI in Income | Amount of (Gain) or Loss Reclassified from AOCI in Income | |||||||||||||||||||||||||||
Derivatives in Cash Flow Hedging Relationships | |||||||||||||||||||||||||||||
(Effective Portion) for the year ended December 31, | (Effective Portion) for the year ended December 31, | ||||||||||||||||||||||||||||
2013 | 2012 | (Effective Portion) | 2013 | 2012 | |||||||||||||||||||||||||
Interest rate contracts | $ | -6,601 | $ | -16,762 | Interest income/expense | $ | 28,111 | $ | 23,779 | ||||||||||||||||||||
Foreign exchange contracts | 3,684 | 21,834 | Costs of Revenue | -3,251 | -5,414 | ||||||||||||||||||||||||
Foreign exchange contracts | Interest income/expense | 589 | 582 | ||||||||||||||||||||||||||
$ | -2,917 | $ | 5,072 | $ | 25,449 | $ | 18,947 | ||||||||||||||||||||||
Derivatives not Designated as Hedging Instruments | Amount of (Gain) or Loss Recognized in Income on Derivatives for the year ended December 31, | ||||||||||||||||||||||||||||
Location of (Gain) or Loss Recognized in Income on Derivatives | |||||||||||||||||||||||||||||
2013 | 2012 | ||||||||||||||||||||||||||||
Foreign exchange contracts | Selling, general and administrative expense | ||||||||||||||||||||||||||||
$ | -15,190 | $ | -8,804 | ||||||||||||||||||||||||||
Foreign exchange contracts | Interest income/expense | 7,161 | 8,033 | ||||||||||||||||||||||||||
$ | -8,029 | $ | -771 |
Other_Comprehensive_Income_Tab
Other Comprehensive Income (Tables) | 12 Months Ended | |||||||||||||||
Dec. 31, 2013 | ||||||||||||||||
Other Comprehensive Income (Tables) [Abstract] | ' | |||||||||||||||
Schedule of components of comrehensive income | ' | |||||||||||||||
Pretax | Tax effect | Net, before non-controlling interests | Non-controlling interests | Other comprehensive income (loss), net of tax | ||||||||||||
Year ended December 31, 2011 | ||||||||||||||||
Other comprehensive income (loss) relating to cash flow hedges: | ||||||||||||||||
Changes in fair value of cash flow hedges during the period | $ | -104,130 | $ | 41,825 | $ | -62,305 | $ | - | $ | -62,305 | ||||||
Reclassification adjustments | 1,684 | -796 | 888 | - | 888 | |||||||||||
Total other comprehensive income (loss) relating to cash flow hedges | -102,446 | 41,029 | -61,417 | - | -61,417 | |||||||||||
Foreign-currency translation adjustment | -179,987 | - | -179,987 | -1,247 | -181,234 | |||||||||||
Defined benefit pension plans: | ||||||||||||||||
Actuarial (loss) gain on defined benefit pension plans | -90,643 | 34,930 | -55,713 | - | -55,713 | |||||||||||
Reclassification adjustments | 8,737 | -3,342 | 5,395 | - | 5,395 | |||||||||||
Total other comprehensive income (loss) relating to defined benefit pension plans | -81,906 | 31,588 | -50,318 | - | -50,318 | |||||||||||
Other comprehensive income (loss) | $ | -364,339 | $ | 72,617 | $ | -291,722 | $ | -1,247 | $ | -292,969 | ||||||
Year ended December 31, 2012 | ||||||||||||||||
Other comprehensive income (loss) relating to cash flow hedges: | ||||||||||||||||
Changes in fair value of cash flow hedges during the period | $ | 5,072 | $ | -21,171 | $ | -16,099 | $ | - | $ | -16,099 | ||||||
Reclassification adjustments | 18,947 | -4,968 | 13,979 | - | 13,979 | |||||||||||
Total other comprehensive income (loss) relating to cash flow hedges | 24,019 | -26,139 | -2,120 | - | -2,120 | |||||||||||
Foreign-currency translation adjustment | 63,982 | - | 63,982 | -179 | 63,803 | |||||||||||
Defined benefit pension plans: | ||||||||||||||||
Actuarial (loss) gain on defined benefit pension plans | -121,512 | 42,159 | -79,353 | - | -79,353 | |||||||||||
Reclassification adjustments | 18,334 | -7,189 | 11,145 | - | 11,145 | |||||||||||
Total other comprehensive income (loss) relating to defined benefit pension plans | -103,178 | 34,970 | -68,208 | - | -68,208 | |||||||||||
Other comprehensive income (loss) | $ | -15,177 | $ | 8,831 | $ | -6,346 | $ | -179 | $ | -6,525 | ||||||
Year ended December 31, 2013 | ||||||||||||||||
Other comprehensive income (loss) relating to cash flow hedges: | ||||||||||||||||
Changes in fair value of cash flow hedges during the period | $ | -2,917 | $ | 1,346 | $ | -1,571 | $ | - | $ | -1,571 | ||||||
Reclassification adjustments | 25,449 | -7,393 | 18,056 | - | 18,056 | |||||||||||
Total other comprehensive income (loss) relating to cash flow hedges | 22,532 | -6,047 | 16,485 | - | 16,485 | |||||||||||
Foreign-currency translation adjustment | -112,395 | - | -112,395 | -2,044 | -114,439 | |||||||||||
Defined benefit pension plans: | ||||||||||||||||
Actuarial (loss) gain on defined benefit pension plans | 39,571 | -17,828 | 21,743 | - | 21,743 | |||||||||||
Reclassification adjustments | 25,418 | -9,725 | 15,693 | - | 15,693 | |||||||||||
Total other comprehensive income (loss) relating to defined benefit pension plans | 64,989 | -27,553 | 37,436 | - | 37,436 | |||||||||||
Other comprehensive income (loss) | $ | -24,874 | $ | -33,600 | $ | -58,474 | $ | -2,044 | $ | -60,518 | ||||||
Details about AOCI Components | Amount of (Gain) Loss reclassified from AOCI in Income | Location of (Gain) Loss reclassified from AOCI in Income | ||||||||||||||
For the years ended December 31, | ||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||
(Gain) Loss related to cash flow hedges | ||||||||||||||||
Interest rate contracts | $ | 28,111 | $ | 23,779 | $ | 5,946 | Interest income/expense | |||||||||
foreign exchange contracts | -3,251 | -5,414 | -4,262 | Costs of Revenue | ||||||||||||
foreign exchange contracts | 589 | 582 | - | Interest income/expense | ||||||||||||
25,449 | 18,947 | 1,684 | Total before tax | |||||||||||||
-7,393 | -4,968 | -796 | Tax expense or benefit | |||||||||||||
$ | 18,056 | $ | 13,979 | $ | 888 | Net of tax | ||||||||||
Actuarial (Gain) Loss on defined benefit pension plans | ||||||||||||||||
Actuarial (gains) losses | $ | 25,418 | $ | 18,334 | $ | 8,737 | -1 | |||||||||
25,418 | 18,334 | 8,737 | Total before tax | |||||||||||||
-9,725 | -7,189 | -3,342 | Tax expense or benefit | |||||||||||||
$ | 15,693 | $ | 11,145 | $ | 5,395 | Net of tax | ||||||||||
Total reclassifications for the period | $ | 33,749 | $ | 25,124 | $ | 6,283 | Net of tax | |||||||||
(1) Included in the computation of net periodic pension cost (see Note 12 for additional details). |
Other_Comprehensive_Income_Los1
Other Comprehensive Income (Loss) (Tables 1) | 12 Months Ended | |||||||||||||||||||
Dec. 31, 2013 | ||||||||||||||||||||
Other comprehensive income loss net of tax portion attributables to parent [Abstract] | ' | |||||||||||||||||||
Changes in Accumulated Other comprehensive income (loss) | ' | |||||||||||||||||||
Gain (Loss) related to cash flow hedges | Actuarial gain (loss) on defined benefit pension plans | Gain (Loss) related to foreign-currency translation | Total, before non-controlling interests | Non-controlling interests | Total | |||||||||||||||
Balance at December 31, 2010 | $ | -74,804 | $ | -60,897 | $ | -58,344 | $ | -194,045 | $ | 4,295 | $ | -189,750 | ||||||||
Other comprehensive income before reclassifications | -62,305 | -55,713 | -179,987 | -298,005 | -1,247 | -299,252 | ||||||||||||||
Amounts reclassified from AOCI | 888 | 5,395 | - | 6,283 | - | 6,283 | ||||||||||||||
Net current-period other comprehensive income | -61,417 | -50,318 | -179,987 | -291,722 | -1,247 | -292,969 | ||||||||||||||
Balance at December 31, 2011 | $ | -136,221 | $ | -111,215 | $ | -238,331 | $ | -485,767 | $ | 3,048 | $ | -482,719 | ||||||||
Other comprehensive income before reclassifications | -16,099 | -79,353 | 63,982 | -31,470 | -179 | -31,649 | ||||||||||||||
Amounts reclassified from AOCI | 13,979 | 11,145 | - | 25,124 | - | 25,124 | ||||||||||||||
Net current-period other comprehensive income | -2,120 | -68,208 | 63,982 | -6,346 | -179 | -6,525 | ||||||||||||||
Balance at December 31, 2012 | $ | -138,341 | $ | -179,423 | $ | -174,349 | $ | -492,113 | $ | 2,869 | $ | -489,244 | ||||||||
Other comprehensive income before reclassifications | -1,571 | 21,743 | -112,395 | -92,223 | -2,044 | -94,267 | ||||||||||||||
Amounts reclassified from AOCI | 18,056 | 15,693 | - | 33,749 | - | 33,749 | ||||||||||||||
Net current-period other comprehensive income | 16,485 | 37,436 | -112,395 | -58,474 | -2,044 | -60,518 | ||||||||||||||
Balance at December 31, 2013 | $ | -121,856 | $ | -141,987 | $ | -286,744 | $ | -550,587 | $ | 825 | $ | -549,762 |
Business_Segment_Information_T
Business Segment Information (Tables) | 12 Months Ended | ||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||
Business Segment Information (Tables) [Abstract] | ' | ||||||||||||||||
Schedule of segment reporting information by segment | ' | ||||||||||||||||
North America Segment | International Segment | Segment Total | Corporate | Total | |||||||||||||
2013 | |||||||||||||||||
Net revenue external customers | $ | 9,606,111 | $ | 4,970,319 | $ | 14,576,430 | $ | 33,297 | $ | 14,609,727 | |||||||
Inter - segment revenue | 7,045 | - | 7,045 | -7,045 | - | ||||||||||||
Revenue | 9,613,156 | 4,970,319 | 14,583,475 | 26,252 | 14,609,727 | ||||||||||||
Depreciation and amortization | -330,371 | -185,570 | -515,941 | -132,284 | -648,225 | ||||||||||||
Operating Income | 1,623,984 | 858,308 | 2,482,292 | -226,096 | 2,256,196 | ||||||||||||
Income (loss) from equity method investees | 19,297 | 1,672 | 20,969 | 5,136 | 26,105 | ||||||||||||
Segment assets | 14,698,039 | 6,177,482 | 20,875,521 | 2,244,385 | 23,119,906 | ||||||||||||
thereof investments in equity method investees | 268,370 | 396,524 | 664,894 | -448 | 664,446 | ||||||||||||
Capital expenditures, acquisitions and investments (1) | 789,340 | 286,420 | 1,075,760 | 167,903 | 1,243,663 | ||||||||||||
2012 | |||||||||||||||||
Net revenue external customers | $ | 9,031,108 | $ | 4,740,132 | $ | 13,771,240 | $ | 29,042 | $ | 13,800,282 | |||||||
Inter - segment revenue | 10,072 | - | 10,072 | -10,072 | - | ||||||||||||
Revenue | 9,041,180 | 4,740,132 | 13,781,312 | 18,970 | 13,800,282 | ||||||||||||
Depreciation and amortization | -310,216 | -175,504 | -485,720 | -117,176 | -602,896 | ||||||||||||
Operating Income | 1,615,348 | 809,269 | 2,424,617 | -206,044 | 2,218,573 | ||||||||||||
Income (loss) from equity method investees | 23,408 | 919 | 24,327 | -6,885 | 17,442 | ||||||||||||
Segment assets | 14,170,453 | 5,892,477 | 20,062,930 | 2,263,068 | 22,325,998 | ||||||||||||
thereof investments in equity method investees | 266,521 | 378,626 | 645,147 | -7,774 | 637,373 | ||||||||||||
Capital expenditures, acquisitions and investments (2) | 2,147,522 | 230,888 | 2,378,410 | 175,808 | 2,554,218 | ||||||||||||
2011 | |||||||||||||||||
Net revenue external customers | $ | 7,925,472 | $ | 4,627,950 | $ | 12,553,422 | $ | 17,093 | $ | 12,570,515 | |||||||
Inter - segment revenue | 9,196 | - | 9,196 | -9,196 | - | ||||||||||||
Revenue | 7,934,668 | 4,627,950 | 12,562,618 | 7,897 | 12,570,515 | ||||||||||||
Depreciation and amortization | -269,055 | -173,600 | -442,655 | -114,628 | -557,283 | ||||||||||||
Operating Income | 1,435,450 | 807,437 | 2,242,887 | -167,995 | 2,074,892 | ||||||||||||
Income (loss) from equity method investees | 32,387 | 69 | 32,456 | -1,497 | 30,959 | ||||||||||||
Segment assets | 11,761,777 | 5,589,421 | 17,351,198 | 2,181,652 | 19,532,850 | ||||||||||||
thereof investments in equity method investees | 322,990 | 370,447 | 693,437 | -1,412 | 692,025 | ||||||||||||
Capital expenditures, acquisitions and investments (3) | 1,055,183 | 1,161,825 | 2,217,008 | 166,176 | 2,383,184 | ||||||||||||
(1) North America and International acquisitions exclude $48,231 and $18,686, respectively, of non-cash acquisitions and investments for 2013. | |||||||||||||||||
(2) North America and International acquisitions exclude $484,699 and $6,624, respectively, of non-cash acquisitions and investments for 2012. | |||||||||||||||||
(3) North America and International acquisitions exclude $6,000 and $225,034, respectively, of non-cash acquisitions and investments for 2011. | |||||||||||||||||
Schedule of revenue from external customers | ' | ||||||||||||||||
Germany | North America | Rest of the World | Total | ||||||||||||||
2013 | |||||||||||||||||
Net revenue | $ | 437,459 | $ | 9,606,111 | $ | 4,566,157 | $ | 14,609,727 | |||||||||
Long-lived assets | 609,040 | 12,891,384 | 3,226,779 | 16,727,203 | |||||||||||||
2012 | |||||||||||||||||
Net revenue | $ | 409,195 | $ | 9,031,108 | $ | 4,359,979 | $ | 13,800,282 | |||||||||
Long-lived assets | 493,782 | 12,428,762 | 3,185,773 | 16,108,317 | |||||||||||||
2011 | |||||||||||||||||
Net revenue | $ | 422,476 | $ | 7,925,472 | $ | 4,222,567 | $ | 12,570,515 | |||||||||
Long-lived assets | 420,573 | 10,326,615 | 3,040,872 | 13,788,060 |
Supplementary_Cash_Flow_Inform1
Supplementary Cash Flow Information (Tables) | 12 Months Ended | |||||||||
Dec. 31, 2013 | ||||||||||
Supplementary Cash Flow Information (Tables) [Abstract] | ' | |||||||||
Cash Flow Supplemental [Text Block] | ' | |||||||||
2013 | 2012 | 2011 | ||||||||
Supplementary cash flow information: | ||||||||||
Cash paid for interest | $ | 374,648 | $ | 349,415 | $ | 259,835 | ||||
Cash paid for income taxes(1) | $ | 542,625 | $ | 552,711 | $ | 455,805 | ||||
Cash inflow for income taxes from stock option exercises | $ | 8,882 | $ | 21,008 | $ | 13,010 | ||||
Supplemental disclosures of cash flow information: | ||||||||||
Details for acquisitions: | ||||||||||
Assets acquired | $ | -417,669 | $ | -2,519,189 | $ | -1,684,630 | ||||
Liabilities assumed | 31,335 | 241,342 | 215,253 | |||||||
Noncontrolling interest subject to put provisions | 15,460 | 123,210 | 26,684 | |||||||
Noncontrolling interest | 9,104 | 104,947 | 20,983 | |||||||
Obligations assumed in connection with acquisition | 66,917 | 6,624 | 20,016 | |||||||
Cash paid | -294,853 | -2,043,066 | -1,401,694 | |||||||
Less cash acquired | 6,858 | 173,278 | 47,461 | |||||||
Net cash paid for acquisitions | -287,995 | -1,869,788 | -1,354,233 | |||||||
Cash paid for investments | -195,921 | -387 | -419,040 | |||||||
Cash paid for intangible assets | -11,809 | -8,733 | -12,056 | |||||||
Total cash paid for acquisitions and investments, net of cash acquired, and purchases of intangible assets | $ | -495,725 | $ | -1,878,908 | $ | -1,785,329 | ||||
(1) Net of tax refund. |
Supplemental_Condensed_Combini1
Supplemental Condensed Combining Information (Tables) | 12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Supplemental Condensed Combining Information (Tables) [Abstract] | ' | ' | ' | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income statement information segregated by issuers and guarantors | ' | ' | ' | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
For the year ended December 31, 2013 | For the year ended December 31, 2012 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuer | Guarantors | Issuer | Guarantors | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net revenue | $ | - | $ | - | $ | 2,084,014 | $ | - | $ | 15,825,782 | $ | -3,300,069 | $ | 14,609,727 | Net revenue | $ | - | $ | - | $ | 1,884,622 | $ | - | $ | 14,806,815 | $ | -2,891,155 | $ | 13,800,282 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cost of revenue | - | - | 1,356,114 | - | 11,789,397 | -3,274,181 | 9,871,330 | Cost of revenue | - | - | 1,197,337 | - | 10,876,513 | -2,874,821 | 9,199,029 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gross profit | - | - | 727,900 | - | 4,036,385 | -25,888 | 4,738,397 | Gross profit | - | - | 687,285 | - | 3,930,302 | -16,334 | 4,601,253 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Operating expenses (income): | Operating expenses (income): | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Selling, general and administrative(1) | - | 184,054 | 284,589 | -128,356 | 2,150,296 | -134,187 | 2,356,396 | Selling, general and administrative (1) | - | 59,222 | 203,284 | -51,963 | 2,030,970 | 29,536 | 2,271,049 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Research and development | - | - | 72,638 | - | 53,336 | -169 | 125,805 | Research and development | - | - | 69,025 | - | 42,442 | 164 | 111,631 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Operating (loss) income | - | -184,054 | 370,673 | 128,356 | 1,832,753 | 108,468 | 2,256,196 | Operating (loss) income | - | -59,222 | 414,976 | 51,963 | 1,856,890 | -46,034 | 2,218,573 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other (income) expense: | Other (income) expense: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest, net | -6,871 | 210,759 | 5,922 | 176,643 | 22,108 | - | 408,561 | Investment gain | - | - | - | - | -139,600 | - | -139,600 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other, net | - | -1,545,184 | 259,165 | -824,853 | - | 2,110,872 | - | Interest, net | -6,839 | 216,914 | 2,682 | 156,794 | 71,797 | -15,288 | 426,060 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income (loss) before income taxes | 6,871 | 1,150,371 | 105,586 | 776,566 | 1,810,645 | -2,002,404 | 1,847,635 | Other, net | - | -1,531,505 | 261,505 | -921,180 | - | 2,191,180 | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income tax expense (benefit) | 2,494 | 40,481 | 108,837 | -19,049 | 652,672 | -193,423 | 592,012 | Income (loss) before income taxes | 6,839 | 1,255,369 | 150,789 | 816,349 | 1,924,693 | -2,221,926 | 1,932,113 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net Income (loss) | 4,377 | 1,109,890 | -3,251 | 795,615 | 1,157,973 | -1,808,981 | 1,255,623 | Income tax expense (benefit) | 2,482 | 68,560 | 119,255 | -41,356 | 698,353 | -242,158 | 605,136 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net Income attributable to noncontrolling interests | - | - | - | - | 145,733 | - | 145,733 | Net Income (loss) | 4,357 | 1,186,809 | 31,534 | 857,705 | 1,226,340 | -1,979,768 | 1,326,977 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net income (loss) attributable to shareholders of FMC-AG & Co. KGaA | $ | 4,377 | $ | 1,109,890 | $ | -3,251 | $ | 795,615 | $ | 1,012,240 | $ | -1,808,981 | $ | 1,109,890 | Net Income attributable to noncontrolling interests | - | - | - | - | 140,168 | - | 140,168 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net income (loss) attributable to shareholders of FMC-AG & Co. KGaA | $ | 4,357 | $ | 1,186,809 | $ | 31,534 | $ | 857,705 | $ | 1,086,172 | $ | -1,979,768 | $ | 1,186,809 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(1) Selling, general and administrative is presented net of gain on sale of dialysis clinics and net of income from equity method investees. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(1) Selling, general and administrative is presented net of gain on sale of dialysis clinics, net of income from equity method investees and net of other operating expenses. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance sheet information segregated by issuers and guarantors | ' | ' | ' | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
At December 31, 2013 | At December 31, 2012 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuer | Guarantors | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | Issuer | Guarantors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Current assets: | Current assets: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash and cash equivalents | $ | 0 | $ | 13 | $ | 4,490 | $ | - | $ | 672,206 | $ | 6,068 | $ | 682,777 | Cash and cash equivalents | $ | 1 | $ | 78 | $ | 501 | $ | - | $ | 686,457 | $ | 1,003 | $ | 688,040 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trade accounts receivable, less allowance for doubtful accounts | - | - | 152,480 | - | 2,882,736 | 2,058 | 3,037,274 | Trade accounts receivable, less allowance for doubtful accounts | - | - | 170,627 | - | 2,848,797 | - | 3,019,424 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounts receivable from related parties | 1,269,092 | 960,137 | 815,748 | 1,643,394 | 4,073,975 | -8,609,228 | 153,118 | Accounts receivable from related parties | 1,269,471 | 2,257,445 | 1,449,317 | 3,562,953 | 4,398,630 | -12,800,007 | 137,809 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories | - | - | 287,625 | - | 946,790 | -137,311 | 1,097,104 | Inventories | - | - | 271,039 | - | 885,613 | -119,843 | 1,036,809 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Prepaid expenses and other current assets | - | 71,939 | 41,240 | 167 | 879,085 | 44,960 | 1,037,391 | Prepaid expenses and other current assets | - | 72,022 | 27,693 | 167 | 837,152 | 40,503 | 977,537 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deferred taxes | - | - | - | - | 322,337 | -43,285 | 279,052 | Deferred taxes | - | - | - | - | 311,280 | -43,443 | 267,837 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total current assets | 1,269,092 | 1,032,089 | 1,301,583 | 1,643,561 | 9,777,129 | -8,736,738 | 6,286,716 | Total current assets | 1,269,472 | 2,329,545 | 1,919,177 | 3,563,120 | 9,967,929 | -12,921,787 | 6,127,456 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property, plant and equipment, net | - | 734 | 238,469 | - | 2,980,268 | -127,517 | 3,091,954 | Property, plant and equipment, net | - | 611 | 206,873 | - | 2,856,000 | -122,881 | 2,940,603 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Intangible assets | - | 501 | 73,166 | - | 684,290 | -81 | 757,876 | Intangible assets | - | 584 | 67,874 | - | 641,714 | -56 | 710,116 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill | - | - | 62,829 | - | 11,595,358 | - | 11,658,187 | Goodwill | - | - | 54,848 | - | 11,367,041 | - | 11,421,889 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deferred taxes | - | 80,931 | 14,209 | - | 118,306 | -109,279 | 104,167 | Deferred taxes | - | 51,111 | 10,123 | - | 131,452 | -103,534 | 89,152 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other assets (1) | - | 13,955,933 | 47,661 | 12,583,246 | 5,234,132 | -30,599,966 | 1,221,006 | Other assets (1) | - | 12,675,998 | 650,255 | 11,766,104 | -4,751,531 | -19,304,044 | 1,036,782 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total assets | $ | 1,269,092 | $ | 15,070,188 | $ | 1,737,917 | $ | 14,226,807 | $ | 30,389,483 | $ | -39,573,581 | $ | 23,119,906 | Total assets | $ | 1,269,472 | $ | 15,057,849 | $ | 2,909,150 | $ | 15,329,224 | $ | 20,212,605 | $ | -32,452,302 | $ | 22,325,998 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Current liabilities: | Current liabilities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounts payable | $ | - | $ | 2,193 | $ | 28,689 | $ | - | $ | 511,715 | $ | - | $ | 542,597 | Accounts payable | $ | - | $ | 1,935 | $ | 41,114 | $ | - | $ | 579,245 | $ | - | $ | 622,294 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounts payable to related parties | - | 1,896,712 | 522,719 | 1,600,480 | 4,931,344 | -8,827,326 | 123,929 | Accounts payable to related parties | - | 2,234,205 | 491,525 | 1,598,852 | 8,663,240 | -12,864,472 | 123,350 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued expenses and other current liabilities | 29,770 | 45,897 | 129,727 | 9,403 | 1,786,709 | 11,027 | 2,012,533 | Accrued expenses and other current liabilities | 29,771 | 27,530 | 102,728 | 3,157 | 1,611,997 | 12,288 | 1,787,471 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term borrowings and other financial liabilities | - | 60 | - | - | 96,588 | - | 96,648 | Short-term borrowings and other financial liabilities | - | 38 | - | - | 117,812 | - | 117,850 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term borrowings from related parties | - | - | - | - | 62,342 | - | 62,342 | Short-term borrowings from related parties | - | - | - | - | 3,973 | - | 3,973 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Current portion of long-term debt and capital lease obligations | - | 271,090 | - | 200,000 | 40,280 | - | 511,370 | Current portion of long-term debt and capital lease obligations | - | 207,160 | - | 100,000 | 27,587 | - | 334,747 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income tax payable | - | 114,197 | - | - | 56,163 | - | 170,360 | Income tax payable | - | 130,636 | - | - | 19,367 | - | 150,003 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deferred taxes | - | 2,331 | 9,002 | - | 64,539 | -41,678 | 34,194 | Deferred taxes | - | 1,622 | 8,126 | - | 61,774 | -41,219 | 30,303 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total current liabilities | 29,770 | 2,332,480 | 690,137 | 1,809,883 | 7,549,680 | -8,857,977 | 3,553,973 | Total current liabilities | 29,771 | 2,603,126 | 643,493 | 1,702,009 | 11,084,995 | -12,893,403 | 3,169,991 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long term debt and capital lease obligations, less current portion | 1,167,466 | 96,699 | - | 2,438,189 | 7,478,944 | -3,434,378 | 7,746,920 | Long term debt and capital lease obligations, less current portion | 1,172,397 | 285,049 | - | 2,559,340 | 7,020,190 | -3,251,236 | 7,785,740 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long term debt from related parties | - | 3,359,606 | - | 2,092,818 | 6,940 | -5,459,364 | - | Long term debt from related parties | - | 3,212,455 | 657,284 | 2,019,925 | 64,530 | -5,898,020 | 56,174 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other liabilities | - | 5,616 | 6,028 | - | 298,313 | 19,604 | 329,561 | Other liabilities | - | 6,696 | 12,679 | 110,637 | 96,322 | 33,923 | 260,257 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pension liabilities | - | 10,377 | 254,233 | - | 171,248 | - | 435,858 | Pension liabilities | - | 7,753 | 202,219 | - | 247,701 | - | 457,673 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income tax payable | 2,287 | 30,846 | - | - | 20,262 | 123,538 | 176,933 | Income tax payable | 2,113 | 264 | - | - | 52,684 | 146,581 | 201,642 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deferred taxes | - | - | - | - | 768,156 | -24,766 | 743,390 | Deferred taxes | - | - | - | - | 685,158 | -21,157 | 664,001 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total liabilities | 1,199,523 | 5,835,624 | 950,398 | 6,340,890 | 16,293,543 | -17,633,343 | 12,986,635 | Total liabilities | 1,204,281 | 6,115,343 | 1,515,675 | 6,391,911 | 19,251,580 | -21,883,312 | 12,595,478 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Noncontrolling interests subject to put provisions | - | - | 0 | - | 648,251 | - | 648,251 | Noncontrolling interests subject to put provisions | - | - | - | - | 523,260 | - | 523,260 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total FMC-AG & Co. KGaA shareholders' equity | 69,569 | 9,234,564 | 787,519 | 7,885,917 | 13,197,233 | -21,940,238 | 9,234,564 | Total FMC-AG & Co. KGaA shareholders' equity | 65,191 | 8,942,506 | 1,393,475 | 8,937,313 | 173,011 | -10,568,990 | 8,942,506 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Noncontrolling interests not subject to put provisions | - | - | - | - | 250,456 | - | 250,456 | Noncontrolling interests not subject to put provisions | - | - | - | - | 264,754 | - | 264,754 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total equity | 69,569 | 9,234,564 | 787,519 | 7,885,917 | 13,447,689 | -21,940,238 | 9,485,020 | Total equity | 65,191 | 8,942,506 | 1,393,475 | 8,937,313 | 437,765 | -10,568,990 | 9,207,260 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total liabilities and equity | $ | 1,269,092 | $ | 15,070,188 | $ | 1,737,917 | $ | 14,226,807 | $ | 30,389,483 | $ | -39,573,581 | $ | 23,119,906 | Total liabilities and equity | $ | 1,269,472 | $ | 15,057,849 | $ | 2,909,150 | $ | 15,329,224 | $ | 20,212,605 | $ | -32,452,302 | $ | 22,325,998 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(1) Other assets are presented net of investment in equity method investees. | (1) Other assets are presented net of investment in equity method investees. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Statement of cash flows information segregated by issuers and guarantors | ' | ' | ' | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
For the year ended December 31, 2013 | For the year ended December 31, 2012 | For the year ended December 31, 2011 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuer | Guarantors | Issuer | Guarantors | Issuer | Guarantors | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Operating Activities: | Operating Activities: | Operating Activities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net income (loss) | $ | 4,377 | $ | 1,109,890 | $ | -3,251 | $ | 795,615 | $ | 1,157,973 | $ | -1,808,981 | $ | 1,255,623 | Net income (loss) | $ | 4,357 | $ | 1,186,809 | $ | 31,534 | $ | 857,705 | $ | 1,226,340 | $ | -1,979,768 | $ | 1,326,977 | Net income (loss) | $ | 3,334 | $ | 1,071,154 | $ | 14,915 | $ | 600,613 | $ | 999,109 | $ | -1,511,863 | $ | 1,177,262 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adjustments to reconcile net income to net cash provided by (used in) operating activities: | Adjustments to reconcile net income to net cash provided by (used in) operating activities: | Adjustments to reconcile net income to net cash provided by (used in) operating activities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity affiliate income | - | -924,138 | - | -824,853 | - | 1,748,991 | - | Equity affiliate income | - | -1,002,965 | - | -921,180 | - | 1,924,145 | - | Equity affiliate income | - | -872,048 | - | -691,312 | - | 1,563,360 | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Depreciation and amortization | - | 689 | 52,029 | - | 629,071 | -33,564 | 648,225 | Depreciation and amortization | - | 519 | 47,832 | - | 583,375 | -28,830 | 602,896 | Depreciation and amortization | - | 858 | 49,207 | 5,768 | 514,843 | -13,393 | 557,283 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Change in deferred taxes, net | - | -34,548 | 3,149 | - | 46,888 | 424 | 15,913 | Change in deferred taxes, net | - | 1,994 | 4,113 | - | 71,744 | -2,681 | 75,170 | Change in deferred taxes, net | - | 12,593 | 2,724 | - | 150,598 | -6,734 | 159,181 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Gain) loss on sale of fixed assets and investments | - | -43 | 437 | - | -33,378 | - | -32,984 | (Gain) loss on sale of fixed assets and investments | - | -40 | -163 | - | -29,321 | - | -29,524 | (Gain) loss on sale of fixed assets and investments | - | -10 | -184 | - | -8,791 | - | -8,985 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Gain) loss on investments | - | - | -61 | - | - | 61 | - | (Gain) loss on investments | - | 1,247 | - | - | - | -1,247 | - | (Gain) loss on investments | - | 31,502 | 186 | - | - | -31,688 | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Write Up) write-off loans from related parties | - | 91,593 | - | - | - | -91,593 | - | (Write Up) write-off loans from related parties | - | 7,527 | - | - | - | -7,527 | - | (Write Up) write-off loans from related parties | - | 44,807 | - | - | - | -44,807 | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Compensation expense related to stock options | - | 13,593 | - | - | - | - | 13,593 | Investment (gain) | - | - | - | - | -139,600 | - | -139,600 | Compensation expense related to stock options | - | 29,071 | - | - | - | - | 29,071 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash inflow (outflow) from hedging | - | -4,073 | - | - | - | - | -4,073 | Compensation expense related to stock options | - | 26,476 | - | - | - | - | 26,476 | Cash outflow from hedging | - | - | - | - | -58,113 | - | -58,113 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investments in equity method investees, net | - | 22,945 | - | - | -20,610 | - | 2,335 | Cash inflow (outflow) from hedging | - | 1,322 | - | - | -15,269 | - | -13,947 | Investments in equity method investees, net | - | - | - | - | -30,959 | - | -30,959 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Changes in assets and liabilities, net of amounts from businesses acquired: | Investments in equity method investees, net | - | 36,453 | - | - | -13,941 | - | 22,512 | Changes in assets and liabilities, net of amounts from businesses acquired: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trade accounts receivable, net | - | - | 14,851 | - | -54,149 | -1,982 | -41,280 | Changes in assets and liabilities, net of amounts from businesses acquired: | Trade accounts receivable, net | - | - | -13,401 | - | -239,393 | - | -252,794 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories | - | - | -4,162 | - | -70,848 | 20,092 | -54,918 | Trade accounts receivable, net | - | - | -23,848 | - | -19,496 | - | -43,344 | Inventories | - | - | -47,022 | - | -135,071 | 30,203 | -151,890 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Prepaid expenses and other current and non-current assets | - | 46,352 | -11,519 | -123,972 | 151,907 | 5,107 | 67,875 | Inventories | - | - | -40,910 | - | -11,532 | 4,163 | -48,279 | Prepaid expenses and other current and non-current assets | - | -133,691 | -3,048 | 86,497 | -80,570 | -46 | -130,858 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounts receivable from / payable to related parties | -8 | -334,000 | 644,752 | 128,185 | -559,991 | 106,351 | -14,711 | Prepaid expenses and other current and non-current assets | - | 148,172 | -13,633 | -38,496 | 11,299 | -18,929 | 88,413 | Accounts receivable from / payable to related parties | -12,372 | -1,183,881 | -51,617 | 54,300 | 1,239,464 | -62,058 | -16,164 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounts payable, accrued expenses and other current and non-current liabilities | - | 11,469 | 21,203 | 6,246 | 181,426 | -5,080 | 215,264 | Accounts receivable from / payable to related parties | -3,724 | 1,653,955 | -49,477 | 117,090 | -1,788,646 | 55,007 | -15,795 | Accounts payable, accrued expenses and other current and non-current liabilities | 13,775 | -40,619 | 28,385 | 79 | 131,427 | -641 | 132,406 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income tax payable | 174 | 7,917 | - | -19,049 | -23,818 | -1,281 | -36,057 | Accounts payable, accrued expenses and other current and non-current liabilities | - | -1,884 | 33,157 | 1,024 | 193,756 | -467 | 225,586 | Income tax payable | 2,016 | 80,461 | - | -59,093 | -509 | 18,167 | 41,042 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net cash provided by (used in) operating activities | 4,543 | 7,646 | 717,428 | -37,828 | 1,404,471 | -61,455 | 2,034,805 | Income tax payable | 97 | -137 | - | -41,356 | 24,316 | -21,398 | -38,478 | Net cash provided by (used in) operating activities | 6,753 | -959,803 | -19,855 | -3,148 | 2,482,035 | -59,500 | 1,446,482 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net cash provided by (used in) operating activities | 730 | 2,059,448 | -11,395 | -25,213 | 93,025 | -77,532 | 2,039,063 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investing Activities: | Investing Activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Purchases of property, plant and equipment | - | -320 | -76,096 | - | -712,213 | 40,691 | -747,938 | Investing Activities: | Purchases of property, plant and equipment | - | -221 | -54,545 | - | -569,645 | 26,556 | -597,855 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from sale of property, plant and equipment | - | 48 | 583 | - | 19,216 | - | 19,847 | Purchases of property, plant and equipment | - | -485 | -78,272 | - | -638,394 | 41,841 | -675,310 | Proceeds from sale of property, plant and equipment | - | - | 775 | - | 26,550 | - | 27,325 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disbursement of loans to related parties | - | 911,133 | - | 141,347 | - | -1,052,480 | - | Proceeds from sale of property, plant and equipment | - | 40 | 407 | - | 9,220 | - | 9,667 | Disbursement of loans to related parties | - | 1,571,874 | 200 | -1,118,399 | - | -453,675 | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acquisitions and investments, net of cash acquired, and purchases of intangible assets | - | -103,308 | -24,503 | -1,000 | -492,683 | 125,769 | -495,725 | Disbursement of loans to related parties | - | -1,551,372 | - | 289,879 | - | 1,261,493 | - | Acquisitions and investments, net of cash acquired, and purchases of intangible assets | - | -148,331 | -4,554 | - | -2,529,849 | 897,405 | -1,785,329 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from divestitures | - | - | - | - | 18,276 | - | 18,276 | Acquisitions and investments, net of cash acquired, and purchases of intangible assets | - | -1,618,662 | -2,021 | - | -1,876,310 | 1,618,085 | -1,878,908 | Proceeds from divestitures | - | - | 418 | - | 9,990 | -418 | 9,990 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net cash provided by (used in) investing activities | - | 807,553 | -100,016 | 140,347 | -1,167,404 | -886,020 | -1,205,540 | Proceeds from divestitures | - | 44 | - | - | 263,306 | -44 | 263,306 | Net cash provided by (used in) investing activities | - | 1,423,322 | -57,706 | -1,118,399 | -3,062,954 | 469,868 | -2,345,869 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net cash provided by (used in) investing activities | - | -3,170,435 | -79,886 | 289,879 | -2,242,178 | 2,921,375 | -2,281,245 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financing Activities: | Financing Activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term borrowings, net | - | 20 | -613,593 | - | 597,859 | - | -15,714 | Financing Activities: | Short-term borrowings, net | - | 26,284 | 77,481 | -298 | -142,444 | - | -38,977 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term debt and capital lease obligations, net | -4,544 | -140,374 | - | 1,629,443 | -2,713,226 | 1,052,480 | -176,221 | Short-term borrowings, net | - | -24,338 | 91,628 | - | -80,241 | - | -12,951 | Long-term debt and capital lease obligations, net | -64,252 | -221,594 | - | 433,455 | 1,147,586 | 453,675 | 1,748,870 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Increase (decrease) of accounts receivable securitization program | - | - | - | - | 189,250 | - | 189,250 | Long-term debt and capital lease obligations, net | -730 | 1,308,572 | - | -264,666 | 1,380,034 | -1,261,493 | 1,161,717 | Redemption of trust preferred securities | - | - | - | - | -653,760 | - | -653,760 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from exercise of stock options | - | 102,419 | - | - | 8,881 | - | 111,300 | Increase (decrease) of accounts receivable securitization program | - | - | - | - | -372,500 | - | -372,500 | Increase (decrease) of accounts receivable securitization program | - | - | - | - | 24,500 | - | 24,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from conversion of preference shares into ordinary shares | - | 34,784 | - | - | - | - | 34,784 | Proceeds from exercise of stock options | - | 100,178 | - | - | 20,948 | - | 121,126 | Proceeds from exercise of stock options | - | 81,883 | - | - | 13,010 | - | 94,893 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Purchase of treasury stock | - | -505,014 | - | - | - | - | -505,014 | Dividends paid | - | -271,733 | - | - | -241 | 241 | -271,733 | Dividends paid | - | -280,649 | - | - | 22 | -22 | -280,649 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dividends paid | - | -296,134 | - | - | -2,884 | 2,884 | -296,134 | Capital increase (decrease) | - | - | - | - | 1,581,588 | -1,581,588 | - | Capital increase (decrease) | 57,500 | - | - | 688,390 | 151,097 | -896,987 | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Capital increase (decrease) | - | - | - | -1,731,962 | 1,834,786 | -102,824 | - | Distributions to noncontrolling interest | - | - | - | - | -195,023 | - | -195,023 | Distributions to noncontrolling interest | - | - | - | - | -129,542 | - | -129,542 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Distributions to noncontrolling interest | - | - | - | - | -216,758 | - | -216,758 | Contributions from noncontrolling interest | - | - | - | - | 37,704 | - | 37,704 | Contributions from noncontrolling interest | - | - | - | - | 27,824 | - | 27,824 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contributions from noncontrolling interest | - | - | - | - | 66,467 | - | 66,467 | Net cash provided by (used in) financing activities | -730 | 1,112,679 | 91,628 | -264,666 | 2,372,269 | -2,842,840 | 468,340 | Net cash provided by (used in) financing activities | -6,752 | -394,076 | 77,481 | 1,121,547 | 438,293 | -443,334 | 793,159 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net cash provided by (used in) financing activities | -4,544 | -804,299 | -613,593 | -102,519 | -235,625 | 952,540 | -808,040 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Effect of exchange rate changes on cash and cash equivalents | - | -1,616 | 10 | - | 6,196 | - | 4,590 | Effect of exchange rate changes on cash and cash equivalents | - | -216,618 | -1 | - | 257,247 | 22 | 40,650 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Effect of exchange rate changes on cash and cash equivalents | - | -10,965 | 170 | - | -15,693 | - | -26,488 | Cash and Cash Equivalents: | Cash and Cash Equivalents: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash and Cash Equivalents: | Net increase (decrease) in cash and cash equivalents | - | 76 | 357 | - | 229,312 | 1,003 | 230,748 | Net increase (decrease) in cash and cash equivalents | 1 | -147,175 | -81 | - | 114,621 | -32,944 | -65,578 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net increase (decrease) in cash and cash equivalents | -1 | -65 | 3,989 | - | -14,251 | 5,065 | -5,263 | Cash and cash equivalents at beginning of period | 1 | 2 | 144 | - | 457,145 | - | 457,292 | Cash and cash equivalents at beginning of period | - | 147,177 | 225 | - | 342,524 | 32,944 | 522,870 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash and cash equivalents at beginning of period | 1 | 78 | 501 | - | 686,457 | 1,003 | 688,040 | Cash and cash equivalents at end of period | $ | 1 | $ | 78 | $ | 501 | $ | - | $ | 686,457 | $ | 1,003 | $ | 688,040 | Cash and cash equivalents at end of period | $ | 1 | $ | 2 | $ | 144 | $ | - | $ | 457,145 | $ | - | $ | 457,292 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash and cash equivalents at end of period | $ | 0 | $ | 13 | $ | 4,490 | $ | - | $ | 672,206 | $ | 6,068 | $ | 682,777 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Comprehensive income statement information segregated by issuer | ' | ' | ' | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
For the year ended December 31, 2013 | For the year ended December 31, 2012 | For the year ended December 31, 2011 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuer | Guarantors | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | Issuer | Guarantors | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | Issuer | Guarantors | Non-Guarantor Subsidiaries | Combining Adjustment | Combined Total | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | FMC US Finance | FMC - AG & Co. KGaA | D-GmbH | FMCH | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net Income | $ | 4,377 | $ | 1,109,890 | $ | -3,251 | $ | 795,615 | $ | 1,157,973 | $ | -1,808,981 | $ | 1,255,623 | Net Income | $ | 4,357 | $ | 1,186,809 | $ | 31,534 | $ | 857,705 | $ | 1,226,340 | $ | -1,979,768 | $ | 1,326,977 | Net Income | $ | 3,334 | $ | 1,071,154 | $ | 14,915 | $ | 600,613 | $ | 999,109 | $ | -1,511,863 | $ | 1,177,262 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain (loss) related to cash flow hedges | - | 21,020 | - | - | 1,512 | - | 22,532 | Gain (loss) related to cash flow hedges | - | -4,465 | -9 | 11,725 | 16,768 | - | 24,019 | Gain (loss) related to cash flow hedges | - | -124,662 | -269 | 49,857 | -27,372 | - | -102,446 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Actuarial gain (loss) on defined benefit pension plans | - | -971 | -15,150 | 83,597 | -2,487 | - | 64,989 | Actuarial gain (loss) on defined benefit pension plans | - | -2,091 | -46,830 | -49,796 | -4,461 | - | -103,178 | Actuarial gain (loss) on defined benefit pension plans | - | -174 | -6,457 | -74,921 | -354 | - | -81,906 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain (loss) related to foreign currency translation | - | -158,328 | 32,934 | - | -12,896 | 23,851 | -114,439 | Gain (loss) related to foreign currency translation | - | -84,026 | 18,540 | - | 132,627 | -3,338 | 63,803 | Gain (loss) related to foreign currency translation | - | -9,754 | -7,047 | - | -165,371 | 938 | -181,234 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income tax (expense) benefit related to components of other comprehensive income | - | -6,317 | -4,418 | 32,979 | -55,844 | - | -33,600 | Income tax (expense) benefit related to components of other comprehensive income | - | 3,615 | 13,447 | 15,019 | -23,250 | - | 8,831 | Income tax (expense) benefit related to components of other comprehensive income | - | 36,864 | 1,966 | 9,964 | 23,823 | - | 72,617 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other comprehensive income (loss), net of tax | - | -144,596 | 13,366 | 116,576 | -69,715 | 23,851 | -60,518 | Other comprehensive income (loss), net of tax | - | -86,967 | -14,852 | -23,052 | 121,684 | -3,338 | -6,525 | Other comprehensive income (loss), net of tax | - | -97,726 | -11,807 | -15,100 | -169,274 | 938 | -292,969 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total comprehensive income | $ | 4,377 | $ | 965,294 | $ | 10,115 | $ | 912,191 | $ | 1,088,258 | $ | -1,785,130 | $ | 1,195,105 | Total comprehensive income | $ | 4,357 | $ | 1,099,842 | $ | 16,682 | $ | 834,653 | $ | 1,348,024 | $ | -1,983,106 | $ | 1,320,452 | Total comprehensive income | $ | 3,334 | $ | 973,428 | $ | 3,108 | $ | 585,513 | $ | 829,835 | $ | -1,510,925 | $ | 884,293 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Comprehensive income attributable to noncontrolling interests | - | - | - | - | - | 143,689 | 143,689 | Comprehensive income attributable to noncontrolling interests | - | - | - | - | - | 139,989 | 139,989 | Comprehensive income attributable to noncontrolling interests | - | - | - | - | - | 104,861 | 104,861 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Comprehensive income attributable to shareholders of FMC-AG & Co. KGaA | $ | 4,377 | $ | 965,294 | $ | 10,115 | $ | 912,191 | $ | 1,088,258 | $ | -1,928,819 | $ | 1,051,416 | Comprehensive income attributable to shareholders of FMC-AG & Co. KGaA | $ | 4,357 | $ | 1,099,842 | $ | 16,682 | $ | 834,653 | $ | 1,348,024 | $ | -2,123,095 | $ | 1,180,463 | Comprehensive income attributable to shareholders of FMC-AG & Co. KGaA | $ | 3,334 | $ | 973,428 | $ | 3,108 | $ | 585,513 | $ | 829,835 | $ | -1,615,786 | $ | 779,432 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
The_Company_and_Basis_of_Prese2
The Company and Basis of Presentation (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Variable Interest Entity [Line Items] | ' | ' | ' |
Trade accounts receivable | $3,037,274 | $3,019,424 | ' |
Other current assets | 351,615 | 389,020 | ' |
Goodwill | 11,658,187 | 11,421,889 | 9,186,650 |
Equity | 9,234,564 | 8,942,506 | ' |
Revenue | 14,609,727 | 13,800,282 | 12,570,515 |
Funding provided to VIEs through loans and accounts receivable | -150,300 | -146,500 | ' |
Variable Interest Entity [Member] | ' | ' | ' |
Variable Interest Entity [Line Items] | ' | ' | ' |
Trade accounts receivable | 102,549 | 99,061 | ' |
Other current assets | 59,695 | 57,741 | ' |
Property, plant and equipment, intangible assets and other noncurrent assets | 26,274 | 26,823 | ' |
Goodwill | 32,759 | 31,678 | ' |
Accounts payable, accrued expenses and other liabilities | 133,977 | 122,891 | ' |
Noncurrent loans to related parties | 12,998 | 12,998 | ' |
Equity | 74,302 | 79,414 | ' |
Revenue | ($203,333) | ($205,858) | ($195,296) |
Acquisition_of_Liberty_Dialysi3
Acquisition of Liberty Dialysis Holdings (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Business Acquisition [Line Items] | ' | ' | ' |
Description of acquired entity | ' | 'On February 28, 2012, the Company acquired 100% of the equity of Liberty Dialysis Holdings, Inc. (“LD Holdings”), the owner of Liberty Dialysis and owner of a 51% stake in Renal Advantage Partners, LLC (the “Liberty Acquisition”) and accounted for this transaction as a business combination, subject to finalization of the acquisition accounting which will be finalized when certain information arranged to be obtained has been received. LD Holdings mainly provides dialysis services in the United States through the 263 clinics it owns (the “Acquired Clinics”). As we expressly disclose in the Form 20-F (see Item 4B, “Information on the Company – Business Overview – Our Strategy and Competitive Strengths,”) it is part of our stated strategy to expand and complement our existing business through acquisitions. Generally, these acquisitions do not change our business model and are easy to integrate without disruption to our existing business, requiring little or no realignment of our structures. The Liberty Acquisition is consistent in this regard as it involves the acquisition of dialysis clinics, a business in which we are already engaged and, therefore, merely supplements our existing business. Total consideration for the Liberty Acquisition was $2,180,029, consisting of $1,695,330 cash, net of cash acquired and $484,699 non-cash consideration. Accounting standards for business combinations require previously held equity interests to be fair valued with the difference to book value to be recognized as a gain or loss in income. Prior to the Liberty Acquisition, the Company had a 49% equity investment in Renal Advantage Partners, LLC, the fair value of which, $201,915, is included as non-cash consideration. The estimated fair value has been determined based on the discounted cash flow method, utilizing an approximately 13% discount rate. In addition to the Company’s investment, it also had a loan receivable of $279,793 from Renal Advantage Partners, LLC which was retired as part of the transaction. | ' |
Trade accounts receivable | $3,037,274 | $3,019,424 | ' |
Prepaid expenses and other current assets | 1,037,391 | 977,537 | ' |
Deferred Tax Assets, Gross | 622,473 | 636,286 | ' |
Goodwill | 11,658,187 | 11,421,889 | 9,186,650 |
Income tax payable and deferred taxes | -170,360 | -150,003 | ' |
Revenue | 14,609,727 | 13,800,282 | 12,570,515 |
Operating income | 2,256,196 | 2,218,573 | 2,074,892 |
Liberty Dialysis Holdings Inc [Member] | ' | ' | ' |
Business Acquisition [Line Items] | ' | ' | ' |
Other Assets Held for Sale Current | 164,068 | ' | ' |
Trade accounts receivable | 149,219 | ' | ' |
Prepaid expenses and other current assets | 17,458 | ' | ' |
Deferred Tax Assets, Gross | 14,932 | ' | ' |
Property, Plant and Equipment, Gross | 168,335 | ' | ' |
Intangible Assets Current | 84,556 | ' | ' |
Goodwill | 2,003,465 | ' | ' |
Acquisition Accounts Payable | -105,403 | ' | ' |
Income tax payable and deferred taxes | -33,597 | ' | ' |
Short term borrowings from related parties | -72,101 | ' | ' |
Other liabilities | -39,923 | ' | ' |
Noncontrolling interests (subject and not subject to put provisions) | -169,651 | ' | ' |
Total acquisition cost | 2,181,358 | ' | ' |
Investment at acquisition date | -201,915 | ' | ' |
Long Term Note Receivable Acquisitions | -282,784 | ' | ' |
Total Non Cash Items | -484,699 | ' | ' |
Cash Paid For Acquisitions | $1,696,659 | ' | ' |
Acquisition_of_Liberty_Dialysi4
Acquisition of Liberty Dialysis Holdings - Pro Forma (Details) (USD $) | 12 Months Ended | |
In Thousands, except Per Share data, unless otherwise specified | Dec. 31, 2012 | Dec. 31, 2011 |
ProForma | ' | ' |
Pro forma net revenue | $13,900,540 | $13,215,111 |
Pro forma net income attributable to the shareholders of FMC-AG & co. KGaA | $1,054,872 | $1,077,218 |
Pro forma income per ordinary share | ' | ' |
Basic | $3.46 | $3.56 |
Fully diluted | $3.44 | $3.53 |
Acquisitions_and_Investments_D
Acquisitions and Investments (Details) | 12 Months Ended |
Dec. 31, 2012 | |
Business Acquisition [Line Items] | ' |
Description of acquired entity | 'On February 28, 2012, the Company acquired 100% of the equity of Liberty Dialysis Holdings, Inc. (“LD Holdings”), the owner of Liberty Dialysis and owner of a 51% stake in Renal Advantage Partners, LLC (the “Liberty Acquisition”) and accounted for this transaction as a business combination, subject to finalization of the acquisition accounting which will be finalized when certain information arranged to be obtained has been received. LD Holdings mainly provides dialysis services in the United States through the 263 clinics it owns (the “Acquired Clinics”). As we expressly disclose in the Form 20-F (see Item 4B, “Information on the Company – Business Overview – Our Strategy and Competitive Strengths,”) it is part of our stated strategy to expand and complement our existing business through acquisitions. Generally, these acquisitions do not change our business model and are easy to integrate without disruption to our existing business, requiring little or no realignment of our structures. The Liberty Acquisition is consistent in this regard as it involves the acquisition of dialysis clinics, a business in which we are already engaged and, therefore, merely supplements our existing business. Total consideration for the Liberty Acquisition was $2,180,029, consisting of $1,695,330 cash, net of cash acquired and $484,699 non-cash consideration. Accounting standards for business combinations require previously held equity interests to be fair valued with the difference to book value to be recognized as a gain or loss in income. Prior to the Liberty Acquisition, the Company had a 49% equity investment in Renal Advantage Partners, LLC, the fair value of which, $201,915, is included as non-cash consideration. The estimated fair value has been determined based on the discounted cash flow method, utilizing an approximately 13% discount rate. In addition to the Company’s investment, it also had a loan receivable of $279,793 from Renal Advantage Partners, LLC which was retired as part of the transaction. |
Related_Party_Transactions_Det
Related Party Transactions (Details) | 12 Months Ended | 12 Months Ended | 12 Months Ended | |||||||||||||||||||||||||||||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
USD ($) | USD ($) | Fresenius SE [Member] | Fresenius SE [Member] | Fresenius SE [Member] | Fresenius SE [Member] | Fresenius SE [Member] | Fresenius SE [Member] | Fresenius SE [Member] | Fresenius SE [Member] | Fresenius SE [Member] | Fresenius SE [Member] | Fresenius SE [Member] | Fresenius SE [Member] | Fresenius SE [Member] | Fresenius SE [Member] | Fresenius SE [Member] | Fresenius SE [Member] | Fresenius SE [Member] | Fresenius SE [Member] | Fresenius SE [Member] | Fresenius SE [Member] | Fresenius SE [Member] | General Partner [Member] | General Partner [Member] | General Partner [Member] | General Partner [Member] | General Partner [Member] | General Partner [Member] | APP Inc [Member] | APP Inc [Member] | APP Inc [Member] | |
USD ($) | EUR (€) | Services Provided By Related Party [Member] | Services Provided By Related Party [Member] | Services Provided By Related Party [Member] | Services Provided To Related Party [Member] | Services Provided To Related Party [Member] | Services Provided To Related Party [Member] | Operating Lease Agreements [Member] | Operating Lease Agreements [Member] | Operating Lease Agreements [Member] | Sales To Related Party [Member] | Sales To Related Party [Member] | Sales To Related Party [Member] | Purchases From Related Party [Member] | Purchases From Related Party [Member] | Purchases From Related Party [Member] | Accounts Receivable with Related Party [Member] | Accounts Receivable with Related Party [Member] | Accounts Payable With Related Party [Member] | Accounts Payable With Related Party [Member] | Services Provided By Related Party [Member] | Services Provided By Related Party [Member] | Services Provided By Related Party [Member] | Compensation For Risk Exposure [Member] | Compensation For Risk Exposure [Member] | Compensation For Risk Exposure [Member] | Purchases From Related Party [Member] | Purchases From Related Party [Member] | Purchases From Related Party [Member] | |||
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |||||
Related Party Transactions [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
FSE ownership percentage | 31.30% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Amount of transaction | ' | ' | ' | ' | $103,577 | $80,778 | $75,969 | $7,550 | $5,810 | $6,555 | $26,976 | $25,179 | $25,833 | $30,062 | $22,098 | $20,220 | $34,201 | $46,072 | $52,587 | ' | ' | ' | ' | $16,327 | $18,995 | $13,511 | $159 | $94 | $84 | $17,700 | $14,136 | $24,106 |
Annual compensation for assuming unlimited liability, amount of General Partner's invested capital | 21,076 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Due to related parties | 123,929 | 123,350 | 6,068 | 4,400 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 102,731 | 82,029 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Interest rate | ' | ' | 1.56% | 1.56% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Accounts receivable from related parties | $153,118 | $137,809 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $112,568 | $120,071 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Inventories_Details
Inventories (Details) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Inventories (Details) [Abstract] | ' | ' |
Raw materials and purchased components | $195,519 | $154,840 |
Work in process | 76,084 | 83,258 |
Finished goods | 640,355 | 627,338 |
Health care supplies | 185,146 | 171,373 |
Inventories | 1,097,104 | 1,036,809 |
Epo Disclosures [Abstract] | ' | ' |
EPO Inventories | 33,294 | 29,704 |
Unrecorded Unconditional Purchase Obligation [Line Items] | ' | ' |
Unrecorded Unconditional Purchase Obligation, Due within One Year | 337,027 | ' |
Unrecorded Unconditional Purchase Obligation Change In Purchase Obligation | $612,925 | ' |
Prepaid_Expenses_and_Other_Cur2
Prepaid Expenses and Other Current Assets (Details) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Prepaid Expenses And Other Current Assets (Details) [Abstract] | ' | ' |
Rebates | $105,994 | $61,248 |
Taxes Refundable | 133,673 | 149,536 |
Derivatives | 16,664 | 31,235 |
Payments on account | 33,934 | 35,660 |
Prepaid rent | 49,409 | 44,894 |
Leases receivable | 48,538 | 46,198 |
Other | 351,615 | 389,020 |
Prepaid insurance | 41,039 | 24,935 |
Prepaid Deposit | 19,212 | 20,903 |
Total prepaid expenses and other current assets | 1,037,391 | 977,537 |
Cost Report Receivable from Medicare and Medicaid | 130,236 | 86,566 |
Other Deferred Charges | 62,555 | 53,517 |
Amounts Due From Managed Locations | 22,676 | 17,298 |
Receivable For Sale of Investment | $21,846 | $16,527 |
Property_Plant_and_Equipment_D
Property, Plant and Equipment (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Property, Plant and Equipment [Line Items] | ' | ' | ' |
Accumulated depreciation | ($3,506,807) | ($3,134,863) | ' |
Property, plant and equipment, net | 3,091,954 | 2,940,603 | ' |
Depreciation expense | 555,125 | 515,455 | 479,438 |
Land and Land Improvements [Member] | ' | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' | ' |
Property, plant and equipment, gross | 46,689 | 54,775 | ' |
Building and Building Improvements [Member] | ' | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' | ' |
Property, plant and equipment, gross | 2,432,824 | 2,257,002 | ' |
Machinery and Equipment [Member] | ' | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' | ' |
Property, plant and equipment, gross | 3,808,356 | 3,470,972 | ' |
Assets Held under Capital Leases [Member] | ' | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' | ' |
Property, plant and equipment, gross | 43,239 | 36,316 | ' |
Accumulated depreciation | 21,201 | 19,027 | ' |
Construction in Progress [Member] | ' | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' | ' |
Property, plant and equipment, gross | 267,653 | 256,401 | ' |
Assets Leased to Others [Member] | ' | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' | ' |
Property, plant and equipment, gross | $597,024 | $532,088 | ' |
Intangible_Assets_and_Goodwill2
Intangible Assets and Goodwill (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Amortization Expense [Abstract] | ' | ' | ' |
Amortization Of Intangible Assets | $93,100 | $87,441 | $77,845 |
Finite-Lived Intangible Assets, Future Amortization Expense [Abstract] | ' | ' | ' |
2014 | 79,830 | ' | ' |
2015 | 76,717 | ' | ' |
2016 | 74,303 | ' | ' |
2017 | 70,362 | ' | ' |
2018 | 67,793 | ' | ' |
Indefinite Lived Intangible Assets [Line Items] | ' | ' | ' |
Carrying Amount | 217,669 | 218,055 | ' |
Intangible Assets | 757,876 | 710,116 | ' |
Finite-Lived Intangible Assets [Line Items] | ' | ' | ' |
Gross Carrying Amount | 1,248,678 | 1,124,041 | ' |
Accumulated Amortization | -708,471 | -631,980 | ' |
Goodwill [Roll Forward] | ' | ' | ' |
Goodwill | 11,421,889 | 9,186,650 | ' |
Goodwill acquired | 258,216 | 2,193,287 | ' |
Reclassifications | 419 | ' | ' |
Foreign Currency Translation Adjustment | -22,337 | 41,952 | ' |
Goodwill | 11,658,187 | 11,421,889 | 9,186,650 |
North America [Member] | ' | ' | ' |
Goodwill [Roll Forward] | ' | ' | ' |
Goodwill | 9,487,013 | 7,314,622 | ' |
Goodwill acquired | 158,582 | 2,172,181 | ' |
Foreign Currency Translation Adjustment | 52 | 210 | ' |
Goodwill | 9,645,647 | 9,487,013 | ' |
International [Member] | ' | ' | ' |
Goodwill [Roll Forward] | ' | ' | ' |
Goodwill | 1,521,359 | 1,464,089 | ' |
Goodwill acquired | 99,634 | 21,106 | ' |
Reclassifications | -3,807 | -5,188 | ' |
Foreign Currency Translation Adjustment | -23,029 | 41,352 | ' |
Goodwill | 1,594,157 | 1,521,359 | ' |
Reporting Segment Total [Member] | ' | ' | ' |
Goodwill [Roll Forward] | ' | ' | ' |
Goodwill | 11,008,372 | 8,778,711 | ' |
Goodwill acquired | 258,216 | 2,193,287 | ' |
Reclassifications | -3,807 | -5,188 | ' |
Foreign Currency Translation Adjustment | -22,977 | 41,562 | ' |
Goodwill | 11,239,804 | 11,008,372 | ' |
Corporates [Member] | ' | ' | ' |
Goodwill [Roll Forward] | ' | ' | ' |
Goodwill | 413,517 | 407,939 | ' |
Reclassifications | 4,226 | 5,188 | ' |
Foreign Currency Translation Adjustment | 640 | 390 | ' |
Goodwill | 418,383 | 413,517 | ' |
Noncompete Agreements [Member] | ' | ' | ' |
Finite-Lived Intangible Assets [Line Items] | ' | ' | ' |
Gross Carrying Amount | 325,335 | 317,080 | ' |
Accumulated Amortization | -240,412 | -213,639 | ' |
Developed Technology Rights [Member] | ' | ' | ' |
Finite-Lived Intangible Assets [Line Items] | ' | ' | ' |
Gross Carrying Amount | 106,510 | 107,696 | ' |
Accumulated Amortization | -44,584 | -40,849 | ' |
License and distribution agreements [Member] | ' | ' | ' |
Finite-Lived Intangible Assets [Line Items] | ' | ' | ' |
Gross Carrying Amount | 223,701 | 225,393 | ' |
Accumulated Amortization | -112,697 | -98,757 | ' |
Self-developed software [Member] | ' | ' | ' |
Finite-Lived Intangible Assets [Line Items] | ' | ' | ' |
Gross Carrying Amount | 105,087 | 72,328 | ' |
Accumulated Amortization | -46,097 | -32,496 | ' |
Other intangible assets category [Member] | ' | ' | ' |
Finite-Lived Intangible Assets [Line Items] | ' | ' | ' |
Gross Carrying Amount | 350,475 | 343,867 | ' |
Accumulated Amortization | -264,031 | -246,239 | ' |
Construction in Progress [Member] | ' | ' | ' |
Finite-Lived Intangible Assets [Line Items] | ' | ' | ' |
Gross Carrying Amount | 39,570 | 57,677 | ' |
Customer Relationships Domain [Member] | ' | ' | ' |
Finite-Lived Intangible Assets [Line Items] | ' | ' | ' |
Gross Carrying Amount | 98,000 | ' | ' |
Accumulated Amortization | -650 | ' | ' |
Tradename [Member] | ' | ' | ' |
Indefinite Lived Intangible Assets [Line Items] | ' | ' | ' |
Intangible Assets | 210,630 | 209,712 | ' |
Management contracts [Member] | ' | ' | ' |
Indefinite Lived Intangible Assets [Line Items] | ' | ' | ' |
Intangible Assets | $7,039 | $8,343 | ' |
Other_Assets_and_Note_Receivab
Other Assets and Note Receivables (USD $) | 12 Months Ended |
In Thousands, unless otherwise specified | Dec. 31, 2013 |
Accounts Notes And Loans Receivable | ' |
Borrowings Available Under Notes Receivable | $200,000 |
Notes Receivable Cash Interest Rate | 10.75% |
Notes Receivable PIK Interest Rate | 11.75% |
Notes Receivable Net Payment | 165,542 |
Notes Receivable Balance | 170,000 |
Notes Receivable Interest Income | $3,097 |
Accrued_Expenses_and_Other_Cur1
Accrued Expenses and Other Current Liabilities (Details) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Accrued Expenses And Other Liabilities (Details) [Abstract] | ' | ' |
Accrued salaries, wages and incentive plan compensations | $542,230 | $481,920 |
Unapplied cash and receivable credits | 302,337 | 198,834 |
Accrued insurance | 201,346 | 187,254 |
Derivative financial instruments | 25,701 | 26,578 |
Special charge for legal matters | 115,000 | 115,000 |
Other | 507,432 | 478,667 |
Interest Accrual | 122,166 | 111,532 |
Witholding tax and VAT | 93,407 | 96,157 |
Accrued Operating Expenses | 102,914 | 91,529 |
Total accrued expenses and other current liabilities | $2,012,533 | $1,787,471 |
Recovered_Sheet2
Short-term Borrowings and Other Financial Liabilities and Short-term Borrowings from Related Parties (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Short Term Borrowings Other Financial Liabilities And Short Term Borrowings From Related Parties (Details) [Abstract] | ' | ' | ' |
Other financial liabilities | $232,943 | $261,825 | ' |
Related Party Transaction [Line Items] | ' | ' | ' |
Interest Expense Related Party | 547 | 1,468 | 2,362 |
Short-term borrowings and other financial liabilities | 96,648 | 117,850 | ' |
Short Term Borrowings Due To Related Parties Current | $62,342 | $3,973 | ' |
Lines of credit weighted average interest rate | 4.00% | 4.93% | ' |
Fresenius SE [Member] | ' | ' | ' |
Related Party Transaction [Line Items] | ' | ' | ' |
Related Party Transaction Rate | 1.56% | ' | ' |
Longterm_Debt_and_Capital_Leas2
Long-term Debt and Capital Lease Obligations (Details) | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2012 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | USD ($) | USD ($) | Term Loan A [Member] | Term Loan A [Member] | Revolving Credit USD [Member] | Revolving Credit USD [Member] | Revolving Credit EUR [Member] | Revolving Credit EUR [Member] | Revolving Credit EUR [Member] | Revolving Credit EUR [Member] | Senior Notes [Member] | Senior Notes [Member] | 2010 5.5% | 2010 5.5% | 2011 3.73% | 2011 3.73% | 2007 6 7/8% | 2011 6.5% EUR | 2011 6.5% EUR | 2011 6.5% USD | 2012 5.625% | 2012 5.25% | 2012 5.25% | 2011 5.75% | 2011 5.25% | 2011 5.25% | 2012 5.875% | Euro Notes [Member] | Euro Notes [Member] | EIB Agreements [Member] | EIB Agreements [Member] | EIB Revolving Credit Facility [Member] | EIB Loan 2005 [Member] | EIB Loan 2006 [Member] | EIB Loan 2006 [Member] | EIB Loan 2009 [Member] | EIB Loan 2009 [Member] |
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | EUR (€) | USD ($) | EUR (€) | USD ($) | USD ($) | USD ($) | EUR (€) | USD ($) | EUR (€) | USD ($) | USD ($) | EUR (€) | USD ($) | USD ($) | USD ($) | EUR (€) | USD ($) | USD ($) | EUR (€) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |||
Debt Instrument [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Senior Credit Agreement | $2,707,145 | $2,659,340 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Senior Long Term Notes | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,824,753 | 4,743,442 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 46,545 | 51,951 | 193,074 | 324,334 | ' | ' | ' | ' | ' | ' |
Capital lease obligations | 24,264 | 15,618 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Other | 111,259 | 163,802 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Long-term debt and capital lease obligations | 8,258,290 | 8,120,487 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Less current maturities | -511,370 | -334,747 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total long-term debt less current maturities | 7,746,920 | 7,785,740 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revolving credit maximum amount available | 3,789,550 | 3,859,700 | 2,500,000 | 2,600,000 | 600,000 | 600,000 | 689,550 | 500,000 | 659,700 | 500,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revolving credit balance outstanding | 2,707,145 | 2,659,340 | 2,500,000 | ' | 138,190 | 59,340 | 68,955 | 50,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Balance outstanding | 193,074 | 324,334 | ' | ' | ' | ' | ' | ' | ' | ' | 4,824,753 | ' | 342,944 | ' | 137,910 | ' | 496,894 | 546,531 | ' | 396,297 | 800,000 | 344,775 | ' | 645,672 | 413,730 | ' | 700,000 | ' | ' | ' | ' | 90,812 | 48,806 | 124,119 | 118,746 | 68,955 | 65,970 |
Senior Notes Issued February 2011 [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuer | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 'FMC Finance VI S.A. 2010 | 'FMC Finance VI S.A. 2010 | 'FMC Finance VIII S.A. 2011 | 'FMC Finance VIII S.A. 2011 | 'FMC US Finance, Inc. 2007 | 'FMC Finance VIII S.A. 2011 | 'FMC Finance VIII S.A. 2011 | 'FMC US Finance II, Inc. 2011 | 'FMC US Finance II, Inc. 2012 | 'FMC Finance VIII S.A. 2012 | 'FMC Finance VIII S.A. 2012 | 'FMC US Finance, Inc. 2011 | 'FMC Finance VII S.A. 2011 | 'FMC Finance VII S.A. 2011 | 'FMC US Finance II, Inc. 2012 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Face amount | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 250,000 | ' | 100,000 | 500,000 | ' | 400,000 | 400,000 | 800,000 | ' | 250,000 | 650,000 | ' | 300,000 | 700,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stated interest rate | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 5.50% | 5.50% | 3.73% | 3.73% | 6.88% | 6.50% | 6.50% | 6.50% | 5.63% | 5.25% | 5.25% | 5.75% | 5.25% | 5.25% | 5.88% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Accounts receivable facility | 351,250 | 162,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Long Term Debt From Related Parties | 0 | 56,174 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total Long Term Debt | 7,746,920 | 7,841,914 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Annual Payments [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
2014 | 511,370 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
2015 | 233,589 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
2016 | 1,038,599 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
2017 | 2,613,096 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
2018 | 953,423 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Thereafter | 2,926,290 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total | $8,276,367 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Employee_Benefit_Plans_Details
Employee Benefit Plans (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Change in benefit obligations | ' | ' | ' |
Foreign currency translation | ($11,998) | ($4,955) | ' |
Service cost | 15,900 | 10,704 | 10,625 |
Interest cost | 26,859 | 26,194 | 24,822 |
Transfer of plan participants | -32 | -68 | ' |
Actuarial (gain) loss | -34,698 | 122,800 | ' |
Benefits paid | -16,817 | -21,883 | ' |
Other adjustments | 2,203 | ' | ' |
Change in plan assets | ' | ' | ' |
Fair value of plan assets at end of year | 228,393 | 218,990 | ' |
Actual return on plan assets | 23,058 | 18,356 | ' |
Employer contributions | 11,339 | 10,804 | ' |
Benefits paid, fair value | -14,295 | -19,757 | ' |
Fair value of plan assets at end of year | 248,495 | 228,393 | 218,990 |
Funded status, end of year | ' | ' | ' |
Funded status at end of year | 412,365 | 427,054 | ' |
Amounts recognized in consolidated balance sheets | ' | ' | ' |
Pension liabilities, current | 4,221 | 3,693 | ' |
Pension liabilities, noncurrent | 435,858 | 457,673 | ' |
Pension plan with an accumulated benefit obliagation in excess of plan assets | ' | ' | ' |
Accumulated benefit obligation for all defined benefit plans | 614,576 | 616,572 | ' |
Accumulated benefit obligation for all defined benefit plans with an obligation in excess of plan assets | 614,576 | 616,572 | ' |
Net amount recognized | ' | ' | ' |
Benefit plans offered by other subsidiaries | 29,321 | 35,798 | ' |
Net amount recognized | $441,686 | $462,852 | ' |
Employee_Benefit_Plans_Details1
Employee Benefit Plans (Details 1) (United States Pension Plans of US Entity, Defined Benefit [Member], USD $) | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
In Thousands, unless otherwise specified | |||
United States Pension Plans of US Entity, Defined Benefit [Member] | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Defined Benefit Plan, Benefit Obligation | $660,860 | $655,447 | $512,745 |
Employee_Benefit_Plans_Details2
Employee Benefit Plans (Details 2) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Pre-tax changes recognized in Other Comprehensive Income (AOCI) [Abstract] | ' | ' | ' |
Adjustments related to pensions beginning balance | ' | ' | $102,872 |
Actuarial (gain) loss for the year | -44,118 | 119,685 | 91,693 |
Amortization of unrealized losses | -25,418 | -18,334 | -8,737 |
Foreign currency translation adjustment | 3,984 | 1,827 | -1,050 |
Adjustments related to pensions ending balance | 222,967 | 287,956 | 184,778 |
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract] | ' | ' | ' |
Discount rate | 4.55% | 4.14% | ' |
Rate of compensation increase | 3.29% | 3.32% | ' |
Components Of Net Periodic Benefit Cost [Abstract] | ' | ' | ' |
Service cost | 15,900 | 10,704 | 10,625 |
Interest cost | 26,859 | 26,194 | 24,822 |
Expected return on plan assets | -13,638 | -15,241 | -17,750 |
Amortization of unrealized losses | 25,418 | 18,334 | 8,737 |
Net periodic benefit costs | 54,539 | 39,991 | 26,434 |
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract] | ' | ' | ' |
Discount rate | 4.14% | 5.10% | 5.70% |
Expected return on plan assets | 6.00% | 7.00% | 7.50% |
Rate of compensation increase | 3.32% | 3.69% | 4.00% |
Defined Benefit Plan, Estimated Future Benefit Payments [Abstract] | ' | ' | ' |
2014 | 17,824 | ' | ' |
2015 | 19,294 | ' | ' |
2016 | 21,041 | ' | ' |
2017 | 22,963 | ' | ' |
2018 | 24,542 | ' | ' |
2019 - 2023 | $156,106 | ' | ' |
Employee_Benefit_Plans_Details3
Employee Benefit Plans (Details 3) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Fair Value Measurements By Level [Line Items] | ' | ' |
Total | $248,495 | $228,393 |
Equity Funds [Member] | ' | ' |
Fair Value Measurements By Level [Line Items] | ' | ' |
Equity investments | 62,003 | 58,511 |
Other types of investments | 5,603 | 4,259 |
Government Bonds [Member] | ' | ' |
Fair Value Measurements By Level [Line Items] | ' | ' |
Fixed income investments | 4,913 | 9,859 |
All Other Corporate Bonds [Member] | ' | ' |
Fair Value Measurements By Level [Line Items] | ' | ' |
Fixed income investments | 155,389 | 152,332 |
Other Bonds [Member] | ' | ' |
Fair Value Measurements By Level [Line Items] | ' | ' |
Fixed income investments | 1,437 | 457 |
U S Treasury Money Market Funds [Member] | ' | ' |
Fair Value Measurements By Level [Line Items] | ' | ' |
Fixed income investments | 19,150 | 2,975 |
Fair Value, Inputs, Level 1 [Member] | ' | ' |
Fair Value Measurements By Level [Line Items] | ' | ' |
Total | 28,693 | 15,738 |
Fair Value, Inputs, Level 1 [Member] | Equity Funds [Member] | ' | ' |
Fair Value Measurements By Level [Line Items] | ' | ' |
Equity investments | 205 | ' |
Other types of investments | 5,603 | 4,259 |
Fair Value, Inputs, Level 1 [Member] | Government Bonds [Member] | ' | ' |
Fair Value Measurements By Level [Line Items] | ' | ' |
Fixed income investments | 3,735 | 8,504 |
Fair Value, Inputs, Level 1 [Member] | All Other Corporate Bonds [Member] | ' | ' |
Fair Value Measurements By Level [Line Items] | ' | ' |
Fixed income investments | ' | 2,975 |
Fair Value, Inputs, Level 1 [Member] | U S Treasury Money Market Funds [Member] | ' | ' |
Fair Value Measurements By Level [Line Items] | ' | ' |
Fixed income investments | 19,150 | ' |
Significant Observable Inputs (Level 2) | ' | ' |
Fair Value Measurements By Level [Line Items] | ' | ' |
Total | 219,802 | 212,655 |
Significant Observable Inputs (Level 2) | Equity Funds [Member] | ' | ' |
Fair Value Measurements By Level [Line Items] | ' | ' |
Equity investments | 61,798 | 58,511 |
Significant Observable Inputs (Level 2) | Government Bonds [Member] | ' | ' |
Fair Value Measurements By Level [Line Items] | ' | ' |
Fixed income investments | 1,178 | 1,355 |
Significant Observable Inputs (Level 2) | All Other Corporate Bonds [Member] | ' | ' |
Fair Value Measurements By Level [Line Items] | ' | ' |
Fixed income investments | 155,389 | 152,332 |
Significant Observable Inputs (Level 2) | Other Bonds [Member] | ' | ' |
Fair Value Measurements By Level [Line Items] | ' | ' |
Fixed income investments | $1,437 | $457 |
Employee_Benefit_Plans_Details4
Employee Benefit Plans (Details 4) (USD $) | Dec. 31, 2013 |
In Thousands, unless otherwise specified | |
Discount Rate [Member] | ' |
Defined Benefit Plan Liability Increase Decrease (Line Items) | ' |
0.5% Increase | ($54,247) |
0.5% Decrease | 62,866 |
Rate of Compensation Increase [Member] | ' |
Defined Benefit Plan Liability Increase Decrease (Line Items) | ' |
0.5% Increase | 7,230 |
0.5% Decrease | -7,159 |
Rate Of Pension Increase [Member] | ' |
Defined Benefit Plan Liability Increase Decrease (Line Items) | ' |
0.5% Increase | 18,573 |
0.5% Decrease | ($16,893) |
Noncontrolling_Interests_Subje2
Noncontrolling Interests Subject to Put Provisions (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Temporary Equity [Line Items] | ' | ' | ' |
Noncontrolling interests subject to put provisions beginning balance | $523,260 | ' | ' |
Dividends paid | -296,134 | -271,733 | -280,649 |
Purchase (sale) of noncontrolling interests | -15,173 | 59,787 | 3,789 |
Cash contributions from noncontrolling interests | -32,275 | -26,428 | -59,066 |
Changes in fair value of noncontrolling interests | -108,575 | 18,880 | -86,233 |
Net income attributable to noncontrolling interest | 1,255,623 | 1,326,977 | 1,177,262 |
Other Comprehensive Income Loss Net Of Tax | -60,518 | -6,525 | -292,969 |
Noncontrolling interests subject to put provisions ending balance | 648,251 | 523,260 | ' |
Noncontrolling interests subject to put provisions [Member] | ' | ' | ' |
Temporary Equity [Line Items] | ' | ' | ' |
Noncontrolling interests subject to put provisions beginning balance | 523,260 | 410,491 | 279,709 |
Dividends paid | -122,179 | -114,536 | -43,104 |
Purchase (sale) of noncontrolling interests | 6,723 | 134,643 | 37,786 |
Cash contributions from noncontrolling interests | 17,767 | 16,565 | 7,222 |
Changes in fair value of noncontrolling interests | 108,575 | -18,880 | 86,233 |
Net income attributable to noncontrolling interest | 113,156 | 94,718 | 42,857 |
Other Comprehensive Income Loss Net Of Tax | 949 | 259 | -212 |
Noncontrolling interests subject to put provisions ending balance | $648,251 | $523,260 | $410,491 |
Sources_Of_Revenue_Details
Sources Of Revenue (Details) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Patient Service Revenue by Payor [Line Items] | ' | ' |
Patient Service Revenue | $9,057,006 | $8,510,165 |
Medicare ESRD program | ' | ' |
Patient Service Revenue by Payor [Line Items] | ' | ' |
Patient Service Revenue | 4,411,285 | 4,029,773 |
Private/alternative payors | ' | ' |
Patient Service Revenue by Payor [Line Items] | ' | ' |
Patient Service Revenue | 3,841,473 | 3,605,081 |
Medicaid and other government sources | ' | ' |
Patient Service Revenue by Payor [Line Items] | ' | ' |
Patient Service Revenue | 392,908 | 474,520 |
Hospitals | ' | ' |
Patient Service Revenue by Payor [Line Items] | ' | ' |
Patient Service Revenue | $411,340 | $400,791 |
Shareholders_Equity_Details
Shareholders' Equity (Details) (USD $) | 12 Months Ended | ||
In Thousands, except Share data, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Class of Stock [Line Items] | ' | ' | ' |
Common stock authorized | 392,462,972 | ' | ' |
Weighted average remaining contractual life in years | '2 years 6 months | ' | ' |
Payment of dividends | $296,134 | $271,733 | $280,649 |
Common Stock, No par value [Member] | ' | ' | ' |
Class of Stock [Line Items] | ' | ' | ' |
Stock options beginning balance | 10,791,000 | 11,147,000 | ' |
Stock options exercised during the period | 2,280,000 | ' | ' |
Preferred Stock, No par value [Member] | ' | ' | ' |
Class of Stock [Line Items] | ' | ' | ' |
Stock options beginning balance | 0 | 38,000 | ' |
Stock options exercised during the period | 2,000 | ' | ' |
Shareholders_Equity_Details_1
Shareholders' Equity (Details 1) | 12 Months Ended | |||||||||
In Thousands, except Share data, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 |
May 2013 [Member] | May 2013 [Member] | June 2013[Member] | June 2013[Member] | July 2013 [Member] | July 2013 [Member] | August 2013 [Member] | August 2013 [Member] | Total [Member] | Total [Member] | |
USD ($) | EUR (€) | USD ($) | EUR (€) | USD ($) | EUR (€) | USD ($) | EUR (€) | USD ($) | EUR (€) | |
shares repurchased (line items) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Average price paid per share | $68.48 | € 52.96 | $69.95 | € 53.05 | $64.63 | € 49.42 | $64.30 | € 48.40 | $66.90 | € 51 |
Total number of shares purchased as part of publicly announced plans or programs | 1,078,255 | 1,078,255 | 2,502,552 | 2,502,552 | 2,972,770 | 2,972,770 | 995,374 | 995,374 | 7,548,951 | 7,548,951 |
Total Value of Shares Repurchased | $73,842 | € 57,107 | $175,047 | € 132,769 | $192,124 | € 146,916 | $64,001 | € 48,174 | $505,014 | € 384,966 |
Earnings_Per_Share_Details
Earnings Per Share (Details) (USD $) | 12 Months Ended | ||
In Thousands, except Share data, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Numerators: | ' | ' | ' |
Income attributable to the Company | $1,109,890 | $1,186,809 | $1,071,154 |
Less: Dividend preference on Preference shares | ' | 102 | 110 |
Income available to all classes of shares | $1,109,890 | $1,186,707 | $1,071,044 |
Denominators: | ' | ' | ' |
Weighted average number of ordinary shares outstanding | 301,877,303 | 301,139,652 | 299,012,744 |
Weighted average number of preference shares outstanding | 1,937,819 | 3,969,307 | 3,961,617 |
Total weighted average shares outstanding | 303,815,122 | 305,108,959 | 302,974,361 |
Potentially dilutive Ordinary shares | 673,089 | 1,761,064 | 1,795,743 |
Potentially dilutive Preference shares | ' | 16,851 | 20,184 |
Total weighted average Ordinary shares outstanding assuming dilution | 302,550,392 | 302,900,716 | 300,808,487 |
Total weighted average Preference shares outstanding assuming dilution | 1,937,819 | 3,986,158 | 3,981,801 |
Basic income per Ordinary share | $3.65 | $3.89 | $3.54 |
Fully diluted income per Ordinary share | $3.65 | $3.87 | $3.51 |
Stock_Options_Details
Stock Options (Details) | 12 Months Ended | 12 Months Ended | ||||
In Thousands, except Per Share data, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 |
USD ($) | USD ($) | USD ($) | EUR (€) | EUR (€) | Common Stock, No par value [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' | ' | ' |
Awards granted | ' | ' | ' | ' | ' | 2,141 |
Weighted average exercise price | $68.61 | $75.41 | ' | € 49.75 | € 57.15 | ' |
Options Awarded | ' | ' | ' | ' | ' | 2,141 |
Employee Service Share-based Compensation, Aggregate Disclosures [Abstract] | ' | ' | ' | ' | ' | ' |
Compensation expense | $13,593 | $26,476 | $29,071 | ' | ' | ' |
Stock_Options_Details_1
Stock Options (Details 1) | 12 Months Ended | 12 Months Ended | |||||||||
In Thousands, except Share data, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 |
Common Stock, No par value [Member] | Common Stock, No par value [Member] | Common Stock, No par value [Member] | Common Stock, No par value [Member] | Preferred Stock, No par value [Member] | Preferred Stock, No par value [Member] | Converted From Preference Shares [Member] | Converted From Preference Shares [Member] | Converted Into Ordinary Shares [Member] | Converted Into Ordinary Shares [Member] | ||
USD ($) | EUR (€) | USD ($) | EUR (€) | USD ($) | EUR (€) | USD ($) | EUR (€) | USD ($) | EUR (€) | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options beginning balance | ' | 11,147,000 | 11,147,000 | ' | ' | 38,000 | 38,000 | ' | ' | ' | ' |
Awards granted | ' | 2,141,000 | 2,141,000 | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options exercised during the period | ' | 2,280,000 | 2,280,000 | ' | ' | 2,000 | 2,000 | ' | ' | ' | ' |
Options forfeited | ' | 249,000 | 249,000 | ' | ' | 4,000 | 4,000 | ' | ' | ' | ' |
Stock options ending balance | ' | 10,791,000 | 10,791,000 | ' | ' | 0 | 0 | ' | ' | ' | ' |
Options converted | ' | ' | ' | ' | ' | ' | ' | 32,000 | 32,000 | 32,000 | 32,000 |
Stock Options Transactions Weighted Average Price Per Share [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Weighted average price per share beginning balance | ' | $58.83 | € 42.66 | ' | ' | $26.56 | € 19.26 | ' | ' | ' | ' |
Granted | ' | $68.61 | € 49.75 | ' | ' | ' | ' | ' | ' | ' | ' |
Forfeited | ' | $61.71 | € 44.75 | ' | ' | $32.49 | € 23.56 | ' | ' | ' | ' |
Exercised | ' | $46.56 | € 33.76 | ' | ' | $25.31 | € 18.35 | ' | ' | ' | ' |
Weighted average price per share ending balance | ' | $63.20 | € 45.83 | ' | ' | $0 | € 0 | ' | ' | ' | ' |
ShareBasedCompensationArrangementsByShareBasedPaymentAwardsOptionsConvertedInPeriodWeightedAverageExercisePrice | ' | ' | ' | ' | ' | ' | ' | $26.01 | € 18.86 | $26.01 | € 18.86 |
Share Based Compensation Arrangement By Share Based Payment Awards Option Vested And Expected To Vest [LineItems] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of options | ' | ' | ' | 4,711 | 4,711 | ' | ' | ' | ' | ' | ' |
Weighted average remaining contractual life in years | '2 years 6 months | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Weighted average exercise price | ' | $50.21 | € 36.41 | ' | ' | ' | ' | ' | ' | ' | ' |
Aggregate intrinsic value | ' | ' | ' | $99,568 | € 72,198 | ' | ' | ' | ' | ' | ' |
Stock_Options_Details_2
Stock Options (Details 2) | 12 Months Ended | |||
Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2012 | |
USD ($) | EUR (€) | USD ($) | EUR (€) | |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] | ' | ' | ' | ' |
Expected dividend yield | 2.00% | 2.00% | 1.61% | 1.61% |
Risk - free interest rate | 1.33% | 1.33% | 1.09% | 1.09% |
Expected volatility | 22.44% | 22.44% | 22.20% | 22.20% |
Weighted average exercise price | $68.61 | € 49.75 | $75.41 | € 57.15 |
Income_Taxes_Details
Income Taxes (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Income before income taxes is attributable to the following geographic locations: | ' | ' | ' |
Germany | $234,336 | $263,651 | $344,267 |
United States | 1,254,690 | 1,356,094 | 1,122,800 |
Other | 358,609 | 312,368 | 311,292 |
Income before income taxes | 1,847,635 | 1,932,113 | 1,778,359 |
Current: | ' | ' | ' |
Germany | 81,117 | 52,862 | 67,484 |
United States | 387,017 | 342,250 | 278,634 |
Other | 116,186 | 139,136 | 106,087 |
Total income tax expense current | 584,320 | 534,248 | 452,205 |
Deferred: | ' | ' | ' |
Germany | -33,106 | 10,478 | 14,565 |
United States | 47,298 | 98,200 | 139,282 |
Other | -6,500 | -37,790 | -4,955 |
Total income tax expense deferred | 7,692 | 70,888 | 148,892 |
Income tax expense | 592,012 | 605,136 | 601,097 |
Effective Income Tax Rate, Continuing Operations, Tax Rate Reconciliation [Abstract] | ' | ' | ' |
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate | 28.46% | 28.71% | 29.13% |
Deferred tax assets: | ' | ' | ' |
Accounts receivable, primarily due to allowance for doubtful accounts | 8,789 | 5,847 | ' |
Inventory, primarily due to additional costs capitalized for tax purposes, and inventory reserve accounts | 9,731 | 9,434 | ' |
Plant, equipment, intangible assets and other noncurrent assets, principally due to differences in depreciation and amortization | 20,093 | 28,470 | ' |
Accrued expenses and other liabilities for financial accounting purposes, not currently tax deductible | 305,664 | 318,827 | ' |
Net operating loss carryforwards, tax credit carryforwards and interest carryforwards | 141,727 | 107,595 | ' |
Derivatives | 2,169 | 4,856 | ' |
Stock-based compensation expense | 22,710 | 24,758 | ' |
Other | 13,632 | 13,136 | ' |
Total deferred tax assets | 622,473 | 636,286 | ' |
Less: valuation allowance [N] | -48,563 | -44,191 | ' |
Net deferred tax assets | 573,910 | 592,095 | ' |
Pensions | 97,958 | 123,363 | ' |
Deferred tax liabilities: | ' | ' | ' |
Accounts receivable | 43,031 | 17,036 | ' |
Inventory, primarily due to inventory reserve accounts for tax purposes | 12,264 | 11,847 | ' |
Accrued expenses and other liabilities for financial reporting purposes, not currently tax deductible | 17,197 | 21,651 | ' |
Plant, equipment and intangible assets, primarily due to differences in depreciation and amortization | 776,254 | 748,271 | ' |
Other | 117,255 | 128,403 | ' |
Total deferred tax liabilities | 968,275 | 929,410 | ' |
Net deferred tax assets (liabilities) | -394,365 | -337,315 | ' |
Estimated future tax liabilities associtaed with earnings that are likely to be distributed in 2011 and following years | ' | 12,853 | ' |
Unrecognized tax benefits (net of interest) | ' | ' | ' |
Beginning balance | 225,198 | 223,829 | 405,900 |
Increases in unrecognized tax benefits prior periods | 25,260 | 13,232 | 24,046 |
Decreases in unrecognized tax benefits prior periods | -11,445 | -5,913 | -24,897 |
Increases in unrecognized tax benefits current period | 10,062 | 17,903 | 16,157 |
Changes related to settlements with tax authorities | -52,325 | -14,763 | -208,484 |
Reductions as a result of a lapse of the statute of limitations | 0 | 0 | -3,100 |
Foreign currency translation | 3,174 | -9,090 | 14,207 |
Ending balance | 199,924 | 225,198 | 223,829 |
Unrecognized tax benefits which would affect the effective tax rate if recognized | ' | 162,010 | ' |
Amount of potential reduction of unrecognized tax benefits | ' | 205,781 | ' |
Valuation Allowance [Line Items] | ' | ' | ' |
Valuation allowance increase | 8,619 | 8,302 | ' |
Operating Loss Carryforwards [Line Items] | ' | ' | ' |
Net operating loss carryforwards | 506,682 | ' | ' |
Income Tax Examination [Line Items] | ' | ' | ' |
Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority | ' | 37,000 | ' |
Interest and penalties recognized | ' | 2,525 | ' |
Accrual for tax related interest and penalties | ' | 60,705 | ' |
Operating Loss Carryforwards Expiration In One Year [Member] | ' | ' | ' |
Operating Loss Carryforwards [Line Items] | ' | ' | ' |
Net operating loss carryforwards | 38,550 | ' | ' |
Operating Loss Carryforwards Expiration In Two Years [Member] | ' | ' | ' |
Operating Loss Carryforwards [Line Items] | ' | ' | ' |
Net operating loss carryforwards | 38,134 | ' | ' |
Operating Loss Carryforwards Expiration In Three Years [Member] | ' | ' | ' |
Operating Loss Carryforwards [Line Items] | ' | ' | ' |
Net operating loss carryforwards | 54,139 | ' | ' |
Operating Loss Carryforwards Expiration In Four Years [Member] | ' | ' | ' |
Operating Loss Carryforwards [Line Items] | ' | ' | ' |
Net operating loss carryforwards | 55,956 | ' | ' |
Operating Loss Carryforwards Expiration In Five Years [Member] | ' | ' | ' |
Operating Loss Carryforwards [Line Items] | ' | ' | ' |
Net operating loss carryforwards | 50,907 | ' | ' |
Operating Loss Carryforwards Expiration In Six Years [Member] | ' | ' | ' |
Operating Loss Carryforwards [Line Items] | ' | ' | ' |
Net operating loss carryforwards | 39,707 | ' | ' |
Operating Loss Carryforwards Expiration In Seven Years [Member] | ' | ' | ' |
Operating Loss Carryforwards [Line Items] | ' | ' | ' |
Net operating loss carryforwards | 33,619 | ' | ' |
Operating Loss Carryforwards Expiration In Eight Years [Member] | ' | ' | ' |
Operating Loss Carryforwards [Line Items] | ' | ' | ' |
Net operating loss carryforwards | 34,042 | ' | ' |
Operating Loss Carryforwards Expiration In Nine Years [Member] | ' | ' | ' |
Operating Loss Carryforwards [Line Items] | ' | ' | ' |
Net operating loss carryforwards | 34,046 | ' | ' |
Operating Loss Carryforwards Expiration In Ten Years And Thereafter [Member] | ' | ' | ' |
Operating Loss Carryforwards [Line Items] | ' | ' | ' |
Net operating loss carryforwards | 34,676 | ' | ' |
Operating Loss Carryforwards No Expiration Date [Member] | ' | ' | ' |
Operating Loss Carryforwards [Line Items] | ' | ' | ' |
Net operating loss carryforwards | $92,906 | ' | ' |
Income_Taxes_Details_1
Income Taxes (Details 1) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Reconciliation between the expected and actual income tax expense | ' | ' | ' |
Expected corporate income tax expense | $538,770 | $554,613 | $506,121 |
Tax free income [N] | -64,141 | -90,943 | -38,926 |
Tax rate differentials | 132,977 | 137,527 | 140,079 |
Non-deductible expenses | 20,564 | 19,961 | 4,536 |
Taxes for prior year | -6,389 | 22,420 | 144 |
Change in valuation allowance | 3,154 | -19,680 | 5,544 |
Noncontrolling partnership interests [N] | -55,023 | -49,081 | -31,300 |
Other | 26,969 | 32,452 | 21,782 |
Tax portion of income from at equity investments | -4,869 | -2,133 | -6,883 |
Income tax expense | $592,012 | $605,136 | $601,097 |
Effective tax rate | 32.04% | 31.32% | 33.80% |
Operating_Leases_Details
Operating Leases (Details) (USD $) | Dec. 31, 2013 |
In Thousands, unless otherwise specified | |
Operating Leases Future Minimum Payments Receivable (Details) [Abstract] | ' |
2014 | $609,521 |
2015 | 524,898 |
2016 | 456,143 |
2016 | 354,705 |
2017 | 277,940 |
Thereafter | 1,002,340 |
Total | $3,225,547 |
Commitments_and_Contingencies_
Commitments and Contingencies (Details) (Insurance Claims [Member], USD $) | Dec. 31, 2013 |
In Thousands, unless otherwise specified | |
Insurance Claims [Member] | ' |
Loss Contingencies [Line Items] | ' |
Loss Contingency Accrual Carrying Value Current | $115,000 |
Financial_Instruments_Details
Financial Instruments (Details) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2010 |
In Thousands, unless otherwise specified | ||||
Assets: | ' | ' | ' | ' |
Cash and cash equivalents | $682,777 | $688,040 | $457,292 | $522,870 |
Liabilities: | ' | ' | ' | ' |
Short-term borrowings | 96,648 | 117,850 | ' | ' |
Short-term borrowings from related parties | 62,342 | 3,973 | ' | ' |
Senior Credit Agreement | 2,707,145 | 2,659,340 | ' | ' |
Noncontrolling interests subject to put provisions | 648,251 | 523,260 | ' | ' |
Euro Notes [Member] | ' | ' | ' | ' |
Liabilities: | ' | ' | ' | ' |
Senior Long Term Notes | 46,545 | 51,951 | ' | ' |
Senior Notes [Member] | ' | ' | ' | ' |
Liabilities: | ' | ' | ' | ' |
Senior Long Term Notes | 4,824,753 | 4,743,442 | ' | ' |
Carrying Reported Amount Fair Value Disclosure [Member] | ' | ' | ' | ' |
Assets: | ' | ' | ' | ' |
Cash and cash equivalents | 682,777 | 688,040 | ' | ' |
Accounts receivable | 3,190,392 | 3,157,233 | ' | ' |
Long-term notes receivable | 165,807 | 0 | ' | ' |
Liabilities: | ' | ' | ' | ' |
Accounts Payable | 666,526 | 745,644 | ' | ' |
Short-term borrowings | 158,990 | 121,823 | ' | ' |
Long term debt, excluding Amended 2006 Senior Credit Agreement, Euro Notes and Senior Notes | 679,847 | 721,928 | ' | ' |
Senior Credit Agreement | 2,707,145 | 2,659,340 | ' | ' |
Noncontrolling interests subject to put provisions | 648,251 | 523,260 | ' | ' |
Carrying Reported Amount Fair Value Disclosure [Member] | Euro Notes [Member] | ' | ' | ' | ' |
Liabilities: | ' | ' | ' | ' |
Senior Long Term Notes | 46,545 | 51,951 | ' | ' |
Carrying Reported Amount Fair Value Disclosure [Member] | Senior Notes [Member] | ' | ' | ' | ' |
Liabilities: | ' | ' | ' | ' |
Senior Long Term Notes | 4,824,753 | 4,743,442 | ' | ' |
Portion At Fair Value Fair Value Disclosure [Member] | ' | ' | ' | ' |
Assets: | ' | ' | ' | ' |
Cash and cash equivalents | 682,777 | 688,040 | ' | ' |
Accounts receivable | 3,190,392 | 3,157,233 | ' | ' |
Long-term notes receivable | 175,768 | 0 | ' | ' |
Liabilities: | ' | ' | ' | ' |
Accounts Payable | 666,526 | 745,644 | ' | ' |
Short-term borrowings | 158,990 | 121,823 | ' | ' |
Long term debt, excluding Amended 2006 Senior Credit Agreement, Euro Notes and Senior Notes | 679,847 | 721,928 | ' | ' |
Senior Credit Agreement | 2,710,270 | 2,652,840 | ' | ' |
Noncontrolling interests subject to put provisions | 648,251 | 523,260 | ' | ' |
Portion At Fair Value Fair Value Disclosure [Member] | Euro Notes [Member] | ' | ' | ' | ' |
Liabilities: | ' | ' | ' | ' |
Senior Long Term Notes | 47,423 | 54,574 | ' | ' |
Portion At Fair Value Fair Value Disclosure [Member] | Senior Notes [Member] | ' | ' | ' | ' |
Liabilities: | ' | ' | ' | ' |
Senior Long Term Notes | $5,348,679 | $5,296,325 | ' | ' |
Financial_Instruments_Details_
Financial Instruments (Details 1) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Designated As Hedging Instrument [Member] | ' | ' |
Derivatives Fair Value [Line Items] | ' | ' |
Assets | $5,744 | $8,781 |
Liabilities | -7,485 | -13,918 |
Nondesignated as Hedging Instrument [Member] | ' | ' |
Derivatives Fair Value [Line Items] | ' | ' |
Assets | 12,739 | 23,528 |
Liabilities | -23,802 | -19,360 |
Foreign Exchange Contract Current [Member] | Designated As Hedging Instrument [Member] | ' | ' |
Derivatives Fair Value [Line Items] | ' | ' |
Assets | 4,985 | 7,839 |
Liabilities | -2,719 | -7,510 |
Foreign Exchange Contract Current [Member] | Nondesignated as Hedging Instrument [Member] | ' | ' |
Derivatives Fair Value [Line Items] | ' | ' |
Assets | 11,679 | 23,396 |
Liabilities | -22,982 | -19,068 |
Foreign Exchange Contract Non Current [Member] | Designated As Hedging Instrument [Member] | ' | ' |
Derivatives Fair Value [Line Items] | ' | ' |
Assets | 759 | 942 |
Liabilities | -374 | -187 |
Foreign Exchange Contract Non Current [Member] | Nondesignated as Hedging Instrument [Member] | ' | ' |
Derivatives Fair Value [Line Items] | ' | ' |
Assets | 1,060 | 132 |
Liabilities | -820 | -292 |
Interest Rate Contract Non Current Dollar [Member] | Designated As Hedging Instrument [Member] | ' | ' |
Derivatives Fair Value [Line Items] | ' | ' |
Liabilities | ' | -6,221 |
Interest Rate Contract Non Current Yen [Member] | Designated As Hedging Instrument [Member] | ' | ' |
Derivatives Fair Value [Line Items] | ' | ' |
Liabilities | ($4,392) | ' |
Financial_Instruments_Details_1
Financial Instruments (Details 2) (USD $) | 12 Months Ended | |
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 |
Derivative Instruments Gain Loss [Line Items] | ' | ' |
Amount of Gain or (Loss) Recognized in OCI on Derivatives (Effective Portion) | ($2,917) | $5,072 |
Amount of (Gain) or Loss Recognized in Income on Derivatives | 25,449 | 18,947 |
Interest Rate Contract [Member] | ' | ' |
Derivative Instruments Gain Loss [Line Items] | ' | ' |
Amount of Gain or (Loss) Recognized in OCI on Derivatives (Effective Portion) | -6,601 | -16,762 |
Foreign Exchange Contract [Member] | ' | ' |
Derivative Instruments Gain Loss [Line Items] | ' | ' |
Amount of Gain or (Loss) Recognized in OCI on Derivatives (Effective Portion) | 3,684 | 21,834 |
Nondesignated as Hedging Instrument [Member] | ' | ' |
Derivative Instruments Gain Loss [Line Items] | ' | ' |
Amount of (Gain) or Loss Recognized in Income on Derivatives | -8,029 | -771 |
Interest Income Expense [Member] | ' | ' |
Derivative Instruments Gain Loss [Line Items] | ' | ' |
Amount of (Gain) or Loss Recognized in Income on Derivatives | 28,111 | 23,779 |
Interest Income Expense [Member] | Designated As Hedging Instrument [Member] | Foreign Exchange Contract [Member] | ' | ' |
Derivative Instruments Gain Loss [Line Items] | ' | ' |
Amount of (Gain) or Loss Recognized in Income on Derivatives | 589 | 582 |
Interest Income Expense [Member] | Nondesignated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | ' | ' |
Derivative Instruments Gain Loss [Line Items] | ' | ' |
Amount of (Gain) or Loss Recognized in Income on Derivatives | 7,161 | 8,033 |
Cost Of Sale [Member] | ' | ' |
Derivative Instruments Gain Loss [Line Items] | ' | ' |
Amount of (Gain) or Loss Recognized in Income on Derivatives | -3,251 | -5,414 |
Selling general and administrative expense [Member] | Nondesignated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | ' | ' |
Derivative Instruments Gain Loss [Line Items] | ' | ' |
Amount of (Gain) or Loss Recognized in Income on Derivatives | ($15,190) | ($8,804) |
Other_Comprehensive_Income_Los2
Other Comprehensive Income (Loss) (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax [Abstract] | ' | ' | ' |
Changes in fair value of cash flow hedges during the period - pretax | ($2,917) | $5,072 | ($104,130) |
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax | 1,346 | -21,171 | 41,825 |
Changes in fair value of cash flow hedges during the period, OCI net of tax | -1,571 | -16,099 | -62,305 |
Reclassification adjustments - pretax | 25,449 | 18,947 | 1,684 |
Reclassification adjustments - tax effect | -7,393 | -4,968 | -796 |
Reclassification adjustments - net | 18,056 | 13,979 | 888 |
Total other comprehensive income (loss) relating to cash flow hedges, pretax | 22,532 | 24,019 | -102,446 |
Total other comprehensive income (loss) relating to cash flow hedges, tax effect | -6,047 | -26,139 | 41,029 |
Foreign-currency translation adjustment - pretax | -114,439 | 63,803 | -181,234 |
Foreign-currency translation adjustment - net | -112,395 | 63,982 | -179,987 |
Other comprehensive income (loss) - tax effect | -33,600 | 8,831 | 72,617 |
Other comprehensive income (loss), net of tax | ($60,518) | ($6,525) | ($292,969) |
Other_Comprehensive_Income_Los3
Other Comprehensive Income (Loss) (Details 1) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Other Comprehensive Income Loss Net Of Tax | ($60,518) | ($6,525) | ($292,969) |
Other comprehensive income (loss) relating to cash flow hedges, pretax: | ' | ' | ' |
Changes in fair value of cash flow hedges during the period, pretax | -2,917 | 5,072 | -104,130 |
Reclassification adjustments, pretax | -25,449 | -18,947 | -1,684 |
Total other comprehensive income (loss) relating to cash flow hedges, pretax | 22,532 | 24,019 | -102,446 |
Foreign-currency translation adjustment, pretax | -112,395 | 63,982 | -179,987 |
Defined benefit pension plans, pretax: | ' | ' | ' |
Actuarial (loss) gain on defined benefit pension plans, pretax | -39,571 | 121,512 | 90,643 |
Reclassification adjustments, pretax | 25,418 | 18,334 | 8,737 |
Total other comprehensive income (loss) relating to defined benefit pension plans, pretax | 64,989 | -103,178 | -81,906 |
Other comprehensive income (loss), pretax | -24,874 | -15,177 | -364,339 |
Other Comprehensive Income (Loss), Tax | ' | ' | ' |
Other comprehensive income (loss) relating to cash flow hedges, tax effect: | -6,047 | -26,139 | 41,029 |
Changes in fair value of cash flow hedges during the period, tax effect | 1,346 | -21,171 | 41,825 |
Reclassification adjustments, tax effect | 7,393 | 4,968 | 796 |
Total other comprehensive income (loss) relating to cash flow hedges, tax effect | -6,047 | -26,139 | 41,029 |
Changes in fair value of cash flow hedges during the period, tax effect | 1,346 | -21,171 | 41,825 |
Reclassification adjustments, tax effect | 7,393 | 4,968 | 796 |
Defined benefit pension plans, tax effect: | -27,553 | 34,970 | -31,588 |
Actuarial (loss) gain on defined benefit pension plans, tax effect | -17,828 | 42,159 | 34,930 |
Reclassification adjustments, tax effect | 9,725 | 7,189 | 3,342 |
Total other comprehensive income (loss) relating to defined benefit pension plans, tax effect | 27,553 | -34,970 | 31,588 |
Actuarial (loss) gain on defined benefit pension plans, tax effect | -17,828 | 42,159 | 34,930 |
Reclassification adjustments, tax effect | 9,725 | 7,189 | 3,342 |
Other comprehensive income (loss), tax effect | -33,600 | 8,831 | 72,617 |
Comprehensive Income (Loss), Net before NCI | ' | ' | ' |
Other comprehensive income (loss) relating to cash flow hedges, net before NCI: | 16,485 | -2,120 | -61,417 |
Changes in fair value of cash flow hedges during the period, net before NCI | -1,571 | -16,099 | -62,305 |
Reclassification adjustments, net before NCI | -18,056 | -13,979 | -888 |
Total other comprehensive income (loss) relating to cash flow hedges, net before NCI | 16,485 | -2,120 | -61,417 |
Changes in fair value of cash flow hedges during the period, net before NCI | -1,571 | -16,099 | -62,305 |
Reclassification adjustments, net before NCI | -18,056 | -13,979 | -888 |
Foreign-currency translation adjustment, net before NCI | -112,395 | 63,982 | -179,987 |
Defined benefit pension plans, net before NCI: | ' | ' | ' |
Actuarial (loss) gain on defined benefit pension plans, net before NCI | 21,743 | -79,353 | -55,713 |
Reclassification adjustments, net before NCI | 15,693 | 11,145 | 5,395 |
Total other comprehensive income (loss) relating to defined benefit pension plans, net before NCI | -37,436 | 68,208 | -50,318 |
Other comprehensive income (loss), net before NCI | -58,474 | -6,346 | -291,722 |
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest | ' | ' | ' |
Other comprehensive income (loss) relating to cash flow hedges, net before NCI: | 16,485 | -2,120 | -61,417 |
Changes in fair value of cash flow hedges during the period, net before NCI | -1,571 | -16,099 | -62,305 |
Reclassification adjustments, net before NCI | -18,056 | -13,979 | -888 |
Foreign-currency translation adjustment, Non-controlling interests | ' | -179 | -1,247 |
Other comprehensive income (loss), Non-controlling interests | ' | ' | -1,247 |
Other comprehensive income (loss) relating to cash flow hedges, OCI net of tax: | ' | ' | ' |
Changes in fair value of cash flow hedges during the period, OCI net of tax | -1,571 | -16,099 | -62,305 |
Reclassification adjustments, OCI net of tax | -18,056 | -13,979 | -888 |
Foreign-currency translation adjustment, net before NCI | -112,395 | 63,982 | -179,987 |
Defined benefit pension plans, OCI net of tax: | ' | ' | ' |
Actuarial (loss) gain on defined benefit pension plans, OCI net of tax | 21,743 | -79,353 | -55,713 |
Reclassification adjustments, OCI net of tax | 15,693 | 11,145 | 5,395 |
Other comprehensive income (loss), net of tax | ($60,518) | ($6,525) | ($292,969) |
Other_Comprehensive_Income_Los4
Other Comprehensive Income (Loss) (Details 2) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Other Comprehensive Income Loss Net Of Tax | ($60,518) | ($6,525) | ($292,969) |
Statement [Line Items] | ' | ' | ' |
Balance | -492,113 | -485,767 | -194,045 |
Other comprehensive income before reclassifications | -92,223 | -31,470 | -298,005 |
Amounts reclassified from Accumulated Other comprehensive income | -33,749 | -25,124 | -6,283 |
Net current period other comprehensive income | -60,518 | -6,525 | -292,969 |
Balance | -550,587 | -492,113 | -485,767 |
Total FMC-AG and Co. KGaA [Member] | ' | ' | ' |
Statement [Line Items] | ' | ' | ' |
Balance | -489,244 | -482,719 | -189,750 |
Other comprehensive income before reclassifications | -94,267 | -31,649 | -299,252 |
Amounts reclassified from Accumulated Other comprehensive income | -33,749 | -25,124 | -6,283 |
Net current period other comprehensive income | -58,474 | -6,346 | -291,722 |
Balance | -549,762 | -489,244 | -482,719 |
AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember | ' | ' | ' |
Statement [Line Items] | ' | ' | ' |
Balance | -138,341 | -136,221 | -74,804 |
Other comprehensive income before reclassifications | -1,571 | -16,099 | -62,305 |
Amounts reclassified from Accumulated Other comprehensive income | -18,056 | -13,979 | -888 |
Net current period other comprehensive income | 16,485 | -2,120 | -61,417 |
Balance | -121,856 | -138,341 | -136,221 |
AccumulatedDefinedBenefitPlansAdjustmentMember | ' | ' | ' |
Statement [Line Items] | ' | ' | ' |
Balance | -179,423 | -111,215 | -60,897 |
Other comprehensive income before reclassifications | 21,743 | -79,353 | -55,713 |
Amounts reclassified from Accumulated Other comprehensive income | -15,693 | -11,145 | -5,395 |
Net current period other comprehensive income | 37,436 | -68,208 | -50,318 |
Balance | -141,987 | -179,423 | -111,215 |
AccumulatedTranslationAdjustmentMember | ' | ' | ' |
Statement [Line Items] | ' | ' | ' |
Balance | -174,349 | -238,331 | -58,344 |
Other comprehensive income before reclassifications | -112,395 | 63,982 | -179,987 |
Net current period other comprehensive income | -112,395 | 63,982 | -179,987 |
Balance | -286,744 | -174,349 | -238,331 |
Noncontrolling interests not subject to put provisions [Member] | ' | ' | ' |
Statement [Line Items] | ' | ' | ' |
Balance | 2,869 | 3,048 | 4,295 |
Other comprehensive income before reclassifications | -2,044 | -179 | -1,247 |
Net current period other comprehensive income | -2,044 | -179 | -1,247 |
Balance | $825 | $2,869 | $3,048 |
Other_Comprehensive_Income_Los5
Other Comprehensive Income (Loss) (Details 3) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Other Comprehensive Income Loss Net Of Tax | ($60,518) | ($6,525) | ($292,969) |
(Gains) and losses on cash flow hedges | ' | ' | ' |
Interest rate Contracts | 28,111 | 23,779 | 5,946 |
foreign exchange contracts Costs of Revenue | -3,251 | -5,414 | -4,262 |
foreign exchange contracts Interest income expense | 589 | 582 | ' |
Total before tax | -2,917 | 5,072 | -104,130 |
Tax expense or benefit | -1,346 | 21,171 | -41,825 |
Net of tax | -1,571 | -16,099 | -62,305 |
Amortization of defined benefit pension items: | ' | ' | ' |
Actuarial (gains)/losses | -25,418 | -18,334 | -8,737 |
Total before tax | -39,571 | 121,512 | 90,643 |
Tax expense or benefit | 17,828 | -42,159 | -34,930 |
Total reclassification for the period | ($33,749) | ($25,124) | ($6,283) |
Supplementary_Cash_Flow_Inform2
Supplementary Cash Flow Information (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Supplementary cash flow information: | ' | ' | ' |
Cash paid for interest | $374,648 | $349,415 | $259,835 |
Cash paid for income taxes, net of tax refund | 542,625 | 552,711 | 455,805 |
Tax Benefit From Stock Options Exercised 1 | 8,882 | 21,008 | 13,010 |
Supplemental disclosures of cash flow information, details for acquisitions: | ' | ' | ' |
Assets acquired | -417,669 | -2,519,189 | -1,684,630 |
Liabilities assumed | 31,335 | 241,342 | 215,253 |
Noncontrolling interest subject to put provisions | 15,460 | 123,210 | 26,684 |
Noncontrolling interest | 9,104 | 104,947 | 20,983 |
Obligations assumed in connection with acquisition | 66,917 | 6,624 | 20,016 |
Cash paid | -294,853 | -2,043,066 | -1,401,694 |
Less cash acquired | 6,858 | 173,278 | 47,461 |
Net cash paid for acquisitions | -287,995 | -1,869,788 | -1,354,233 |
Cash Paid For Investments | -195,921 | -387 | -419,040 |
Cash Paid For Intangible Assets | -11,809 | -8,733 | -12,056 |
Cash paid for acquisitions and investments net of cash acquired and purchases of intangible assets | ($495,725) | ($1,878,908) | ($1,785,329) |
Business_Segment_Information_D
Business Segment Information (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Entity-Wide Information, Revenue from External Customer [Line Items] | ' | ' | ' |
Segment revenue | $4,970,319 | ' | ' |
Income (Loss) From Equity Method Investments | -26,105 | -17,442 | -30,959 |
thereof investment in equity method investees | 664,446 | 637,373 | ' |
Total FMC-AG and Co. KGaA [Member] | ' | ' | ' |
Entity-Wide Information, Revenue from External Customer [Line Items] | ' | ' | ' |
Net revenue from external customers | 14,609,727 | 13,800,282 | 12,570,515 |
Segment revenue | 14,609,727 | 13,800,282 | 12,570,515 |
Segment depreciation and amortization | -648,225 | -602,896 | -557,283 |
Segment operating income | 2,256,196 | 2,218,573 | 2,074,892 |
Income (Loss) From Equity Method Investments | 26,105 | 17,442 | 30,959 |
Segment assets | 23,119,906 | 22,325,998 | 19,532,850 |
thereof investment in equity method investees | 664,446 | 637,373 | 692,025 |
Capital expenditures, acquisitions and investments | 1,243,663 | 2,554,218 | 2,383,184 |
Segment Total [Member] | ' | ' | ' |
Entity-Wide Information, Revenue from External Customer [Line Items] | ' | ' | ' |
Net revenue from external customers | 14,576,430 | 13,771,240 | 12,553,422 |
Inter - segment revenue | 7,045 | 10,072 | 9,196 |
Segment revenue | 14,583,475 | 13,781,312 | 12,562,618 |
Segment depreciation and amortization | -515,941 | -485,720 | -442,655 |
Segment operating income | 2,482,292 | 2,424,617 | 2,242,887 |
Income (Loss) From Equity Method Investments | 20,969 | 24,327 | 32,456 |
Segment assets | 20,875,521 | 20,062,930 | 17,351,198 |
thereof investment in equity method investees | 664,894 | 645,147 | 693,437 |
Capital expenditures, acquisitions and investments | 1,075,760 | 2,378,410 | 2,217,008 |
North America [Member] | ' | ' | ' |
Entity-Wide Information, Revenue from External Customer [Line Items] | ' | ' | ' |
Net revenue from external customers | 9,606,111 | 9,031,108 | 7,925,472 |
Inter - segment revenue | 7,045 | 10,072 | 9,196 |
Segment revenue | 9,613,156 | 9,041,180 | 7,934,668 |
Segment depreciation and amortization | -330,371 | -310,216 | -269,055 |
Segment operating income | 1,623,984 | 1,615,348 | 1,435,450 |
Income (Loss) From Equity Method Investments | 19,297 | 23,408 | 32,387 |
Segment assets | 14,698,039 | 14,170,453 | 11,761,777 |
thereof investment in equity method investees | 268,370 | 266,521 | 322,990 |
Capital expenditures, acquisitions and investments | 789,340 | 2,147,522 | 1,055,183 |
International [Member] | ' | ' | ' |
Entity-Wide Information, Revenue from External Customer [Line Items] | ' | ' | ' |
Net revenue from external customers | 4,970,319 | 4,740,132 | 4,627,950 |
Segment revenue | ' | 4,740,132 | 4,627,950 |
Segment depreciation and amortization | -185,570 | -175,504 | -173,600 |
Segment operating income | 858,308 | 809,269 | 807,437 |
Income (Loss) From Equity Method Investments | 1,672 | 919 | 69 |
Segment assets | 6,177,482 | 5,892,477 | 5,589,421 |
thereof investment in equity method investees | 396,524 | 378,626 | 370,447 |
Capital expenditures, acquisitions and investments | 286,420 | 230,888 | 1,161,825 |
Corporates [Member] | ' | ' | ' |
Entity-Wide Information, Revenue from External Customer [Line Items] | ' | ' | ' |
Net revenue from external customers | 33,297 | 29,042 | 17,093 |
Inter - segment revenue | -7,045 | -10,072 | -9,196 |
Segment revenue | 26,252 | 18,970 | 7,897 |
Segment depreciation and amortization | -132,284 | -117,176 | -114,628 |
Segment operating income | -226,096 | -206,044 | -167,995 |
Income (Loss) From Equity Method Investments | 5,136 | -6,885 | -1,497 |
Segment assets | 2,244,385 | 2,263,068 | 2,181,652 |
thereof investment in equity method investees | -448 | -7,774 | -1,412 |
Capital expenditures, acquisitions and investments | $167,903 | $175,808 | $166,176 |
Business_Segment_Information_D1
Business Segment Information (Details 1) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Revenues From External Customers And Long Lived Assets [Line Items] | ' | ' | ' |
Long-lived assets | $16,727,203 | $16,108,317 | $13,788,060 |
Germany [Member] | ' | ' | ' |
Revenues From External Customers And Long Lived Assets [Line Items] | ' | ' | ' |
Net revenue external customers | 437,459 | 409,195 | 422,476 |
Long-lived assets | 609,040 | 493,782 | 420,573 |
North America [Member] | ' | ' | ' |
Revenues From External Customers And Long Lived Assets [Line Items] | ' | ' | ' |
Net revenue external customers | 9,606,111 | 9,031,108 | 7,925,472 |
Long-lived assets | 12,891,384 | 12,428,762 | 10,326,615 |
Remaining World [Member] | ' | ' | ' |
Revenues From External Customers And Long Lived Assets [Line Items] | ' | ' | ' |
Net revenue external customers | 4,566,157 | 4,359,979 | 4,222,567 |
Long-lived assets | $3,226,779 | $3,185,773 | $3,040,872 |
Supplemental_Condensed_Combini2
Supplemental Condensed Combining Information (Details) (USD $) | 12 Months Ended | |||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2010 |
Consolidated Statements of Income | ' | ' | ' | ' |
Net revenue | $14,609,727 | $13,800,282 | $12,570,515 | ' |
Cost of revenues | 9,871,330 | 9,199,029 | 8,418,474 | ' |
Gross profit | 4,738,397 | 4,601,253 | 4,152,041 | ' |
Selling, general and administrative | 2,356,396 | 2,271,049 | ' | ' |
Research and development | 125,805 | 111,631 | 110,834 | ' |
Operating income | 2,256,196 | 2,218,573 | 2,074,892 | ' |
Investment gain | 0 | 139,600 | ' | ' |
Interest, net | -408,561 | -426,060 | ' | ' |
Income before income taxes | 1,847,635 | 1,932,113 | 1,778,359 | ' |
Income tax expense | 592,012 | 605,136 | 601,097 | ' |
Net Income | 1,255,623 | 1,326,977 | 1,177,262 | ' |
Less: Net income attributable to noncontrolling interests | 145,733 | 140,168 | 106,108 | ' |
Income attributable to the Company | 1,109,890 | 1,186,809 | 1,071,154 | ' |
Current assets: | ' | ' | ' | ' |
Cash and cash equivalents | 682,777 | 688,040 | 457,292 | 522,870 |
Trade accounts receivable less allowance for doubtful accounts of $328,893 in 2012 and $299,751 in 2011 | 3,037,274 | 3,019,424 | ' | ' |
Accounts receivable from related parties | 153,118 | 137,809 | ' | ' |
Inventories | 1,097,104 | 1,036,809 | ' | ' |
Prepaid expenses and other current assets | 1,037,391 | 977,537 | ' | ' |
Deferred tax asset, current | 279,052 | 267,837 | ' | ' |
Total current assets | 6,286,716 | 6,127,456 | ' | ' |
Property, plant and equipment, net | 3,091,954 | 2,940,603 | ' | ' |
Intangible assets | 757,876 | 710,116 | ' | ' |
Goodwill | 11,658,187 | 11,421,889 | 9,186,650 | ' |
Deferred tax asset, non-current | 104,167 | 89,152 | ' | ' |
Total assets | 23,119,906 | 22,325,998 | ' | ' |
Current liabilities: | ' | ' | ' | ' |
Accounts payable | 542,597 | 622,294 | ' | ' |
Accounts payable to related parties | 123,929 | 123,350 | ' | ' |
Accrued expenses and other current liabilities | 2,012,533 | 1,787,471 | ' | ' |
Short-term borrowings and other financial liabilities | 96,648 | 117,850 | ' | ' |
Short Term Borrowings Due To Related Parties Current | 62,342 | 3,973 | ' | ' |
Current portion of long-term debt and capital lease obligations | 511,370 | 334,747 | ' | ' |
Income tax payable, current | 170,360 | 150,003 | ' | ' |
Deferred tax liability, current | 34,194 | 30,303 | ' | ' |
Total current liabilities | 3,553,973 | 3,169,991 | ' | ' |
Total long-term debt less current maturities | 7,746,920 | 7,785,740 | ' | ' |
Other liabilities | 329,561 | 260,257 | ' | ' |
Pension liabilities | 435,858 | 457,673 | ' | ' |
Income tax payable, non-current | 176,933 | 201,642 | ' | ' |
Deferred tax liability, non-current | 743,390 | 664,001 | ' | ' |
Total liabilities | 12,986,635 | 12,595,478 | ' | ' |
Noncontrolling interests subject to put provisions | 648,251 | 523,260 | ' | ' |
Company shareholders' equity | 9,234,564 | 8,942,506 | ' | ' |
Noncontrolling interests not subject to put provisions | 250,456 | 264,754 | ' | ' |
Total equity | 9,485,020 | 9,207,260 | 8,061,017 | 7,523,911 |
Total liabilities and equity | 23,119,906 | 22,325,998 | ' | ' |
Consolidated Statements of Comprehensive Income | ' | ' | ' | ' |
Net Income | 1,255,623 | 1,326,977 | 1,177,262 | ' |
Other comprehensive income (loss), net of tax | -60,518 | -6,525 | -292,969 | ' |
Total comprehensive income | 1,195,105 | 1,320,452 | 884,293 | ' |
Comprehensive income attributable to noncontrolling interests | -143,689 | -139,989 | -104,861 | ' |
Comprehensive income attributable to the Company | 1,051,416 | 1,180,463 | 779,432 | ' |
Issuers [Member] | FMC US Finance [Member] | ' | ' | ' | ' |
Consolidated Statements of Income | ' | ' | ' | ' |
Selling, general and administrative | ' | ' | 1 | ' |
Operating income | ' | ' | -1 | ' |
Interest, net | 6,871 | 6,839 | -5,351 | ' |
Income before income taxes | 6,871 | 6,839 | 5,350 | ' |
Income tax expense | 2,494 | 2,482 | 2,016 | ' |
Net Income | 4,377 | 4,357 | 3,334 | ' |
Income attributable to the Company | 4,377 | 4,357 | 3,334 | ' |
Current assets: | ' | ' | ' | ' |
Cash and cash equivalents | 0 | 1 | 1 | ' |
Accounts receivable from related parties | 1,269,092 | 1,269,471 | ' | ' |
Total current assets | 1,269,092 | 1,269,472 | ' | ' |
Total assets | 1,269,092 | 1,269,472 | ' | ' |
Current liabilities: | ' | ' | ' | ' |
Accrued expenses and other current liabilities | 29,770 | 29,771 | ' | ' |
Total current liabilities | 29,770 | 29,771 | ' | ' |
Total long-term debt less current maturities | 1,167,466 | 1,172,397 | ' | ' |
Income tax payable, non-current | 2,287 | 2,113 | ' | ' |
Total liabilities | 1,199,523 | 1,204,281 | ' | ' |
Company shareholders' equity | 69,569 | 65,191 | ' | ' |
Total equity | 69,569 | 65,191 | ' | ' |
Total liabilities and equity | 1,269,092 | 1,269,472 | ' | ' |
Consolidated Statements of Comprehensive Income | ' | ' | ' | ' |
Net Income | 4,377 | 4,357 | 3,334 | ' |
Guarantors [Member] | ' | ' | ' | ' |
Consolidated Statements of Income | ' | ' | ' | ' |
Other, net | ' | ' | -1,379,577 | ' |
Current assets: | ' | ' | ' | ' |
Property, plant and equipment, net | 2,980,268 | ' | ' | ' |
Guarantors [Member] | Total FMC-AG and Co. KGaA [Member] | ' | ' | ' | ' |
Consolidated Statements of Income | ' | ' | ' | ' |
Selling, general and administrative | 184,054 | 59,222 | 158,222 | ' |
Operating income | -184,054 | -59,222 | -158,222 | ' |
Investment gain | -22,945 | ' | ' | ' |
Interest, net | -210,759 | -216,914 | 90,148 | ' |
Other, net | -1,545,184 | -1,531,505 | ' | ' |
Income before income taxes | 1,150,371 | 1,255,369 | 1,131,207 | ' |
Income tax expense | 40,481 | 68,560 | 60,053 | ' |
Net Income | 1,109,890 | 1,186,809 | 1,071,154 | ' |
Income attributable to the Company | 1,109,890 | 1,186,809 | 1,071,154 | ' |
Current assets: | ' | ' | ' | ' |
Cash and cash equivalents | 13 | 78 | 2 | 147,177 |
Accounts receivable from related parties | 960,137 | 2,257,445 | ' | ' |
Prepaid expenses and other current assets | 71,939 | 72,022 | ' | ' |
Total current assets | 1,032,089 | 2,329,545 | ' | ' |
Property, plant and equipment, net | 734 | 611 | ' | ' |
Intangible assets | 501 | 584 | ' | ' |
Deferred tax asset, non-current | 80,931 | 51,111 | ' | ' |
Other assets | 13,955,933 | 12,675,998 | ' | ' |
Total assets | 15,070,188 | 15,057,849 | ' | ' |
Current liabilities: | ' | ' | ' | ' |
Accounts payable | 2,193 | 1,935 | ' | ' |
Accounts payable to related parties | 1,896,712 | 2,234,205 | ' | ' |
Accrued expenses and other current liabilities | 45,897 | 27,530 | ' | ' |
Short-term borrowings and other financial liabilities | 60 | 38 | ' | ' |
Current portion of long-term debt and capital lease obligations | 271,090 | 207,160 | ' | ' |
Income tax payable, current | 114,197 | 130,636 | ' | ' |
Deferred tax liability, current | 2,331 | 1,622 | ' | ' |
Total current liabilities | 2,332,480 | 2,603,126 | ' | ' |
Total long-term debt less current maturities | 96,699 | 285,049 | ' | ' |
Long term borrowings from related parties | 3,359,606 | 3,212,455 | ' | ' |
Other liabilities | 5,616 | 6,696 | ' | ' |
Pension liabilities | 10,377 | 7,753 | ' | ' |
Income tax payable, non-current | 30,846 | 264 | ' | ' |
Total liabilities | 5,835,624 | 6,115,343 | ' | ' |
Company shareholders' equity | 9,234,564 | 8,942,506 | ' | ' |
Total equity | 9,234,564 | 8,942,506 | ' | ' |
Total liabilities and equity | 15,070,188 | 15,057,849 | ' | ' |
Consolidated Statements of Comprehensive Income | ' | ' | ' | ' |
Net Income | 1,109,890 | 1,186,809 | 1,071,154 | ' |
Guarantors [Member] | D GmbH [Member] | ' | ' | ' | ' |
Consolidated Statements of Income | ' | ' | ' | ' |
Net revenue | 2,084,014 | 1,884,622 | 1,931,016 | ' |
Cost of revenues | 1,356,114 | 1,197,337 | 1,210,733 | ' |
Gross profit | 727,900 | 687,285 | 720,283 | ' |
Selling, general and administrative | 284,589 | 203,284 | 208,022 | ' |
Research and development | 72,638 | 69,025 | 68,876 | ' |
Operating income | 370,673 | 414,976 | 443,385 | ' |
Interest, net | -5,922 | -2,682 | 6,867 | ' |
Other, net | 259,165 | 261,505 | 297,281 | ' |
Income before income taxes | 105,586 | 150,789 | 139,237 | ' |
Income tax expense | 108,837 | 119,255 | 124,322 | ' |
Net Income | -3,251 | 31,534 | 14,915 | ' |
Income attributable to the Company | -3,251 | 31,534 | 14,915 | ' |
Current assets: | ' | ' | ' | ' |
Cash and cash equivalents | 4,490 | 501 | 144 | 225 |
Trade accounts receivable less allowance for doubtful accounts of $328,893 in 2012 and $299,751 in 2011 | 152,480 | 170,627 | ' | ' |
Accounts receivable from related parties | 815,748 | 1,449,317 | ' | ' |
Inventories | 287,625 | 271,039 | ' | ' |
Prepaid expenses and other current assets | 41,240 | 27,693 | ' | ' |
Total current assets | 1,301,583 | 1,919,177 | ' | ' |
Property, plant and equipment, net | 238,469 | 206,873 | ' | ' |
Intangible assets | 73,166 | 67,874 | ' | ' |
Goodwill | 62,829 | 54,848 | ' | ' |
Deferred tax asset, non-current | 14,209 | 10,123 | ' | ' |
Other assets | 47,661 | 650,255 | ' | ' |
Total assets | 1,737,917 | 2,909,150 | ' | ' |
Current liabilities: | ' | ' | ' | ' |
Accounts payable | 28,689 | 41,114 | ' | ' |
Accounts payable to related parties | 522,719 | 491,525 | ' | ' |
Accrued expenses and other current liabilities | 129,727 | 102,728 | ' | ' |
Deferred tax liability, current | 9,002 | 8,126 | ' | ' |
Total current liabilities | 690,137 | 643,493 | ' | ' |
Long term borrowings from related parties | ' | 657,284 | ' | ' |
Other liabilities | 6,028 | 12,679 | ' | ' |
Pension liabilities | 254,233 | 202,219 | ' | ' |
Total liabilities | 950,398 | 1,515,675 | ' | ' |
Company shareholders' equity | 787,519 | 1,393,475 | ' | ' |
Total equity | 787,519 | 1,393,475 | ' | ' |
Total liabilities and equity | 1,737,917 | 2,909,150 | ' | ' |
Consolidated Statements of Comprehensive Income | ' | ' | ' | ' |
Net Income | -3,251 | 31,534 | 14,915 | ' |
Guarantors [Member] | FMCH [Member] | ' | ' | ' | ' |
Consolidated Statements of Income | ' | ' | ' | ' |
Selling, general and administrative | -128,356 | -51,963 | 67,587 | ' |
Operating income | 128,356 | 51,963 | -67,587 | ' |
Interest, net | -176,643 | -156,794 | 82,205 | ' |
Other, net | -824,853 | -921,180 | -691,312 | ' |
Income before income taxes | 776,566 | 816,349 | 541,520 | ' |
Income tax expense | -19,049 | -41,356 | -59,093 | ' |
Net Income | 795,615 | 857,705 | 600,613 | ' |
Income attributable to the Company | 795,615 | 857,705 | 600,613 | ' |
Current assets: | ' | ' | ' | ' |
Accounts receivable from related parties | 1,643,394 | 3,562,953 | ' | ' |
Prepaid expenses and other current assets | 167 | 167 | ' | ' |
Total current assets | 1,643,561 | 3,563,120 | ' | ' |
Other assets | 12,583,246 | 11,766,104 | ' | ' |
Total assets | 14,226,807 | 15,329,224 | ' | ' |
Current liabilities: | ' | ' | ' | ' |
Accounts payable to related parties | 1,600,480 | 1,598,852 | ' | ' |
Accrued expenses and other current liabilities | 9,403 | 3,157 | ' | ' |
Current portion of long-term debt and capital lease obligations | 200,000 | 100,000 | ' | ' |
Total current liabilities | 1,809,883 | 1,702,009 | ' | ' |
Total long-term debt less current maturities | 2,438,189 | 2,559,340 | ' | ' |
Long term borrowings from related parties | 2,092,818 | 2,019,925 | ' | ' |
Other liabilities | 0 | 110,637 | ' | ' |
Total liabilities | 6,340,890 | 6,391,911 | ' | ' |
Company shareholders' equity | 7,885,917 | 8,937,313 | ' | ' |
Total equity | 7,885,917 | 8,937,313 | ' | ' |
Total liabilities and equity | 14,226,807 | 15,329,224 | ' | ' |
Consolidated Statements of Comprehensive Income | ' | ' | ' | ' |
Net Income | 795,615 | 857,705 | 600,613 | ' |
Non Guarantor Subsidiaries [Member] | ' | ' | ' | ' |
Consolidated Statements of Income | ' | ' | ' | ' |
Net revenue | 15,825,782 | 14,806,815 | 13,498,566 | ' |
Cost of revenues | 11,789,397 | 10,876,513 | 10,020,572 | ' |
Gross profit | 4,036,385 | 3,930,302 | 3,477,994 | ' |
Selling, general and administrative | 2,150,296 | 2,030,970 | 1,611,194 | ' |
Research and development | 53,336 | 42,442 | 41,958 | ' |
Operating income | 1,832,753 | 1,856,890 | 1,824,842 | ' |
Investment gain | 20,610 | -139,600 | ' | ' |
Interest, net | -22,108 | -71,797 | 140,567 | ' |
Income before income taxes | 1,810,645 | 1,924,693 | 1,684,275 | ' |
Income tax expense | 652,672 | 698,353 | 685,166 | ' |
Net Income | 1,157,973 | 1,226,340 | 999,109 | ' |
Less: Net income attributable to noncontrolling interests | 145,733 | 140,168 | ' | ' |
Income attributable to the Company | 1,012,240 | 1,086,172 | 999,109 | ' |
Current assets: | ' | ' | ' | ' |
Cash and cash equivalents | 672,206 | 686,457 | 457,145 | 342,524 |
Trade accounts receivable less allowance for doubtful accounts of $328,893 in 2012 and $299,751 in 2011 | 2,882,736 | 2,848,797 | ' | ' |
Accounts receivable from related parties | 4,073,975 | 4,398,630 | ' | ' |
Inventories | 946,790 | 885,613 | ' | ' |
Prepaid expenses and other current assets | 879,085 | 837,152 | ' | ' |
Deferred tax asset, current | 322,337 | 311,280 | ' | ' |
Total current assets | 9,777,129 | 9,967,929 | ' | ' |
Property, plant and equipment, net | ' | 2,856,000 | ' | ' |
Intangible assets | 684,290 | 641,714 | ' | ' |
Goodwill | 11,595,358 | 11,367,041 | ' | ' |
Deferred tax asset, non-current | 118,306 | 131,452 | ' | ' |
Other assets | 5,234,132 | -4,751,531 | ' | ' |
Total assets | 30,389,483 | 20,212,605 | ' | ' |
Current liabilities: | ' | ' | ' | ' |
Accounts payable | 511,715 | 579,245 | ' | ' |
Accounts payable to related parties | 4,931,344 | 8,663,240 | ' | ' |
Accrued expenses and other current liabilities | 1,786,709 | 1,611,997 | ' | ' |
Short-term borrowings and other financial liabilities | 96,588 | 117,812 | ' | ' |
Short Term Borrowings Due To Related Parties Current | 62,342 | 3,973 | ' | ' |
Current portion of long-term debt and capital lease obligations | 40,280 | 27,587 | ' | ' |
Income tax payable, current | 56,163 | 19,367 | ' | ' |
Deferred tax liability, current | 64,539 | 61,774 | ' | ' |
Total current liabilities | 7,549,680 | 11,084,995 | ' | ' |
Total long-term debt less current maturities | 7,478,944 | 7,020,190 | ' | ' |
Long term borrowings from related parties | 6,940 | 64,530 | ' | ' |
Other liabilities | 298,313 | 96,322 | ' | ' |
Pension liabilities | 171,248 | 247,701 | ' | ' |
Income tax payable, non-current | 20,262 | 52,684 | ' | ' |
Deferred tax liability, non-current | 768,156 | 685,158 | ' | ' |
Total liabilities | 16,293,543 | 19,251,580 | ' | ' |
Noncontrolling interests subject to put provisions | 648,251 | 523,260 | ' | ' |
Company shareholders' equity | 13,197,233 | 173,011 | ' | ' |
Noncontrolling interests not subject to put provisions | 250,456 | 264,754 | ' | ' |
Total equity | 13,447,689 | 437,765 | ' | ' |
Total liabilities and equity | 30,389,483 | 20,212,605 | ' | ' |
Consolidated Statements of Comprehensive Income | ' | ' | ' | ' |
Net Income | 1,157,973 | 1,226,340 | 999,109 | ' |
Combining Adjustment [Member] | ' | ' | ' | ' |
Consolidated Statements of Income | ' | ' | ' | ' |
Net revenue | -3,300,069 | -2,891,155 | -2,859,067 | ' |
Cost of revenues | -3,274,181 | -2,874,821 | -2,812,831 | ' |
Gross profit | -25,888 | -16,334 | -46,236 | ' |
Selling, general and administrative | -134,187 | 29,536 | -78,711 | ' |
Research and development | -169 | 164 | ' | ' |
Operating income | 108,468 | -46,034 | 32,475 | ' |
Interest, net | 0 | 15,288 | -17,903 | ' |
Other, net | 2,110,872 | 2,191,180 | 1,773,608 | ' |
Income before income taxes | -2,002,404 | -2,221,926 | -1,723,230 | ' |
Income tax expense | -193,423 | -242,158 | -211,367 | ' |
Net Income | -1,808,981 | -1,979,768 | -1,511,863 | ' |
Less: Net income attributable to noncontrolling interests | ' | ' | 106,108 | ' |
Income attributable to the Company | -1,808,981 | -1,979,768 | -1,617,971 | ' |
Current assets: | ' | ' | ' | ' |
Cash and cash equivalents | 6,068 | 1,003 | ' | 32,944 |
Trade accounts receivable less allowance for doubtful accounts of $328,893 in 2012 and $299,751 in 2011 | 2,058 | ' | ' | ' |
Accounts receivable from related parties | -8,609,228 | -12,800,007 | ' | ' |
Inventories | -137,311 | -119,843 | ' | ' |
Prepaid expenses and other current assets | 44,960 | 40,503 | ' | ' |
Deferred tax asset, current | -43,285 | -43,443 | ' | ' |
Total current assets | -8,736,738 | -12,921,787 | ' | ' |
Property, plant and equipment, net | -127,517 | -122,881 | ' | ' |
Intangible assets | -81 | -56 | ' | ' |
Deferred tax asset, non-current | -109,279 | -103,534 | ' | ' |
Other assets | -30,599,966 | -19,304,044 | ' | ' |
Total assets | -39,573,581 | -32,452,302 | ' | ' |
Current liabilities: | ' | ' | ' | ' |
Accounts payable to related parties | -8,827,326 | -12,864,472 | ' | ' |
Accrued expenses and other current liabilities | 11,027 | 12,288 | ' | ' |
Deferred tax liability, current | -41,678 | -41,219 | ' | ' |
Total current liabilities | -8,857,977 | -12,893,403 | ' | ' |
Total long-term debt less current maturities | -3,434,378 | -3,251,236 | ' | ' |
Long term borrowings from related parties | -5,459,364 | -5,898,020 | ' | ' |
Other liabilities | 19,604 | 33,923 | ' | ' |
Income tax payable, non-current | 123,538 | 146,581 | ' | ' |
Deferred tax liability, non-current | -24,766 | -21,157 | ' | ' |
Total liabilities | -17,633,343 | -21,883,312 | ' | ' |
Company shareholders' equity | -21,940,238 | -10,568,990 | ' | ' |
Total equity | -21,940,238 | -10,568,990 | ' | ' |
Total liabilities and equity | -39,573,581 | -32,452,302 | ' | ' |
Consolidated Statements of Comprehensive Income | ' | ' | ' | ' |
Net Income | ($1,808,981) | ($1,979,768) | ($1,511,863) | ' |
Supplemental_Condensed_Combini3
Supplemental Condensed Combining Information (Details 1) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Operating Activities: | ' | ' | ' |
Net Income | $1,255,623 | $1,326,977 | $1,177,262 |
Adjustments to reconcile net income to net cash provided by operating activities: | ' | ' | ' |
Depreciation and amortization | 648,225 | 602,896 | 557,283 |
Change in deferred taxes, net | 15,913 | 75,170 | 159,181 |
Investment gain | 0 | 139,600 | ' |
Stock Option Compensation Expense | 13,593 | 26,476 | 29,071 |
Cash outflow from hedging | -4,073 | -13,947 | -58,113 |
Changes in assets and liabilities, net of amounts from businesses acquired: | ' | ' | ' |
Trade accounts receivable, net | -41,280 | -43,344 | -252,794 |
Inventories, net | -54,918 | -48,279 | -151,890 |
Prepaid expenses, other current and non-current assets | 67,875 | 88,413 | -130,858 |
Accounts payable, accrued expenses and other current and non-current liabilities | 215,264 | 225,586 | 132,406 |
Income tax payable | -36,057 | -38,478 | 41,042 |
Net cash provided by (used in) operating activities | 2,034,805 | 2,039,063 | 1,446,482 |
Investing Activities: | ' | ' | ' |
Purchases of property, plant and equipment | -747,938 | -675,310 | -597,855 |
Proceeds from sale of property, plant and equipment | 19,847 | 9,667 | 27,325 |
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets | -495,725 | -1,878,908 | -1,785,329 |
Proceeds from divestitures | 18,276 | 263,306 | 9,990 |
Net cash (used in) provided by investing activities | -1,205,540 | -2,281,245 | -2,345,869 |
Financing Activities: | ' | ' | ' |
Redemption of Trust Preferred Securities | ' | 0 | 653,760 |
Increase (decrease) of accounts receivable securitization program | 189,250 | -372,500 | 24,500 |
Proceeds from exercise of stock options | 111,300 | 121,126 | 94,893 |
Payment of dividends [N] | -296,134 | -271,733 | -280,649 |
Proceeds From Repurchase Of Equity | -505,014 | ' | ' |
Distributions to noncontrolling interests | 216,758 | 195,023 | 129,542 |
Contributions from noncontrolling interests | 66,467 | 37,704 | 27,824 |
Net cash (used in) provided by financing activities | -808,040 | 468,340 | 793,159 |
Proceeds from conversion of preference shares into ordinary shares | 34,784 | ' | ' |
Effect of exchange rate changes on cash and cash equivalents | -26,488 | 4,590 | 40,650 |
Cash and Cash Equivalents: | ' | ' | ' |
(decrease) in cash and cash equivalents | -5,263 | 230,748 | -65,578 |
Cash and cash equivalents at beginning of period | 688,040 | 457,292 | 522,870 |
Cash and cash equivalents at end of period | 682,777 | 688,040 | 457,292 |
Issuers [Member] | FMC US Finance [Member] | ' | ' | ' |
Operating Activities: | ' | ' | ' |
Net Income | 4,377 | 4,357 | 3,334 |
Changes in assets and liabilities, net of amounts from businesses acquired: | ' | ' | ' |
Accounts receivable from/payable to related parties | -8 | -3,724 | -12,372 |
Accounts payable, accrued expenses and other current and non-current liabilities | ' | ' | 13,775 |
Income tax payable | 174 | 97 | 2,016 |
Net cash provided by (used in) operating activities | 4,543 | 730 | 6,753 |
Financing Activities: | ' | ' | ' |
Long-term debt and capital lease obligations, net | -4,544 | -730 | -64,252 |
Proceeds From Repurchase Of Equity | ' | ' | 57,500 |
Net cash (used in) provided by financing activities | -4,544 | -730 | -6,752 |
Cash and Cash Equivalents: | ' | ' | ' |
(decrease) in cash and cash equivalents | ' | ' | 1 |
Cash and cash equivalents at beginning of period | 1 | 1 | ' |
Cash and cash equivalents at end of period | 0 | 1 | 1 |
Guarantors [Member] | Total FMC-AG and Co. KGaA [Member] | ' | ' | ' |
Operating Activities: | ' | ' | ' |
Net Income | 1,109,890 | 1,186,809 | 1,071,154 |
Adjustments to reconcile net income to net cash provided by operating activities: | ' | ' | ' |
Income Loss From Equity Method Investments Net Of Dividends Or Distributions | ' | -36,453 | -872,048 |
Depreciation and amortization | 689 | 519 | 858 |
Change in deferred taxes, net | -34,548 | 1,994 | 12,593 |
(Gain) loss on sale of fixed assets and investments | -43 | -40 | -10 |
Loss (gain) on investments | 0 | 1,247 | 31,502 |
Write-off of loans from related parties | 91,593 | 7,527 | 44,807 |
Investment gain | -22,945 | ' | ' |
Stock Option Compensation Expense | 13,593 | -26,476 | 29,071 |
Cash outflow from hedging | -4,073 | -1,322 | ' |
Changes in assets and liabilities, net of amounts from businesses acquired: | ' | ' | ' |
Prepaid expenses, other current and non-current assets | 46,352 | 148,172 | -133,691 |
Accounts receivable from/payable to related parties | -334,000 | 1,653,955 | -1,183,881 |
Accounts payable, accrued expenses and other current and non-current liabilities | 11,469 | -1,884 | -40,619 |
Income tax payable | 7,917 | -137 | 80,461 |
Net cash provided by (used in) operating activities | 7,646 | 2,059,448 | -959,803 |
Investing Activities: | ' | ' | ' |
Purchases of property, plant and equipment | -320 | -485 | -221 |
Proceeds from sale of property, plant and equipment | 48 | 40 | ' |
Disbursements of loans to related parties | 911,133 | -1,551,372 | 1,571,874 |
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets | -103,308 | -1,618,662 | -148,331 |
Proceeds from divestitures | ' | 44 | ' |
Net cash (used in) provided by investing activities | 807,553 | -3,170,435 | 1,423,322 |
Financing Activities: | ' | ' | ' |
Short-term borrowings, net | 20 | -24,338 | 26,284 |
Long-term debt and capital lease obligations, net | -140,374 | 1,308,572 | -221,594 |
Proceeds from exercise of stock options | 102,419 | 100,178 | 81,883 |
Payment of dividends [N] | -296,134 | -271,733 | -280,649 |
Proceeds From Repurchase Of Equity | -505,014 | ' | ' |
Net cash (used in) provided by financing activities | -804,299 | 1,112,679 | -394,076 |
Proceeds from conversion of preference shares into ordinary shares | -34,784 | ' | ' |
Effect of exchange rate changes on cash and cash equivalents | -10,965 | -1,616 | -216,618 |
Cash and Cash Equivalents: | ' | ' | ' |
(decrease) in cash and cash equivalents | -65 | 76 | -147,175 |
Cash and cash equivalents at beginning of period | 78 | 2 | 147,177 |
Cash and cash equivalents at end of period | 13 | 78 | 2 |
Guarantors [Member] | D GmbH [Member] | ' | ' | ' |
Operating Activities: | ' | ' | ' |
Net Income | -3,251 | 31,534 | 14,915 |
Adjustments to reconcile net income to net cash provided by operating activities: | ' | ' | ' |
Depreciation and amortization | 52,029 | 47,832 | 49,207 |
Change in deferred taxes, net | 3,149 | 4,113 | 2,724 |
(Gain) loss on sale of fixed assets and investments | 437 | -163 | -184 |
Loss (gain) on investments | 61 | ' | 186 |
Changes in assets and liabilities, net of amounts from businesses acquired: | ' | ' | ' |
Trade accounts receivable, net | 14,851 | -23,848 | -13,401 |
Inventories, net | -4,162 | -40,910 | -47,022 |
Prepaid expenses, other current and non-current assets | -11,519 | -13,633 | -3,048 |
Accounts receivable from/payable to related parties | 644,752 | -49,477 | -51,617 |
Accounts payable, accrued expenses and other current and non-current liabilities | 21,203 | 33,157 | 28,385 |
Net cash provided by (used in) operating activities | 717,428 | -11,395 | -19,855 |
Investing Activities: | ' | ' | ' |
Purchases of property, plant and equipment | -76,096 | -78,272 | -54,545 |
Proceeds from sale of property, plant and equipment | 583 | 407 | 775 |
Disbursements of loans to related parties | ' | ' | 200 |
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets | -24,503 | -2,021 | -4,554 |
Proceeds from divestitures | ' | ' | 418 |
Net cash (used in) provided by investing activities | -100,016 | -79,886 | -57,706 |
Financing Activities: | ' | ' | ' |
Short-term borrowings, net | -613,593 | 91,628 | 77,481 |
Net cash (used in) provided by financing activities | -613,593 | 91,628 | 77,481 |
Effect of exchange rate changes on cash and cash equivalents | 170 | 10 | -1 |
Cash and Cash Equivalents: | ' | ' | ' |
(decrease) in cash and cash equivalents | 3,989 | 357 | -81 |
Cash and cash equivalents at beginning of period | 501 | 144 | 225 |
Cash and cash equivalents at end of period | 4,490 | 501 | 144 |
Guarantors [Member] | FMCH [Member] | ' | ' | ' |
Operating Activities: | ' | ' | ' |
Net Income | 795,615 | 857,705 | 600,613 |
Adjustments to reconcile net income to net cash provided by operating activities: | ' | ' | ' |
Income Loss From Equity Method Investments Net Of Dividends Or Distributions | ' | ' | -691,312 |
Depreciation and amortization | ' | ' | 5,768 |
Changes in assets and liabilities, net of amounts from businesses acquired: | ' | ' | ' |
Prepaid expenses, other current and non-current assets | -123,972 | -38,496 | 86,497 |
Accounts receivable from/payable to related parties | 128,185 | 117,090 | 54,300 |
Accounts payable, accrued expenses and other current and non-current liabilities | 6,246 | 1,024 | 79 |
Income tax payable | -19,049 | -41,356 | -59,093 |
Net cash provided by (used in) operating activities | -37,828 | -25,213 | -3,148 |
Investing Activities: | ' | ' | ' |
Disbursements of loans to related parties | 141,347 | 289,879 | -1,118,399 |
Net cash (used in) provided by investing activities | 140,347 | 289,879 | -1,118,399 |
Financing Activities: | ' | ' | ' |
Short-term borrowings, net | ' | ' | -298 |
Long-term debt and capital lease obligations, net | 1,629,443 | -264,666 | 433,455 |
Proceeds From Repurchase Of Equity | ' | ' | 688,390 |
Net cash (used in) provided by financing activities | -102,519 | -264,666 | 1,121,547 |
Non Guarantor Subsidiaries [Member] | ' | ' | ' |
Operating Activities: | ' | ' | ' |
Net Income | 1,157,973 | 1,226,340 | 999,109 |
Adjustments to reconcile net income to net cash provided by operating activities: | ' | ' | ' |
Income Loss From Equity Method Investments Net Of Dividends Or Distributions | ' | 13,941 | 30,959 |
Depreciation and amortization | 629,071 | 583,375 | 514,843 |
Change in deferred taxes, net | 46,888 | 71,744 | 150,598 |
(Gain) loss on sale of fixed assets and investments | -33,378 | -29,321 | -8,791 |
Loss (gain) on investments | 0 | ' | ' |
Write-off of loans from related parties | 0 | ' | ' |
Investment gain | 20,610 | -139,600 | ' |
Cash outflow from hedging | ' | 15,269 | 58,113 |
Changes in assets and liabilities, net of amounts from businesses acquired: | ' | ' | ' |
Trade accounts receivable, net | -54,149 | -19,496 | -239,393 |
Inventories, net | -70,848 | -11,532 | -135,071 |
Prepaid expenses, other current and non-current assets | 151,907 | 11,299 | -80,570 |
Accounts receivable from/payable to related parties | -559,991 | -1,788,646 | 1,239,464 |
Accounts payable, accrued expenses and other current and non-current liabilities | 181,426 | 193,756 | 131,427 |
Income tax payable | -23,818 | 24,316 | -509 |
Net cash provided by (used in) operating activities | 1,404,471 | 93,025 | 2,482,035 |
Investing Activities: | ' | ' | ' |
Purchases of property, plant and equipment | -712,213 | -638,394 | -569,645 |
Proceeds from sale of property, plant and equipment | 19,216 | 9,220 | 26,550 |
Disbursements of loans to related parties | 0 | ' | ' |
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets | -492,683 | -1,876,310 | -2,529,849 |
Proceeds from divestitures | 18,276 | 263,306 | 9,990 |
Net cash (used in) provided by investing activities | -1,167,404 | -2,242,178 | -3,062,954 |
Financing Activities: | ' | ' | ' |
Short-term borrowings, net | 597,859 | -80,241 | -142,444 |
Long-term debt and capital lease obligations, net | -2,713,226 | 1,380,034 | 1,147,586 |
Redemption of Trust Preferred Securities | -1,834,786 | -1,581,588 | 653,760 |
Increase (decrease) of accounts receivable securitization program | 189,250 | -372,500 | 24,500 |
Proceeds from exercise of stock options | 8,881 | 20,948 | 13,010 |
Payment of dividends [N] | -2,884 | -241 | 22 |
Proceeds From Repurchase Of Equity | ' | ' | 151,097 |
Distributions to noncontrolling interests | 216,758 | -195,023 | -129,542 |
Contributions from noncontrolling interests | 66,467 | 37,704 | 27,824 |
Net cash (used in) provided by financing activities | -235,625 | 2,372,269 | 438,293 |
Effect of exchange rate changes on cash and cash equivalents | -15,693 | 6,196 | 257,247 |
Cash and Cash Equivalents: | ' | ' | ' |
(decrease) in cash and cash equivalents | -14,251 | 229,312 | 114,621 |
Cash and cash equivalents at beginning of period | 686,457 | 457,145 | 342,524 |
Cash and cash equivalents at end of period | 672,206 | 686,457 | 457,145 |
Combining Adjustment [Member] | ' | ' | ' |
Operating Activities: | ' | ' | ' |
Net Income | -1,808,981 | -1,979,768 | -1,511,863 |
Adjustments to reconcile net income to net cash provided by operating activities: | ' | ' | ' |
Income Loss From Equity Method Investments Net Of Dividends Or Distributions | ' | ' | 1,563,360 |
Depreciation and amortization | -33,564 | -28,830 | -13,393 |
Change in deferred taxes, net | 424 | -2,681 | -6,734 |
Loss (gain) on investments | -61 | -1,247 | -31,688 |
Write-off of loans from related parties | ' | -7,527 | -44,807 |
Changes in assets and liabilities, net of amounts from businesses acquired: | ' | ' | ' |
Trade accounts receivable, net | -1,982 | ' | ' |
Inventories, net | 20,092 | 4,163 | 30,203 |
Prepaid expenses, other current and non-current assets | 5,107 | -18,929 | -46 |
Accounts receivable from/payable to related parties | 106,351 | 55,007 | -62,058 |
Accounts payable, accrued expenses and other current and non-current liabilities | -5,080 | -467 | -641 |
Income tax payable | -1,281 | -21,398 | 18,167 |
Net cash provided by (used in) operating activities | -61,455 | -77,532 | -59,500 |
Investing Activities: | ' | ' | ' |
Purchases of property, plant and equipment | 40,691 | 41,841 | 26,556 |
Disbursements of loans to related parties | -1,052,480 | 1,261,493 | -453,675 |
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets | 125,769 | 1,618,085 | 897,405 |
Proceeds from divestitures | ' | -44 | -418 |
Net cash (used in) provided by investing activities | -886,020 | 2,921,375 | 469,868 |
Financing Activities: | ' | ' | ' |
Long-term debt and capital lease obligations, net | 1,052,480 | -1,261,493 | 453,675 |
Redemption of Trust Preferred Securities | 102,824 | 1,581,588 | ' |
Payment of dividends [N] | 2,884 | 241 | -22 |
Proceeds From Repurchase Of Equity | ' | ' | -896,987 |
Net cash (used in) provided by financing activities | 952,540 | -2,842,840 | -443,334 |
Effect of exchange rate changes on cash and cash equivalents | ' | ' | 22 |
Cash and Cash Equivalents: | ' | ' | ' |
(decrease) in cash and cash equivalents | 5,065 | 1,003 | -32,944 |
Cash and cash equivalents at beginning of period | 1,003 | ' | 32,944 |
Cash and cash equivalents at end of period | $6,068 | $1,003 | ' |
Development_of_Allowance_for_D1
Development of Allowance for Doubtful Accounts (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Valuation Allowance [Line Items] | ' | ' | ' |
Allowance for doubtful accounts as of January 1 | $328,893 | $299,751 | $277,139 |
Premiums Receivable, Allowance for Doubtful Accounts, Period Increase (Decrease) | 336,090 | 303,508 | 241,598 |
Premiums Receivable, Allowance for Doubtful Accounts, Write Offs Against Allowance | -249,783 | -273,643 | -214,612 |
Allowance for Loan and Lease Losses, Foreign Currency Translation | -2,035 | -723 | -4,374 |
Allowance for doubtful accounts as of December 31 | $413,165 | $328,893 | $299,751 |